,trial_id,discovery_date,title,summary,link,published_date,source,relevant,Sources__source_id,Sources__name,Sources__link
0,549142,2023-08-02 12:40:50.000000,"Development, Reliability and Validity of the Telerehabilitation Usability Questionnaire- TrUQ",<b>Condition</b>:    Neurological Disease<br /><b>Intervention</b>:    Other: Development of the Telerehabilitation Usability Questionnaire<br /><b>Sponsor</b>:    Gazi University<br /><b>Not yet recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT05970939?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-08-02 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1,548852,2023-07-31 16:20:47.742577,Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive<br /><b>Interventions</b>:    Device: Cionic Neural Sleeve NS-100;   Device: Actigraph accelerometer<br /><b>Sponsor</b>:    Cionic, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05964829,2023-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2,548149,2023-07-27 13:50:48.271892,Investigation The Effect of Conventional Vs. Individualized tDCS Intensity to Achieve Uniform E-Fields,<b>Conditions</b>:    Multiple Sclerosis;   Neurophysiologic Abnormality<br /><b>Intervention</b>:    Device: Transcranial direct current stimulation (tDCS)<br /><b>Sponsors</b>:    Koen Cuypers;   BOF-BILA<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05962281,2023-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3,548148,2023-07-27 13:50:48.231152,Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).,"<b>Conditions</b>:    Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Cladribine Subcutaneous Injection;   Drug: 0.9% Chloride Injection Sodium<br /><b>Sponsors</b>:    Institute of Psychiatry and Neurology, Warsaw;   Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences;   Mossakowski Medical Research Centre Polish Academy of Sciences;   Poznan University of Medical Sciences;   Military Institute of Aviation Medicine<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05961644,2023-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4,548147,2023-07-27 13:50:48.188463,Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Magnetic Resonance Imaging;   Other: Blood withdrawal;   Other: Neuropsychological tests<br /><b>Sponsor</b>:    University Hospital, Montpellier<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05962177,2023-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
5,547537,2023-07-24 14:20:46.038680,Effects of Antiviral Therapies on Epstein-Barr Virus Replication,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Truvada (tenofovir/emtricitabine)<br /><b>Sponsors</b>:    Massachusetts General Hospital;   Solving MS<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05957913,2023-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
6,547536,2023-07-24 14:20:46.022891,Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Device: Transcranial Direct Current Stimulation;   Device: Sham transcranial direct current stimulation<br /><b>Sponsors</b>:    The University of Texas at Dallas;   University of Texas Southwestern Medical Center<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05958381,2023-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
7,547535,2023-07-24 14:20:45.959256,Structured Exercise Training in Newly Diagnosed Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Structured exercise training<br /><b>Sponsor</b>:    Istanbul University - Cerrahpasa (IUC)<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05957809,2023-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
8,546901,2023-07-21 13:40:44.879338,Effectiveness of Dry Needling for Improving Gait in the Patient With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: dry needling + physiotherapy (standard/usual care);   Other: sham dry needling + physiotherapy (standard/usual care)<br /><b>Sponsor</b>:    Hospital Universitario de Canarias<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05956119,2023-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
9,546610,2023-07-20 15:30:48.418581,Meeting an Unmet Need in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Unified Protocol<br /><b>Sponsor</b>:    Kessler Foundation<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05953519,2023-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
10,546609,2023-07-20 15:30:48.391573,Effect of High Intensity Interval Training in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: high intensity interval training<br /><b>Sponsor</b>:    Cairo University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05954195,2023-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
11,546313,2023-07-19 15:40:47.184108,High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners,<b>Conditions</b>:    Neurologic Disorder;   Parkinson Disease;   Spinal Cord Injuries;   Spina Bifida;   Stroke;   Poliomyelitis;   Multiple Sclerosis;   Brain Injuries<br /><b>Intervention</b>:    Behavioral: HIFT<br /><b>Sponsor</b>:    Arkansas Colleges of Health Education<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05951985,2023-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
12,546087,2023-07-18 12:20:45.561122,Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Device: MS Care Platform (icobrain ms and icompanion ms)<br /><b>Sponsors</b>:    Hoffmann-La Roche;   icometrix<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05949580,2023-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
13,546086,2023-07-18 12:20:45.548403,Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05950308,2023-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
14,545225,2023-07-14 17:31:37.441651,Exploring Accessible Beauty for Individuals With Upper Extremity Deficits,"<b>Conditions</b>:    Stroke, Ischemic;   Stroke Hemorrhagic;   Stroke (CVA) or TIA;   Stroke, Acute;   Traumatic Brain Injury;   SCI - Spinal Cord Injury;   Ehlers-Danlos Syndromes (EDS);   Lupus Erythematosus;   Guillain-Barre Syndrome;   Multiple Sclerosis;   Myasthenia Gravis;   Amyotrophic Lateral Sclerosis;   Graves Disease;   Muscular Dystrophies<br /><b>Intervention</b>:    Other: Use of Rare Beauty makeup products<br /><b>Sponsor</b>:    Casa Colina Hospital and Centers for Healthcare<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05945784,2023-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
15,545015,2023-07-13 17:01:22.346107,Outcomes of Group Dance and Movement Training in Ambulatory MS Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Group Dance and Movement Training<br /><b>Sponsor</b>:    GroundWorks DanceTheater<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05943145,2023-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
16,544816,2023-07-12 12:40:47.606805,Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Visual Evoked Potential (VEP);   Device: Somatosensory evoked potential (SSEP);   Device: Transcranial magnetic motor evoked potentials (TCmMEP);   Device: Tesla Brain MRI;   Diagnostic Test: Blood test - Neurofilament light chain (NfL);   Diagnostic Test: Blood test - EBV serology<br /><b>Sponsor</b>:    Brugmann University Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05941975,2023-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
17,544620,2023-07-11 14:01:23.197335,Study Protocol of Online DBT-Mindfulness Intervention in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Online DBT-Mindfulness Intervention;   Behavioral: Online psychoeducational intervention<br /><b>Sponsor</b>:    University of Vic - Central University of Catalonia<br /><b>Recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT05938842?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-07-11 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
18,544604,2023-07-11 12:10:46.915800,"A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safe...","<p>EudraCT Number: 2018-000284-93<br />Sponsor Protocol Number: Mapi_GADepotPhaseIII-001<br />Sponsor Name: Mapi Pharma Ltd.<br />Start Date: 2019-12-10<br />Medical condition: Relapsing forms of Multiple Sclerosis (RMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000284-93/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000284-93/BG"">BG</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-000284-93,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
19,544386,2023-07-10 12:20:42.339666,Osmotin Plant Protein for Progressive Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Dietary Supplement: Osmotin<br /><b>Sponsors</b>:    Ospedale Policlinico San Martino;   Italian Multiple Sclerosis Foundation;   S. Andrea Hospital<br /><b>Recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT05937802?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-07-10 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
20,544385,2023-07-10 12:20:42.326178,Plantar Sensitivity Training and Aerobic Exercise Training in Patients With Multiple Sclerosis (PlaSTAcET Study),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: plantar sensitivity training;   Other: aerobic exercise training<br /><b>Sponsors</b>:    Istanbul Arel University;   Istanbul University - Cerrahpasa (IUC)<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05937971,2023-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
21,543876,2023-07-07 12:51:17.679124,"Mad Dog Cooking Class Series: Effects on Dietary Self-efficacy, Eating Behaviors and Health Outcomes","<b>Conditions</b>:    Spinal Cord Injuries;   Multiple Sclerosis;   Diet, Healthy;   Inflammation;   Depression;   Adherence, Treatment<br /><b>Intervention</b>:    Other: Mad Dog cooking class series<br /><b>Sponsor</b>:    Brock University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05934968,2023-06-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
22,543680,2023-07-06 15:00:58.688644,Exploring the Gut-Brain Axis in Ageing and Neurodegeneration,"<b>Conditions</b>:    Healthy;   Prodromal Alzheimer's Disease;   Parkinson Disease;   Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Magnetic Resonance Imaging;   Behavioral: Neuropsychological protocol;   Behavioral: Eating habits;   Diagnostic Test: Microbiome analyses;   Diagnostic Test: Inflammatory markers;   Diagnostic Test: Alzheimer's Disease biomarkers<br /><b>Sponsors</b>:    IRCCS San Camillo, Venezia, Italy;   IRCCS Centro San Giovanni di Dio Fatebenefratelli;   Università Ca' Foscari Venezia<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05934188,2023-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
23,543476,2023-07-05 13:10:52.169566,"Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis",<b>Conditions</b>:    Older Adults;   Multiple Sclerosis;   Cognitive Impairment;   Walking Impairment<br /><b>Interventions</b>:    Behavioral: Aerobic and Resistance Exercise Program (GEMS program);   Behavioral: Flexibility and Stretching Program (FLEX-MS program)<br /><b>Sponsor</b>:    University of Illinois at Chicago<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05930821,2023-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
24,543475,2023-07-05 13:10:52.122824,A Feasibility Pilot Study on Lee Silverman Voice Treatment-Loud: a Telerehabilitation Approach,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: LSVT-Loud delivered by telerehabilitation;   Other: LSVT-Loud in the clinic<br /><b>Sponsors</b>:    Fondazione Don Carlo Gnocchi Onlus;   Fondazione Italiana Sclerosi Multipla<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05930379,2023-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
25,542984,2023-07-03 15:10:48.181188,Aromatherapy With Lavender Essential Oil in Patients With Multiple Sclerosis,"<b>Conditions</b>:    Aromatherapy;   Randomized Controlled Trial;   Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: lavender oil<br /><b>Sponsor</b>:    Ataturk University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05929638,2023-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
26,542983,2023-07-03 15:10:48.168926,Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Diagnostic Test: blood tests drawn days 1, 8, 22 and 90 of the study<br /><b>Sponsors</b>:    Dignity Health Medical Foundation;   Dolly Roy MD PhD (author);   J. Michael Menke (statistician);   Sabeen Lulu MD (Principal Investigator)<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05926167,2023-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
27,542189,2023-06-30 08:11:20.894554,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, a...","<p>EudraCT Number: 2020-005117-41<br />Sponsor Protocol Number: ICP-CL-00112<br />Sponsor Name: InnoCare Pharma, Inc.<br />Start Date: 2021-06-30<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005117-41/PL"">PL</a> (Restarted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-005117-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
28,542038,2023-06-29 13:40:44.533303,A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS),<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05925049,2023-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
29,541497,2023-06-27 13:21:11.382794,Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Dietary Supplement: Vivomixx®;   Dietary Supplement: Conjugated linoleic acid (CLA/Tonalin® FFA 80);   Other: Maltose placebo;   Other: Sunflower oil placebo<br /><b>Sponsor</b>:    Westfälische Wilhelms-Universität Münster<br /><b>Not yet recruiting</b>",http://classic.clinicaltrials.gov/ct2/show/NCT05920018?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-06-27 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
30,540021,2023-06-22 14:20:45.157511,Smart Wearable Device (gaitQ): Walk Better Project,<b>Conditions</b>:    Parkinson Disease;   Stroke;   Multiple Sclerosis;   Osteoporosis;   Arthritis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    University of Exeter;   GaitQ company<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05913219,2023-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
31,540020,2023-06-22 14:20:45.125215,"EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)","<b>Conditions</b>:    Sclerosis, Multiple;   MS (Multiple Sclerosis);   Spastic;   Spasticity, Muscle;   Oxygen Consumption<br /><b>Intervention</b>:    Device: EXOPULSE Mollii Suit Stimulation<br /><b>Sponsor</b>:    Sheikh Shakhbout Medical City<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05912595,2023-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
32,539959,2023-06-22 09:00:48.000000,"A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of...","<p>EudraCT Number: 2021-000838-34<br />Sponsor Protocol Number: NOE-TSC-201<br />Sponsor Name: Noema Pharma<br />Start Date: 2023-05-30<br />Medical condition: Tuberous Sclerosis Complex<br />Disease: <br />Version: 21.0<br />SOC Term: 10010331 - Congenital, familial and genetic disorders<br />Classification Code: 10080584<br />Term: Tuberous sclerosis complex<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000838-34/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000838-34/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000838-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
33,539308,2023-06-18 16:00:47.877104,"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis",<b>Condition</b>:    Relapsing-remitting Multiple Sclerosis<br /><b>Interventions</b>:    Biological: CT-P53;   Biological: US-Ocrevus;   Biological: EU-Ocrevus<br /><b>Sponsor</b>:    Celltrion<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05906992,2023-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
34,538987,2023-06-15 16:30:41.328073,Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Cladribine 10 mg oral tablet<br /><b>Sponsors</b>:    Pontificia Universidade Católica do Rio Grande do Sul;   Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05902429,2023-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
35,538850,2023-06-13 15:40:48.333694,The Exopulse Mollii Suit Study - a Database for Routine Follow-up of Clinical Outcomes,<b>Conditions</b>:    Cerebral Palsy;   Multiple Sclerosis;   Stroke;   Spinal Cord Injuries;   Neurologic Disorder<br /><b>Intervention</b>:    Device: Exopulse Mollii Suit<br /><b>Sponsor</b>:    Exoneural Network AB<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05901259,2023-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
36,538638,2023-06-09 14:30:47.316641,Efficiency of Different Exercise Approaches in Individuals Providing Primary Care to MS,<b>Condition</b>:    Back Pain<br /><b>Interventions</b>:    Other: Pilates Exercise;   Other: Mckenzie Exercise<br /><b>Sponsor</b>:    Istanbul Medipol University Hospital<br /><b>Not yet recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT05896995?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-06-09 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
37,538637,2023-06-09 14:30:47.265514,Effectiveness of Powerball System in People With Multiple Sclerosis,"<b>Conditions</b>:    Neurologic Disorder;   Multiple Sclerosis<br /><b>Interventions</b>:    Device: NDS-Powerball®,;   Other: Conventional treatment<br /><b>Sponsor</b>:    Universidad Rey Juan Carlos<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05895734,2023-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
38,538542,2023-06-08 11:10:42.583956,"A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis","<p>EudraCT Number: 2006-002982-38<br />Sponsor Protocol Number: 27025<br />Sponsor Name: Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany<br />Start Date: 2006-11-29<br />Medical condition: Subjects at high risk of converting to Multiple Sclerosis<br />Disease: <br />Version: 9.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: <br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/LT"">LT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2006-002982-38,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
39,538435,2023-06-07 12:50:42.279113,Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration,"<b>Conditions</b>:    Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Metformin Hydrochloride 850 mg Oral Tablet;   Drug: Placebo<br /><b>Sponsors</b>:    University Hospital, Antwerp;   University Hospital, Ghent;   Hasselt University;   AZ Sint-Jan AV;   Noorderhart Pelt;   National MS Center Melsbroek<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05893225,2022-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
40,538285,2023-06-06 12:50:42.940754,MS Fatigue and tDCS on Fatigue in Multiple Sclerosis,<b>Condition</b>:    Fatigue in Multiple Sclerosis<br /><b>Interventions</b>:    Procedure: Real left prefrontal tDCS - sham;   Procedure: Sham - Real left prefrontal tDCS<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05890885?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-06-06 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
41,538128,2023-06-05 13:30:45.596685,Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Seated Physical activity INtervention for persons with MS, ""SPIN"" program- Intervention Condition;   Behavioral: Wellness for MS (WellMS)- Control Condition<br /><b>Sponsors</b>:    University of North Texas, Denton, TX;   University of Illinois at Chicago;   Craig Hospital;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05888727,2023-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
42,538100,2023-06-05 09:00:45.000000,"An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis or primary progressive multiple sclero...","<p>EudraCT Number: 2015-004616-37<br />Sponsor Protocol Number: ML29966<br />Sponsor Name: GENENTECH Inc.<br />Start Date: 2016-08-03<br />Medical condition: Relapsing Multiple Sclerosis (RMS)/Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004616-37/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004616-37/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2015-004616-37,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
43,536707,2023-06-01 13:20:47.096553,Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises,<b>Conditions</b>:    Multiple Sclerosis;   Ataxia<br /><b>Interventions</b>:    Device: paraspinal vibration;   Device: gastrosoleus muscle complex vibration;   Other: Control Exercise<br /><b>Sponsor</b>:    Hacettepe University<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05885282,2023-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
44,536280,2023-05-31 14:20:33.991777,Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability,<b>Conditions</b>:    Inflammation;   Spinal Cord Injuries;   Multiple Sclerosis;   Muscular Dystrophies;   Diet Habit<br /><b>Intervention</b>:    Behavioral: Mad Dog Dietary Consultation<br /><b>Sponsor</b>:    Brock University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05881122,2023-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
45,536279,2023-05-31 14:20:33.978062,Study to Evaluate the Maintenance of Efficacy When Transitioning From Anti-CD20 Therapy to Ublituximab (ENHANCE),"<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Biological: Ublituximab<br /><b>Sponsor</b>:    TG Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05877963,2023-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
46,535846,2023-05-30 12:40:45.850455,The Effect of the Level of Hand Fatigability on Multiple Sclerosis on General Fatigue and Functionality,<b>Conditions</b>:    Fatigue;   Functionality;   Multiple Sclerosis;   Dexterity<br /><b>Intervention</b>:    Diagnostic Test: Nine-Hole Peg Test (NHPT)<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05880745,2023-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
47,534031,2023-05-26 13:50:46.061145,The Neural Mechanisms of Split-belt Treadmill Adaptation in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Split-belt Treadmill;   Device: Transcutaneous Electrical Nerve Stimulation (TENS)<br /><b>Sponsors</b>:    Colorado State University;   National Multiple Sclerosis Society<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05878873,2023-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
48,532412,2023-05-23 14:30:46.161462,Exergaming With Immersive Virtual Reality For People With Multiple Sclerosis (ExeRVIEM),<b>Conditions</b>:    Multiple Sclerosis;   Physical Therapy;   Exercise;   Virtual Reality Exposure Therapy;   Rehabilitation<br /><b>Interventions</b>:    Other: ExeRVIEM Program;   Other: Usual center program<br /><b>Sponsors</b>:    University of Vigo;   Asociación Viguesa de Esclerosis Múltiple de Pontevedra<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05870254?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-05-23 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
49,529544,2023-05-18 13:20:41.601084,"A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis","<b>Conditions</b>:    Multiple Sclerosis;   MS;   Depression<br /><b>Intervention</b>:    Behavioral: MS CATCH<br /><b>Sponsors</b>:    University of California, San Francisco;   United States Department of Defense<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05865405,2023-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
50,528470,2023-05-16 13:10:48.397316,Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Dalfampridine Pill;   Drug: Placebo<br /><b>Sponsors</b>:    D'Youville College;   Acorda Therapeutics;   University at Buffalo<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05859802?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-05-16 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
51,526560,2023-05-12 14:50:44.286979,"EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)","<b>Conditions</b>:    Sclerosis, Multiple;   MS (Multiple Sclerosis);   Spasticity, Muscle;   Spastic<br /><b>Intervention</b>:    Device: EXOPULSE Mollii Suit Stimulation<br /><b>Sponsor</b>:    Sheikh Shakhbout Medical City<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05857280,2023-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
52,525906,2023-05-11 12:50:46.739961,"First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641",<b>Conditions</b>:    Autoimmune Diseases;   Multiple Sclerosis<br /><b>Intervention</b>:    Drug: LPX-TI641<br /><b>Sponsor</b>:    LAPIX Therapeutics Inc.<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05853835,2023-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
53,524393,2023-05-09 13:20:55.136460,Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy,<b>Conditions</b>:    Multiple Sclerosis;   Progressive Multifocal Leukoencephalopathy<br /><b>Intervention</b>:    Drug: 89 Zr-Df-crefmirlimab<br /><b>Sponsor</b>:    National Institute of Neurological Disorders and Stroke (NINDS)<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05849467,2023-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
54,523695,2023-05-08 14:21:16.571044,Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue,<b>Conditions</b>:    Multiple Sclerosis;   Fatigue<br /><b>Interventions</b>:    Behavioral: 4-week Relaxation Training;   Behavioral: 4-week Behavioral Activation;   Behavioral: 4-week Cognitive Therapy<br /><b>Sponsor</b>:    University of Washington<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05848323,2023-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
55,522232,2023-05-06 13:21:00.621615,Evaluation of the Microbiome in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: SIMBA Capsule<br /><b>Sponsors</b>:    Nimble Science Ltd.;   IGY Life Sciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05844826,2023-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
56,521405,2023-05-05 08:50:49.046409,An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis,"<p>EudraCT Number: 2019-003625-16<br />Sponsor Protocol Number: TG1101-RMS303<br />Sponsor Name: TG Therapeutics, Inc.<br />Start Date: 2020-04-15<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003625-16/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003625-16/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003625-16,2020-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
57,520895,2023-05-04 11:50:46.533561,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...","<p>EudraCT Number: 2019-001862-13<br />Sponsor Protocol Number: AB19001<br />Sponsor Name: ABScience<br />Start Date: 2020-03-12<br />Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/SE"">SE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/ES"">ES</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/IE"">IE</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/IT"">IT</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/GR"">GR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-001862-13,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
58,520204,2023-05-03 13:00:49.159044,The Effect of Telerehabilitation on Balance in People With Multiple Sclerosis,"<b>Condition</b>:    Telerehabilitation<br /><b>Interventions</b>:    Other: Individual telerehabilitation;   Other: Home exercises based on videos<br /><b>Sponsor</b>:    Charles University, Czech Republic<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05839977?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-05-02 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
59,520201,2023-05-03 13:00:49.147746,The Effect of Hope Placement Program on Diagnosed With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: psychotherapeutic intervention<br /><b>Sponsor</b>:    Ondokuz Mayıs University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05840653,2021-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
60,518846,2023-05-01 13:31:07.228529,Multiple Sclerosis Falls Insight Track,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: MS FIT: Falls Insight Track<br /><b>Sponsors</b>:    University of California, San Francisco;   National Institutes of Health (NIH);   National Library of Medicine (NLM)<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05837949,2023-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
61,516567,2023-04-28 13:20:45.004543,Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS,"<b>Conditions</b>:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases<br /><b>Intervention</b>:    Drug: Rituximab<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   Stichting Treatmeds<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05834855,2023-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
62,516561,2023-04-28 13:20:44.986728,Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    National MS Center Melsbroek<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05834335,2023-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
63,516558,2023-04-28 13:20:44.975650,Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Keeogo;   Other: adviced home practice<br /><b>Sponsor</b>:    Pôle Saint Hélier<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05835622,2023-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
64,515740,2023-04-27 13:31:05.160691,AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Fludarabine Phosphate for Injection<br /><b>Sponsor</b>:    St. Petersburg State Pavlov Medical University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05832515?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-04-27 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
65,514318,2023-04-25 13:20:47.927839,Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM),"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: S1PR analysis on immune cells<br /><b>Sponsor</b>:    University Hospital Inselspital, Berne<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05828901,2023-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
66,513470,2023-04-24 13:20:45.838063,Cubii for Exercise in People With MS,"<b>Conditions</b>:    Multiple Sclerosis;   Fatigue;   Activity, Motor;   Quality of Life<br /><b>Intervention</b>:    Device: Cubii elliptical<br /><b>Sponsor</b>:    University of Washington<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05826431,2023-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
67,513464,2023-04-24 13:20:45.823086,Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo,<b>Condition</b>:    Secondary Progressive Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05826028,2023-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
68,510847,2023-04-21 06:50:59.539607,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","<p>EudraCT Number: 2019-004857-10<br />Sponsor Protocol Number: GN41851<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-11-20<br />Medical condition: Relapsing multiple sclerosis (RMS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-004857-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
69,510276,2023-04-20 12:45:41.842907,Arm Swing During Walking in Early Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Upper Extremity Problem;   Gait Disorders, Neurologic<br /><b>Interventions</b>:    Other: Evaluation of the arm swing during gait;   Other: Functional Tests<br /><b>Sponsor</b>:    Istanbul University - Cerrahpasa (IUC)<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05821257,2023-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
70,509622,2023-04-19 17:43:35.240753,Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries,"<b>Conditions</b>:    Traumatic Brain Injury;   Stroke;   Multiple Sclerosis;   Parkinson Disease;   Epilepsy;   Brain Tumor<br /><b>Intervention</b>:    Diagnostic Test: Neuropsychological Assessment<br /><b>Sponsors</b>:    Umeå University;   Västerbotten County Council, Sweden<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05819008,2023-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
71,509610,2023-04-19 17:43:35.209483,Multiple Sclerosis and Fatigue Assessment,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    Asli Celik;   Gazi University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05820334,2023-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
72,508798,2023-04-18 13:00:51.083644,Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome,<b>Conditions</b>:    Multiple Sclerosis;   Radiologically Isolated Syndrome;   Epstein-Barr Virus<br /><b>Intervention</b>:    Other: NO INTERVENTION<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05815108?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-04-17 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
73,508790,2023-04-18 13:00:51.054591,MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: MSCopilot® mobile application<br /><b>Sponsor</b>:    Ad scientiam<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05816122,2023-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
74,508741,2023-04-18 10:31:39.182027,"Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T...","<p>EudraCT Number: 2020-003231-19<br />Sponsor Protocol Number: ViRap<br />Sponsor Name: The Children's Memorial Health Institute<br />Start Date: Information not available in EudraCT<br />Medical condition: Tuberous Sclerosis Complex
Epilepsy
Tumors associated with Tuberous Sclerosis Complex<br />Disease: <br />Population Age: Infants and toddlers, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003231-19/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003231-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
75,504716,2023-04-13 13:00:46.896594,Trabecular Bone Score in Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Endocrine System Diseases;   Neurologic Disorder<br /><b>Intervention</b>:    Diagnostic Test: sm tbs group<br /><b>Sponsor</b>:    IRCCS Centro Neurolesi ""Bonino-Pulejo""<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05811689?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-04-13 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
76,504714,2023-04-13 13:00:46.889232,A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,<b>Condition</b>:    Relapsing-remitting Multiple Sclerosis (RRMS)<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05811416,2023-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
77,504713,2023-04-13 13:00:46.885446,Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Device: Transcranial static magnetic field stimulation (tSMS);   Device: Sham Transcranial static magnetic field stimulation (tSMS)<br /><b>Sponsor</b>:    Neuromed IRCCS<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05811013,2023-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
78,504711,2023-04-13 13:00:46.874756,Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Dimethyl Fumarate 240 MG [Tecfidera]<br /><b>Sponsor</b>:    IRCCS Centro Neurolesi ""Bonino-Pulejo""<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05811949,2023-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
79,504548,2023-04-13 06:01:23.885672,"Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study","<p>EudraCT Number: 2018-000620-34<br />Sponsor Protocol Number: Imatinib-MS<br />Sponsor Name: Department of Clinical Neuroscience, Karolinska Institutet<br />Start Date: 2018-04-24<br />Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther...<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028247<br />Term: Multiple sclerosis like syndrome<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000620-34/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000620-34/DE"">DE</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-000620-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
80,504122,2023-04-12 13:20:45.817925,Feasibility and Safety of the 360-degree Turn Test Delivered Via Telehealth,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: 360-degree Turn Test;   Other: Expanded Disability Status Scale;   Other: Perceived Exertion<br /><b>Sponsor</b>:    Uskudar State Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05809505,2023-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
81,504121,2023-04-12 13:20:45.814266,Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Fatigue<br /><b>Interventions</b>:    Device: Transcranial Magnetic Stimulation;   Drug: Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule<br /><b>Sponsor</b>:    Hospital San Carlos, Madrid<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05809414,2023-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
82,504118,2023-04-12 13:20:45.801420,Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study,<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05809986,2023-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
83,503415,2023-04-11 13:20:47.667958,Gut Microbiome and Depression,<b>Conditions</b>:    Multiple Sclerosis;   Depression<br /><b>Intervention</b>:    Other: Neuro-QoL T-score determination<br /><b>Sponsors</b>:    Washington University School of Medicine;   University of Connecticut;   University of Texas<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05808101?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-04-11 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
84,502747,2023-04-10 12:50:44.717820,A Study of Imaging in Demyelinating Diseases,<b>Conditions</b>:    Multiple Sclerosis;   Inflammatory Demyelinating Disease<br /><b>Interventions</b>:    Drug: C-11 ER176 Radiotracer;   Drug: C11 Pittsburgh Compound B;   Diagnostic Test: PET/CT scan;   Diagnostic Test: MRI<br /><b>Sponsor</b>:    Mayo Clinic<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05805839,2023-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
85,501034,2023-04-07 12:40:54.269411,Muscle Vibration and Fatigue in Patients With MS,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: vibra plus<br /><b>Sponsor</b>:    IRCCS Centro Neurolesi ""Bonino-Pulejo""<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05783999,2023-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
86,499541,2023-04-05 12:50:49.531288,"A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial","<p>EudraCT Number: 2020-003874-30<br />Sponsor Protocol Number: MS700568_0158<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2021-02-03<br />Medical condition: Highly-active relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003874-30/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003874-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
87,498644,2023-04-04 12:40:53.740770,Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA),"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Mavenclad<br /><b>Sponsor</b>:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05797740,2023-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
88,498641,2023-04-04 12:40:53.727963,A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis,<b>Condition</b>:    Relapsing Forms of Multiple Sclerosis<br /><b>Interventions</b>:    Drug: BIIB091;   Drug: DRF;   Drug: Placebo<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05798520,2023-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
89,497738,2023-04-03 13:30:47.202183,An Observational Study of Patients Living With Chronic Neurological Diseases,"<b>Conditions</b>:    Neurological Diseases or Conditions;   Dementia of Alzheimer Type;   Alzheimer Disease;   Mild Cognitive Impairment;   Parkinson Disease;   Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Target PharmaSolutions, Inc.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05796037,2023-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
90,494609,2023-03-31 14:01:24.868533,Ukulele Playing to Improve Cognition in People With Multiple Sclerosis: A Feasibility Study,"<b>Conditions</b>:    Multiple Sclerosis;   Pathologic Processes;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases<br /><b>Interventions</b>:    Behavioral: Music Training Intervention;   Behavioral: Music Listening<br /><b>Sponsor</b>:    University of Texas at Austin<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05792176,2023-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
91,492838,2023-03-29 13:11:45.784861,Evaluation of a Self-management Program to Prevent Falls in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Fall prevention program;   Other: Brochure<br /><b>Sponsor</b>:    Karolinska Institutet<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05789225,2023-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
92,491899,2023-03-28 13:41:41.571487,Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Neuro-Degenerative Disease;   Aging<br /><b>Intervention</b>:    Other: No intervention<br /><b>Sponsors</b>:    Karolinska Institutet;   Karolinska University Hospital<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05787704,2023-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
93,491897,2023-03-28 13:41:41.566227,Identifying and Characterizing Preclinical MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: biological samples<br /><b>Sponsors</b>:    Yale University;   Roche-Genentech<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05787795,2023-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
94,491860,2023-03-28 12:20:47.153646,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Effic...","<p>EudraCT Number: 2016-001448-21<br />Sponsor Protocol Number: MS200527-0086<br />Sponsor Name: Merck KGaA<br />Start Date: 2017-02-16<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-001448-21,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
95,489900,2023-03-24 13:01:11.157720,Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: 18F-florbetaben PET/CT<br /><b>Sponsor</b>:    Istituti Clinici Scientifici Maugeri SpA<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05783934,2023-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
96,489370,2023-03-23 13:20:53.918133,A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    Celestra Health Systems;   University of Ottawa;   The Ottawa Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05781113,2023-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
97,488775,2023-03-22 13:20:41.409635,Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS,<b>Condition</b>:    Patient Participation<br /><b>Interventions</b>:    Dietary Supplement: Prebiotics and Probiotics supplementation;   Dietary Supplement: Placebo supplementation;   Procedure: peripheral blood withdrawal;   Procedure: Transcranial Magnetic Stimulation (TMS)<br /><b>Sponsors</b>:    Neuromed IRCCS;   I.R.C.C.S. Fondazione Santa Lucia<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05779449?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-22 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
98,488070,2023-03-21 13:00:54.730090,Mechanical Determinants of Upper Limbs Oscillation During Gait,<b>Conditions</b>:    Multiple Sclerosis;   Poststroke/CVA Hemiparesis;   Parkinson Disease;   Cerebral Palsy;   Amputation<br /><b>Interventions</b>:    Other: Healthy subjects;   Other: Pathologic group<br /><b>Sponsor</b>:    Istituto Auxologico Italiano<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05778474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
99,488062,2023-03-21 13:00:54.699587,Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Ozanimod Oral Capsule<br /><b>Sponsor</b>:    I.R.C.C.S. Fondazione Santa Lucia<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05777902?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
100,488061,2023-03-21 13:00:54.692173,"Determination of Compliance to Mediterranean Diet, Impacts on Walking and Quality of Life in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    University of Gaziantep<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05777629?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
101,487578,2023-03-20 17:40:48.917752,Diagnostic Value of eVOG,<b>Conditions</b>:    Multiple Sclerosis;   Radiologically Isolated Syndrome;   White Matter Lesions<br /><b>Intervention</b>:    Procedure: eVOG<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05776511,2023-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
102,487576,2023-03-20 17:40:48.910361,Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years,<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05776888,2023-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
103,487403,2023-03-20 09:00:55.265771,"Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial","<p>EudraCT Number: 2021-004791-34<br />Sponsor Protocol Number: BLOOMS<br />Sponsor Name: VU medical center<br />Start Date: 2022-03-16<br />Medical condition: Multiple sclerosis<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004791-34/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-004791-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
104,485713,2023-03-17 13:10:43.899977,Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): A randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis.,"<p>EudraCT Number: 2020-002981-15<br />Sponsor Protocol Number: DanNORMS<br />Sponsor Name: Danish Multiple Sclerosis Center, Rigshospitalet<br />Start Date: 2020-12-15<br />Medical condition: Multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002981-15/DK"">DK</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-002981-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
105,485075,2023-03-16 13:10:54.523340,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,<b>Condition</b>:    Overactive Bladder<br /><b>Intervention</b>:    Procedure: Repeated cystometries with bladder sensations assessment<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05772637?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-16 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
106,483864,2023-03-14 13:20:41.996891,A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Drug: Dimethyl Fumarate;   Drug: Disease-Modifying Therapies (DMTs)<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05767736,2023-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
107,480677,2023-03-09 13:50:42.458081,Czech Pharmaco-epidemiological Study on Disease Modifying Drugs,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab<br /><b>Sponsor</b>:    IMPULS Endowment Fund<br /><b>Completed</b>",https://clinicaltrials.gov/show/NCT05762003,2023-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
108,480049,2023-03-08 15:40:45.761255,Awareness of Osteoporosis in Multiple Sclerosis Patients,<b>Conditions</b>:    Multiple Sclerosis;   Osteoporosis;   Osteoporosis Risk<br /><b>Intervention</b>:    Other: Patient Participation Form<br /><b>Sponsor</b>:    Uskudar State Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05760651,2023-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
109,480043,2023-03-08 15:40:45.736206,"Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group","<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Anti-Mullerian hormone (AMH) level;   Other: Antral follicle count (AFC);   Other: Clinical assessment<br /><b>Sponsor</b>:    University Hospital, Bordeaux<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05754593,2023-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
110,479313,2023-03-07 14:30:48.449222,PURO - PUlmonary Rehabilitation With O-RAGT Platform,<b>Conditions</b>:    Multiple Sclerosis;   Spinal Cord Injury;   Stroke;   Traumatic Brain Damage<br /><b>Intervention</b>:    Device: UANGO suite exoskeleton<br /><b>Sponsors</b>:    Fondazione Don Carlo Gnocchi Onlus;   Roessingh Research and Development;   Hospital Nacional de Parapléjicos de Toledo;   Lithuanian University of Health Sciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05757830,2023-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
111,479303,2023-03-07 14:30:48.420176,RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.,<b>Conditions</b>:    Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Perfusion of treatment Rituximab;   Drug: Perfusion of treatment Ocrelizumab<br /><b>Sponsor</b>:    Rennes University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05758831,2023-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
112,478564,2023-03-06 14:00:44.891062,WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: GEMS Plus;   Behavioral: GEMS<br /><b>Sponsor</b>:    Kessler Foundation<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05755061?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-06 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
113,475659,2023-03-02 14:20:38.322417,"Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hasselt University<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05752630,2023-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
114,475630,2023-03-02 13:00:59.400210,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO
INVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS","<p>EudraCT Number: 2021-003772-14<br />Sponsor Protocol Number: GN43271<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-11-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-003772-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
115,473826,2023-02-28 11:30:48.818923,Pain in Neurorehabilitation Through Wearable Devices: an Exploratory Study,<b>Conditions</b>:    Pain;   Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: monitoring<br /><b>Sponsor</b>:    Azienda Usl di Bologna<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05747040,2023-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
116,473824,2023-02-28 11:30:48.813750,Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis,<b>Conditions</b>:    Healthy;   Multiple Sclerosis<br /><b>Intervention</b>:    Biological: Blood sample<br /><b>Sponsor</b>:    Centre Hospitalier Régional d'Orléans<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05746845,2023-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
117,473822,2023-02-28 11:30:48.808518,Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: quantification of sensory and autonomic small nerve fibers by punch skin biopsy;   Diagnostic Test: Cardiovascular Reflexes testing;   Other: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms<br /><b>Sponsor</b>:    Istituti Clinici Scientifici Maugeri SpA<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05748015?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-28 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
118,473819,2023-02-28 11:30:48.799803,The Impact of Interferon Beta 1a on Egyptian Relapse-Remitting Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood sample collection<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05735067,2023-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
119,470466,2023-02-23 13:50:46.069497,Reliability and Validity of Outcome Measures for Pain in Multiple Sclerosis,<b>Condition</b>:    Pain<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hasselt University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05742152?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-23 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
120,470464,2023-02-23 13:50:46.060988,Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Dietary Supplement: Nicotinamid riboside;   Dietary Supplement: Placebo<br /><b>Sponsor</b>:    Haukeland University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05740722,2023-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
121,469469,2023-02-21 14:11:14.728214,"High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Procedure: High-Intensity Treadmill Training;   Procedure: Treadmill Training with Perturbations;   Procedure: Standard Treadmill Training<br /><b>Sponsors</b>:    Marquette University;   Indiana University;   Medical College of Wisconsin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05735691?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-20 12:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
122,468988,2023-02-20 18:00:48.990340,Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning,"<p>EudraCT Number: 2005-003068-47<br />Sponsor Protocol Number: UROBOTOX 1<br />Sponsor Name: Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken<br />Start Date: 2005-09-22<br />Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003068-47/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2005-003068-47,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
123,467452,2023-02-17 14:21:17.227069,A Pilot Randomized Controlled Trial: CoINTEGRATE,<b>Conditions</b>:    Neurocognitive Disorders;   Cognitive Dysfunction;   Traumatic Brain Injury;   Multiple Sclerosis;   Mild Cognitive Impairment<br /><b>Interventions</b>:    Behavioral: CRT;   Behavioral: CBT;   Behavioral: Modifiable lifestyle factors;   Behavioral: Usual care Psychoeducation<br /><b>Sponsor</b>:    University of Michigan<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05732285,2023-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
124,466827,2023-02-16 13:50:49.867602,Dalfampridine in Egyptian Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;   Drug: Placebo<br /><b>Sponsor</b>:    Ain Shams University<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05730738,2021-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
125,465051,2023-02-13 14:20:51.092046,At-Home Gait Assessment,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    NYU Langone Health;   United States Department of Defense<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05724901,2023-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
126,463534,2023-02-10 19:10:47.052580,"A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label
Extension to Assess the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Effect on Disease Progression of BIIB105
...","<p>EudraCT Number: 2020-000207-36<br />Sponsor Protocol Number: 275AS101<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2020-11-18<br />Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10010331 - Congenital, familial and genetic disorders<br />Classification Code: 10052653<br />Term: Amyotrophic lateral sclerosis gene carrier<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000207-36/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000207-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
127,462197,2023-02-08 15:40:41.814791,Ultra-high-field Brain MRI in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Brain MRI (3T, 7T, 9.4T)<br /><b>Sponsors</b>:    Zuyderland Medisch Centrum;   Scannexus<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05718947,2023-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
128,461268,2023-02-07 01:20:40.481718,A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis,"<p>EudraCT Number: 2017-002631-42<br />Sponsor Protocol Number: MS700568_0022<br />Sponsor Name: Merck KGaA <br />Start Date: 2018-04-18<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-002631-42,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
129,461011,2023-02-06 13:47:37.569301,Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study,"<b>Conditions</b>:    Multiple Sclerosis;   Urinary Bladder, Overactive<br /><b>Interventions</b>:    Device: WeB;   Other: Standard pelvic floor physical therapy<br /><b>Sponsors</b>:    University of California, San Francisco;   National Multiple Sclerosis Society<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05715268,2023-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
130,461006,2023-02-06 13:47:37.556197,Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation;   Other: Home-based landscape observation with virtual-reality for upper limb rehabilitation<br /><b>Sponsors</b>:    IRCCS San Raffaele;   Istituto di Neuroscienze Consiglio Nazionale delle Ricerche<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05713890,2023-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
131,459539,2023-02-03 13:40:45.373603,"Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: 800g Challenge<br /><b>Sponsor</b>:    University of North Texas, Denton, TX<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05712408,2023-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
132,458148,2023-01-31 15:01:20.991586,Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis;   Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Eye tracking;   Diagnostic Test: Microperimetry;   Diagnostic Test: Optical coherence tomography (OCT);   Diagnostic Test: Visual processing speed test<br /><b>Sponsors</b>:    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Fundación Eugenio Rodríguez Pascual;   Hospital del Río Hortega<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05706220?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-31 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
133,458146,2023-01-31 15:01:20.985511,Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS),<b>Condition</b>:    Relapse Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood Draw<br /><b>Sponsor</b>:    Thomas Jefferson University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05705986?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-31 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
134,457773,2023-01-30 14:42:42.738076,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: RO7121932<br /><b>Sponsor</b>:    Hoffmann-La Roche<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05704361,2023-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
135,456540,2023-01-27 16:47:09.042140,The 'Wearing Off' Effect of DMT,,https://clinicaltrials.gov/show/NCT05627271,2022-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
136,456472,2023-01-27 14:10:49.062160,A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05701423,2023-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
137,455969,2023-01-26 14:20:45.348870,Multiple Sclerosis and Respiratory and Functional Capacity,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test<br /><b>Sponsors</b>:    Nigde Omer Halisdemir University;   Pamukkale University<br /><b>Completed</b>",https://clinicaltrials.gov/show/NCT05697523,2023-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
138,454477,2023-01-23 13:40:48.110763,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...","<p>EudraCT Number: 2010-020315-36<br />Sponsor Protocol Number: WA21093<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2011-10-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/CZ"">CZ</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020315-36,,17,,17,WHO XML import,https://trialsearch.who.int/
139,453260,2023-01-20 09:47:09.794479,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT04486716,2020-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
140,452970,2023-01-19 13:40:49.701276,Cognitive Reserve-building Activities in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Cognitive Leisure Activities<br /><b>Sponsors</b>:    Rigshospitalet, Denmark;   University of Copenhagen<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05691192,2023-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
141,452592,2023-01-18 14:20:48.914198,A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Biological: Alemtuzumab;   Drug: Fingolimod;   Drug: Glatiramer acetate;   Biological: Interferon beta;   Biological: Natalizumab;   Biological: Ocrelizumab;   Biological: Peginterferon beta-1a;   Drug: Siponimod<br /><b>Sponsor</b>:    Biogen<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05688436,2023-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
142,452482,2023-01-18 07:47:08.577111,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,,https://clinicaltrials.gov/ct2/show/NCT04667949,2020-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
143,452191,2023-01-17 13:40:47.568125,Multiple Sclerosis Prediction and Monitoring of Progression Study,"<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Device: Bytelfies kit - sensor dot<br /><b>Sponsors</b>:    University Hospital, Ghent;   University Ghent;   Byteflies<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05685784?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-16 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
144,450990,2023-01-13 13:40:49.376847,"Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Other: NeuroQuant;   Other: Automated Neuropsychological Assessment Matrices;   Other: EDSS;   Other: Physical Examination<br /><b>Sponsor</b>:    George Washington University<br /><b>Completed</b>",https://clinicaltrials.gov/show/NCT05684016,2015-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
145,450755,2023-01-12 14:21:20.036202,Efficacy of Square- Stepping Exercises in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Square Step Exercises Program;   Other: Home Exercise Program<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05682963,2022-12-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
146,448739,2023-01-04 13:51:09.887364,"Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Procedure: Controlled combined exercise group;   Procedure: Conventional rehabilitation<br /><b>Sponsor</b>:    University Hospital Ostrava<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05671588,2022-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
147,448738,2023-01-04 13:51:09.884242,CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Custom study version of icompanion app<br /><b>Sponsor</b>:    icometrix<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05671055,2022-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
148,448311,2023-01-03 09:40:59.539622,"Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...","<p>EudraCT Number: 2007-006338-32<br />Sponsor Protocol Number: WA21493<br />Sponsor Name: Hoffman La Roche Ltd<br />Start Date: 2008-05-06<br />Medical condition: Relapsing remitting multiple sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006338-32,,17,,17,WHO XML import,https://trialsearch.who.int/
149,443239,2022-12-24 12:33:08.200346,Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study,Condition:    Secondary Progressive Multiple Sclerosis With Inflammatory Disease ActivityIntervention:    Other: SiponimodSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04895202,2021-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
150,442545,2022-12-23 13:30:50.591339,An Observational Biomarker Study in Multiple Sclerosis (MS) Patients,"<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    LAPIX Therapeutics Inc.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05663853,2022-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
151,442543,2022-12-23 13:30:50.586314,Validity and Reliability of Lower Extremity Position Test in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Sensory Impairments, Proprioception, Validity, Reliability<br /><b>Intervention</b>:    Diagnostic Test: Lower extremity position test<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05663541,2022-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
152,441839,2022-12-22 13:40:50.276553,Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Eye-Tracking<br /><b>Sponsor</b>:    Innodem Neurosciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05661266,2022-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
153,441035,2022-12-21 13:41:10.668762,A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05658601,2022-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
154,441033,2022-12-21 13:41:10.661311,VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS),"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Multiple Sclerosis Clinical Care Delivery<br /><b>Sponsors</b>:    The Cleveland Clinic;   University of California, San Francisco;   University of Washington<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05660187,2022-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
155,440325,2022-12-20 13:50:47.658084,Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Drug: Avonex;   Biological: Tysabri;   Drug: Dimethyl Fumarate<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05658497,2022-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
156,440322,2022-12-20 13:50:47.652801,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Dimethyl fumarate<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05658484,2022-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
157,440234,2022-12-20 10:30:42.669915,"PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FO...","<p>EudraCT Number: 2019-003607-35<br />Sponsor Protocol Number: C0221002<br />Sponsor Name: Pfizer Inc.<br />Start Date: 2020-10-26<br />Medical condition: Focal Segmental Glomerulosclerosis (FSGS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10038359 - Renal and urinary disorders<br />Classification Code: 10067757<br />Term: Focal segmental glomerulosclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003607-35,,17,,17,WHO XML import,https://trialsearch.who.int/
158,437647,2022-12-16 13:52:31.855338,Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects,<b>Condition</b>:    Vitamin d Deficiency<br /><b>Interventions</b>:    Drug: Vitamin D;   Drug: Placebo<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05654818?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-16 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
159,436950,2022-12-15 12:40:57.014223,"A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero...","<p>EudraCT Number: 2016-003100-30<br />Sponsor Protocol Number: EFC13429<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2017-04-04<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 19.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/ES"">ES</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PT"">PT</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BE"">BE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BG"">BG</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/3rd"">Outside EU/EEA</a>, <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PL"">PL</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003100-30,,17,,17,WHO XML import,https://trialsearch.who.int/
160,436537,2022-12-14 14:10:44.983240,Silent Progression Activity Monitoring - SPAM Study,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: NO INTERVENTION<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05650281,2022-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
161,436100,2022-12-13 13:50:56.957492,"The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis","<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Healthy Controls<br /><b>Intervention</b>:    Behavioral: Neuropsychological tests and psychological questionnaires<br /><b>Sponsors</b>:    Centre d'Investigation Clinique et Technologique 805;   University Paris 8 Vincennes Saint Denis;   ARSEP foundation<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05648292,2022-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
162,434400,2022-12-09 14:21:13.617512,Nomad P-KAFO Study,"<b>Conditions</b>:    Cerebrovascular Accident;   Post-polio Syndrome;   Spinal Cord Injuries;   Multiple Sclerosis;   Muscular Dystrophy;   Paralysis<br /><b>Intervention</b>:    Device: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)<br /><b>Sponsor</b>:    Shirley Ryan AbilityLab<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05644522,2022-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
163,433982,2022-12-08 14:20:46.612312,The Reliability and Validity of the L-test in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: L test;   Other: Timed Up and Go test;   Other: 10 meter walk test;   Other: Six Minute Walk Test;   Other: The timed 360° turn test<br /><b>Sponsor</b>:    Gazi University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05641714,2022-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
164,433759,2022-12-07 23:25:07.521692,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,,https://clinicaltrials.gov/ct2/show/NCT04667117,2020-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
165,433600,2022-12-07 14:32:28.633066,Physical Activity in Persons Newly Diagnosed With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Behavioral: Physical activity behavioral intervention in persons newly diagnosed with MS<br /><b>Sponsor</b>:    University of Alabama at Birmingham<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05641532,2022-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
166,433247,2022-12-06 15:04:19.709460,The Effect of Augmented Reality Based Telerehabilitation Application on Neuromuscular and Sensorimotor Parameters in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Augmented Reality Based Telerehabilitation Application;   Other: Training face-to-face<br /><b>Sponsor</b>:    Ankara Yildirim Beyazıt University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05639517,2022-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
167,431629,2022-12-02 15:20:34.418148,A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,<b>Conditions</b>:    Age-Related Macular Degeneration;   Allergies;   Alpha-Gal Syndrome;   Alzheimer Disease;   Amyloidosis;   Ankylosing Spondylitis;   Arthritis;   Alopecia Areata;   Asthma;   Atopic Dermatitis;   Autism;   Autoimmune Hepatitis;   Behcet's Disease;   Beta-Thalassemia;   Cancer;   Celiac Disease;   Kidney Diseases;   COPD;   Crohn Disease;   Cystic Fibrosis;   Diabetes;   Dravet Syndrome;   DMD;   Fibromyalgia;   Graves Disease;   Thyroid Diseases;   Hepatitis;   Hidradenitis Suppurativa;   ITP;   Leukemia;   ALS;   Lupus or SLE;   Lymphoma;   Multiple Sclerosis;   Myasthenia Gravis;   Heart Diseases;   Parkinson Disease;   Pemphigus Vulgaris;   Cirrhosis;   Psoriasis;   Schizophrenia;   Scleroderma;   Sickle Cell Disease;   Stroke;   Ulcerative Colitis;   Vasculitis;   Vitiligo<br /><b>Intervention</b>:    Diagnostic Test: Specimen sample<br /><b>Sponsor</b>:    Sanguine Biosciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05635266,2022-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
168,431628,2022-12-02 15:20:34.416494,Kesimpta (Ofatumumab) Pregnancy Registry,<b>Conditions</b>:    Multiple Sclerosis;   Pregnancy<br /><b>Intervention</b>:    Other: Kesimpta<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05634967,2022-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
169,431626,2022-12-02 15:20:34.412534,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,<b>Condition</b>:    Vestibular Rehabilitation in MS<br /><b>Interventions</b>:    Other: Cawthorne Cooksey exercise protocol;   Other: conventional vestibular rehabilitation<br /><b>Sponsor</b>:    October 6 University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05635890?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-02 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
170,431620,2022-12-02 15:20:34.400246,Disability Level and Trunk Control in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Assessment<br /><b>Sponsors</b>:    Hacettepe University;   Bandırma Onyedi Eylül University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05634993,2022-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
171,431375,2022-12-01 15:16:35.846814,Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05633875,2022-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
172,431188,2022-11-30 16:42:07.943009,Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.,<b>Condition</b>:    Chronic Migraine; Multiple Sclerosis; Motoneuron Disease<br /><b>Intervention</b>:    Other: no comparator - TAU (Treatment-as-usual)<br /><b>Sponsor</b>:    Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05623254,2022-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
173,431008,2022-11-29 13:50:55.520797,A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: SAR443820;   Other: Placebo<br /><b>Sponsor</b>:    Sanofi<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05630547,2022-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
174,430181,2022-11-25 14:50:51.915053,Sunlight-mediated Inter-organ Leukocyte Exchange,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: 311 nm narrowband UVB irradiation<br /><b>Sponsor</b>:    University Hospital Muenster<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05627609,2022-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
175,428981,2022-11-18 14:10:45.500399,OFSEP Very High Definition Cohort,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsor</b>:    EDMUS Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05622643,2022-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
176,427945,2022-11-14 13:29:35.166945,The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis,<b>Conditions</b>:    Falls;   Motor Imagery;   Multiple Sclerosis;   Balance;   Fatigue<br /><b>Intervention</b>:    Other: Motor Imagery as compared to physical practice for balance tasks<br /><b>Sponsor</b>:    Dominican University of New York<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05615207,2022-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
177,427943,2022-11-14 13:29:35.160973,Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis,"<b>Conditions</b>:    Erectile Dysfunction Due to Diseases Classified Elsewhere;   Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Device: bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).;   Device: placebo BEMER<br /><b>Sponsor</b>:    Imam Abdulrahman Bin Faisal University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05615454,2022-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
178,426577,2022-11-09 13:22:21.097464,Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Clinical assessment;   Other: Classical cognitive evaluation of several domains:;   Other: Ecological evaluation;   Behavioral: Patent reported outcomes (PRO's);   Other: Telerehabilitation : active procedure;   Other: Telerehabilitation : comparator procedure<br /><b>Sponsors</b>:    University Hospital, Bordeaux;   Celgene<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05611047,2022-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
179,426374,2022-11-09 00:15:47.456296,Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies,,https://clinicaltrials.gov/ct2/show/NCT05566756,2022-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
180,423964,2022-11-04 13:00:15.542187,Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve,"<b>Conditions</b>:    Demyelinating Diseases;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder Attack;   Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease;   Optic Neuritis<br /><b>Intervention</b>:    Other: non-interventional study<br /><b>Sponsor</b>:    Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05605951,2022-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
181,423961,2022-11-04 13:00:15.536060,"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05605782,2022-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
182,423441,2022-11-03 13:00:16.745266,"Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS","<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures);   Other: Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)<br /><b>Sponsor</b>:    Assiut University<br /><b>Completed</b>",https://clinicaltrials.gov/show/NCT05604092,2022-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
183,422154,2022-11-01 06:30:17.217248,Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis,"<p>EudraCT Number: 2014-005129-10<br />Sponsor Protocol Number: Elovaara09112014<br />Sponsor Name: Irina Elovaara<br />Start Date: 2015-01-27<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 17.1<br />SOC Term: 100000004852<br />Classification Code: 10064137<br />Term: Progression of multiple sclerosis<br />Level: LLT<br />Version: 17.1<br />SOC Term: 100000004852<br />Classification Code: 10070425<br />Term: Multiple sclerosis exacerbation<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005129-10/FI"">FI</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005129-10,,17,,17,WHO XML import,https://trialsearch.who.int/
184,418050,2022-10-28 12:45:13.649755,"Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain","<b>Conditions</b>:    Multiple Sclerosis;   Spasticity, Muscle;   Pain<br /><b>Intervention</b>:    Device: FlowOx 2.0<br /><b>Sponsor</b>:    Otivio AS<br /><b>Enrolling by invitation</b>",https://clinicaltrials.gov/show/NCT05598736,2022-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
185,416680,2022-10-27 13:47:00.076321,Safety and Efficacy Study of Fingolimod in Taiwanese Adults (= 20years) With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04480853,2020-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
186,416599,2022-10-27 12:30:18.003110,Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients,<b>Conditions</b>:    Shingles;   Zoster<br /><b>Intervention</b>:    Biological: recombinant zoster vaccine<br /><b>Sponsor</b>:    Prof Patrice Lalive<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05596526?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-27 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
187,412930,2022-10-25 08:00:17.576790,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2017-004703-51<br />Sponsor Protocol Number: COMB157G2399<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-01-10<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-004703-51,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
188,412442,2022-10-25 00:40:14.485582,"AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...","<p>EudraCT Number: 2016-002667-34<br />Sponsor Protocol Number: WA39085<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-03-06<br />Medical condition: Relapsing-remitting multiple sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002667-34,,17,,17,WHO XML import,https://trialsearch.who.int/
189,412421,2022-10-25 00:15:18.515701,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-
Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy
and Safety of BG00012 and BIIB017 ...","<p>EudraCT Number: 2018-000516-22<br />Sponsor Protocol Number: 800MS301<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-07-08<br />Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/PT"">PT</a> (Not Authorised), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/EE"">EE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/HU"">HU</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000516-22,,17,,17,WHO XML import,https://trialsearch.who.int/
190,407407,2022-10-21 12:25:18.740122,Turkish Version of F-2-MS,"<b>Conditions</b>:    Cultural Adaptation;   Reliability;   Validity;   Multiple Sclerosis;   Fatigue<br /><b>Intervention</b>:    Other: Cultural adaptation, reliability and validity<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05590533,2022-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
191,404355,2022-10-19 12:50:08.887350,Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Neurogenic Bladder<br /><b>Interventions</b>:    Diagnostic Test: Urodynamic Study (Filling cystometry and pressure-flow study);   Diagnostic Test: Questionnaires;   Diagnostic Test: Uroflowmetry<br /><b>Sponsor</b>:    Koç University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05587101,2022-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
192,404354,2022-10-19 12:50:08.884841,Teleassessment in Ataxic Multiple Sclerosis,<b>Conditions</b>:    Ataxia;   Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hacettepe University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05585541,2022-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
193,403105,2022-10-17 17:35:19.146681,"A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101","<p>EudraCT Number: 2022-000253-92<br />Sponsor Protocol Number: EHP-101-MS02<br />Sponsor Name: Emerald Health Pharmaceuticals Inc.<br />Start Date: 2022-10-14<br />Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000253-92/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000253-92,,17,,17,WHO XML import,https://trialsearch.who.int/
194,401170,2022-10-14 12:55:15.648650,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   High-Intensity Interval Training;   Motor Symptoms<br /><b>Interventions</b>:    Behavioral: HIIT;   Behavioral: MCT<br /><b>Sponsor</b>:    Klinik Valens<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05562414,2022-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
195,400545,2022-10-13 15:57:03.370462,Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatunumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05576779,2022-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
196,400302,2022-10-13 06:40:18.064662,"Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers...","<p>EudraCT Number: 2020-004431-24<br />Sponsor Protocol Number: 67896153MSC3001<br />Sponsor Name: Janssen-Cilag International NV<br />Start Date: 2022-09-30<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/SE"">SE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004431-24,,17,,17,WHO XML import,https://trialsearch.who.int/
197,399851,2022-10-12 12:05:13.557013,Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®,"<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Interventions</b>:    Other: Neurostatus-SMARTCARE;   Other: Standard Neurostatus-EDSS<br /><b>Sponsors</b>:    University Hospital, Basel, Switzerland;   Novartis Pharma AG, Basel, Switzerland<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05575843,2022-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
198,397230,2022-10-07 13:05:19.200393,Effect of Arm Ergometer Exercise Training on Upper Extremity Function in People With Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: exercise<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05571631,2022-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
199,397229,2022-10-07 13:05:19.193478,Effectiveness of Telerehabilitation Interventions in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: telerehabilitation<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05571826,2022-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
200,394699,2022-10-03 13:45:16.832507,"""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis""",<b>Conditions</b>:    Multiple Sclerosis;   Ataxia;   Paraplegia<br /><b>Intervention</b>:    Device: Atalante<br /><b>Sponsor</b>:    Multiple Sclerosis Center of Catalonia<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05563402,2022-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
201,392448,2022-09-30 12:40:12.831847,Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers,"<b>Condition</b>:    Multiple Sclerosis, Vocal Biomarkers, Non Motor Symptoms<br /><b>Intervention</b>:    Other: Voice analysis<br /><b>Sponsors</b>:    University Hospital Inselspital, Berne;   AUDEERING GMBH<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05561621,2022-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
202,392446,2022-09-30 12:40:12.826069,Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain,"<b>Conditions</b>:    Multiple Sclerosis;   Spasticity, Muscle;   Pain, Chronic<br /><b>Interventions</b>:    Device: FlowOx 2.0;   Device: FlowOx2.0 (Sham)<br /><b>Sponsor</b>:    Otivio AS<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05562453,2022-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
203,391648,2022-09-29 12:35:19.146318,The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: a-tDCS<br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05560139,2022-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
204,391460,2022-09-29 06:05:13.299425,The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus,"<p>EudraCT Number: 2021-001144-98<br />Sponsor Protocol Number: LUB-COV-2021-01<br />Sponsor Name: Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie<br />Start Date: 2021-04-20<br />Medical condition: SARS-CoV-2 infection with one or more of the following symptoms: fever, cough, muscle aches, mild breathlessness, chest pain, diarrhea, nausea, vomiting, anosmia, lack of taste, sore throat, nasal ...<br />Disease: <br />Version: 23.1<br />SOC Term: 100000004848<br />Classification Code: 10084355<br />Term: COVID-19 virus test positive<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001144-98/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001144-98,,17,,17,WHO XML import,https://trialsearch.who.int/
205,391452,2022-09-29 06:05:13.287465,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...","<p>EudraCT Number: 2012-003176-39<br />Sponsor Protocol Number: 205MS303<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2013-05-31<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003176-39,,17,,17,WHO XML import,https://trialsearch.who.int/
206,391003,2022-09-28 14:15:14.249469,Effect of the Vojta Therapy in Patients Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Randomized clinical trial.<br /><b>Sponsors</b>:    Aymara Abreu Corrales;   University of Salamanca<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05558683,2022-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
207,388063,2022-09-23 12:25:18.584554,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...","<p>EudraCT Number: 2019-003919-53<br />Sponsor Protocol Number: GN41791<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-12-17<br />Medical condition: Primary Progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003919-53,,17,,17,WHO XML import,https://trialsearch.who.int/
208,385651,2022-09-19 13:30:17.667371,EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis,<b>Condition</b>:    Cognitive Change<br /><b>Intervention</b>:    Behavioral: EMRESERVA<br /><b>Sponsor</b>:    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05546424?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-19 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
209,384566,2022-09-17 16:52:59.582237,A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT05334472,2022-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
210,384166,2022-09-17 00:10:14.971105,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...","<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV"">LV</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001341-40,,17,,17,WHO XML import,https://trialsearch.who.int/
211,383892,2022-09-16 14:10:13.594162,"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases",<b>Conditions</b>:    Autoimmune Diseases;   Inflammatory Disease;   Acquired Bone Marrow Aplasia;   Systemic Lupus Erythematosus;   Multiple Sclerosis;   Gvhd;   Rheumatoid Arthritis;   Autoimmune Thyroiditis;   Vitiligo;   Alopecia;   Atopic Dermatitis<br /><b>Intervention</b>:    Other: Blood sample taken at a single time point<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05544448,2022-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
212,383890,2022-09-16 14:10:13.588187,Cognitive Markers in Prodromal MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Active tDCS<br /><b>Sponsors</b>:    NYU Langone Health;   National Multiple Sclerosis Society<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05543915,2022-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
213,383885,2022-09-16 14:10:13.573490,The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Action Observation Therapy<br /><b>Sponsor</b>:    Shiraz University of Medical Sciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05543213,2022-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
214,383310,2022-09-15 10:45:15.934300,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,<b>Conditions</b>:    Multiple Sclerosis;   Reflexology;   Urinary Incontinence<br /><b>Intervention</b>:    Other: Reflexology and kegel exercises<br /><b>Sponsor</b>:    Ondokuz Mayıs University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05541965,2022-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
215,382897,2022-09-14 15:35:19.909417,Vancomycin Study in Multiple Sclerosis (MS),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Vancomycin;   Drug: Placebo<br /><b>Sponsors</b>:    Icahn School of Medicine at Mount Sinai;   Doris Duke Charitable Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05539729,2022-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
216,380247,2022-09-09 15:00:11.488291,DECISIve - DiagnosE Using the Central veIn SIgn v1.0,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Lumbar puncture;   Diagnostic Test: MRI<br /><b>Sponsor</b>:    Nottingham University Hospitals NHS Trust<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05533905,2022-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
217,379693,2022-09-08 13:20:18.373479,A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05532163,2022-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
218,379691,2022-09-08 13:20:18.369338,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Allogeneic umbilical cord mesenchymal stem cells;   Biological: Control group<br /><b>Sponsor</b>:    Ever Supreme Bio Technology Co., Ltd.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05532943,2022-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
219,379244,2022-09-07 14:40:13.228894,High Intensity Interval Gait Training in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis,Gait, Exercise<br /><b>Interventions</b>:    Behavioral: Moderate paced continuous gait training;   Behavioral: High Intensity Interval gait training<br /><b>Sponsor</b>:    City University of New York<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05529498,2022-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
220,378779,2022-09-06 14:55:13.287943,Risk Perception in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: High Efficacy Therapy (HET);   Other: Non High Efficacy Therapy (Non-HET)<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05528666,2022-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
221,376552,2022-09-02 15:55:22.461574,Effects of Dual-Task Training in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Dual-Task Training;   Other: Home Exercise Program<br /><b>Sponsor</b>:    Ege University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05526287,2022-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
222,375907,2022-09-01 12:35:18.990114,A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®,"<p>EudraCT Number: 2017-002632-17<br />Sponsor Protocol Number: MS700568_0021<br />Sponsor Name: Merck KGaA<br />Start Date: 2018-01-30<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002632-17,,17,,17,WHO XML import,https://trialsearch.who.int/
223,375273,2022-08-31 14:55:12.096764,Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Acupuncture Active;   Other: Acupuncture Sham<br /><b>Sponsor</b>:    University of Sao Paulo<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05523466,2022-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
224,374738,2022-08-30 19:15:12.856445,"Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TSQ","<b>Condition</b>:    Neurological Disease<br /><b>Intervention</b>:    Other: Development of the Telerehabilitation Satisfaction Questionnaire<br /><b>Sponsor</b>:    Gazi University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05520554?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-30 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
225,373795,2022-08-29 12:20:12.112100,Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-remitting<br /><b>Intervention</b>:    Other: Peer support<br /><b>Sponsor</b>:    Nantes University Hospital<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05519553,2022-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
226,370859,2022-08-25 12:45:08.900676,"A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...","<p>EudraCT Number: 2018-002145-11<br />Sponsor Protocol Number: 101MS329<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-03-21<br />Medical condition: Relapsing-remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002145-11,,17,,17,WHO XML import,https://trialsearch.who.int/
227,370808,2022-08-25 11:05:08.383517,"Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Guidelines for Exercise in Multiple Sclerosis (GEMS);   Behavioral: FLEX Stretching and Toning Program<br /><b>Sponsors</b>:    University of Illinois at Chicago;   University of Alabama at Birmingham;   Bristol-Myers Squibb Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05516537,2022-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
228,370807,2022-08-25 11:05:08.380598,Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Genetic: Genetic polymorphism;   Diagnostic Test: Measurement of fingolimod and fingolimod-phosphate concentrations<br /><b>Sponsor</b>:    University Hospital, Caen<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05516303?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-25 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
229,369103,2022-08-23 06:00:10.564226,"An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...","<p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE"">SE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI"">FI</a> (Restarted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000826-22,,17,,17,WHO XML import,https://trialsearch.who.int/
230,368478,2022-08-22 12:55:10.890711,Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Other: Multiparametric assessment<br /><b>Sponsors</b>:    University Hospital of Mont-Godinne;   Saint-Luc University Hospital<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05510817?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-22 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
231,368474,2022-08-22 12:55:10.884001,Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Cognitive Rehabilitation<br /><b>Sponsors</b>:    University of Nottingham;   MS Society;   University of Lincoln<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05509426,2022-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
232,364489,2022-08-17 12:50:07.394575,"A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...","<p>EudraCT Number: 2015-000922-12<br />Sponsor Protocol Number: TV44400-CNS-40083<br />Sponsor Name: Teva Pharmaceutical Industries, Ltd<br />Start Date: 2016-01-04<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 18.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000922-12,,17,,17,WHO XML import,https://trialsearch.who.int/
233,364474,2022-08-17 12:50:07.035462,"The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Exercise training<br /><b>Sponsors</b>:    Saglik Bilimleri Universitesi;   Ankara University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05505383?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-17 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
234,364469,2022-08-17 12:15:16.361992,"Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years","<p>EudraCT Number: 2014-005003-24<br />Sponsor Protocol Number: 109MS202<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2015-06-01<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 17.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 17.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/BE"">BE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005003-24,,17,,17,WHO XML import,https://trialsearch.who.int/
235,363697,2022-08-16 11:20:12.715644,A Measurement Study of TIS-modNV and AccuGait Force Platform in People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    Nordlandssykehuset HF;   Nord University;   Helse Nord<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05503628?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-16 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
236,363692,2022-08-16 11:20:12.701964,Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Power Life Sciences Inc.<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05503524,2022-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
237,363672,2022-08-16 10:15:16.351517,"A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY...","<p>EudraCT Number: 2012-002714-40<br />Sponsor Protocol Number: RPC01-201<br />Sponsor Name: Receptos, Inc.<br />Start Date: 2013-05-09<br />Medical condition: RELAPSING MULTIPLE SCLEROSIS<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002714-40,,17,,17,WHO XML import,https://trialsearch.who.int/
238,362944,2022-08-15 10:45:08.852519,Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Transcutaneous electrical nerve stimulation<br /><b>Sponsor</b>:    University of Colorado, Boulder<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05500963,2022-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
239,361659,2022-08-13 12:42:11.120527,Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis,"<p>EudraCT Number: 2021-003677-66<br />Sponsor Protocol Number: RESTORE<br />Sponsor Name: Amsterdam University Medical Center<br />Start Date: 2022-02-14<br />Medical condition: Multiple sclerosis (MS)
Internuclear ophthalmoparesis (INO)<br />Disease: <br />Version: 21.0<br />SOC Term: 100000004852<br />Classification Code: 10080865<br />Term: Multiple sclerosis lesion<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003677-66/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003677-66,,17,,17,WHO XML import,https://trialsearch.who.int/
240,361454,2022-08-13 04:12:37.212398,Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China,,https://clinicaltrials.gov/ct2/show/NCT05199571,2022-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
241,360541,2022-08-11 12:55:08.944779,A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,"<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Mitoxantrone Hydrochloride Liposome Injection<br /><b>Sponsor</b>:    CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05496894,2022-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
242,360540,2022-08-11 12:55:08.935585,Exercise Effects in Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Other: Exercise Group 1;   Other: Exercise Group 2;   Other: Exercise Group 3<br /><b>Sponsors</b>:    University of Regina;   First Steps Wellness Centre;   Saskatchewan Health Research Foundation;   University of Saskatchewan<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05496881,2022-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
243,360050,2022-08-10 08:48:55.200584,Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf,,https://clinicaltrials.gov/ct2/show/NCT05266469,2022-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
244,360049,2022-08-10 08:48:55.199298,"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.",,https://clinicaltrials.gov/ct2/show/NCT05084638,2021-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
245,359663,2022-08-09 12:40:08.602077,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2018-001511-73<br />Sponsor Protocol Number: WA40404<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2019-12-23<br />Medical condition: <br />Disease: <br />Population Age: <br />Gender: <br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001511-73,,17,,17,WHO XML import,https://trialsearch.who.int/
246,359658,2022-08-09 12:40:08.319270,Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System,<b>Conditions</b>:    Multiple Sclerosis;   Stroke;   Parkinson Disease;   Acquired Brain Injury<br /><b>Intervention</b>:    Device: Robotic Assisted Gait Training with G-EO system<br /><b>Sponsor</b>:    Fondazione Don Carlo Gnocchi Onlus<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05493514?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-09 12:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
247,359450,2022-08-09 00:30:12.873049,A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),"<p>EudraCT Number: 2016-001166-29<br />Sponsor Protocol Number: inims-009<br />Sponsor Name: University Medical Centre Hamburg-Eppendorf<br />Start Date: 2020-03-18<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001166-29/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001166-29,2019-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
248,359260,2022-08-08 11:25:14.909900,MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Magnetic Resonance Spectroscopy<br /><b>Intervention</b>:    Other: magnetic resonance spectroscopy<br /><b>Sponsor</b>:    Poitiers University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05491031,2022-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
249,357196,2022-08-01 14:05:08.992058,Common and Specific Information From Neuroimaging and Smartphone,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: eGait<br /><b>Sponsors</b>:    Nantes University Hospital;   Rennes University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05482906,2022-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
250,357195,2022-08-01 14:05:08.989228,Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Other: Autologous hematopoietic stem cell transplantation;   Drug: Cyclophosphamide/ATG;   Drug: Cyclophosphamide/Rituximab<br /><b>Sponsor</b>:    Scripps Health<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05482542,2022-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
251,357132,2022-08-01 11:55:08.693864,"A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone...","<p>EudraCT Number: 2006-001827-21<br />Sponsor Protocol Number: CoSim-01<br />Sponsor Name: Glostrup Hospital, Dep. of Neurology<br />Start Date: 2009-03-06<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001827-21/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001827-21,,17,,17,WHO XML import,https://trialsearch.who.int/
252,355015,2022-07-29 15:12:09.261553,"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...","<p>EudraCT Number: 2011-001442-15<br />Sponsor Protocol Number: CFTY720D2324<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2011-08-26<br />Medical condition: relapsing remitting multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/GR"">GR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001442-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
253,354001,2022-07-29 07:55:06.859149,"A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis","<p>EudraCT Number: 2005-001567-55<br />Sponsor Protocol Number: DAC-1012<br />Sponsor Name: Protein Design Labs, Inc.<br />Start Date: 2006-06-23<br />Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001567-55,2005-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
254,353998,2022-07-29 07:55:06.854174,"A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.","<p>EudraCT Number: 2004-002571-16<br />Sponsor Protocol Number: MBP8298-01 Amendment 04<br />Sponsor Name: BioMS Technology Corp<br />Start Date: 2007-06-29<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/LT"">LT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/LV"">LV</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002571-16,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
255,351469,2022-07-28 11:11:55.735831,FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS,"<p>EudraCT Number: 2013-001409-10<br />Sponsor Protocol Number: FATIMS1.0<br />Sponsor Name: Odense University Hospital<br />Start Date: 2013-08-08<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 100000004852<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001409-10/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001409-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
256,351201,2022-07-28 08:25:12.318980,Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.,"<p>EudraCT Number: 2012-003418-15<br />Sponsor Protocol Number: SSP<br />Sponsor Name: Medizinische Universität Wien<br />Start Date: 2012-10-23<br />Medical condition: Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step ph...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003418-15/AT"">AT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003418-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
257,345885,2022-07-26 12:25:09.652859,"Effect of Tai Chi on Balance, Mood, Cognition, and Quality of Life in Patients With Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: ""Tai-chi"" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes<br /><b>Sponsor</b>:    Comenius University<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05474209?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-26 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
258,334452,2022-07-22 14:20:11.040205,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...","<p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: Sanofi-aventis recherche & développement<br />Start Date: 2022-07-21<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000049-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
259,334055,2022-07-22 11:15:09.382328,GentleCath™ Air for Men Intermittent Catheter With FeelClean™ Technology,<b>Conditions</b>:    Bladder Outlet Obstruction;   Multiple Sclerosis;   Cauda Equina Syndrome;   Enlarged Prostate With Lower Urinary Tract Symptoms;   Parkinson Disease;   Lower Urinary Tract Symptoms;   Detrusor Underactivity;   Spinal Cord Injuries<br /><b>Intervention</b>:    Device: Intermittent self-catheterisation<br /><b>Sponsor</b>:    ConvaTec Inc.<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05470751,2022-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
260,334052,2022-07-22 11:15:09.375567,Closed Kinetic Chain Exercises for Balance and Gait Rehabilitation for People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Combination Product: Telko plus conventional physical therapy (CPT)<br /><b>Sponsor</b>:    Anas Radi Hassan Alashram<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05460299,2022-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
261,333284,2022-07-22 05:28:03.917167,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,,https://clinicaltrials.gov/ct2/show/NCT04878211,2021-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
262,330654,2022-07-21 10:50:05.623200,Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Circuit training followed by telerehabilitation;   Other: Usual care<br /><b>Sponsor</b>:    Brno University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05469568,2022-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
263,327489,2022-07-20 11:50:06.632653,RELAXaHEAD for Headache Patients (Phase II),"<b>Conditions</b>:    Migraine;   Headache;   Multiple Sclerosis;   Insomnia<br /><b>Interventions</b>:    Behavioral: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR);   Behavioral: Monitored Usual Care (MUC)<br /><b>Sponsors</b>:    NYU Langone Health;   Center for Advancing Point of Care Technologies;   National Heart, Lung, and Blood Institute (NHLBI)<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05466682,2022-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
264,327361,2022-07-20 10:50:07.508940,"An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis","<p>EudraCT Number: 2013-002916-28<br />Sponsor Protocol Number: EMR200166-001<br />Sponsor Name: Merck KGaA<br />Start Date: 2013-12-12<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10067063<br />Term: Progressive relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002916-28/LV"">LV</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002916-28,2013-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
265,321804,2022-07-18 10:35:05.909973,Memory Rehabilitation Strategies in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Cognitive Rehabilitation;   Behavioral: Combined Rehabilitation;   Behavioral: Motor Rehabilitation<br /><b>Sponsor</b>:    I.R.C.C.S. Fondazione Santa Lucia<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05462678?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-18 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
266,314260,2022-07-15 12:45:06.942727,Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301,"<p>EudraCT Number: 2013-003795-13<br />Sponsor Protocol Number: CRAD001M2305<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2014-12-10<br />Medical condition: Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)<br />Disease: <br />Version: 21.0<br />SOC Term: 100000004850<br />Classification Code: 10045138<br />Term: Tuberous sclerosis<br />Level: LLT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003795-13/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003795-13/PL"">PL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003795-13,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
267,310358,2022-07-14 11:07:07.912983,Fatigue and Sleep Quality in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Reiki<br /><b>Sponsor</b>:    Istanbul Sabahattin Zaim University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05456464,2022-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
268,309308,2022-07-11 10:45:06.450197,Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion,<b>Condition</b>:    Trigeminal Neuralgia<br /><b>Intervention</b>:    Device: Deep brain stimulation<br /><b>Sponsor</b>:    Université de Sherbrooke<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05451251?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-11 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
269,309305,2022-07-11 10:45:06.447701,Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms,"<b>Conditions</b>:    Multiple Sclerosis;   Mild Cognitive Impairment;   Cancer<br /><b>Interventions</b>:    Other: CT-100 DiNaMo;   Other: Care-as-Usual<br /><b>Sponsor</b>:    Click Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05438147,2022-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
270,309294,2022-07-11 10:45:06.438306,"Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells<br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05451069,2022-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
271,308231,2022-07-11 05:50:07.081428,"A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...","<p>EudraCT Number: 2015-003471-30<br />Sponsor Protocol Number: D-FR-52120-222<br />Sponsor Name: Ipsen Innovation<br />Start Date: 2016-09-26<br />Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10038359 - Renal and urinary disorders<br />Classification Code: 10046543<br />Term: Urinary incontinence<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/RO"">RO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/PL"">PL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003471-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
272,294370,2022-07-08 13:50:08.133008,Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation (NeuroPsyc),<b>Conditions</b>:    Multiple Sclerosis;   Epilepsy;   Parkinson Disease;   Dementia;   Stroke<br /><b>Intervention</b>:    Behavioral: Psychometric Evaluations<br /><b>Sponsor</b>:    Neuromed IRCCS<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/show/NCT05450237,2022-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
273,294362,2022-07-08 13:50:08.051654,Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Scale for the Assessment of Sensory Integration in Adults<br /><b>Sponsor</b>:    Pomeranian Medical University Szczecin<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05449574?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-08 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
274,289503,2022-07-07 13:50:06.032417,Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Exercise Program;   Telerehabilitation;   Autoimmune Disorder<br /><b>Interventions</b>:    Other: Fatigue Severity Scale;   Other: Berg Balance Test;   Other: Time up and go- 25 steps walking test;   Other: Multiple Sclerosis Quality of Life;   Other: Brief International Cognitive Assessment for MS (BICAMS);   Other: Beck Depression and Anxiety Scale<br /><b>Sponsor</b>:    Muğla Sıtkı Koçman University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05447143?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-07 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
275,288222,2022-07-07 07:10:07.376837,Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004731-76<br />Sponsor Protocol Number: LTS16004<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2019-04-18<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10067063<br />Term: Progressive relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004731-76,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
276,284701,2022-07-06 13:46:51.450978,Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Other: Clinical assessment<br /><b>Sponsors</b>:    NHS Greater Glasgow and Clyde;   Biogen<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05446285?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-06 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
277,283085,2022-07-06 04:45:53.980722,A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation,,https://clinicaltrials.gov/ct2/show/NCT05090371,2021-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
278,279539,2022-07-05 09:45:08.278074,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease","<p>EudraCT Number: 2016-001634-10<br />Sponsor Protocol Number: M15-566<br />Sponsor Name: AbbVie Deutschland GmbH & Co. KG<br />Start Date: 2017-08-23<br />Medical condition: Alzheimer's Disease<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001634-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
279,278959,2022-07-05 06:31:52.363008,An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC),"<p>EudraCT Number: 2020-005752-38<br />Sponsor Protocol Number: CBAF312ADE03<br />Sponsor Name: Novartis Pharma GmbH<br />Start Date: 2021-03-18<br />Medical condition:  secondary progressive multiple sclerosis (SPMS) <br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005752-38/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005752-38,2021-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
280,266994,2022-07-01 14:47:06.185610,Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Wellness Patient Message<br /><b>Sponsor</b>:    Johns Hopkins University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05442112,2022-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
281,266988,2022-07-01 14:47:06.178929,Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Placebo;   Drug: Masitinib (4.5)<br /><b>Sponsor</b>:    AB Science<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05441488,2022-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
282,266340,2022-07-01 08:36:50.661441,Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial.,"<p>EudraCT Number: 2016-004819-12<br />Sponsor Protocol Number: FullResponders<br />Sponsor Name: OSPEDALE SAN RAFFAELE<br />Start Date: 2018-01-10<br />Medical condition: Relapsing-Remitting multiple sclerosis (RR-MS),<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004819-12/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004819-12,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
283,263953,2022-06-30 15:05:07.894115,A Study of LP-168 in Healthy Volunteers,<b>Conditions</b>:    Multiple Sclerosis;   NMO Spectrum Disorder<br /><b>Interventions</b>:    Drug: LP-168 tablet;   Drug: LP-168 Placebo tablet<br /><b>Sponsor</b>:    Guangzhou Lupeng Pharmaceutical Company LTD.<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05432713,2022-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
284,263952,2022-06-30 15:05:07.892856,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,<b>Conditions</b>:    Multiple Sclerosis;   Dysuria;   Lower Urinary Tract Symptoms;   Voiding Dysfunction;   Urinary Retention<br /><b>Interventions</b>:    Drug: Tamsulosin;   Drug: Placebo<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05439902,2022-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
285,263946,2022-06-30 15:05:07.887310,"Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    doaa mokhtar mahmoud<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05438693?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-30 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
286,263720,2022-06-30 13:10:07.429058,"Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 ...","<p>EudraCT Number: 2009-011470-15<br />Sponsor Protocol Number: AC-058B202<br />Sponsor Name: ACTELION Pharmaceuticals Ltd<br />Start Date: 2010-03-30<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011470-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
287,260463,2022-06-29 14:10:57.224724,A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS),<b>Condition</b>:    Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Device: PoNS®<br /><b>Sponsor</b>:    Helius Medical Inc<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05437276,2022-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
288,259738,2022-06-29 08:20:14.299583,The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial,"<p>EudraCT Number: 2018-002315-98<br />Sponsor Protocol Number: MedicalcannabisMSSCI2018<br />Sponsor Name: Aarhus Universitetshospital<br />Start Date: 2018-12-06<br />Medical condition: Central neuropathic pain and spasticity<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10077975<br />Term: Central neuropathic pain<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002315-98/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002315-98,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
289,259594,2022-06-29 07:25:28.997346,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis","<p>EudraCT Number: 2019-002625-29<br />Sponsor Protocol Number: GWSP19066<br />Sponsor Name: GW Pharma Limited<br />Start Date: 2020-01-14<br />Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002625-29,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
290,259020,2022-06-29 02:45:53.850455,Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy,,https://clinicaltrials.gov/ct2/show/NCT05376579,2022-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
291,257014,2022-06-28 13:35:06.755691,Qualitative Study Patient & Physician Experiences Botox COVID-19,<b>Conditions</b>:    Chronic Brain Injury;   Cerebral Stroke;   MS (Multiple Sclerosis)<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    East Kent Hospitals University NHS Foundation Trust<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05435404?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-28 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
292,253327,2022-06-27 13:30:06.499720,Blood Flow Restriction And Veterans With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Low-Load Exercise with Blood Flow Restriction;   Other: Low-Load Exercise Control Group<br /><b>Sponsor</b>:    VA Office of Research and Development<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05433103,2022-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
293,253321,2022-06-27 13:30:06.486520,Figure of 8 Walk Test in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Assesment<br /><b>Sponsor</b>:    Kahramanmaras Sutcu Imam University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05433714,2022-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
294,252595,2022-06-27 07:10:07.122661,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
295,248011,2022-06-25 12:51:53.078174,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,,https://clinicaltrials.gov/ct2/show/NCT04869358,2021-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
296,238945,2022-06-22 14:05:06.715126,A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Back Pain<br /><b>Intervention</b>:    Other: home - exercise program<br /><b>Sponsor</b>:    University of Arkansas<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05427045,2022-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
297,238944,2022-06-22 14:05:06.713734,Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study,<b>Conditions</b>:    Multiple Sclerosis;   Multiple Sclerosis Lesion;   Multiple Sclerosis Brain Lesion<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    University of Ljubljana;   Novartis;   General and Teaching Hospital Celje;   University Medical Centre Ljubljana;   University Medical Centre Maribor;   General Hospital Izola<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05426980,2022-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
298,235662,2022-06-21 14:30:07.076364,"Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt",<b>Condition</b>:    Relapsing-Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Fingolimod<br /><b>Sponsor</b>:    Hikma Pharmaceuticals LLC<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05423769,2022-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
299,220059,2022-06-16 12:41:47.930743,PTNS for Female Patients Suffering From Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Overactive Bladder<br /><b>Interventions</b>:    Device: PTNS Treatment;   Device: Sham PTNS Treatment<br /><b>Sponsor</b>:    William Beaumont Hospitals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05422625,2022-06-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
300,218958,2022-06-16 05:44:17.796074,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,,https://clinicaltrials.gov/ct2/show/NCT04593927,2020-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
301,215828,2022-06-15 11:10:05.936487,Designing Virtual Reality-based Software for People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Exergaming<br /><b>Sponsors</b>:    Yuzuncu Yıl University;   Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05420532,2022-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
302,215160,2022-06-15 06:55:08.370544,"An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued t...","<p>EudraCT Number: 2016-002977-37<br />Sponsor Protocol Number: CRAD001M2X02B<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2017-08-25<br />Medical condition: Refractory seizures associated with tuberous sclerosis complex<br />Disease: <br />Version: 20.0<br />SOC Term: 10010331 - Congenital, familial and genetic disorders<br />Classification Code: 10045138<br />Term: Tuberous sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002977-37,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
303,213658,2022-06-14 21:05:12.251263,"Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)",<b>Conditions</b>:    Multiple Sclerosis;   Clinically Isolated Syndrome of Demyelination<br /><b>Interventions</b>:    Drug: Tysabri Injectable Product;   Drug: Placebo<br /><b>Sponsor</b>:    Queen Mary University of London<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05418010,2022-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
304,213655,2022-06-14 21:05:12.248120,IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Drug: IMCY-0141;   Drug: Placebo;   Drug: Dimethyl Fumarate<br /><b>Sponsor</b>:    Imcyse SA<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05417269,2022-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
305,208909,2022-06-13 15:16:50.808302,Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM),"<b>Condition</b>:    Demyelinating Diseases of the Central Nervous System (DDC)<br /><b>Intervention</b>:    Other: Traditional Chinese medicine (TCM)<br /><b>Sponsor</b>:    Dongzhimen Hospital, Beijing<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05415579?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-13 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
306,208903,2022-06-13 15:16:50.804072,"""Outwalk MS"" - Benefits of Outdoor Walking in Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Walking exercise therapy<br /><b>Sponsors</b>:    University of Aarhus;   The Danish MS Society<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05415956,2021-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
307,208299,2022-06-13 11:15:08.487235,"COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis)

A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in...","<p>EudraCT Number: 2016-003587-39<br />Sponsor Protocol Number: COMBAT-MS<br />Sponsor Name: Karolinska Institutet<br />Start Date: 2017-05-22<br />Medical condition: Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and respon...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003587-39/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003587-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
308,198045,2022-06-10 11:50:06.588618,Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases,<b>Conditions</b>:    Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Demyelinating Diseases of the Central Nervous System<br /><b>Intervention</b>:    Drug: Ofatumumab<br /><b>Sponsor</b>:    Tianjin Medical University General Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05414487,2022-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
309,194704,2022-06-09 10:17:19.493858,"Fatigability in Persons With Multiple Sclerosis: Inputs From Cognition, Walking and Coordination","<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Dance therapy;   Other: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability<br /><b>Sponsors</b>:    Hasselt University;   Revalidatie & MS Centrum Overpelt;   National MS Center Melsbroek<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05412043,2021-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
310,192026,2022-06-08 11:01:18.533754,The Effects of Vestibular Exercise and Cervical Stabilization Exercise Training on Balance and Gait in MS Patients,<b>Conditions</b>:    Multiple Sclerosis;   Vestibular;   Exercises<br /><b>Intervention</b>:    Other: Exercises<br /><b>Sponsor</b>:    Sanko University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05409599,2022-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
311,189746,2022-06-07 14:25:07.321561,Accelerated Brain Volume Loss in People With Multiple Sclerosis,<b>Condition</b>:    Retrospective Study<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    National MS Center Melsbroek<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05408767?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-07 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
312,188818,2022-06-07 05:55:06.748331,"A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY","<p>EudraCT Number: 2021-000062-14<br />Sponsor Protocol Number: MN42988<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-10-08<br />Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10071068<br />Term: Clinically isolated syndrome<br />Level: PT<br /><br />Population Age: In utero, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000062-14/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000062-14/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000062-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
313,186918,2022-06-06 12:50:08.897335,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with
Progressive Multiple Sclerosis","<p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-11-04<br />Medical condition: Progressive forms of Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000048-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
314,178960,2022-06-03 10:36:19.788888,The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV,<b>Condition</b>:    COVID-19<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Marie D'hooghe<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05403463?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-03 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
315,178111,2022-06-03 03:07:38.574526,"A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",,https://www.novartis.com//clinicaltrials/study/nct05156281,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
316,178110,2022-06-03 03:07:38.548580,"An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis",,https://www.novartis.com//clinicaltrials/study/nct03650114,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
317,178109,2022-06-03 03:07:38.545757,"A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety &amp; Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase",,https://www.novartis.com//clinicaltrials/study/nct01892722,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
318,176526,2022-06-02 14:30:06.875405,Aerobic Exercise in Persons With Multiple Sclerosis With Restless Legs Syndrome,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Aerobic exercise<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05402956,2022-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
319,176523,2022-06-02 14:30:06.868908,Lifestyle Intervention for Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Lifestyle intervention program ""Leef! met MS""<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   National MS Foundation, The Netherlands;   Voeding Leeft<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05402501,2022-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
320,173628,2022-06-01 13:40:06.832946,COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort,<b>Conditions</b>:    Multiple Sclerosis;   COVID-19<br /><b>Intervention</b>:    Other: NO intervention<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05387395?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-24 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
321,173583,2022-06-01 01:07:37.471620,A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT05344469,2022-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
322,173080,2022-05-26 15:40:06.590034,Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Diffusion-weighted magnetic resonance imaging<br /><b>Sponsor</b>:    Chinese University of Hong Kong<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05391906,2022-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
323,173078,2022-05-26 15:40:06.587955,The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Yönetebilirim<br /><b>Sponsor</b>:    Selcuk University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05393765,2022-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
324,165544,2022-05-24 11:15:10.281955,RIS International Cohort,<b>Conditions</b>:    Multiple Sclerosis;   Radiologically Isolated Syndrome<br /><b>Intervention</b>:    Other: No intervention<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05388331,2022-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
325,162447,2022-05-23 14:52:03.985805,MUSCLE - Nordic Walking in MUltiple SCLErosis,"<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive<br /><b>Interventions</b>:    Other: Nordic Walking (NWG);   Other: Free Walking (FWG);   Other: Health Education (HEG)<br /><b>Sponsors</b>:    Leonardo A. Peyré-Tartaruga;   Aline Nogueira Haas;   Flávia Gomes Martinez<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05385731,2022-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
326,162441,2022-05-23 14:52:03.980540,"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: BCD-132;   Drug: Teriflunomide<br /><b>Sponsor</b>:    Biocad<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05385744,2022-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
327,155972,2022-05-20 15:37:08.289294,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study,,https://clinicaltrials.gov/show/NCT05285904,2022-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
328,152103,2022-05-19 10:50:08.503581,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction",<b>Conditions</b>:    Neurogenic Dysfunction of the Urinary Bladder;   Multiple Sclerosis;   Sacral Neuromodulation;   Bowel Dysfunction;   Sexual Dysfunction;   Quality of Life<br /><b>Interventions</b>:    Device: Turning ON the neuromodulator;   Device: Turning OFF the neuromodulator<br /><b>Sponsor</b>:    Odense University Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05380856,2021-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
329,152097,2022-05-19 10:50:08.498583,Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis,<b>Condition</b>:    Patients With Multiple Sclerosis<br /><b>Intervention</b>:    Other: hospital anxiety and depression scale<br /><b>Sponsor</b>:    Sohag University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05382195,2022-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
330,148510,2022-05-18 10:30:07.168634,Ketamine for Multiple Sclerosis Fatigue,<b>Condition</b>:    Multiple Sclerosis Fatigue<br /><b>Interventions</b>:    Drug: Ketamine;   Drug: Midazolam<br /><b>Sponsors</b>:    Johns Hopkins University;   United States Department of Defense<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05378100,2022-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
331,148506,2022-05-18 10:30:06.026248,Prospective Randomized Endovascular Therapy in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Venous Angioplasty;   Other: Sham Angioplasty<br /><b>Sponsors</b>:    University at Buffalo;   Volcano Corporation<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05380362,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
332,148000,2022-05-18 07:00:06.804299,A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab,"<p>EudraCT Number: 2021-001973-21<br />Sponsor Protocol Number: GNC-402<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2021-07-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001973-21/SE"">SE</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001973-21,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
333,147941,2022-05-18 06:30:06.835832,"A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...","<p>EudraCT Number: 2020-005971-11<br />Sponsor Protocol Number: AP101-02<br />Sponsor Name: AL-S Pharma, AG<br />Start Date: 2021-12-22<br />Medical condition: Amyotrophic Lateral Sclerosis  (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005971-11/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005971-11,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
334,144828,2022-05-17 10:40:08.623870,Investigation of the Effects of Motor Imagery and Action Observation Training in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Motor Imagery training;   Other: Action Observation training;   Other: standard rehabilitation<br /><b>Sponsor</b>:    Hacettepe University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05377476,2022-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
335,141456,2022-05-16 12:00:08.079361,"The Relationship of Neuropathic Pain With Incontinence, Disability and Life Quality in Multiple Sclerosis Patients","<b>Conditions</b>:    Multiple Sclerosis;   Disabilities Multiple;   Quality of Life;   Incontinence, Urinary;   Incontinence Bowel;   Neuropathic Pain<br /><b>Intervention</b>:    Other: Neuropathic Pain<br /><b>Sponsor</b>:    Istanbul University-Cerrahpasa<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05374811,2022-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
336,141452,2022-05-16 12:00:08.075231,An Online Lifestyle Modification Course for People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Lifestyle modification;   Behavioral: Standard-care<br /><b>Sponsor</b>:    University of Melbourne<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05374473?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-16 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
337,131496,2022-05-13 10:40:06.705926,Multiple Sclerosis Intimacy and Sexuality Questionnaire,<b>Conditions</b>:    Multiple Sclerosis;   Sexual Dysfunction;   Questionnaires<br /><b>Intervention</b>:    Other: descriptive study<br /><b>Sponsor</b>:    Bozok University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05374031,2022-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
338,131406,2022-05-13 09:55:08.556701,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...","<p>EudraCT Number: 2012-003056-36<br />Sponsor Protocol Number: CBAF312A2304<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-10-31<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/FR"">FR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
339,127431,2022-05-12 07:25:10.203912,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and...","<p>EudraCT Number: 2015-005431-41<br />Sponsor Protocol Number: BN40900(SA-309JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2017-10-16<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005431-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
340,124335,2022-05-11 11:50:06.264836,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program","<b>Conditions</b>:    Mobility Limitation;   Balance Impairment<br /><b>Intervention</b>:    Other: TIME™ at Home<br /><b>Sponsors</b>:    University of Toronto;   March of Dimes, Canada<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05369741?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-11 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
341,120726,2022-05-10 12:31:31.474909,"A two-year, double-blind, randomized, multicenter, active controlled
study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...","<p>EudraCT Number: 2011-005677-23<br />Sponsor Protocol Number: CFTY720D2311<br />Sponsor Name: Novartis Farma<br />Start Date: 2013-04-02<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 15.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO"">RO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005677-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
342,120464,2022-05-10 10:55:05.903145,In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: In-phase Bilateral Exercises of the upper limbs<br /><b>Sponsors</b>:    Cyprus University of Technology;   The Cyprus Foundation for Muscular Dystrophy Research<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05367947,2022-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
343,120096,2022-05-10 08:45:06.974682,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","<p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd<br />Start Date: 2022-05-09<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005746-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
344,117349,2022-05-09 16:29:12.061311,"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous ...",,https://www.novartis.com//clinicaltrials/study/nct04659863,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
345,116515,2022-05-09 11:40:07.349614,Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body,"<b>Conditions</b>:    Parkinson Disease;   Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: High Intensity Interval Training (HIIT);   Behavioral: Continuous Aerobic Training (CAT);   Behavioral: Movement Advice<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   Netherlands Brain Foundation<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05357638,2022-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
346,116288,2022-05-09 10:45:06.925336,A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-remitting<br /><b>Intervention</b>:    Other: No Intervention<br /><b>Sponsor</b>:    Eisai Korea Inc.<br /><b>Completed</b>",https://clinicaltrials.gov/show/NCT05366036,2022-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
347,114748,2022-05-09 01:29:11.385415,A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (VICTORION-Implement),,https://www.novartis.com//clinicaltrials/study/nct05362903,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
348,114733,2022-05-09 01:29:11.368480,"A Phase Ib&#x2F;II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",,https://www.novartis.com//clinicaltrials/study/nct04699188,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
349,114712,2022-05-09 01:29:11.066436,"A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy",,https://www.novartis.com//clinicaltrials/study/nct04984876,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
350,104550,2022-05-06 16:10:07.230610,"An Open-Label, Randomized, Multicenter, Active-Controlled,
Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in
Pediatric Subjects Aged 10 to Less Than 18 Years f...","<p>EudraCT Number: 2018-003008-38<br />Sponsor Protocol Number: 105MS306<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-06-17<br />Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003008-38,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
351,104154,2022-05-06 14:15:07.338074,Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX),"<b>Condition</b>:    Central Neurogical Impairment<br /><b>Intervention</b>:    Device: DEEPSEN virtual reality mask<br /><b>Sponsor</b>:    University Hospital, Clermont-Ferrand<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05364203?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-06 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
352,99301,2022-05-05 14:25:07.059543,"Exopulse Mollii Suit, Spasticity & Tissue Oxygenation",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Exopulse Mollii Suit;   Device: Exopulse Mollii suit (sham)<br /><b>Sponsor</b>:    Institut De La Colonne Vertebrale Et Des Neurosciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05362006,2022-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
353,95975,2022-05-04 21:09:11.652272,"EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum ( ...",,https://www.novartis.com//clinicaltrials/study/nct04589650,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
354,95971,2022-05-04 21:09:11.647591,"A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)",,https://www.novartis.com//clinicaltrials/study/nct05030428,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
355,95958,2022-05-04 21:09:11.637203,"An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)",,https://www.novartis.com//clinicaltrials/study/nct04952753,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
356,95954,2022-05-04 21:09:11.606332,"An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors",,https://www.novartis.com//clinicaltrials/study/nct04857372,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
357,95948,2022-05-04 21:09:11.599454,"EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Partic ...",,https://www.novartis.com//clinicaltrials/study/nct04899349,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
358,94231,2022-05-04 12:05:07.043552,Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy,"<b>Conditions</b>:    Multiple Sclerosis (MS);   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis Relapse;   Multiple Sclerosis Brain Lesion;   Multiple Sclerosis Benign<br /><b>Interventions</b>:    Drug: Clemastine Fumarate;   Drug: Placebo<br /><b>Sponsors</b>:    University of California, San Francisco;   United States Department of Defense<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05359653,2022-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
359,94036,2022-05-04 11:09:11.866512,"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygou ...",,https://www.novartis.com//clinicaltrials/study/nct04652726,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
360,94028,2022-05-04 11:09:11.856147,The Gilenya Pregnancy Registry,,https://clinicaltrials.gov/show/NCT01285479,2011-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
361,94024,2022-05-04 11:09:11.851733,"A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea&#x2F;Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive ...",,https://www.novartis.com//clinicaltrials/study/nct03474965,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
362,94020,2022-05-04 11:09:11.847179,"A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary S ...",,https://www.novartis.com//clinicaltrials/study/nct04873934,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
363,94016,2022-05-04 11:09:11.841289,"Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)",,https://www.novartis.com//clinicaltrials/study/nct05020873,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
364,94015,2022-05-04 11:09:11.839247,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositi ...",,https://www.novartis.com//clinicaltrials/study/nct04251533,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
365,94001,2022-05-04 11:09:11.714905,"EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no ...",,https://www.novartis.com//clinicaltrials/study/nct04729387,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
366,94000,2022-05-04 11:09:11.710619,"A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma ...",,https://www.novartis.com//clinicaltrials/study/nct04935359,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
367,92248,2022-05-04 01:09:11.499411,A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections,,https://www.novartis.com/clinicaltrials/study/nct04662944,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
368,92246,2022-05-04 01:09:11.497587,"A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy",,https://www.novartis.com//clinicaltrials/study/nct04278417,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
369,92242,2022-05-04 01:09:11.494242,"A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers",,https://www.novartis.com//clinicaltrials/study/nct05195892,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
370,92237,2022-05-04 01:09:11.489874,"Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates &lt;5 kg Body Weight With Acute Uncomplicated Pla ...",,https://www.novartis.com//clinicaltrials/study/nct04300309,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
371,92233,2022-05-04 01:09:11.485987,"A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg&#x2F;ml and 15 mg&#x2F;ml) Used Twice-daily in the Treatment of Post-operative Corneal In ...",,https://www.novartis.com//clinicaltrials/study/nct04630158,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
372,90424,2022-05-03 15:09:11.568795,"An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",,https://www.novartis.com//clinicaltrials/study/nct04720157,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
373,90410,2022-05-03 15:09:11.564555,A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1),,https://www.novartis.com//clinicaltrials/study/nct04980833,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
374,90406,2022-05-03 15:09:11.346630,"A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythem ...",,https://www.novartis.com//clinicaltrials/study/nct03656562,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
375,90107,2022-05-03 13:36:31.600135,Novel Imaging Markers in SPMS,"<b>Conditions</b>:    Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Ferumoxytol infusion;   Drug: Gadoteridol;   Diagnostic Test: MRI Brain and Cervical Spine<br /><b>Sponsor</b>:    University of Utah<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05357833,2022-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
376,90106,2022-05-03 13:36:31.598811,Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?,"<b>Conditions</b>:    Hypogammaglobulinemia;   Multiple Sclerosis;   Fatigue<br /><b>Intervention</b>:    Diagnostic Test: Laboratory test<br /><b>Sponsor</b>:    University Hospital Inselspital, Berne<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05357781,2022-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
377,89189,2022-05-03 07:57:01.149149,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...","<p>EudraCT Number: 2020-004128-41<br />Sponsor Protocol Number: WN42086<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-08-24<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BE"">BE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004128-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
378,87936,2022-05-03 00:09:10.567239,"One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAG ...",,https://www.novartis.com//node/14326,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
379,87905,2022-05-03 00:09:10.490100,"A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema",,https://clinicaltrials.gov/ct2/show/NCT03927690,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
380,85561,2022-05-02 10:41:27.133466,Cognitive-motor Telerehabilitation in MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Cognitive training;   Behavioral: Motor training<br /><b>Sponsors</b>:    Universitair Ziekenhuis Brussel;   National MS Center Melsbroek;   Research Foundation Flanders<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05355389,2022-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
381,73437,2022-04-29 10:45:06.089101,Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Biomarker quantification<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05352971,2022-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
382,72756,2022-04-29 06:45:07.743813,"Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitini...","<p>EudraCT Number: 2010-021219-17<br />Sponsor Protocol Number: AB07002<br />Sponsor Name: AB Science<br />Start Date: 2011-09-12<br />Medical condition: Pacientes con esclerosis múltiple primaria progresiva o secundaria progresiva sin recidiva<br />Disease: <br />Version: 14.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br />Version: 14.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/DE"">DE</a> (Prohibited by CA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/SK"">SK</a> (Prohibited by CA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/BG"">BG</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021219-17,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
383,69697,2022-04-28 11:38:12.160658,"An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomog ...",,https://www.novartis.com//clinicaltrials/study/nct04066244,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
384,69693,2022-04-28 11:38:12.154692,An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants,,https://www.novartis.com//clinicaltrials/study/nct05036668,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
385,69689,2022-04-28 11:38:12.148570,"A Randomized, Open-label, Phase I&#x2F;II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients",,https://www.novartis.com//clinicaltrials/study/nct04097821,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
386,69685,2022-04-28 11:38:12.141544,"International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours",,https://www.novartis.com//clinicaltrials/study/nct03691064,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
387,69530,2022-04-28 10:50:07.021247,Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Firat University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05351411,2022-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
388,69524,2022-04-28 10:50:06.243383,Dry Needling for Treating Spasticity in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Procedure: Dry needling<br /><b>Sponsor</b>:    Hospital Universitario de Canarias<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05351957,2022-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
389,67206,2022-04-27 20:38:12.296045,"A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy",,https://www.novartis.com//clinicaltrials/study/nct04150029,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
390,67204,2022-04-27 20:38:12.290492,"A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinas ...",,https://www.novartis.com//clinicaltrials/study/nct04925479,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
391,67201,2022-04-27 20:38:12.287776,"Two Steps Italian Prospective obsErvationAL Study Assessing the Effectiveness and Outcomes Associated With LUtathera (177Lu) Oxodotreotide Treatment in Adult Subjects With Unresectable or Metastatic, Progressive, Well Differentiated (G1 and G2), Soma ...",,https://www.novartis.com//clinicaltrials/study/nct04727723,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
392,67192,2022-04-27 20:38:12.278163,"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies o ...",,https://www.novartis.com//clinicaltrials/study/nct04353492,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
393,67190,2022-04-27 20:38:12.272063,"A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients",,https://www.novartis.com//clinicaltrials/study/nct04641442,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
394,67184,2022-04-27 20:38:12.269757,"A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.",,https://www.novartis.com//clinicaltrials/study/nct04410523,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
395,67181,2022-04-27 20:38:12.265744,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Patients With Symptomatic COVID-19 - The &quot;EMPATHY&quot; Trial",,https://www.novartis.com//clinicaltrials/study/nct04828161,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
396,67180,2022-04-27 20:38:12.267535,"EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or ...",,https://www.novartis.com//clinicaltrials/study/nct05038735,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
397,65668,2022-04-27 11:41:07.818769,Metformin Treatment in Progressive Multiple Sclerosis,"<b>Conditions</b>:    Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day;   Drug: Placebo oral tablet identical to metformin, up to 4 tablets a day<br /><b>Sponsor</b>:    University of California, Los Angeles<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05349474,2022-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
398,61737,2022-04-26 12:15:31.025176,CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Kappa Free Light Chain (K-FLC)<br /><b>Sponsor</b>:    Aga Khan University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05347277,2022-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
399,58025,2022-04-25 14:10:07.002410,Effect of Computerized Cognitive Training in Persons With MS,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Device: BrainHQ cognitive training;   Device: BrainHQ control games<br /><b>Sponsor</b>:    University of Nebraska<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05345288,2022-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
400,58016,2022-04-25 14:10:06.991055,Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Remotely Delivered and Supported Aerobic Walking Exercise Training;   Behavioral: Remotely Delivered and Supported Stretching and Toning Exercise Training<br /><b>Sponsor</b>:    Kessler Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05344040,2022-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
401,57609,2022-04-25 11:50:07.595172,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease ...","<p>EudraCT Number: 2017-002901-37<br />Sponsor Protocol Number: 251AD201<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2018-06-04<br />Medical condition: Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/FR"">FR</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002901-37,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
402,45848,2022-04-22 12:30:07.387904,Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Adult ALL;   Vitamin D3 Deficiency<br /><b>Interventions</b>:    Dietary Supplement: 25(OH)D3;   Dietary Supplement: vitamin D3<br /><b>Sponsors</b>:    Tehran University of Medical Sciences;   Boston University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05340985,2022-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
403,45846,2022-04-22 12:30:07.386002,Kinesiotape on Balance in With Multiple Sclerosis,<b>Conditions</b>:    Individuals With Multiple Sclerosis;   With Ataxia Symptoms;   No Secondary Disease Affecting Balance<br /><b>Intervention</b>:    Other: Kinesiotape<br /><b>Sponsor</b>:    Firat University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05341895,2022-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
404,45838,2022-04-22 12:30:07.379209,Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: PNF;   Other: Breathing exercises<br /><b>Sponsor</b>:    Biruni University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05342025,2022-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
405,45220,2022-04-22 08:35:07.871592,Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS),"<p>EudraCT Number: 2021-000307-20<br />Sponsor Protocol Number: COMB157GDE01<br />Sponsor Name: Novartis Pharma Vertriebs GmbH <br />Start Date: 2021-04-28<br />Medical condition: relapsing multiple sclerosis <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000307-20/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000307-20,2021-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
406,45216,2022-04-22 08:35:07.865057,"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Onc...","<p>EudraCT Number: 2011-005249-12<br />Sponsor Protocol Number: EFC11759<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2014-08-13<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 17.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/GR"">GR</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/FR"">FR</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/3rd"">Outside EU/EEA</a>, <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/IE"">IE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/SI"">SI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/IT"">IT</a> (Not Authorised)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005249-12,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
407,42025,2022-04-21 11:11:45.684532,Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Internuclear Ophthalmoplegia<br /><b>Interventions</b>:    Drug: Clemastine Fumarate;   Drug: Placebo<br /><b>Sponsor</b>:    Amsterdam UMC, location VUmc<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05338450,2022-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
408,34597,2022-04-19 14:11:14.287635,"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Recruiting</b>",https://clinicaltrials.gov/show/NCT05335031,2022-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
409,33622,2022-04-19 08:45:09.604716,"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...","<p>EudraCT Number: 2013-003752-21<br />Sponsor Protocol Number: BN40898(SA-307JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2014-05-19<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adolescents, Under 18, Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003752-21,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
410,30571,2022-04-18 14:45:08.000000,"A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis","<p>EudraCT Number: 2020-004785-19<br />Sponsor Protocol Number: ACT16877<br />Sponsor Name: Sanofi-Aventis Recherche et Développement<br />Start Date: 2021-06-01<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004785-19,2022-04-18 23:08:27.000000,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
411,30552,2022-04-18 14:35:08.041305,"A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis","<p>EudraCT Number: 2019-002623-14<br />Sponsor Protocol Number: GWSP18023<br />Sponsor Name: GW Pharma Ltd<br />Start Date: 2020-03-17<br />Medical condition: Symptomatic relief of spasticity in Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002623-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
412,30539,2022-04-18 14:30:07.566785,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","<p>EudraCT Number: 2021-000028-36<br />Sponsor Protocol Number: P3-IMU-838-RMS-01<br />Sponsor Name: Immunic AG<br />Start Date: 2022-01-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000028-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
413,30538,2022-04-18 14:30:07.564703,"Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...","<p>EudraCT Number: 2018-001896-19<br />Sponsor Protocol Number: P2-IMU-838-MS<br />Sponsor Name: Immunic AG<br />Start Date: 2018-12-17<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001896-19/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001896-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
414,30523,2022-04-18 14:25:07.924460,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis","<p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000637-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
415,30519,2022-04-18 14:25:07.572884,Study of Empathy in MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Interpersonal Reactivity Index<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05332951,2022-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
416,21883,2022-04-14 10:59:17.162522,Functional Outcomes From Diets in Multiple Sclerosis,<b>Conditions</b>:    Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Glycemic load;   Behavioral: Calorie restriction;   Behavioral: Behavioral support<br /><b>Sponsors</b>:    University of Alabama at Birmingham;   Washington University School of Medicine;   United States Department of Defense<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05327322,2022-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
417,21300,2022-04-13 11:59:18.445167,Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Pain<br /><b>Intervention</b>:    Behavioral: Telerehabilitation-based motor imagery training<br /><b>Sponsors</b>:    Dokuz Eylul University;   Izmir Katip Celebi University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05326711,2021-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
418,21299,2022-04-13 11:59:18.443892,Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: cytof analysis<br /><b>Sponsor</b>:    Rennes University Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05326048,2022-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
419,21298,2022-04-13 11:59:18.442353,L Test in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: L test<br /><b>Sponsor</b>:    Firat University<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05325359,2022-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
420,20707,2022-04-12 12:59:17.118072,Therapeutic Effects of Line Dancing in People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: line dancing<br /><b>Sponsors</b>:    Gazi University;   Hacettepe University;   Fenerbahce University<br /><b>Completed</b>,https://clinicaltrials.gov/show/NCT05322915,2022-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
421,19941,2022-04-11 11:59:20.168812,TENS in Persons With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Trancutaneous Electrical Nerve Stimulation;   Other: Strength training;   Device: Sham stimulation<br /><b>Sponsor</b>:    University Medical Center Groningen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05321927,2022-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
422,19936,2022-04-11 11:59:20.140251,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: MetFORMIN 1000 Mg Oral Tablet;   Drug: Interferon beta-1a<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05298670,2022-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
423,19935,2022-04-11 11:59:19.434725,Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Immersive Virtual Reality Intervention<br /><b>Sponsors</b>:    Glasgow Caledonian University;   MS Society, UK;   NHS Lanarkshire<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05320237,2022-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
424,17697,2022-04-08 19:59:18.794374,Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients,<b>Conditions</b>:    Fatigue;   Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Ozanimod<br /><b>Sponsors</b>:    Brigham and Women's Hospital;   Bristol-Myers Squibb<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05319093,2022-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
425,17415,2022-04-08 12:59:18.909630,"A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...","<p>EudraCT Number: 2018-000001-23<br />Sponsor Protocol Number: DroSpas-1<br />Sponsor Name: Bionorica SE <br />Start Date: 2018-10-25<br />Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000001-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
426,17383,2022-04-08 11:59:17.699002,Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY),"<p>EudraCT Number: 2017-000638-75<br />Sponsor Protocol Number: TG1101-RMS301<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-05<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000638-75,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
427,17382,2022-04-08 11:59:17.697319,Phase III: UbliTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY),"<p>EudraCT Number: 2017-000639-15<br />Sponsor Protocol Number: TG1101-RMS302<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-04<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000639-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
428,17259,2022-04-08 09:59:17.158259,"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis","<p>EudraCT Number: 2016-002937-31<br />Sponsor Protocol Number: MA30143<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2017-09-12<br />Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002937-31,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
429,16302,2022-04-07 11:59:17.157547,"A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the T...","<p>EudraCT Number: 2021-000639-30<br />Sponsor Protocol Number: AB20009<br />Sponsor Name: AB Science<br />Start Date: 2022-01-12<br />Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/GR"">GR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000639-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
430,16099,2022-04-07 07:59:18.430043,"Post-authorization safety study to check the potential association between the safety
profile of beta interferon 1a and the body mass index or pharmacodynamics during the
titration phase","<p>EudraCT Number: 2006-000606-23<br />Sponsor Protocol Number: 26756<br />Sponsor Name: Merck, S.L.<br />Start Date: 2006-11-23<br />Medical condition: Not applicalbe<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000606-23/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000606-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
431,15179,2022-04-06 12:59:16.692334,Exercise and Pregnancy in People With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Pregnancy<br /><b>Intervention</b>:    Other: Moderate-intensity cardiovascular exercise<br /><b>Sponsor</b>:    University of Alberta<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05313204,2022-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
432,14013,2022-04-05 12:59:19.301730,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","<p>EudraCT Number: 2020-005929-89<br />Sponsor Protocol Number: CLOU064C12302<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-01<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SI"">SI</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005929-89,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
433,13981,2022-04-05 12:59:18.848290,Multiple Sclerosis and Overactive Bladder Treatment,<b>Condition</b>:    Neurogenic Bladder Dysfunction<br /><b>Interventions</b>:    Device: Repetitive Transcranial Magnetic Stimulation;   Device: Transcutaneous Posterior Tibial Nerve Stimulation<br /><b>Sponsor</b>:    Istanbul Medipol University Hospital<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05312138?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-05 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
434,12975,2022-04-04 15:59:16.854905,The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.,"<p>EudraCT Number: 2015-001197-18<br />Sponsor Protocol Number: NOR-BGT-14-10665<br />Sponsor Name: Biogen Idec Norway<br />Start Date: 2015-05-20<br />Medical condition: multiple sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001197-18/NO"">NO</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001197-18,2015-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
435,12825,2022-04-04 12:59:16.573010,Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004557-24<br />Sponsor Protocol Number: UKM17_0056<br />Sponsor Name: Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel <br />Start Date: 2019-07-29<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004557-24/DE"">DE</a> (Temporarily Halted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004557-24,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
436,12768,2022-04-04 11:59:20.156553,"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...","<p>EudraCT Number: 2019-004822-15<br />Sponsor Protocol Number: GNC-401<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2020-05-18<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004822-15/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004822-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
437,12682,2022-04-04 09:59:19.594712,"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (...","<p>EudraCT Number: 2014-001579-30<br />Sponsor Protocol Number: TV5600-CNS-20006<br />Sponsor Name: Teva Pharmaceutical Industries Ltd.<br />Start Date: 2014-11-27<br />Medical condition: Primary Progressive Multiple Sclerosis<br />Disease: <br />Version: 19.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/NL"">NL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001579-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
438,9544,2022-04-01 13:59:17.901179,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","<p>EudraCT Number: 2020-000645-14<br />Sponsor Protocol Number: EFC16035<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-10-13<br />Medical condition: Primary Progressive Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000645-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
439,9537,2022-04-01 13:59:17.893220,"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300...","<p>EudraCT Number: 2005-005985-35<br />Sponsor Protocol Number: 1206.15<br />Sponsor Name: Boehringer Ingelheim<br />Start Date: 2006-08-29<br />Medical condition: Relapsing forms of Multiple Sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/CZ"">CZ</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005985-35,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
440,9498,2022-04-01 12:59:18.787053,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...","<p>EudraCT Number: 2015-000392-28<br />Sponsor Protocol Number: 1199.214<br />Sponsor Name: Boehringer Ingelheim bv<br />Start Date: 2015-11-02<br />Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease<br />Disease: <br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10012977<br />Term: Diffuse systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10036814<br />Term: Progressive systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br />Classification Code: 10042954<br />Term: Systemic sclerosis pulmonary<br />Level: PT<br />Version: 19.1<br />SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br />Classification Code: 10025109<br />Term: Lung involvement in systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10042953<br />Term: Systemic sclerosis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/HU"">HU</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000392-28,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
441,9448,2022-04-01 11:59:16.905992,"Multicenter, open-label, 12 weeks,
phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a
(Rebif®) administered In the morning may affEct the severity of Flu-like syndrom...","<p>EudraCT Number: 2013-004450-21<br />Sponsor Protocol Number: EMR200136-570<br />Sponsor Name: Merck Serono S.p.A.<br />Start Date: 2014-02-07<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004450-21/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004450-21,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
442,9442,2022-04-01 11:59:16.901447,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.","<p>EudraCT Number: 2004-000762-13<br />Sponsor Protocol Number: TV-5010/202<br />Sponsor Name: TEVA ITALIA srl<br />Start Date: 2004-08-31<br />Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000762-13/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000762-13,2012-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
443,9371,2022-04-01 09:59:16.534523,"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...","<p>EudraCT Number: 2005-004061-41<br />Sponsor Protocol Number: 101-MS-321<br />Sponsor Name: BIOGEN IDEC LTD<br />Start Date: 2006-06-01<br />Medical condition: Multiple sclerosis (MS)<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GB"">GB</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/BE"">BE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/HU"">HU</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DK"">DK</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/CZ"">CZ</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GR"">GR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004061-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
444,9369,2022-04-01 09:59:16.532908,"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis","<p>EudraCT Number: 2016-004935-18<br />Sponsor Protocol Number: GNC-004<br />Sponsor Name: GeNeuro SA<br />Start Date: 2017-04-12<br />Medical condition: Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/CZ"">CZ</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/PL"">PL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/BG"">BG</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/HR"">HR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004935-18,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
445,9364,2022-04-01 09:59:16.529268,"A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects...","<p>EudraCT Number: 2004-000337-12<br />Sponsor Protocol Number: 24810<br />Sponsor Name: Serono International SA<br />Start Date: 2004-07-23<br />Medical condition: MS with 2 or more relapses within the last 2 years <br />Disease: <br />Version: 7.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: <br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/HU"">HU</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000337-12,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
446,9302,2022-04-01 08:59:22.275820,Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...,"<p>EudraCT Number: 2009-011088-35<br />Sponsor Protocol Number: PACAMUS<br />Sponsor Name: Philipps-Universität Marburg<br />Start Date: 2010-03-24<br />Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive int...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011088-35/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011088-35,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
447,9294,2022-04-01 08:59:22.269992,"A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis","<p>EudraCT Number: 2011-001437-16<br />Sponsor Protocol Number: CFTY720D2319<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-09-19<br />Medical condition: multiple sclerosis<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001437-16/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001437-16,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
448,8416,2022-03-31 16:25:00.344899,"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T","<p>EudraCT Number: 2009-014857-34<br />Sponsor Protocol Number: FAU-001<br />Sponsor Name: Universitätsklinikum Erlangen<br />Start Date: 2010-02-01<br />Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria<br />Disease: <br />Version: 12.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014857-34/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014857-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
449,8412,2022-03-31 16:24:59.950968,A Study for Tysabri Participant Preference,<b>Condition</b>:    Relapsing-Remitting Multiple Sclerosis (RRMS)<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05304520,2022-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
450,8411,2022-03-31 16:24:59.948202,Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05301907,2022-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
451,8278,2022-03-31 14:56:29.614852,Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study,"<p>EudraCT Number: 2013-002113-35<br />Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: Progressive spinal multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002113-35/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002113-35,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
452,8237,2022-03-31 13:56:27.068531,Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study,"<p>EudraCT Number: 2013-002112-27<br />Sponsor Protocol Number: MD1003CT2013-01MS-ON<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10030942<br />Term: Optic neuritis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002112-27/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002112-27/GB"">GB</a> (GB - no longer in EU/EEA)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002112-27,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
453,8153,2022-03-31 10:56:31.359538,"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...","<p>EudraCT Number: 2006-006299-39<br />Sponsor Protocol Number: 191622-082-01<br />Sponsor Name: Allergan<br />Start Date: 2008-04-23<br />Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10046543<br />Term: Urinary incontinence<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006299-39/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006299-39/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006299-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
454,8104,2022-03-31 09:56:28.720059,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis","<p>EudraCT Number: 2020-000647-30<br />Sponsor Protocol Number: EFC16645<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-08-27<br />Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000647-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
455,8086,2022-03-31 08:56:29.209455,"A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dos...","<p>EudraCT Number: 2010-018273-38<br />Sponsor Protocol Number: D1950C00011<br />Sponsor Name: AstraZeneca AB<br />Start Date: 2010-03-22<br />Medical condition: Alzheimer's Disease<br />Disease: <br />Version: 12.1<br />SOC Term: <br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018273-38/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018273-38,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
456,7434,2022-03-30 11:56:31.283489,"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...","<p>EudraCT Number: 2007-001377-28<br />Sponsor Protocol Number: 27577<br />Sponsor Name: Merck Serono International S.A.<br />Start Date: 2008-06-11<br />Medical condition: Adult patients with moderate to severe chronic plaque psoriasis 
-- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10061664<br />Term: Autoimmune disorder<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10025139<br />Term: Lupus erythematosus systemic<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10047888<br />Term: Wegener's granulomatosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10002817<br />Term: Antiphospholipid syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10040767<br />Term: Sjogren's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10039073<br />Term: Rheumatoid arthritis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10045228<br />Term: Type I diabetes mellitus<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10009900<br />Term: Colitis ulcerative<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003827<br />Term: Autoimmune hepatitis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10049046<br />Term: Autoimmune thyroiditis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003822<br />Term: Autoimmune haemolytic anaemia NOS<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10034697<br />Term: Pernicious anemia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028417<br />Term: Myasthenia gravis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018620<br />Term: Goodpasture's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018766<br />Term: Guillain Barre syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10043554<br />Term: Thrombocytopenia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10037153<br />Term: Psoriasis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/PT"">PT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001377-28,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
457,7395,2022-03-30 10:56:26.571489,"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUT...","<p>EudraCT Number: 2020-005448-48<br />Sponsor Protocol Number: CN42097<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2022-03-15<br />Medical condition: Multiple Sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005448-48,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
458,7356,2022-03-30 09:56:28.367759,"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis","<p>EudraCT Number: 2010-020338-25<br />Sponsor Protocol Number: WA25046<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2010-11-02<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DK"">DK</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020338-25,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
459,6978,2022-03-29 22:12:24.271901,Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease,"<p>EudraCT Number: 2006-004784-58<br />Sponsor Protocol Number: MRI-0143<br />Sponsor Name: University of Leuven<br />Start Date: 2007-06-22<br />Medical condition: Crohn's disease<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/GB"">GB</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004784-58,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
460,6977,2022-03-29 22:12:24.270224,"Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...","<p>EudraCT Number: 2007-005994-79<br />Sponsor Protocol Number: 3133K1-3000-WW<br />Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development<br />Start Date: 2008-05-13<br />Medical condition: Enfermedad de Alzheimer

Alzheimer Disease<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10012271<br />Term: Dementia Alzheimer's type<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/GB"">GB</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/PT"">PT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005994-79,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
461,6976,2022-03-29 22:12:24.269551,"A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)","<p>EudraCT Number: 2020-000579-19<br />Sponsor Protocol Number: MAGNET<br />Sponsor Name: Stichting TRICALS Foundation<br />Start Date: 2021-06-25<br />Medical condition: Amyotrophic Lateral Sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000579-19/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000579-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
462,6975,2022-03-29 22:12:24.268675,"An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choi...","<p>EudraCT Number: 2020-004505-32<br />Sponsor Protocol Number: COMB157G3301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-06-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004505-32,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
463,6974,2022-03-29 22:12:24.267781,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","<p>EudraCT Number: 2020-001168-28<br />Sponsor Protocol Number: GN42272<br />Sponsor Name: F. Hoffman-La Roche<br />Start Date: 2021-03-01<br />Medical condition: Relapsing multiple sclerosis (RMS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001168-28,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
464,6973,2022-03-29 22:12:24.267083,"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.","<p>EudraCT Number: 2005-001540-23<br />Sponsor Protocol Number: 309560<br />Sponsor Name: Schering Nordiska AB<br />Start Date: 2006-03-03<br />Medical condition: Early Secondary Progressive Multiple Sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001540-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
465,6972,2022-03-29 22:12:24.266425,"Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.
A cross-over, double-blinded, placebo-controlled study.","<p>EudraCT Number: 2012-005076-34<br />Sponsor Protocol Number: BEL-FMP-12-10325<br />Sponsor Name: Cliniques Universitaires Saint-Luc, Neurologie<br />Start Date: 2013-01-03<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005076-34/BE"">BE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005076-34,2012-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
466,6971,2022-03-29 22:12:24.265589,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN
PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...","<p>EudraCT Number: 2017-004886-29<br />Sponsor Protocol Number: MN39158<br />Sponsor Name: Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd<br />Start Date: 2018-05-22<br />Medical condition: Multiple sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004886-29,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
467,6970,2022-03-29 22:12:24.264629,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS","<p>EudraCT Number: 2020-000893-69<br />Sponsor Protocol Number: BN42082<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-10-28<br />Medical condition: Relapsing Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/IT"">IT</a> (Ongoing)</p>",https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=056-20,2020-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
468,6969,2022-03-29 22:12:24.263390,"Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis","<p>EudraCT Number: 2017-001362-25<br />Sponsor Protocol Number: RAM-MS<br />Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br />Start Date: 2018-05-02<br />Medical condition: Relapsing remitting multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001362-25,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
469,6968,2022-03-29 22:12:24.262728,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","<p>EudraCT Number: 2015-002500-91<br />Sponsor Protocol Number: RPC01-3001<br />Sponsor Name: Celgene International II Sàrl (CIS II)<br />Start Date: 2015-10-12<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002500-91,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
470,6967,2022-03-29 22:12:24.261935,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...","<p>EudraCT Number: 2019-004980-36<br />Sponsor Protocol Number: MS200527-0082<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-09-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004980-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
471,6966,2022-03-29 22:12:24.260701,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously ...,"<p>EudraCT Number: 2019-000069-19<br />Sponsor Protocol Number: MS700568_0026<br />Sponsor Name: Merck KGaA<br />Start Date: 2019-07-12<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/RO"">RO</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
472,6965,2022-03-29 22:12:24.260078,A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409),"<p>EudraCT Number: 2013-003884-71<br />Sponsor Protocol Number: LPS13649<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2015-02-05<br />Medical condition: Relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 17.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003884-71,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
473,6964,2022-03-29 22:12:24.259067,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002700-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
474,6963,2022-03-29 22:12:24.258411,A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis,"<p>EudraCT Number: 2015-005160-41<br />Sponsor Protocol Number: ALK8700-A301<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2016-07-27<br />Medical condition: Relapsing Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/BG"">BG</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005160-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
475,6962,2022-03-29 22:12:24.257643,Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS),"<p>EudraCT Number: 2018-004751-20<br />Sponsor Protocol Number: PB006-03-01<br />Sponsor Name: Polpharma Biologics S.A.<br />Start Date: 2019-07-22<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004751-20,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
476,6961,2022-03-29 22:12:24.256139,"AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2017-001313-93<br />Sponsor Protocol Number: MN39159<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2018-05-03<br />Medical condition: Progressive multiple sclerosis (PMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001313-93,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
477,6960,2022-03-29 22:12:23.976789,"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis","<p>EudraCT Number: 2008-003098-42<br />Sponsor Protocol Number: 108MS303<br />Sponsor Name: Biogen Idec Ltd<br />Start Date: 2009-01-06<br />Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003098-42,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
478,6533,2022-03-28 11:41:38.700399,Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study,<b>Conditions</b>:    Systemic Sclerosis;   Multisystem Disorder<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsors</b>:    Tsinghua University;   Peking Union Medical College Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05297474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-28 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
479,6530,2022-03-28 11:41:38.697822,Gait Analysis in Multiple Sclerosis Patients,<b>Conditions</b>:    Multiple Sclerosis;   3D Gait Analysis;   Vestibular Rehabilitation<br /><b>Interventions</b>:    Other: Vestibular exercises;   Other: Standard neurorehabilitation exercises<br /><b>Sponsors</b>:    Istanbul Kültür University;   Istanbul University-Cerrahpasa<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/show/NCT05299151,2022-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
480,5579,2022-03-25 11:41:38.145928,B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Ocrelizumab<br /><b>Sponsor</b>:    VU University Medical Center<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/show/NCT05296161,2022-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
481,5005,2022-03-23 14:40:22.014022,An Assistive Powered Wheelchair: Stage 2 Trial,<b>Conditions</b>:    Multiple Sclerosis;   Stroke;   Cystic Fibrosis;   Motor Neurone Disease;   Craniocerebral Trauma;   Guillain-Barre Syndrome<br /><b>Intervention</b>:    Device: Powered Wheelchair Obstacle Alerting System<br /><b>Sponsors</b>:    East Kent Hospitals University NHS Foundation Trust;   University of Kent;   Sussex Community NHS Foundation Trust;   KU Leuven;   l'Institut supérieur de l'électronique et du numérique (ISEN) Lille<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05292690?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-23 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
482,4667,2022-03-22 12:37:56.690857,Cellular microRNA Signatures in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Genetic: 50 ml blodd sampling<br /><b>Sponsors</b>:    Institut Pasteur;   Höpital La Pitié-Salpêtrière<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05290688?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-22 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
483,4027,2023-12-06 18:18:31.296123,Longitudinal Optic Neuritis Study (LONS),,http://clinicaltrials.gov/show/NCT00000147,1999-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
484,4026,2023-12-06 18:18:31.269259,Optic Neuritis Treatment Trial (ONTT),,http://clinicaltrials.gov/show/NCT00000146,1999-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
485,4025,2023-12-06 18:18:31.223805,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",,http://clinicaltrials.gov/show/NCT00001781,1999-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
486,4024,2023-12-06 18:18:31.203323,Assessment of Patients With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00001156,1999-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
487,4023,2023-12-06 18:18:31.183155,Zenapax to Treat Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00001934,1999-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
488,4022,2023-12-06 18:18:31.162249,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,,http://clinicaltrials.gov/show/NCT00001669,1999-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
489,4021,2023-12-06 18:18:31.140974,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00004814,2000-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
490,4020,2023-12-06 18:18:31.117292,"Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone",,http://clinicaltrials.gov/show/NCT00004645,2000-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
491,4019,2023-12-06 18:18:31.094996,A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00004816,2000-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
492,4018,2023-12-06 18:18:31.072023,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00004744,2000-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
493,4017,2023-12-06 18:18:31.039801,A multiple randomised controlled trial of cannabinoids on spasticity in multiple sclerosis (MS),,http://isrctn.com/ISRCTN39371386,2000-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
494,4016,2023-12-06 18:18:31.021186,Yoga: Effect on Attention in Aging & Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00010998,2001-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
495,4015,2023-12-06 18:18:30.999125,Natural Antioxidants in the Treatment of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00010842,2001-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
496,4014,2023-12-06 18:18:30.977759,Rolipram to Treat Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00011375,2001-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
497,4013,2023-12-06 18:18:30.956353,"Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00014755,2001-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
498,4012,2023-12-06 18:18:30.934467,Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00017628,2001-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
499,4011,2023-12-06 18:18:30.912612,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00027300,2001-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
500,4010,2023-12-06 18:18:30.892514,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00030966,2002-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
501,4009,2023-12-06 18:18:30.871315,A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00035529,2002-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
502,4008,2023-12-06 18:18:30.850560,"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.",,https://clinicaltrials.gov/show/NCT00037115,2002-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
503,4007,2023-12-06 18:18:30.830383,Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00037102,2002-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
504,4006,2023-12-06 18:18:30.810165,Auditory Function in Patients With and Without Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00037947,2002-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
505,4005,2023-12-06 18:18:30.788666,Treatment of Multiple Sclerosis With Copaxone and Albuterol,,https://clinicaltrials.gov/show/NCT00039988,2002-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
506,4004,2023-12-06 18:18:30.767921,High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00040482,2002-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
507,4003,2023-12-06 18:18:30.745013,Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00043264,2002-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
508,4002,2023-12-06 18:18:30.724717,Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.,,https://clinicaltrials.gov/show/NCT00047580,2002-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
509,4001,2023-12-06 18:18:30.703633,Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT00050232,2002-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
510,4000,2023-12-06 18:18:30.682984,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT00050778,2002-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
511,3999,2023-12-06 18:18:30.662195,Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00053417,2003-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
512,3998,2023-12-06 18:18:30.635078,Improving Memory in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00062972,2003-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
513,3997,2023-12-06 18:18:30.614707,MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00064909,2003-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
514,3996,2023-12-06 18:18:30.593731,Treatment of Multiple Sclerosis Using Over the Counter Inosine,,http://clinicaltrials.gov/show/NCT00067327,2003-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
515,3995,2023-12-06 18:18:30.572216,The evaluation and treatment of cognitive symptoms in patients with multiple sclerosis (MS),,http://isrctn.com/ISRCTN53885363,2003-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
516,3994,2023-12-06 18:18:30.552257,A randomised controlled trial of intravenous steroids at home versus outpatients department for treatment of acute multiple sclerosis relapses,,http://isrctn.com/ISRCTN95588376,2003-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
517,3993,2023-12-06 18:18:30.534861,Treadmill gait training for people with MS; does it improve gait or reduce fatigue?,,http://isrctn.com/ISRCTN78460965,2003-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
518,3992,2023-12-06 18:18:30.515622,A randomised controlled trial investigating the effectiveness of regular group aerobic exercise sessions on the health and psychological well-being of people with mild MS,,http://isrctn.com/ISRCTN14725356,2003-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
519,3991,2023-12-06 18:18:30.496019,Randomised placebo-controlled trial of intravenous methylprednisolone in relapsed multiple sclerosis patients without the need for ranitidine cover,,http://isrctn.com/ISRCTN46231139,2003-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
520,3990,2023-12-06 18:18:30.473650,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00071838,2003-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
521,3989,2023-12-06 18:18:30.450163,Development of a preventive oral health programme for Multiple Sclerosis (MS) patients,,http://isrctn.com/ISRCTN87621500,2004-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
522,3988,2023-12-06 18:18:30.429806,Evaluation of the effectiveness of professionally guided self care for consumers,,http://isrctn.com/ISRCTN59494484,2004-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
523,3987,2023-12-06 18:18:30.408673,Safety of RG2077 in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00076934,2004-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
524,3986,2023-12-06 18:18:30.386855,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00078338,2004-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
525,3985,2023-12-06 18:18:30.361237,Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00079495,2004-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
526,3984,2023-12-06 18:18:30.338232,"A Multi-center, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Methylprednisolone in Combination with Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis",,http://isrctn.com/ISRCTN68218781,2004-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
527,3983,2023-12-06 18:18:30.317206,"An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000047-18,2004-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
528,3982,2023-12-06 18:18:30.295733,Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00086671,2004-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
529,3981,2023-12-06 18:18:30.269424,A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00087529,2004-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
530,3980,2023-12-06 18:18:30.244818,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000462-13,2004-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
531,3979,2023-12-06 18:18:30.224471,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000463-94,2004-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
532,3978,2023-12-06 18:18:30.204177,Informed Shared Decision making In Multiple Sclerosis immunotherapy (ISDIMS). A randomised controlled trial to investigate the effects of an evidence-based decision aid on decision-making about immunotherapy in multiple sclerosis.,,https://www.isrctn.com/ISRCTN25267500,2004-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
533,3977,2023-12-06 18:18:30.180150,"Evidence-Based Self-management In Multiple Sclerosis (EBSIMS). A multi-centre, randomised controlled trial to investigate the effects of a structured educational programme on relapse management in Multiple Sclerosis.",,http://isrctn.com/ISRCTN73885145,2004-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
534,3976,2023-12-06 18:18:30.160621,"A Randomised, Double-blind, Placebo-controlled,  Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000374-31,2004-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
535,3975,2023-12-06 18:18:30.139787,"A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000145-38,2004-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
536,3974,2023-12-06 18:18:30.119808,"A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000555-42,2004-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
537,3973,2023-12-06 18:18:30.100635,The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT00094068,2004-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
538,3972,2023-12-06 18:18:30.078129,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00094172,2004-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
539,3971,2023-12-06 18:18:30.056216,"Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor",,https://clinicaltrials.gov/show/NCT00095329,2004-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
540,3970,2023-12-06 18:18:30.032390,A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00097188,2004-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
541,3969,2023-12-06 18:18:30.008963,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00097331,2004-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
542,3968,2023-12-06 18:18:29.987995,Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00097760,2004-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
543,3967,2023-12-06 18:18:29.950434,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-003943-28,2004-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
544,3966,2023-12-06 18:18:29.928755,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,,http://clinicaltrials.gov/show/NCT00099502,2004-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
545,3965,2023-12-06 18:18:29.906418,"A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004130-14,2005-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
546,3964,2023-12-06 18:18:29.885372,Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects,,http://clinicaltrials.gov/show/NCT00101959,2005-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
547,3963,2023-12-06 18:18:29.863211,A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002567-24,2005-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
548,3962,2023-12-06 18:18:29.815054,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000759-40,2005-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
549,3961,2023-12-06 18:18:29.791502,Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00103974,2005-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
550,3960,2023-12-06 18:18:29.768783,"A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002571-16,2005-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
551,3959,2023-12-06 18:18:29.746075,"A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002509-63,2005-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
552,3958,2023-12-06 18:18:29.727091,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT00104143,2005-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
553,3957,2023-12-06 18:18:29.692099,"A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000171-18,2005-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
554,3956,2023-12-06 18:18:29.671240,"A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis - Oral Cladribine versus Placebo in RRMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005148-28,2005-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
555,3955,2023-12-06 18:18:29.649165,"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00109161,2005-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
556,3954,2023-12-06 18:18:29.627404,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00110396,2005-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
557,3953,2023-12-06 18:18:29.606162,"Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001026-89,2005-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
558,3952,2023-12-06 18:18:29.585144,"AVONEX® Combination Trial - ""ACT""",,http://clinicaltrials.gov/show/NCT00112034,2005-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
559,3951,2023-12-06 18:18:29.563612,A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - UNKEMPT,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004903-39,2005-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
560,3950,2023-12-06 18:18:29.528837,Health Behavior Change in Chronic Disease Management,,http://clinicaltrials.gov/show/NCT00118547,2005-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
561,3949,2023-12-06 18:18:29.508337,A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001949-42,2005-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
562,3948,2023-12-06 18:18:29.475253,Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00122954,2005-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
563,3947,2023-12-06 18:18:29.442167,Study of Oral Fampridine-SR in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00127530,2005-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
564,3946,2023-12-06 18:18:29.421383,POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00127075,2005-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
565,3945,2023-12-06 18:18:29.386187,A randomised controlled trial of cognitive behavioural therapy for fatigue in patients with multiple sclerosis.,,https://anzctr.org.au/ACTRN12605000209695.aspx,2005-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
566,3944,2023-12-06 18:18:29.364092,EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00137176,2005-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
567,3943,2023-12-06 18:18:29.339550,"A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00139789,2005-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
568,3942,2023-12-06 18:18:29.302072,Study Evaluating Mitoxantrone in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00146159,2005-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
569,3941,2023-12-06 18:18:29.276704,EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00146068,2005-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
570,3940,2023-12-06 18:18:29.240569,Modafinil in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00142402,2005-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
571,3939,2023-12-06 18:18:29.217409,Stress Management for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00147446,2005-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
572,3938,2023-12-06 18:18:29.194954,Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval),,https://jrct.niph.go.jp/latest-detail/jRCT1080220031,2005-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
573,3937,2023-12-06 18:18:29.176783,The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00151294,2005-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
574,3936,2023-12-06 18:18:29.157099,Restoration of Walking in Multiple Sclerosis Using Treadmill Training.,,http://clinicaltrials.gov/show/NCT00156676,2005-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
575,3935,2023-12-06 18:18:29.124323,Efficacy and Safety of BG00012 in MS,,https://clinicaltrials.gov/ct2/show/NCT00168701,2005-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
576,3934,2023-12-06 18:18:29.100471,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00206635,2005-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
577,3933,2023-12-06 18:18:29.077131,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,,https://clinicaltrials.gov/show/NCT00185211,2005-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
578,3932,2023-12-06 18:18:29.057049,Pregnancy Exposure Registry for Avonex (Interferon Beta-1a),,http://clinicaltrials.gov/show/NCT00168714,2005-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
579,3931,2023-12-06 18:18:29.035631,Improving New Learning and Memory in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00166283,2005-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
580,3930,2023-12-06 18:18:29.011867,Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness,,https://clinicaltrials.gov/show/NCT00203021,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
581,3929,2023-12-06 18:18:28.987069,"A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose",,http://clinicaltrials.gov/show/NCT00202982,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
582,3928,2023-12-06 18:18:28.962773,Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00202410,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
583,3927,2023-12-06 18:18:28.924028,Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia,,http://clinicaltrials.gov/show/NCT00202397,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
584,3926,2023-12-06 18:18:28.902681,"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - BECAUSE - Betaferon in Early SPMS - SCAndinavian study on USE of double dose",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001540-23,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
585,3925,2023-12-06 18:18:28.882275,Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00179478,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
586,3924,2023-12-06 18:18:28.859384,Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00200655,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
587,3923,2023-12-06 18:18:28.835407,Study on Cognitive Disorders of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01074619,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
588,3922,2023-12-06 18:18:28.811725,Multiple Sclerosis Rehabilitation Study,,http://clinicaltrials.gov/show/NCT00202254,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
589,3921,2023-12-06 18:18:28.789265,Gene Expression in MS Patients Before and During Treatment With Interferon-beta,,https://clinicaltrials.gov/show/NCT00202384,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
590,3920,2023-12-06 18:18:28.766112,A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.,,http://clinicaltrials.gov/show/NCT00203073,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
591,3919,2023-12-06 18:18:28.742123,"Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00190268,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
592,3918,2023-12-06 18:18:28.703460,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,,http://clinicaltrials.gov/show/NCT00206648,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
593,3917,2023-12-06 18:18:28.681372,Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline,,http://clinicaltrials.gov/show/NCT00203112,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
594,3916,2023-12-06 18:18:28.657863,A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00203086,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
595,3915,2023-12-06 18:18:28.636707,Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine,,http://clinicaltrials.gov/show/NCT00203099,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
596,3914,2023-12-06 18:18:28.614341,"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT00220779,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
597,3913,2023-12-06 18:18:28.591871,A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT00213135,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
598,3912,2023-12-06 18:18:28.567387,Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate,,https://clinicaltrials.gov/show/NCT00203047,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
599,3911,2023-12-06 18:18:28.542630,Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx,,https://clinicaltrials.gov/show/NCT00211887,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
600,3910,2023-12-06 18:18:28.520488,A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00207727,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
601,3909,2023-12-06 18:18:28.498318,Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS,,http://clinicaltrials.gov/show/NCT00202995,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
602,3908,2023-12-06 18:18:28.475075,"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI",,http://clinicaltrials.gov/show/NCT00176592,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
603,3907,2023-12-06 18:18:28.400575,"Fluoxetine therapy in Multiple Sclerosis. 
A double blind, randomised, placebo-controlled, phase II study in patients with relapsing Multiple Sclerosis.",,https://www.onderzoekmetmensen.nl/en/trial/23750,2005-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
604,3906,2023-12-06 18:18:28.382157,Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00223457,2005-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
605,3905,2023-12-06 18:18:28.361985,Study Evaluating CCI-779 in Relapsing Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00228397,2005-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
606,3904,2023-12-06 18:18:28.339981,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00219908,2005-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
607,3903,2023-12-06 18:18:28.319475,Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00223301,2005-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
608,3902,2023-12-06 18:18:28.298972,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.,,http://clinicaltrials.gov/show/NCT00220922,2005-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
609,3901,2023-12-06 18:18:28.278104,A double-blind placebo-controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS),,http://isrctn.com/ISRCTN98373474,2005-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
610,3900,2023-12-06 18:18:28.243480,A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®,,https://clinicaltrials.gov/show/NCT00239993,2005-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
611,3899,2023-12-06 18:18:28.207618,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,,http://clinicaltrials.gov/show/NCT00228163,2005-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
612,3898,2023-12-06 18:18:28.185346,Cognitive Effects of Immunomodulatory Drugs in MS,,http://clinicaltrials.gov/show/NCT00229502,2005-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
613,3897,2023-12-06 18:18:28.152169,A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003410-15,2005-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
614,3896,2023-12-06 18:18:28.131933,Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS,,http://clinicaltrials.gov/show/NCT00232193,2005-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
615,3895,2023-12-06 18:18:28.109980,The effects of exercise upon health related quality of life in multiple sclerosis patients,,http://isrctn.com/ISRCTN23845069,2005-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
616,3894,2023-12-06 18:18:28.089276,A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis,,http://isrctn.com/ISRCTN31557558,2005-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
617,3893,2023-12-06 18:18:28.069283,Rehabilitation of Memory in Neurological Disabilities - Pilot study,,http://isrctn.com/ISRCTN92582254,2005-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
618,3892,2023-12-06 18:18:28.050945,"A Preliminary Investigation Into The Effect Of Home Standing Programs On Lower Limb Spasticity, Spasm, Pain and Well-being For Individuals With Progressive Multiple Sclerosis (MS)",,http://isrctn.com/ISRCTN34844778,2005-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
619,3891,2023-12-06 18:18:28.032485,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00235989,2005-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
620,3890,2023-12-06 18:18:28.011631,A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy,,http://clinicaltrials.gov/show/NCT00238654,2005-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
621,3889,2023-12-06 18:18:27.990719,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.,,http://clinicaltrials.gov/show/NCT00240032,2005-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
622,3888,2023-12-06 18:18:27.970098,A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone,,http://clinicaltrials.gov/show/NCT00240006,2005-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
623,3887,2023-12-06 18:18:27.948271,A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED),,https://clinicaltrials.gov/show/NCT00239655,2005-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
624,3886,2023-12-06 18:18:27.926992,Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00241254,2005-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
625,3885,2023-12-06 18:18:27.893203,Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability,,https://clinicaltrials.gov/show/NCT00242177,2005-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
626,3884,2023-12-06 18:18:27.862224,Autologous T Cell Vaccine (TCV) for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00245622,2005-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
627,3883,2023-12-06 18:18:27.841968,Functioning & Disability and Quality of Life in an Australian Community Cohorts with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12605000676617.aspx,2005-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
628,3882,2023-12-06 18:18:27.821417,TYSABRI Long Term Re-Dosing Study,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004061-41,2005-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
629,3881,2023-12-06 18:18:27.802269,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00246324,2005-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
630,3880,2023-12-06 18:18:27.781773,"Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie

A monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004403-37,2005-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
631,3879,2023-12-06 18:18:27.759870,"An extended clinical study in subjects with multiple sclerosis who successfully completed the LAQ/5062 and LAQ/5063 study, to assess the safety of laquinimod (experimental drug) when taken for a long period of time and how it affects the course of the disease.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004334-41,2005-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
632,3878,2023-12-06 18:18:27.737617,Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00248378,2005-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
633,3877,2023-12-06 18:18:27.715274,"A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis - D2301",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000365-19,2005-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
634,3876,2023-12-06 18:18:27.695056,"A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004289-18,2005-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
635,3875,2023-12-06 18:18:27.672558,"A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003930-16,2005-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
636,3874,2023-12-06 18:18:27.639697,"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation",,https://anzctr.org.au/ACTRN12605000769684.aspx,2005-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
637,3873,2023-12-06 18:18:27.618954,Simvastatin Treatment of Patients With Acute Optic Neuritis,,http://clinicaltrials.gov/show/NCT00261326,2005-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
638,3872,2023-12-06 18:18:27.598194,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",,https://clinicaltrials.gov/show/NCT00262314,2005-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
639,3871,2023-12-06 18:18:27.576134,A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005211-21,2005-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
640,3870,2023-12-06 18:18:27.554924,"Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005263-29,2005-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
641,3869,2023-12-06 18:18:27.532107,: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003903-35,2005-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
642,3868,2023-12-06 18:18:27.511342,FOCUS Fatigue Outcome in Copaxone USers,,http://clinicaltrials.gov/show/NCT00267319,2005-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
643,3867,2023-12-06 18:18:27.489366,Interferon ß-1b Treatment by Cyclical Administration,,https://clinicaltrials.gov/show/NCT00270816,2005-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
644,3866,2023-12-06 18:18:27.465233,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,,https://clinicaltrials.gov/show/NCT00273364,2006-05-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
645,3865,2023-12-06 18:18:27.443058,Open-Label Natalizumab Safety Extension Study,,http://clinicaltrials.gov/show/NCT00276172,2006-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
646,3864,2023-12-06 18:18:27.420213,Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00276341,2006-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
647,3863,2023-12-06 18:18:27.398312,Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00278655,2006-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
648,3862,2023-12-06 18:18:27.376020,Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT00280592,2006-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
649,3861,2023-12-06 18:18:27.354552,The safety of Cpn10 in patients with multiple sclerosis,,https://anzctr.org.au/ACTRN12606000037505.aspx,2006-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
650,3860,2023-12-06 18:18:27.335451,Natalizumab Re-Initiation of Dosing,,https://clinicaltrials.gov/show/NCT00306592,2006-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
651,3859,2023-12-06 18:18:27.308114,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,,https://clinicaltrials.gov/show/NCT00288626,2006-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
652,3858,2023-12-06 18:18:27.284282,Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up,,http://clinicaltrials.gov/show/NCT00289159,2006-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
653,3857,2023-12-06 18:18:27.262666,A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00288990,2006-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
654,3856,2023-12-06 18:18:27.240479,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00289978,2006-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
655,3855,2023-12-06 18:18:27.218927,Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain,,http://clinicaltrials.gov/show/NCT00291148,2006-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
656,3854,2023-12-06 18:18:27.196692,A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00292266,2006-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
657,3853,2023-12-06 18:18:27.171533,Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects,,http://clinicaltrials.gov/show/NCT00292253,2006-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
658,3852,2023-12-06 18:18:27.149945,CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis - CogniMS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005989-37,2006-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
659,3851,2023-12-06 18:18:27.129315,A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy Study,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005751-18,2006-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
660,3850,2023-12-06 18:18:27.109772,Phase II High-Dose Cyclophosphamide for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00296205,2006-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
661,3849,2023-12-06 18:18:27.086847,"A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.

                This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005265-11,2006-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
662,3848,2023-12-06 18:18:27.066466,Natalizumab (Tysabri) Re-Initiation of Dosing,,https://clinicaltrials.gov/show/NCT00297232,2006-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
663,3847,2023-12-06 18:18:27.041793,Combination Therapy of Betaseron-Prograf in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00298662,2006-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
664,3846,2023-12-06 18:18:27.018371,Trial of Memantine for Cognitive Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00300716,2006-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
665,3845,2023-12-06 18:18:26.994201,"Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001009-25,2006-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
666,3844,2023-12-06 18:18:26.943152,A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties,,http://clinicaltrials.gov/show/NCT00315367,2006-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
667,3843,2023-12-06 18:18:26.920899,Betaseron Pregnancy Registry,,https://clinicaltrials.gov/show/NCT00317564,2006-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
668,3842,2023-12-06 18:18:26.892434,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,,https://clinicaltrials.gov/show/NCT00317941,2006-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
669,3841,2023-12-06 18:18:26.858054,Cognitive-behavior Therapy for MS-Related Chronic Pain,,https://clinicaltrials.gov/show/NCT00323271,2006-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
670,3840,2023-12-06 18:18:26.837431,Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00324506,2006-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
671,3839,2023-12-06 18:18:26.815332,"Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine  Vitamin B12  plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-006071-12,2006-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
672,3838,2023-12-06 18:18:26.792224,"A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase - D2302 & E1",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000704-17,2006-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
673,3837,2023-12-06 18:18:26.770516,"Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005592-14,2006-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
674,3836,2023-12-06 18:18:26.750741,Biomarkers in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00325988,2006-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
675,3835,2023-12-06 18:18:26.726046,"Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting multiple sclerosis. - SELECT",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001161-42,2006-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
676,3834,2023-12-06 18:18:26.702638,"A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002037-20,2006-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
677,3833,2023-12-06 18:18:26.665104,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00333138,2006-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
678,3832,2023-12-06 18:18:26.642129,Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness,,http://clinicaltrials.gov/show/NCT00334100,2006-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
679,3831,2023-12-06 18:18:26.618260,Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy,,http://clinicaltrials.gov/show/NCT00336557,2006-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
680,3830,2023-12-06 18:18:26.593817,Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).,,https://clinicaltrials.gov/show/NCT00337779,2006-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
681,3829,2023-12-06 18:18:26.571439,Safety and Efficacy Study of Oral IFN-tau in Patients with Relapsing-Remitting Multiple Sclerosis,,https://anzctr.org.au/ACTRN12606000241538.aspx,2006-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
682,3828,2023-12-06 18:18:26.552107,Rebif® Pregnancy Registry,,https://clinicaltrials.gov/show/NCT00338741,2006-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
683,3827,2023-12-06 18:18:26.531076,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,,https://clinicaltrials.gov/show/NCT00340834,2006-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
684,3826,2023-12-06 18:18:26.510295,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00342134,2006-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
685,3825,2023-12-06 18:18:26.473646,Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation,,http://clinicaltrials.gov/show/NCT00342381,2006-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
686,3824,2023-12-06 18:18:26.452245,Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study,,http://clinicaltrials.gov/show/NCT00343590,2006-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
687,3823,2023-12-06 18:18:26.414509,"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005985-35,2006-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
688,3822,2023-12-06 18:18:26.395630,Monotherapy Phase II Dose Ranging Study of DAC HYP in Relapsing Remitting Multiple Sclerosis,,https://anzctr.org.au/ACTRN12606000306516.aspx,2006-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
689,3821,2023-12-06 18:18:26.377828,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00355134,2006-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
690,3820,2023-12-06 18:18:26.331751,Omega-3 Fatty Acid Treatment in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00360906,2006-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
691,3819,2023-12-06 18:18:26.310887,"A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001947-70,2006-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
692,3818,2023-12-06 18:18:26.291520,"Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002633-20,2006-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
693,3817,2023-12-06 18:18:26.272074,Dexamethason for the treatment of exacerbations in multiple sclerosis.,,https://www.onderzoekmetmensen.nl/en/trial/22907,2006-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
694,3816,2023-12-06 18:18:26.251517,Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00364936,2006-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
695,3815,2023-12-06 18:18:26.229433,The Myer Foundation Study into Multiple Sclerosis,,https://anzctr.org.au/ACTRN12606000359538.aspx,2006-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
696,3814,2023-12-06 18:18:26.207390,Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00367484,2006-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
697,3813,2023-12-06 18:18:26.186366,"A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002361-39,2006-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
698,3812,2023-12-06 18:18:26.164937,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT00370071,2006-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
699,3811,2023-12-06 18:18:26.140585,Casemanagement for people with Multiple Sclerosis.,,https://www.onderzoekmetmensen.nl/en/trial/24943,2006-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
700,3810,2023-12-06 18:18:26.113930,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,,https://clinicaltrials.gov/show/NCT00376506,2006-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
701,3809,2023-12-06 18:18:26.090345,"A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002982-38,2006-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
702,3808,2023-12-06 18:18:26.069828,Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00381264,2006-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
703,3807,2023-12-06 18:18:26.033980,BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00382629,2006-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
704,3806,2023-12-06 18:18:26.013914,Multiple Sclerosis and Heavy Progressive Resistance Training,,http://clinicaltrials.gov/show/NCT00381576,2006-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
705,3805,2023-12-06 18:18:25.992196,"Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003361-14,2006-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
706,3804,2023-12-06 18:18:25.971614,Feasibility study to compare self-help interventions of fatigue management in patients with multiple sclerosis: a randomised controlled trial,,http://isrctn.com/ISRCTN43867447,2006-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
707,3803,2023-12-06 18:18:25.950711,fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls,,http://clinicaltrials.gov/show/NCT00391352,2006-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
708,3802,2023-12-06 18:18:25.926852,Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS,,https://clinicaltrials.gov/show/NCT00391079,2006-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
709,3801,2023-12-06 18:18:25.905742,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00099307,2004-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
710,3800,2023-12-06 18:18:25.881884,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00395317,2006-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
711,3799,2023-12-06 18:18:25.861992,Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS),,http://clinicaltrials.gov/show/NCT00395200,2006-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
712,3798,2023-12-06 18:18:25.840473,"Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with central neuropathic pain",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004255-38,2006-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
713,3797,2023-12-06 18:18:25.820950,"Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002856-14,2006-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
714,3796,2023-12-06 18:18:25.801970,"A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine 
for Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003384-30,2006-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
715,3795,2023-12-06 18:18:25.782123,An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00398528,2006-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
716,3794,2023-12-06 18:18:25.759543,"A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003037-32,2006-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
717,3793,2023-12-06 18:18:25.737675,Testosterone Treatment for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00405353,2006-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
718,3792,2023-12-06 18:18:25.697313,Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00411723,2006-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
719,3791,2023-12-06 18:18:25.674997,Efficacy of client-centred occupational therapy in patients with multiple sclerosis: a cluster-randomised trial.,,https://www.onderzoekmetmensen.nl/en/trial/22768,2006-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
720,3790,2023-12-06 18:18:25.654116,"A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004893-29,2006-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
721,3789,2023-12-06 18:18:25.632898,"International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg  and (Phase B) open-label Betaseron/Betaferon 500 µg


                version: final internal approved
 - Beyond Follow-up",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005270-47,2006-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
722,3788,2023-12-06 18:18:25.611970,Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00414453,2006-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
723,3787,2023-12-06 18:18:25.588036,Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks,,https://clinicaltrials.gov/show/NCT00418145,2007-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
724,3786,2023-12-06 18:18:25.554999,Levetiracetam in Central Pain in Multiple Sclerosis(MS),,http://clinicaltrials.gov/show/NCT00423527,2007-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
725,3785,2023-12-06 18:18:25.533946,Ambulation Study in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00424359,2007-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
726,3784,2023-12-06 18:18:25.511872,A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00424788,2007-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
727,3783,2023-12-06 18:18:25.476696,RNF and Betaseron® Tolerability Study,,https://clinicaltrials.gov/show/NCT00428584,2007-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
728,3782,2023-12-06 18:18:25.420669,The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00430599,2007-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
729,3781,2023-12-06 18:18:25.394688,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00432900,2007-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
730,3780,2023-12-06 18:18:25.370141,"Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002204-33,2007-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
731,3779,2023-12-06 18:18:25.349090,"A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003134-14,2007-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
732,3778,2023-12-06 18:18:25.311340,An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-007057-42,2007-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
733,3777,2023-12-06 18:18:25.286223,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),,https://clinicaltrials.gov/show/NCT00436826,2007-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
734,3776,2023-12-06 18:18:25.261762,"Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)",,http://clinicaltrials.gov/show/NCT00439257,2007-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
735,3775,2023-12-06 18:18:25.238210,"A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/A",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003697-10,2007-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
736,3774,2023-12-06 18:18:25.217745,"Effect of Cannabis Based Medicine Extract  Sativex  on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis  a double blind, randomised, placebo-controlled, crossover study.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000393-47,2007-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
737,3773,2023-12-06 18:18:25.195674,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006323-39,2007-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
738,3772,2023-12-06 18:18:25.173286,Biobank For MS And Other Demyelinating Diseases,,https://clinicaltrials.gov/show/NCT00445367,2007-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
739,3771,2023-12-06 18:18:25.150963,Flupirtin as Oral Treatment in MS - FLORIMS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005262-39,2007-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
740,3770,2023-12-06 18:18:25.114489,"A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established Spasticity Resulting from Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000236-16,2007-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
741,3769,2023-12-06 18:18:25.091228,A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT00451204,2007-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
742,3768,2023-12-06 18:18:25.053328,Avonex dose titration study in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12607000184471.aspx,2007-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
743,3767,2023-12-06 18:18:25.029971,A Study to Test the Use of Duloxetine for Pain in MS,,https://clinicaltrials.gov/show/NCT00457730,2007-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
744,3766,2023-12-06 18:18:25.006154,"A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005972-42,2007-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
745,3765,2023-12-06 18:18:24.984214,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",,http://clinicaltrials.gov/show/NCT00461396,2007-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
746,3764,2023-12-06 18:18:24.956377,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,,https://clinicaltrials.gov/ct2/show/NCT00464074,2007-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
747,3763,2023-12-06 18:18:24.935147,Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS,,http://clinicaltrials.gov/show/NCT00463710,2007-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
748,3762,2023-12-06 18:18:24.897243,One Year Extension Study To Protocol C2/5/TZ:MS-05,,http://clinicaltrials.gov/show/NCT00464958,2007-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
749,3761,2023-12-06 18:18:24.874420,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000192-42,2007-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
750,3760,2023-12-06 18:18:24.852472,Aspirin for Treatment of Multiple Sclerosis-Related Fatigue,,https://clinicaltrials.gov/show/NCT00467584,2007-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
751,3759,2023-12-06 18:18:24.831697,Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00468182,2007-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
752,3758,2023-12-06 18:18:24.812319,Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00468611,2007-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
753,3757,2023-12-06 18:18:24.784180,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00469378,2007-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
754,3756,2023-12-06 18:18:24.761137,Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006465-16,2007-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
755,3755,2023-12-06 18:18:24.739260,Rebif New Formulation (RNF) Quality of Life (QOL) Study,,https://clinicaltrials.gov/show/NCT00472797,2007-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
756,3754,2023-12-06 18:18:24.714344,Optimizing IFN Beta - 1B Dose,,http://clinicaltrials.gov/show/NCT00473213,2007-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
757,3753,2023-12-06 18:18:24.691503,Pregnancy Exposure Registry for Tysabri®,,http://clinicaltrials.gov/show/NCT00472992,2007-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
758,3752,2023-12-06 18:18:24.650698,An open-label follow-on study to assess the ongoing safety of MBP8298 in subjects with secondary progressive multiple sclerosis,,http://isrctn.com/ISRCTN31894936,2007-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
759,3751,2023-12-06 18:18:24.629122,TYSABRI Global Observational Program in Safety,,http://clinicaltrials.gov/show/NCT00477113,2007-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
760,3750,2023-12-06 18:18:24.592956,Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00480181,2007-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
761,3749,2023-12-06 18:18:24.570163,TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World,,http://clinicaltrials.gov/show/NCT00483847,2007-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
762,3748,2023-12-06 18:18:24.545686,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT00483652,2007-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
763,3747,2023-12-06 18:18:24.508898,"A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002138-13,2007-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
764,3746,2023-12-06 18:18:24.488701,IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00488839,2007-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
765,3745,2023-12-06 18:18:24.465706,"A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006872-39,2007-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
766,3744,2023-12-06 18:18:24.441411,Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00490906,2007-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
767,3743,2023-12-06 18:18:24.411132,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,,http://clinicaltrials.gov/show/NCT00493116,2007-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
768,3742,2023-12-06 18:18:24.386685,Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy,,http://clinicaltrials.gov/show/NCT00493077,2007-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
769,3741,2023-12-06 18:18:24.364618,Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00492765,2007-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
770,3740,2023-12-06 18:18:24.343766,GER-009-06-AVX Early Therapy in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00492570,2007-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
771,3739,2023-12-06 18:18:24.322012,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,,http://clinicaltrials.gov/show/NCT00492466,2007-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
772,3738,2023-12-06 18:18:24.291838,Tysabri Observational Program,,https://clinicaltrials.gov/show/NCT00493298,2007-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
773,3737,2023-12-06 18:18:24.251474,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT00497952,2007-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
774,3736,2023-12-06 18:18:24.229290,"Visual Impairment, Oscillopsia and Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT00498199,2007-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
775,3735,2023-12-06 18:18:24.205173,"A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005910-11,2007-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
776,3734,2023-12-06 18:18:24.181011,"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone",,http://clinicaltrials.gov/show/NCT00501696,2007-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
777,3733,2023-12-06 18:18:24.160459,Neuroprotection With Riluzole Patients With Early Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00501943,2007-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
778,3732,2023-12-06 18:18:24.136271,"Study Title:  A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003226-19,2007-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
779,3731,2023-12-06 18:18:24.113207,Whole Body Vibration Therapy in Participants With MS Related Balance Deficits,,http://clinicaltrials.gov/show/NCT00510523,2007-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
780,3730,2023-12-06 18:18:24.090436,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001161-14,2007-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
781,3729,2023-12-06 18:18:24.068508,"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006299-39,2007-06-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
782,3728,2023-12-06 18:18:24.047189,A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006347-31,2007-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
783,3727,2023-12-06 18:18:24.026345,Promoting Physical Activity for Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00513448,2007-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
784,3726,2023-12-06 18:18:23.986554,"A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity. - SONIC",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005523-42,2007-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
785,3725,2023-12-06 18:18:23.949220,Natalizumab High Titer Immunogenicity and Safety,,https://clinicaltrials.gov/show/NCT00516893,2007-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
786,3724,2023-12-06 18:18:23.926321,"Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer acetate in patients with multiple sclerosis with relapses",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003997-24,2007-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
787,3723,2023-12-06 18:18:23.907564,Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),,https://clinicaltrials.gov/show/NCT00525668,2007-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
788,3722,2023-12-06 18:18:23.886886,Avonex 15 Year Long Term Follow-up Study,,http://clinicaltrials.gov/show/NCT00525343,2007-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
789,3721,2023-12-06 18:18:23.865959,"An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001152-12,2007-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
790,3720,2023-12-06 18:18:23.847221,"Effectiveness of robotic-assisted walking (lokomat) on quality of life, gait, activity level, and balance in patients with multiple sclerosis",,http://isrctn.com/ISRCTN69803702,2007-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
791,3719,2023-12-06 18:18:23.827407,A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00529581,2007-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
792,3718,2023-12-06 18:18:23.800929,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",,https://clinicaltrials.gov/show/NCT00530348,2007-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
793,3717,2023-12-06 18:18:23.765319,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,,http://clinicaltrials.gov/show/NCT00534261,2007-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
794,3716,2023-12-06 18:18:23.737942,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00536120,2007-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
795,3715,2023-12-06 18:18:23.707968,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00537082,2007-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
796,3714,2023-12-06 18:18:23.679821,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001162-32,2007-04-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
797,3713,2023-12-06 18:18:23.655013,CLARITY Extension Study,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000381-20,2007-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
798,3712,2023-12-06 18:18:23.631334,BENEFIT Extension Study,,http://clinicaltrials.gov/show/NCT00544037,2007-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
799,3711,2023-12-06 18:18:23.606876,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",,https://clinicaltrials.gov/show/NCT00548405,2007-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
800,3710,2023-12-06 18:18:23.575627,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT00548769,2007-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
801,3709,2023-12-06 18:18:23.551213,Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie - MIMIK,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001962-34,2007-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
802,3708,2023-12-06 18:18:23.529796,Safety Study of Natalizumab to Treat Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00559702,2007-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
803,3707,2023-12-06 18:18:23.491985,Effective exercise for people with Multiple Sclerosis,,http://isrctn.com/ISRCTN89009719,2007-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
804,3706,2023-12-06 18:18:23.439348,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004223-38,2007-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
805,3705,2023-12-06 18:18:23.405256,Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001958-99,2007-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
806,3704,2023-12-06 18:18:23.368824,How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose,,http://clinicaltrials.gov/show/NCT00574041,2007-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
807,3703,2023-12-06 18:18:23.343628,"An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004122-24,2007-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
808,3702,2023-12-06 18:18:23.324653,Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00587691,2007-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
809,3701,2023-12-06 18:18:23.302536,FolateScan in Autoimmune Disease,,http://clinicaltrials.gov/show/NCT00588393,2007-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
810,3700,2023-12-06 18:18:23.276831,Teleconference Fatigue Management for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00591721,2007-12-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
811,3699,2023-12-06 18:18:23.237759,Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00595920,2008-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
812,3698,2023-12-06 18:18:23.215886,Eszopiclone for Improving Sleep in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00594087,2008-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
813,3697,2023-12-06 18:18:23.193879,BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon ß-1a (Avonex®),,https://clinicaltrials.gov/show/NCT00605215,2008-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
814,3696,2023-12-06 18:18:23.168908,HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS - ND,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000586-38,2008-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
815,3695,2023-12-06 18:18:23.147682,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00599274,2008-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
816,3694,2023-12-06 18:18:23.116970,"A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3. - SM3",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002305-23,2008-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
817,3693,2023-12-06 18:18:23.094719,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects,,https://clinicaltrials.gov/show/NCT00612872,2008-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
818,3692,2023-12-06 18:18:23.074561,Locomotor Training in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00607126,2008-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
819,3691,2023-12-06 18:18:23.054364,"Etude pilote multicentrique de phase IV, en ouvert, randomisée, en groupe parallèles destinée à évaluer l'éfficacité d'un protocole de rééducation fonctionnelle des patients atteints d'une forme récurrente/rémittente de sclérose en plaques et traités par Betaferon. - KinéSEP",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006673-24,2008-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
820,3690,2023-12-06 18:18:23.034955,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta 1a (Rebif®) as an open-label rater-blind calibrator,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004452-36,2008-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
821,3689,2023-12-06 18:18:23.015824,12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT00616733,2008-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
822,3688,2023-12-06 18:18:22.993903,AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS,,https://clinicaltrials.gov/show/NCT00617383,2008-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
823,3687,2023-12-06 18:18:22.972879,Atorvastatin in Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00616187,2008-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
824,3686,2023-12-06 18:18:22.948364,Motor Imagery Practice in Neurological Rehabilitation,,http://clinicaltrials.gov/show/NCT00618085,2008-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
825,3685,2023-12-06 18:18:22.924681,Combination Therapy Using Cellcept and Rebif in RRMS,,http://clinicaltrials.gov/show/NCT00618527,2008-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
826,3684,2023-12-06 18:18:22.890328,Transition to Rebif New Formulation,,https://clinicaltrials.gov/show/NCT00619307,2008-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
827,3683,2023-12-06 18:18:22.870336,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow®"" Assay.",,http://clinicaltrials.gov/show/NCT00618267,2008-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
828,3682,2023-12-06 18:18:22.849368,Management of Pain in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00621374,2008-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
829,3681,2023-12-06 18:18:22.829224,Flupirtine as Oral Treatment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00623415,2008-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
830,3680,2023-12-06 18:18:22.808687,"Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006338-32,2008-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
831,3679,2023-12-06 18:18:22.776049,Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.,,http://clinicaltrials.gov/show/NCT00630383,2008-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
832,3678,2023-12-06 18:18:22.756142,Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells,,https://clinicaltrials.gov/show/NCT00630721,2008-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
833,3677,2023-12-06 18:18:22.732358,"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001377-28,2008-02-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
834,3676,2023-12-06 18:18:22.711460,Memantine for Spasticity in MS Patients,,https://clinicaltrials.gov/show/NCT00638027,2008-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
835,3675,2023-12-06 18:18:22.689319,Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS,,https://clinicaltrials.gov/show/NCT00638196,2008-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
836,3674,2023-12-06 18:18:22.667066,Memantine Therapy for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00638833,2008-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
837,3673,2023-12-06 18:18:22.631869,A global clinical study in patients with relapsing-remitting multiple sclerosis to investigate the effect of two different dose regimens of ocrelizumab compared to a placebo or Avonex by measuring the effect on brain lesions seen on MRI,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006338-32,2008-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
838,3672,2023-12-06 18:18:22.607958,Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients,,https://clinicaltrials.gov/show/NCT00640328,2008-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
839,3671,2023-12-06 18:18:22.584405,"Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000490-37,2008-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
840,3670,2023-12-06 18:18:22.565615,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),,https://clinicaltrials.gov/show/NCT00642902,2008-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
841,3669,2023-12-06 18:18:22.544295,Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00644904,2008-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
842,3668,2023-12-06 18:18:22.520922,Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00645749,2008-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
843,3667,2023-12-06 18:18:22.497253,Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00647348,2008-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
844,3666,2023-12-06 18:18:22.474393,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",,https://clinicaltrials.gov/show/NCT00649792,2008-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
845,3665,2023-12-06 18:18:22.450912,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",,https://clinicaltrials.gov/show/NCT00648908,2008-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
846,3664,2023-12-06 18:18:22.428517,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT00654927,2008-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
847,3663,2023-12-06 18:18:22.406452,efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002627-32,2008-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
848,3662,2023-12-06 18:18:22.384543,The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007394-22,2008-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
849,3661,2023-12-06 18:18:22.362741,Cognitive behavioural therapy (CBT) for adjustment to early stage multiple sclerosis: Manual development and a randomised controlled trial comparing CBT to supportive listening,,http://isrctn.com/ISRCTN91377356,2008-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
850,3660,2023-12-06 18:18:22.329616,Telephone Intervention for Pain Study (TIPS),,http://clinicaltrials.gov/show/NCT00663663,2008-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
851,3659,2023-12-06 18:18:22.303217,Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT00666224,2008-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
852,3658,2023-12-06 18:18:22.278883,Minocycline in Clinically Isolated Syndromes (CIS),,https://clinicaltrials.gov/show/NCT00666887,2008-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
853,3657,2023-12-06 18:18:22.254914,Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo,,http://clinicaltrials.gov/show/NCT00668343,2008-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
854,3656,2023-12-06 18:18:22.234099,An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00670449,2008-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
855,3655,2023-12-06 18:18:22.212792,Effectiveness of a Structured Information interview in people with newly-diagnosed Multiple Sclerosis,,http://isrctn.com/ISRCTN81072971,2008-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
856,3654,2023-12-06 18:18:22.190734,"A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with relapsing remitting multiple sclerosis.",,https://anzctr.org.au/ACTRN12608000226303.aspx,2008-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
857,3653,2023-12-06 18:18:22.169916,Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00674934,2008-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
858,3652,2023-12-06 18:18:22.145918,A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00676156,2008-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
859,3651,2023-12-06 18:18:22.124084,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,,http://clinicaltrials.gov/show/NCT00675883,2008-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
860,3650,2023-12-06 18:18:22.103192,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT00676715,2008-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
861,3649,2023-12-06 18:18:22.079781,"International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patients with relapsing form of multiple sclerosis (RMS) - RebiSmartTM in RMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000499-25,2008-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
862,3648,2023-12-06 18:18:22.058530,A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00678795,2008-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
863,3647,2023-12-06 18:18:22.035354,Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00678496,2008-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
864,3646,2023-12-06 18:18:22.013608,"Effects of a cognitive-behavioural mindfulness intervention upon quality of life, depression and fatigue among multiple sclerosis (MS) patients",,http://isrctn.com/ISRCTN21643919,2008-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
865,3645,2023-12-06 18:18:21.988338,Cannabis for Spasticity in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00260741,2005-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
866,3644,2023-12-06 18:18:21.967221,"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",,https://clinicaltrials.gov/show/NCT00681538,2008-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
867,3643,2023-12-06 18:18:21.946003,Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00688948,2008-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
868,3642,2023-12-06 18:18:21.926235,Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00695084,2008-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
869,3641,2023-12-06 18:18:21.901993,Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00702468,2008-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
870,3640,2023-12-06 18:18:21.878852,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",,http://clinicaltrials.gov/show/NCT00702065,2008-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
871,3639,2023-12-06 18:18:21.845309,Gene Expression Profiles in Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00704834,2008-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
872,3638,2023-12-06 18:18:21.824205,"A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. - N/A",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002096-27,2008-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
873,3637,2023-12-06 18:18:21.804710,Lido Workset Study,,https://clinicaltrials.gov/show/NCT00710645,2008-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
874,3636,2023-12-06 18:18:21.782173,A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT00711646,2008-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
875,3635,2023-12-06 18:18:21.762825,Cognitive Testing for the Pain Quality Assessment Scale (PQAS),,http://clinicaltrials.gov/show/NCT00715598,2008-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
876,3634,2023-12-06 18:18:21.727190,Amiloride Treatment in Multiple Sclerosis - Amiloride in MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004051-11,2008-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
877,3633,2023-12-06 18:18:21.707258,CDP323 Biomarker Study,,http://clinicaltrials.gov/show/NCT00726648,2008-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
878,3632,2023-12-06 18:18:21.685227,"A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFR",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002560-34,2008-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
879,3631,2023-12-06 18:18:21.659796,Oral Cladribine in Early Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00725985,2008-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
880,3630,2023-12-06 18:18:21.622725,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT00735007,2008-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
881,3629,2023-12-06 18:18:21.596379,"The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis
A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007759-15,2008-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
882,3628,2023-12-06 18:18:21.575120,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005213-22,2008-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
883,3627,2023-12-06 18:18:21.554370,A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State,,http://clinicaltrials.gov/show/NCT00744679,2008-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
884,3626,2023-12-06 18:18:21.533298,"An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease",,https://clinicaltrials.gov/show/NCT00745615,2008-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
885,3625,2023-12-06 18:18:21.515365,Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri,,http://clinicaltrials.gov/show/NCT00752778,2008-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
886,3624,2023-12-06 18:18:21.495540,"A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004579-22,2008-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
887,3623,2023-12-06 18:18:21.474985,American Ginseng Treatment for Multiple Sclerosis Related Fatigue,,https://clinicaltrials.gov/show/NCT00754832,2008-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
888,3622,2023-12-06 18:18:21.452240,Duloxetine for Multiple Sclerosis Pain,,https://clinicaltrials.gov/show/NCT00755807,2008-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
889,3621,2023-12-06 18:18:21.431447,Chronotherapy in Acute Multiple Sclerosis (MS) Attack,,http://clinicaltrials.gov/show/NCT00764413,2008-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
890,3620,2023-12-06 18:18:21.410266,Lokomat Training Effects on MS Gait Abnormalities,,http://clinicaltrials.gov/show/NCT00766272,2008-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
891,3619,2023-12-06 18:18:21.385311,Targeted Lower Extremity Joint Training,,http://clinicaltrials.gov/show/NCT00765544,2008-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
892,3618,2023-12-06 18:18:21.360074,"A Long-Term Open Label Extension Study to assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-007663-25,2008-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
893,3617,2023-12-06 18:18:21.340034,Cognitive behavioural therapy software for the treatment of depression in people with multiple sclerosis,,http://isrctn.com/ISRCTN81846800,2008-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
894,3616,2023-12-06 18:18:21.318127,A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a,,http://clinicaltrials.gov/show/NCT00771043,2008-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
895,3615,2023-12-06 18:18:21.298191,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis TOWER,,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=111-08,2008-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
896,3614,2023-12-06 18:18:21.278753,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00772525,2008-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
897,3613,2023-12-06 18:18:21.246433,Group exercise therapy for mobility and balance in people with multiple sclerosis,,http://isrctn.com/ISRCTN78227711,2008-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
898,3612,2023-12-06 18:18:21.218112,AIMSPRO® and the bladder in multiple sclerosis (MS),,http://isrctn.com/ISRCTN17551402,2008-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
899,3611,2023-12-06 18:18:21.172748,Mesenchymal Stem Cells for the Treatment of MS,,https://clinicaltrials.gov/show/NCT00781872,2008-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
900,3610,2023-12-06 18:18:21.152915,Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients,,https://clinicaltrials.gov/show/NCT00784836,2008-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
901,3609,2023-12-06 18:18:21.117996,Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00785473,2008-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
902,3608,2023-12-06 18:18:21.083371,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,,https://clinicaltrials.gov/show/NCT00787657,2008-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
903,3607,2023-12-06 18:18:21.056383,"Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple
___________________________________________________________________
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001999-67,2008-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
904,3606,2023-12-06 18:18:21.019414,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004954-34,2008-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
905,3605,2023-12-06 18:18:20.985420,Sunphenon in Progressive Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00799890,2008-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
906,3604,2023-12-06 18:18:20.963520,An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005559-46,2008-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
907,3603,2023-12-06 18:18:20.942756,A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005304-93,2008-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
908,3602,2023-12-06 18:18:20.921298,"An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) - Atacicept 28063 (RMS) extension study",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005021-11,2008-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
909,3601,2023-12-06 18:18:20.900757,Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00819195,2008-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
910,3600,2023-12-06 18:18:20.879806,,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003696-12,2006-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
911,3599,2023-12-06 18:18:20.855630,Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00812474,2008-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
912,3598,2023-12-06 18:18:20.834713,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,,https://clinicaltrials.gov/show/NCT00813969,2008-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
913,3597,2023-12-06 18:18:20.811840,Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004753-14,2008-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
914,3596,2023-12-06 18:18:20.790625,"Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007459-28,2008-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
915,3595,2023-12-06 18:18:20.758583,Feasibility of abdominal massage for the alleviation of the symptoms of constipation in people with multiple sclerosis,,http://isrctn.com/ISRCTN01328898,2009-05-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
916,3594,2023-12-06 18:18:20.738403,A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function,,http://clinicaltrials.gov/show/NCT00818038,2009-05-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
917,3593,2023-12-06 18:18:20.718692,Therapy Optimization in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00819000,2009-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
918,3592,2023-12-06 18:18:20.698117,A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005125-11,2009-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
919,3591,2023-12-06 18:18:20.672442,"AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,
randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001031-63,2007-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
920,3590,2023-12-06 18:18:20.650547,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,,https://clinicaltrials.gov/show/NCT00828204,2009-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
921,3589,2023-12-06 18:18:20.611004,Safety of Polyphenon E in Multiple Sclerosis Pilot Study,,https://clinicaltrials.gov/show/NCT00836719,2009-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
922,3588,2023-12-06 18:18:20.584636,Lokomat Treadmill Training Effects on MS Gait,,https://clinicaltrials.gov/show/NCT00835835,2009-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
923,3587,2023-12-06 18:18:20.562747,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,,https://clinicaltrials.gov/show/NCT00837785,2009-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
924,3586,2023-12-06 18:18:20.542499,Exercise Intervention for Multiple Sclerosis: the Sheffield ExIMS trial,,http://isrctn.com/ISRCTN41541516,2009-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
925,3585,2023-12-06 18:18:20.524065,Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00841321,2009-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
926,3584,2023-12-06 18:18:20.503800,Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis.,,https://rpcec.sld.cu/en/trials/RPCEC00000073-En,2009-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
927,3583,2023-12-06 18:18:20.485911,The Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT00843128,2009-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
928,3582,2023-12-06 18:18:20.463697,"A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008719-25,2009-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
929,3581,2023-12-06 18:18:20.439202,"Atacicept in Multiple Sclerosis Extension Study, Phase II",,https://clinicaltrials.gov/show/NCT00853762,2009-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
930,3580,2023-12-06 18:18:20.417726,Low Fat Diet and Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00852722,2009-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
931,3579,2023-12-06 18:18:20.393983,Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00854750,2009-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
932,3578,2023-12-06 18:18:20.373443,Expiratory Muscle Training for Persons With Neurodegenerative Disease,,https://clinicaltrials.gov/show/NCT00856518,2009-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
933,3577,2023-12-06 18:18:20.351029,"A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007015-32,2009-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
934,3576,2023-12-06 18:18:20.330745,Differential Immune Effects of Natalizumab,,http://clinicaltrials.gov/show/NCT00859482,2009-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
935,3575,2023-12-06 18:18:20.308671,"Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy",,http://clinicaltrials.gov/show/NCT00861172,2009-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
936,3574,2023-12-06 18:18:20.287936,"A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell/antibody response panel to predict the clinical effect of Octagam® 5% in subjects with relapsing/remitting multiple sclerosis",,http://isrctn.com/ISRCTN57377482,2009-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
937,3573,2023-12-06 18:18:20.269441,A Randomized Exercise Trial for Wheelchair Users,,http://clinicaltrials.gov/show/NCT00866112,2009-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
938,3572,2023-12-06 18:18:20.236224,A Study for Patients With Secondary Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00869726,2009-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
939,3571,2023-12-06 18:18:20.213872,Chronic disease selfmanagement program for employees with a chronic disease.,,https://www.onderzoekmetmensen.nl/en/trial/24127,2009-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
940,3570,2023-12-06 18:18:20.189676,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",,https://clinicaltrials.gov/show/NCT00871780,2009-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
941,3569,2023-12-06 18:18:20.166188,"Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006786-92,2009-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
942,3568,2023-12-06 18:18:20.134488,A Study for Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00870155,2009-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
943,3567,2023-12-06 18:18:20.107922,Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00872053,2009-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
944,3566,2023-12-06 18:18:20.085966,Physical Disability in Patients Treated With Betaferon,,http://clinicaltrials.gov/show/NCT00873340,2009-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
945,3565,2023-12-06 18:18:20.066836,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT00879658,2009-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
946,3564,2023-12-06 18:18:20.033001,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,,https://clinicaltrials.gov/show/NCT00881205,2009-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
947,3563,2023-12-06 18:18:20.014654,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00882453,2009-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
948,3562,2023-12-06 18:18:19.994091,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT00882999,2009-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
949,3561,2023-12-06 18:18:19.975159,Functional and Physiological Responses to Lokomat Therapy (Pilot Study),,http://clinicaltrials.gov/show/NCT00883142,2009-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
950,3560,2023-12-06 18:18:19.953107,A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011523-31,2009-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
951,3559,2023-12-06 18:18:19.933455,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,,https://clinicaltrials.gov/show/NCT00884481,2009-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
952,3558,2023-12-06 18:18:19.912605,"A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered
daily in subjects with relapsing remitting multiple sclerosis (RRMS)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011234-99,2009-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
953,3557,2023-12-06 18:18:19.896167,Bayer/Cognitive Assessments With Multiple Sclerosis Subjects,,http://clinicaltrials.gov/show/NCT00888277,2009-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
954,3556,2023-12-06 18:18:19.876930,Study to investigate the combination of methylprednisolone and interferon-beta in the treatment of multiple sclerosis,,http://isrctn.com/ISRCTN16202527,2009-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
955,3555,2023-12-06 18:18:19.859566,Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002626-11,2009-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
956,3554,2023-12-06 18:18:19.841070,'Getting the Balance Right' - A comparison of physiotherapy and exercise treatments for people with multiple sclerosis (MS),,http://isrctn.com/ISRCTN77610415,2009-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
957,3553,2023-12-06 18:18:19.821827,BEYOND Pilot Study,,http://clinicaltrials.gov/show/NCT00893217,2009-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
958,3552,2023-12-06 18:18:19.803651,Zoledronate to prevent bone loss in acute multiple sclerosis,,http://isrctn.com/ISRCTN87039596,2009-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
959,3551,2023-12-06 18:18:19.786828,Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS A,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007549-29,2009-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
960,3550,2023-12-06 18:18:19.767974,"A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009503-19,2009-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
961,3549,2023-12-06 18:18:19.750908,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",,https://clinicaltrials.gov/show/NCT00902135,2009-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
962,3548,2023-12-06 18:18:19.731660,Patient education programme for early multiple sclerosis (MS),,http://isrctn.com/ISRCTN12440282,2009-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
963,3547,2023-12-06 18:18:19.696954,Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities,,http://clinicaltrials.gov/show/NCT00906737,2009-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
964,3546,2023-12-06 18:18:19.662186,A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00914290,2009-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
965,3545,2023-12-06 18:18:19.643776,Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers,,http://clinicaltrials.gov/show/NCT00913666,2009-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
966,3544,2023-12-06 18:18:19.624043,Immunogenicity and Safety Study of Serum-Free Avonex,,http://clinicaltrials.gov/show/NCT00912860,2009-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
967,3543,2023-12-06 18:18:19.605294,A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers,,http://clinicaltrials.gov/show/NCT00913250,2009-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
968,3542,2023-12-06 18:18:19.582734,Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction,,https://clinicaltrials.gov/show/NCT00913510,2009-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
969,3541,2023-12-06 18:18:19.538205,Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe,,http://clinicaltrials.gov/show/NCT00915577,2009-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
970,3540,2023-12-06 18:18:19.519618,Open-Label Safety Extension Study of Avonex,,http://clinicaltrials.gov/show/NCT00915460,2009-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
971,3539,2023-12-06 18:18:19.477872,Progression of Cognitive and Physical Symptoms in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00922831,2009-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
972,3538,2023-12-06 18:18:19.458224,Rajavtihi Neuronal Adult Stem Cells Project,,https://clinicaltrials.gov/show/NCT00927108,2009-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
973,3537,2023-12-06 18:18:19.438140,"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",,https://clinicaltrials.gov/show/NCT00928967,2009-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
974,3536,2023-12-06 18:18:19.415270,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,,https://clinicaltrials.gov/show/NCT00930553,2009-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
975,3535,2023-12-06 18:18:19.395328,Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008554-23,2009-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
976,3534,2023-12-06 18:18:19.375963,Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone,,https://clinicaltrials.gov/show/NCT00947895,2009-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
977,3533,2023-12-06 18:18:19.344477,Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA),,https://clinicaltrials.gov/show/NCT00937157,2009-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
978,3532,2023-12-06 18:18:19.322087,Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects,,https://clinicaltrials.gov/show/NCT00938366,2009-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
979,3531,2023-12-06 18:18:19.302236,Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study,,http://clinicaltrials.gov/show/NCT00937677,2009-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
980,3530,2023-12-06 18:18:19.280294,"A clinical study in subjects with multiple sclerosis who successfully
                completed the MS-LAQ-301 (ALLEGRO) study, to assess the safety of
                laquinimod (experimental drug) when taken for a long period of time and
                how it affects the course of the disease.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012989-30,2009-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
981,3529,2023-12-06 18:18:19.262337,High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00939549,2009-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
982,3528,2023-12-06 18:18:19.244243,Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00940719,2009-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
983,3527,2023-12-06 18:18:19.225668,Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment,,http://clinicaltrials.gov/show/NCT00942214,2009-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
984,3526,2023-12-06 18:18:19.206632,Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b,,http://clinicaltrials.gov/show/NCT00942591,2009-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
985,3525,2023-12-06 18:18:19.186747,"A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis - B2201",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011626-34,2009-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
986,3524,2023-12-06 18:18:19.163035,TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00944190,2009-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
987,3523,2023-12-06 18:18:19.142974,Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI,,https://clinicaltrials.gov/show/NCT00947232,2009-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
988,3522,2023-12-06 18:18:19.123343,Safety of New Formulation of Glatiramer Acetate,,https://clinicaltrials.gov/show/NCT00947752,2009-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
989,3521,2023-12-06 18:18:19.101259,Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor,,https://clinicaltrials.gov/show/NCT00954421,2009-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
990,3520,2023-12-06 18:18:19.079680,"Multicenter, open-label, 12 weeks Phase IV study to  assess adherence to treatment in relapsing multiple  sclerosis (RMS) subjects switching from other  injectable DMDs using ReBiSmart to self-inject Rebif  New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) - BRIDGE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013333-24,2009-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
991,3519,2023-12-06 18:18:19.062229,Cinnovex versus Avonex clinica Trial,,http://en.irct.ir/trial/1189,2009-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
992,3518,2023-12-06 18:18:19.044530,Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS),,https://clinicaltrials.gov/show/NCT00950248,2009-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
993,3517,2023-12-06 18:18:19.024262,Escitalopram (Lexapro) for Depression MS or ALS,,https://clinicaltrials.gov/show/NCT00965497,2009-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
994,3516,2023-12-06 18:18:19.002843,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",,https://clinicaltrials.gov/show/NCT00958009,2009-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
995,3515,2023-12-06 18:18:18.981855,Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00959218,2009-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
996,3514,2023-12-06 18:18:18.958309,A clinical trial to study the effect of R-TPR-011 in patients with multiple sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=848,2009-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
997,3513,2023-12-06 18:18:18.938251,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00963833,2009-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
998,3512,2023-12-06 18:18:18.917643,Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions,,http://clinicaltrials.gov/show/NCT00970333,2009-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
999,3511,2023-12-06 18:18:18.898174,Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00972062,2009-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1000,3510,2023-12-06 18:18:18.875555,"ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013695-46,2009-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1001,3509,2023-12-06 18:18:18.857165,"A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013884-21,2009-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1002,3508,2023-12-06 18:18:18.838287,Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00981084,2009-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1003,3507,2023-12-06 18:18:18.817459,Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy,,https://clinicaltrials.gov/show/NCT00981643,2009-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1004,3506,2023-12-06 18:18:18.798126,Clinical trial phase II of oral hebal compoenent (BMP) in patient with multiple sclerosis,,http://en.irct.ir/trial/1190,2009-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1005,3505,2023-12-06 18:18:18.775029,"A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS",,https://clinicaltrials.gov/show/NCT00988052,2009-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1006,3504,2023-12-06 18:18:18.751753,Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT00986960,2009-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1007,3503,2023-12-06 18:18:18.730561,The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections,,https://clinicaltrials.gov/ct2/show/NCT00988988,2009-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1008,3502,2023-12-06 18:18:18.709222,Rehabilitation of functional muscle and motor capacity in neurodegenerative disease: Multiple Sclerosis research,,http://isrctn.com/ISRCTN60122826,2009-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1009,3501,2023-12-06 18:18:18.688240,Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study,,http://clinicaltrials.gov/show/NCT01006941,2009-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1010,3500,2023-12-06 18:18:18.663718,"To determine if treatment with BIIB017 can decrease the number of MS relapses during a certain time period for patients with RMS. Other goals of the study are to determine if, over time, BIIB017 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse.",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=876,2009-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1011,3499,2023-12-06 18:18:18.642300,Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT00997438,2009-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1012,3498,2023-12-06 18:18:18.618434,"Fase de extensión del estudio CBAF312A2201 con enmascaramiento de la dosis para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de BAF312 administrado por vía oral una vez al día a pacientes con esclerosis múltiple recurrente",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014392-51,2009-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1013,3497,2023-12-06 18:18:18.596768,"A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial - PRISMS-15",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015502-19,2009-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1014,3496,2023-12-06 18:18:18.574330,The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01005095,2009-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1015,3495,2023-12-06 18:18:18.546579,"Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01006265,2009-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1016,3494,2023-12-06 18:18:18.511955,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006333-27,2009-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1017,3493,2023-12-06 18:18:18.491906,A clinical trial to determine the efficacy and safety of BG00012 in patients with relapsing remitting multiple sclerosis.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=356,2009-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1018,3492,2023-12-06 18:18:18.459550,The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor,,http://clinicaltrials.gov/show/NCT01018485,2009-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1019,3491,2023-12-06 18:18:18.439379,Efficacy of ramatroban in multiple sclerosis patients,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003319,2009-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1020,3490,2023-12-06 18:18:18.420584,Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - HINABS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013284-19,2009-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1021,3489,2023-12-06 18:18:18.401614,"Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).
 
A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016087-37,2009-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1022,3488,2023-12-06 18:18:18.384306,Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies,,http://clinicaltrials.gov/show/NCT01020370,2009-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1023,3487,2023-12-06 18:18:18.364046,Natalizumabbehandling af progressiv multipel sklerose - NAPMS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016703-35,2009-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1024,3486,2023-12-06 18:18:18.345056,Effects of Training on Central Auditory Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01023074,2009-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1025,3485,2023-12-06 18:18:18.314438,Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01024777,2009-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1026,3484,2023-12-06 18:18:18.282263,"A study designed to determine safety and efficacy of Daclizumab High
Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have
Completed Treatment in a previous study, 205MS202 (SELECTION)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015318-23,2009-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1027,3483,2023-12-06 18:18:18.247869,Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,,https://clinicaltrials.gov/show/NCT01028209,2009-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1028,3482,2023-12-06 18:18:18.226442,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,,http://clinicaltrials.gov/show/NCT01031459,2009-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1029,3481,2023-12-06 18:18:18.206091,Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15),,http://clinicaltrials.gov/show/NCT01034644,2009-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1030,3480,2023-12-06 18:18:18.184175,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,,http://clinicaltrials.gov/show/NCT01031199,2009-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1031,3479,2023-12-06 18:18:18.163109,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,,https://clinicaltrials.gov/show/NCT01034579,2009-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1032,3478,2023-12-06 18:18:18.142940,Effects of Vaporized Marijuana on Neuropathic Pain,,https://clinicaltrials.gov/show/NCT01037088,2009-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1033,3477,2023-12-06 18:18:18.117839,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",,https://clinicaltrials.gov/show/NCT01036165,2009-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1034,3476,2023-12-06 18:18:18.091071,A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT01037907,2009-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1035,3475,2023-12-06 18:18:18.068215,"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T - Gadovist in MS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014857-34,2009-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1036,3474,2023-12-06 18:18:18.032637,Sensori-motor Integration Training in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01040117,2009-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1037,3473,2023-12-06 18:18:18.011017,Patient Research Cohort: Rapidly Evolving Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01044576,2010-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1038,3472,2023-12-06 18:18:17.973692,"A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01047319,2010-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1039,3471,2023-12-06 18:18:17.952751,"A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014339-19,2010-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1040,3470,2023-12-06 18:18:17.932869,Pulse ACTH vs. MP for MS,,https://clinicaltrials.gov/show/NCT01049451,2010-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1041,3469,2023-12-06 18:18:17.910732,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01051349,2010-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1042,3468,2023-12-06 18:18:17.888343,étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015934-30,2010-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1043,3467,2023-12-06 18:18:17.866114,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01058005,2010-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1044,3466,2023-12-06 18:18:17.845164,Climate Influence on Physiotherapy in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01057719,2010-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1045,3465,2023-12-06 18:18:17.821896,"A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=337,2010-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1046,3464,2023-12-06 18:18:17.801198,Randomized Treatment Interruption of Natalizumab - RESTORE,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017490-38,2010-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1047,3463,2023-12-06 18:18:17.780645,Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011088-35,2010-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1048,3462,2023-12-06 18:18:17.730000,"A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design",,https://clinicaltrials.gov/show/NCT01067521,2010-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1049,3461,2023-12-06 18:18:17.704333,The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment,,http://clinicaltrials.gov/show/NCT01067573,2010-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1050,3460,2023-12-06 18:18:17.677939,Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01071512,2010-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1051,3459,2023-12-06 18:18:17.655384,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,,https://clinicaltrials.gov/show/NCT01070836,2010-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1052,3458,2023-12-06 18:18:17.632458,JC-Virus (JCV) Antibody Program,,https://clinicaltrials.gov/show/NCT01070823,2010-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1053,3457,2023-12-06 18:18:17.610878,Treatment Interruption of Natalizumab,,https://clinicaltrials.gov/show/NCT01071083,2010-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1054,3456,2023-12-06 18:18:17.592225,"Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort",,http://clinicaltrials.gov/show/NCT01070719,2010-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1055,3455,2023-12-06 18:18:17.571921,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,,http://clinicaltrials.gov/show/NCT01071694,2010-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1056,3454,2023-12-06 18:18:17.552487,Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01074346,2010-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1057,3453,2023-12-06 18:18:17.530070,Neuroprotection and Repair in Optic Neuritis,,http://clinicaltrials.gov/show/NCT01073813,2010-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1058,3452,2023-12-06 18:18:17.507841,Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking?,,https://clinicaltrials.gov/show/NCT01074827,2010-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1059,3451,2023-12-06 18:18:17.486626,Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina,,http://clinicaltrials.gov/show/NCT01080014,2010-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1060,3450,2023-12-06 18:18:17.462761,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®,,http://clinicaltrials.gov/show/NCT01075880,2010-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1061,3449,2023-12-06 18:18:17.437352,An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers,,http://clinicaltrials.gov/show/NCT01075737,2010-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1062,3448,2023-12-06 18:18:17.411495,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period",,https://clinicaltrials.gov/show/NCT01076595,2010-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1063,3447,2023-12-06 18:18:17.390656,REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIR,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016824-29,2010-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1064,3446,2023-12-06 18:18:17.367404,Natalizumab Treatment of Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01077466,2010-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1065,3445,2023-12-06 18:18:17.344397,Autologous Stem Cell Transplant for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01099930,2010-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1066,3444,2023-12-06 18:18:17.320917,"A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019029-32,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1067,3443,2023-12-06 18:18:17.300928,"Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)",,http://clinicaltrials.gov/show/NCT01080053,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1068,3442,2023-12-06 18:18:17.279947,"Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)",,http://clinicaltrials.gov/show/NCT01080027,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1069,3441,2023-12-06 18:18:17.258181,To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01079975,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1070,3440,2023-12-06 18:18:17.234929,"A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina",,http://clinicaltrials.gov/show/NCT01080001,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1071,3439,2023-12-06 18:18:17.210519,To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01080040,2010-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1072,3438,2023-12-06 18:18:17.186997,Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01080573,2010-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1073,3437,2023-12-06 18:18:17.163147,Improving Hand Use in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01081275,2010-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1074,3436,2023-12-06 18:18:17.141467,Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial,,https://clinicaltrials.gov/show/NCT01085318,2010-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1075,3435,2023-12-06 18:18:17.120241,An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period,,http://clinicaltrials.gov/show/NCT01112657,2010-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1076,3434,2023-12-06 18:18:17.098028,A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years,,http://clinicaltrials.gov/show/NCT01084798,2010-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1077,3433,2023-12-06 18:18:17.068612,Effects of lipoic acid on inflammation and antioxidant factors in multiple sclerosis,,http://en.irct.ir/trial/2373,2010-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1078,3432,2023-12-06 18:18:17.049034,The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001496-11,2010-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1079,3431,2023-12-06 18:18:17.018999,"Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b",,http://clinicaltrials.gov/show/NCT01111656,2010-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1080,3430,2023-12-06 18:18:16.996805,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005167-33,2010-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1081,3429,2023-12-06 18:18:16.975727,A randomised controlled trial of a self-management programme for fatigue in multiple sclerosis,,http://isrctn.com/ISRCTN76517470,2010-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1082,3428,2023-12-06 18:18:16.953328,Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01089686,2010-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1083,3427,2023-12-06 18:18:16.930674,The purpose of this study is to determine the effect of 2 different doses of daclizumab on reducing relapses in subjects with relapsing-remitting MS.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=947,2010-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1084,3426,2023-12-06 18:18:16.909116,Intravenous treatment with Mitoxantrone in active secondary progressive multiple sclerosis: effects on adaptive immune system.,,https://www.onderzoekmetmensen.nl/en/trial/26011,2010-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1085,3425,2023-12-06 18:18:16.887720,"The effect of family center empowerment model on skill, attitude and knowledge of multiple sclerosis caregivers",,http://en.irct.ir/trial/2731,2010-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1086,3424,2023-12-06 18:18:16.862786,"Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT01093326,2010-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1087,3423,2023-12-06 18:18:16.836178,"A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase - EXALT",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011888-37,2010-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1088,3422,2023-12-06 18:18:16.814407,ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01097668,2010-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1089,3421,2023-12-06 18:18:16.790450,Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01097538,2010-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1090,3420,2023-12-06 18:18:16.767461,An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF),,http://clinicaltrials.gov/show/NCT01110993,2010-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1091,3419,2023-12-06 18:18:16.730199,Relationship between IL-6 and TNF-&#945; polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m.  Open label multicentre study - Flu-like Symdrome,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017003-28,2010-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1092,3418,2023-12-06 18:18:16.707458,Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.,,http://clinicaltrials.gov/show/NCT01101776,2010-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1093,3417,2023-12-06 18:18:16.685025,Hydroxyurea in Primary Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01103583,2010-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1094,3416,2023-12-06 18:18:16.662019,Patient Education Programme for Multiple Sclerosis (MS) Immunotherapy,,http://isrctn.com/ISRCTN83438362,2010-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1095,3415,2023-12-06 18:18:16.642200,Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01106365,2010-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1096,3414,2023-12-06 18:18:16.620531,Vitamin D treatment effect on retinal nerve fiber loss after optic neuritis.,,https://www.onderzoekmetmensen.nl/en/trial/26942,2010-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1097,3413,2023-12-06 18:18:16.598664,A dose blind extension clinical trial to determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in patients with relapsing remitting multiple sclerosis.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1495,2010-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1098,3412,2023-12-06 18:18:16.578404,"An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.",,http://clinicaltrials.gov/show/NCT01108887,2010-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1099,3411,2023-12-06 18:18:16.556804,Spinal cord stimulation for the treatment of central pain in Multiple Sclerosis,,http://isrctn.com/ISRCTN36818685,2010-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1100,3410,2023-12-06 18:18:16.536527,An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters,,http://clinicaltrials.gov/show/NCT01112345,2010-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1101,3409,2023-12-06 18:18:16.516678,Evaluation of adjustment groups for people with Multiple Sclerosis,,http://isrctn.com/ISRCTN29381417,2010-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1102,3408,2023-12-06 18:18:16.494888,Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery,,https://clinicaltrials.gov/show/NCT01117090,2010-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1103,3407,2023-12-06 18:18:16.472107,A Cooperative Clinical Study of Abatacept in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01116427,2010-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1104,3406,2023-12-06 18:18:16.424834,The effect of self care program based on orem self care model on multiple sclerosis patient's self concept,,http://en.irct.ir/trial/2733,2010-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1105,3405,2023-12-06 18:18:16.404264,The effect of family-centered empowerment model on the quality of life of multiple sclerosis caregivers,,http://en.irct.ir/trial/2732,2010-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1106,3404,2023-12-06 18:18:16.386254,Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01122056,2010-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1107,3403,2023-12-06 18:18:16.366473,Wearing textured insoles in shoes to help selfmanagement for people with MS: an exploratory study of the effects on balance,,http://isrctn.com/ISRCTN02778739,2010-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1108,3402,2023-12-06 18:18:16.346403,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects,,http://clinicaltrials.gov/show/NCT01125475,2010-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1109,3401,2023-12-06 18:18:16.326772,Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects,,http://clinicaltrials.gov/show/NCT01128075,2010-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1110,3400,2023-12-06 18:18:16.308234,"A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with relapsing forms of multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019028-30,2010-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1111,3399,2023-12-06 18:18:16.291246,A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01142583,2010-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1112,3398,2023-12-06 18:18:16.270477,An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy,,http://clinicaltrials.gov/show/NCT01141751,2010-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1113,3397,2023-12-06 18:18:16.248734,A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01144351,2010-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1114,3396,2023-12-06 18:18:16.222125,An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients,,http://clinicaltrials.gov/show/NCT01142453,2010-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1115,3395,2023-12-06 18:18:16.201877,An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01142557,2010-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1116,3394,2023-12-06 18:18:16.181705,An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone,,http://clinicaltrials.gov/show/NCT01142518,2010-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1117,3393,2023-12-06 18:18:16.162104,A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®),,http://clinicaltrials.gov/show/NCT01142492,2010-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1118,3392,2023-12-06 18:18:16.139468,A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone,,https://clinicaltrials.gov/show/NCT01142466,2010-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1119,3391,2023-12-06 18:18:16.118319,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT01143441,2010-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1120,3390,2023-12-06 18:18:16.098886,Natalizumab De-escalation With Interferon Beta-1b,,https://clinicaltrials.gov/show/NCT01144052,2010-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1121,3389,2023-12-06 18:18:16.077291,Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01149525,2010-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1122,3388,2023-12-06 18:18:16.055318,"A multicentre randomised double-blind, double-dummy placebo-controlled study to assess the efficacy, safety and cost utility of Probiotic prophylaxis of spinal cord injury Urinary Tract Infection. A Therapeutic Trial. (ProSCIUTTU)",,https://anzctr.org.au/ACTRN12610000512022.aspx,2010-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1123,3387,2023-12-06 18:18:16.033893,Long-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020515-37,2010-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1124,3386,2023-12-06 18:18:16.015163,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01156311,2010-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1125,3385,2023-12-06 18:18:15.994923,Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance,,http://clinicaltrials.gov/show/NCT01156298,2010-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1126,3384,2023-12-06 18:18:15.975692,Effect of progressive muscle relaxation on pain of multiple sclerosis patients,,http://en.irct.ir/trial/2736,2010-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1127,3383,2023-12-06 18:18:15.956769,The effect of progressive Muscle Relaxation program on self efficacy and Quality of life in caregivers of patients with multiple sclerosis,,http://en.irct.ir/trial/2735,2010-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1128,3382,2023-12-06 18:18:15.939663,Early Cognitive Impairment in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01157728,2010-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1129,3381,2023-12-06 18:18:15.919577,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01158183,2010-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1130,3380,2023-12-06 18:18:15.898209,A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018705-11,2010-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1131,3379,2023-12-06 18:18:15.877922,Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients,,https://clinicaltrials.gov/show/NCT01167426,2010-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1132,3378,2023-12-06 18:18:15.846712,Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01181115,2010-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1133,3377,2023-12-06 18:18:15.828144,Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS),,http://clinicaltrials.gov/show/NCT01181089,2010-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1134,3376,2023-12-06 18:18:15.808327,Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01184833,2010-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1135,3375,2023-12-06 18:18:15.788545,JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01185717,2010-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1136,3374,2023-12-06 18:18:15.765780,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT01188811,2010-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1137,3373,2023-12-06 18:18:15.742059,"Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients
with Relapsing-Remitting MS receiving Rebif® treatment.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020328-23,2010-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1138,3372,2023-12-06 18:18:15.706649,Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01191996,2010-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1139,3371,2023-12-06 18:18:15.683714,Assessment of Patient Use of a New Device: RebiSmart,,http://clinicaltrials.gov/show/NCT01195870,2010-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1140,3370,2023-12-06 18:18:15.663070,Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration,,http://clinicaltrials.gov/show/NCT01195857,2010-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1141,3369,2023-12-06 18:18:15.642946,Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01225289,2010-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1142,3368,2023-12-06 18:18:15.619633,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01216072,2010-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1143,3367,2023-12-06 18:18:15.598041,Telehealth-Based Exercise Program to Treat Fatigue in MS,,https://clinicaltrials.gov/show/NCT01198977,2010-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1144,3366,2023-12-06 18:18:15.577756,Efficacy and Safety of Daclizumab High Yield Process Versus Interferon &amp;#946; 1a in Patients With Relapsing-Remitting Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1463,2010-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1145,3365,2023-12-06 18:18:15.557210,Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01199640,2010-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1146,3364,2023-12-06 18:18:15.534130,Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01201707,2010-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1147,3363,2023-12-06 18:18:15.512636,Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01201343,2010-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1148,3362,2023-12-06 18:18:15.491168,Experimental Evaluation of Wheelchair-Mounted Robotic Arms,,http://clinicaltrials.gov/show/NCT01652352,2010-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1149,3361,2023-12-06 18:18:15.470725,Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples,,https://clinicaltrials.gov/show/NCT01206023,2010-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1150,3360,2023-12-06 18:18:15.451442,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),,https://clinicaltrials.gov/show/NCT01207648,2010-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1151,3359,2023-12-06 18:18:15.415594,Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01207856,2010-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1152,3358,2023-12-06 18:18:15.391837,"A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022066-28,2010-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1153,3357,2023-12-06 18:18:15.370195,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),,https://clinicaltrials.gov/show/NCT01212094,2010-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1154,3356,2023-12-06 18:18:15.348324,Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01214317,2010-04-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1155,3355,2023-12-06 18:18:15.325999,Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial,,http://clinicaltrials.gov/show/NCT01216137,2010-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1156,3354,2023-12-06 18:18:15.294184,Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01219647,2010-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1157,3353,2023-12-06 18:18:15.275883,Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01220830,2010-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1158,3352,2023-12-06 18:18:15.241456,A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis,,https://jrct.niph.go.jp/latest-detail/jRCT2080221270,2010-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1159,3351,2023-12-06 18:18:15.209845,Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01226654,2010-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1160,3350,2023-12-06 18:18:15.189880,CytotronÂ® Delivered Rotational Field Quantum Magnetic Resonance Therapy for Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=2311,2010-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1161,3349,2023-12-06 18:18:15.166334,To evaluate the safety and efficacy of DAC HYP in subjects with Multiple Sclerosis who have completed treatment in study 205MS201 (SELECT).,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1902,2010-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1162,3348,2023-12-06 18:18:15.147125,The effects of  Hayateno rehabilitation center multidisciplinary  protocol  on Multiple sclerosis patient's quality of life,,http://en.irct.ir/trial/4713,2010-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1163,3347,2023-12-06 18:18:15.120560,Mesenchymal Stem Cell Transplantation in MS,,http://clinicaltrials.gov/show/NCT01228266,2010-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1164,3346,2023-12-06 18:18:15.099984,Boswellic Acids in Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014724-32,2010-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1165,3345,2023-12-06 18:18:15.081151,"A study investigating safety, tolerability and efficacy of ECP002A (?9-THC) in Multiple Sclerosis patients suffering from spasticity and pain.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-022033-28,2010-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1166,3344,2023-12-06 18:18:15.063370,"Family center empowerment model on skill, attitude and knowledge of multiple sclerosis",,http://en.irct.ir/trial/2737,2010-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1167,3343,2023-12-06 18:18:15.045999,Progressive muscle relaxation on general health and sleep quality of multiple sclerosis caregivers,,http://en.irct.ir/trial/2738,2010-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1168,3342,2023-12-06 18:18:15.028569,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",,http://clinicaltrials.gov/show/NCT01235455,2010-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1169,3341,2023-12-06 18:18:15.008728,Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.,,http://clinicaltrials.gov/show/NCT01235221,2010-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1170,3340,2023-12-06 18:18:14.988386,Lubiprostone in Patients With Multiple Sclerosis Associated Constipation,,https://clinicaltrials.gov/show/NCT01236534,2010-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1171,3339,2023-12-06 18:18:14.966032,Mindfulness Based Stress Reduction in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01419301,2010-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1172,3338,2023-12-06 18:18:14.946755,Exercise Training for Multiple Sclerosis (MS) Patients,,https://anzctr.org.au/ACTRN12610000976088.aspx,2010-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1173,3337,2023-12-06 18:18:14.926564,"Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple Sclerosis",,http://drks.de/search/en/trial/DRKS00000438,2010-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1174,3336,2023-12-06 18:18:14.906723,Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023172-12,2010-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1175,3335,2023-12-06 18:18:14.875792,Safety Study of BIIB033 in Subjects With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01244139,2010-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1176,3334,2023-12-06 18:18:14.852657,"A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. - ND",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023023-19,2010-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1177,3333,2023-12-06 18:18:14.820328,"Switch To RItuXimab in MS
A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach 
 - STRIX-MS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023021-38,2010-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1178,3332,2023-12-06 18:18:14.801979,Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01250665,2010-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1179,3331,2023-12-06 18:18:14.782379,Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab,,http://clinicaltrials.gov/show/NCT01250678,2010-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1180,3330,2023-12-06 18:18:14.762770,"Effect of oral herbal oil supplement (Cannabis Sativa L, Oenothera Biennis L) and advising diet with Hot nature on multiple sclerosis  patients",,http://en.irct.ir/trial/1823,2010-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1181,3329,2023-12-06 18:18:14.744462,Vitamin D Pilot Study in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01257958,2010-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1182,3328,2023-12-06 18:18:14.721906,"An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000256-26,2010-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1183,3327,2023-12-06 18:18:14.702712,The Effect of Educational Program Based on BASNEF Model  on behavioral methods of stress management in patients with multiple sclerosis,,http://en.irct.ir/trial/4870,2010-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1184,3326,2023-12-06 18:18:14.681833,A Pilot Study of Lithium in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01259388,2010-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1185,3325,2023-12-06 18:18:14.661069,Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI),,http://clinicaltrials.gov/show/NCT01264848,2010-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1186,3324,2023-12-06 18:18:14.623302,"A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=098-10,2011-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1187,3323,2023-12-06 18:18:14.604111,Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01271699,2011-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1188,3322,2023-12-06 18:18:14.583275,Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study,,https://clinicaltrials.gov/show/NCT01272128,2011-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1189,3321,2023-12-06 18:18:14.563426,Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01272596,2011-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1190,3320,2023-12-06 18:18:14.544499,Visual Reconstitution Therapy After Optic Neuritis,,https://clinicaltrials.gov/show/NCT01274702,2011-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1191,3319,2023-12-06 18:18:14.525769,MITOXANTRONE/GLATIRAMER ACETATE COMBINED  TREATMENT IN THE THERAPY OF  SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDY,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010661-23,2011-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1192,3318,2022-03-18 12:44:44.032425,Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients,"<b>Conditions</b>:    Multiple Sclerosis;   Autoimmune Blistering Disease;   B-Cell Deficiency<br /><b>Intervention</b>:    Biological: COVID19 vaccine<br /><b>Sponsors</b>:    Yale University;   National Institute of Allergy and Infectious Diseases (NIAID);   Robert Leet and Clara Guthrie Patterson Trust<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/show/NCT05286242,2022-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1193,3317,2023-12-06 18:18:14.490401,Motor Training and White Matter in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01279655,2011-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1194,3316,2023-12-06 18:18:14.470159,Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program,,http://clinicaltrials.gov/show/NCT01281657,2011-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1195,3315,2023-12-06 18:18:14.448405,The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01280539,2011-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1196,3314,2023-12-06 18:18:14.427216,"Ensayo Clínico Fase IIa, Multicéntrico, Doble Ciego para Evaluar la Eficacia y Seguridad de dosis bajas de Diazoxida oral en el tratamiento de la Esclerosis Múltiple",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023048-34,2011-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1197,3313,2023-12-06 18:18:14.405774,Evaluation of serum levels of chemokines during interferon beta treatment in multiple sclerosis patients,,http://isrctn.com/ISRCTN45526724,2011-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1198,3312,2023-12-06 18:18:14.387069,Advanced MRI Measures of Repair in Alemtuzumab Treated Patients,,https://clinicaltrials.gov/show/NCT01307332,2011-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1199,3311,2023-12-06 18:18:14.351694,High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023678-38,2011-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1200,3310,2023-12-06 18:18:14.333811,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015319-41,2011-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1201,3309,2023-12-06 18:18:14.314041,Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024561-43,2011-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1202,3308,2022-03-18 12:44:43.303079,Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Ocrelizumab;   Drug: Placebo for Ocrelizumab<br /><b>Sponsors</b>:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence (ACE)<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05285891,2022-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1203,3307,2023-12-06 18:18:14.278737,Effects of coenzyme Q10 on antioxidant factors in multiple sclerosis,,http://en.irct.ir/trial/2376,2011-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1204,3306,2023-12-06 18:18:14.240823,Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit,,https://clinicaltrials.gov/show/NCT01299025,2011-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1205,3305,2023-12-06 18:18:14.217911,Depression in MS: The effectiveness of web-based self-help treatment.,,https://www.onderzoekmetmensen.nl/en/trial/20843,2011-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1206,3304,2023-12-06 18:18:14.190231,Nurse-Led Manualized Telephone Support Intervention,,http://clinicaltrials.gov/show/NCT01302431,2011-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1207,3303,2023-12-06 18:18:14.169764,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01310166,2011-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1208,3302,2023-12-06 18:18:14.147295,Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01303770,2011-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1209,3301,2023-12-06 18:18:14.128257,A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01318421,2011-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1210,3300,2023-12-06 18:18:14.106739,Effect of magnetic therapy on MS fatigue,,http://en.irct.ir/trial/6244,2011-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1211,3299,2023-12-06 18:18:14.084768,A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024477-39,2011-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1212,3298,2023-12-06 18:18:14.065044,Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01324232,2011-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1213,3297,2023-12-06 18:18:14.045816,Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01615887,2011-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1214,3296,2023-12-06 18:18:14.027130,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01416155,2011-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1215,3295,2023-12-06 18:18:14.002044,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01328379,2011-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1216,3294,2023-12-06 18:18:09.834609,Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01753375,2012-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1217,3293,2023-12-06 18:18:00.134718,Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients,,https://clinicaltrials.gov/show/NCT02664623,2016-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1218,3292,2023-12-06 18:17:54.044527,Comparison of Two Community Based Exercise Protocols in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03429062,2018-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1219,3291,2023-12-06 18:17:36.517157,Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia,,https://clinicaltrials.gov/show/NCT05327894,2022-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1220,3290,2023-12-06 18:17:30.704740,Are participants of balance programs achieving and maintaining a reduction in falls risk?,,https://anzctr.org.au/ACTRN12623001190695.aspx,2023-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1221,3289,2023-12-06 18:17:30.656915,Using advanced MRI to explore metabolism and tissue structure in multiple sclerosis (MISSION MIMS),,https://www.isrctn.com/ISRCTN10088443,2023-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1222,3288,2023-12-06 13:40:54.158573,Balance Targeted Exercises for Individuals With MS,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Behavioral: Balance targeted exercises
<br /><b>Sponsors</b>: University of Miami
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06159361?cond=Multiple+Sclerosis,2023-12-06 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1223,3287,2023-12-05 15:03:21.402823,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...","<p>EudraCT Number: 2019-001862-13<br />Sponsor Protocol Number: AB19001<br />Sponsor Name: ABScience<br />Start Date: 2020-03-12<br />Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/SE"">SE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/ES"">ES</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/IE"">IE</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/IT"">IT</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001862-13/GR"">GR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-001862-13,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
1224,3286,2023-12-05 14:03:24.956354,Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France,"<b>Conditions</b>: Multiple Sclerosis (MS)
<br /><b>Interventions</b>: Other: ofatumumab
<br /><b>Sponsors</b>: Novartis Pharmaceuticals
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06157086?cond=Multiple+Sclerosis,2023-12-05 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1225,3285,2023-12-05 14:03:24.938109,Kesimpta Pregnancy and Infant Safety Study Using Real World Data,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Multiple sclerosis disease modifying drug
<br /><b>Sponsors</b>: Novartis Pharmaceuticals
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06156683?cond=Multiple+Sclerosis,2023-12-05 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1226,3284,2023-12-01 14:23:18.150850,Neural Mobilization on Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: neurodynamic mobilization exercise; Other: strengthening exercises
<br /><b>Sponsors</b>: Kahramanmaras Sutcu Imam University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/study/NCT06153264?cond=Multiple+Sclerosis,2023-12-01 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1227,3283,2023-11-27 14:03:22.142271,HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS),"<b>Conditions</b>: Multiple Sclerosis; Cognitive Dysfunction; Memory Disorders
<br /><b>Interventions</b>: Behavioral: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)
<br /><b>Sponsors</b>: Dartmouth-Hitchcock Medical Center
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06145737,2023-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1228,3282,2023-11-22 13:43:10.591844,Blood Flow Restriction Training in Multiple Sclerosis,"<b>Conditions</b>: MS
<br /><b>Interventions</b>: Other: strengthening ex with BFR training; Other: strengthening ex
<br /><b>Sponsors</b>: Cairo University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/study/NCT06143930?cond=Multiple+Sclerosis,2023-11-22 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1229,3281,2023-11-22 13:43:10.579433,A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk,"<b>Conditions</b>: Relapsing Multiple Sclerosis
<br /><b>Interventions</b>: Other: No intervention
<br /><b>Sponsors</b>: TG Therapeutics, Inc.
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06143514,2023-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1230,3280,2023-11-22 13:43:10.557401,Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.,"<b>Conditions</b>: Multiple Sclerosis; Overactive Bladder Syndrome
<br /><b>Interventions</b>: Device: TTNS (Transcutaneous tibial nerve stimulation); Device: PNS (Parasacral nerve stimulation); Device: Sham stimulation; Behavioral: Behavioral treatment
<br /><b>Sponsors</b>: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization; Marmara University
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06143397,2023-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1231,3279,2023-11-21 00:00:00.000000,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01326715,2011-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1232,3278,2023-11-21 00:00:00.000000,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021978-11,2011-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1233,3277,2023-11-21 00:00:00.000000,"Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical",,http://clinicaltrials.gov/show/NCT01330498,2011-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1234,3276,2023-11-21 00:00:00.000000,The effect of methylprednisolon plus mitoxantrone in the treatment of progressive multiple sclerosis,,http://en.irct.ir/trial/5799,2011-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1235,3275,2023-11-21 00:00:00.000000,Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01337427,2011-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1236,3274,2023-11-21 00:00:00.000000,Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01333358,2011-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1237,3273,2023-11-21 00:00:00.000000,A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024000-10,2011-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1238,3272,2023-11-21 00:00:00.000000,Riboflavin and multiple sclerosis,,http://en.irct.ir/trial/6325,2011-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1239,3271,2023-11-21 00:00:00.000000,Ampyra for Optic Neuritis in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01337986,2011-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1240,3270,2023-11-21 00:00:00.000000,Psychometric Validation of Cognitive Endpoints,,http://clinicaltrials.gov/show/NCT01335633,2011-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1241,3269,2023-11-21 00:00:00.000000,Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.,,https://clinicaltrials.gov/show/NCT01424462,2011-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1242,3268,2023-11-21 00:00:00.000000,GSK2018682 FTIH in Healthy Volunteers,,https://clinicaltrials.gov/show/NCT01387217,2011-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1243,3267,2023-11-21 00:00:00.000000,"« GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude clinique menée dans plusieurs centres français, d'une durée de 4 mois, visant à comparer la réponse à l'initiation du traitement par fingolimod (Gilenya®) selon le profil d'anxiété chez des patients adultes présentant une sclérose en plaques rémittente-récurrente très active.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001280-49,2011-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1244,3266,2023-11-21 00:00:00.000000,"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",,https://clinicaltrials.gov/show/NCT01440101,2011-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1245,3265,2023-11-21 00:00:00.000000,Supported Treadmill Training for Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01339234,2011-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1246,3264,2023-11-21 00:00:00.000000,"Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: Preliminary findings of a randomized, placebo-controlled trial",,http://en.irct.ir/trial/6636,2011-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1247,3263,2023-11-21 00:00:00.000000,Intermittent self catheterisation in people with multiple sclerosis,,http://isrctn.com/ISRCTN46706125,2011-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1248,3262,2023-11-21 00:00:00.000000,Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant,,https://clinicaltrials.gov/show/NCT01392872,2011-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1249,3261,2023-11-21 00:00:00.000000,The effect of yoga on MS,,http://en.irct.ir/trial/6755,2011-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1250,3260,2023-11-21 00:00:00.000000,Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI),,http://clinicaltrials.gov/show/NCT01356134,2011-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1251,3259,2023-11-21 00:00:00.000000,Depression and Fatigue in MS Patients Treated With Betaferon.,,http://clinicaltrials.gov/show/NCT01354665,2011-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1252,3258,2023-11-21 00:00:00.000000,A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01356940,2011-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1253,3257,2023-11-21 00:00:00.000000,Worms for immune regulation of multiple sclerosis - MS and hookworm,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005008-24,2011-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1254,3256,2023-11-21 00:00:00.000000,A medical nutrition formula for the treatment of relapsing multiple sclerosis,,http://isrctn.com/ISRCTN87818535,2011-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1255,3255,2023-11-21 00:00:00.000000,Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001160-21,2011-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1256,3254,2023-11-21 00:00:00.000000,Clinical study using positron emission tomography(PET),,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006648,2011-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1257,3253,2023-11-21 00:00:00.000000,Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01359566,2011-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1258,3252,2023-11-21 00:00:00.000000,Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01360489,2011-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1259,3251,2023-11-21 00:00:00.000000,"A long term, 50 week, Phase IV multi-centre study to determine if Sativex has an effect on cognition (thinking ability) when prescribed to patients with spasticity due to MS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000926-31,2011-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1260,3250,2023-11-21 00:00:00.000000,"Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)",,https://clinicaltrials.gov/show/NCT01381354,2011-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1261,3249,2023-11-21 00:00:00.000000,Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01411514,2011-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1262,3248,2023-11-21 00:00:00.000000,A study to evaluate disease control and safety in patients with RRMS switching from natalizumab to fingolimod,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001442-15,2011-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1263,3247,2023-11-21 00:00:00.000000,Avonex PEN Satisfaction and Patients Experience Clinical Trial,,http://clinicaltrials.gov/show/NCT01366040,2011-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1264,3246,2023-11-21 00:00:00.000000,PRISM Registry: Pseudobulbar Affect Registry Series,,http://clinicaltrials.gov/show/NCT01366027,2011-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1265,3245,2023-11-21 00:00:00.000000,BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis),,https://clinicaltrials.gov/show/NCT01371760,2011-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1266,3244,2023-11-21 00:00:00.000000,A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001692-39,2011-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1267,3243,2023-11-21 00:00:00.000000,NOGO-A in Multiple Sclerosis FTIH,,https://clinicaltrials.gov/show/NCT01424423,2011-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1268,3242,2023-11-21 00:00:00.000000,Change in neck vein flow after chronic cerebro-spinal venous insufficiency (CCSVI) therapy in patients with multiple sclerosis,,http://isrctn.com/ISRCTN24087468,2011-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1269,3241,2023-11-21 00:00:00.000000,Therapeutic effect of saffron on cognitive function  in multiple sclerosis patients,,https://anzctr.org.au/ACTRN12611000610932.aspx,2011-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1270,3240,2023-11-21 00:00:00.000000,"A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000888-27,2011-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1271,3239,2023-11-21 00:00:00.000000,Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01380041,2011-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1272,3238,2023-11-21 00:00:00.000000,Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01377870,2011-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1273,3237,2023-11-21 00:00:00.000000,Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life,,http://clinicaltrials.gov/show/NCT01377805,2011-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1274,3236,2023-11-21 00:00:00.000000,Assay for detection of neutralizing antibodies against interferon-beta in multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006860,2011-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1275,3235,2023-11-21 00:00:00.000000,Can a video based short training intervention increase the extent to which patients and their doctors cooperate in treatment decision making?,,http://isrctn.com/ISRCTN78716079,2011-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1276,3234,2023-11-21 00:00:00.000000,Healthy Volunteer Study Using 3 Different Formulations of Firategrast,,https://clinicaltrials.gov/show/NCT01416363,2011-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1277,3233,2023-11-21 00:00:00.000000,Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases,,https://clinicaltrials.gov/show/NCT01384825,2011-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1278,3232,2023-11-21 00:00:00.000000,Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01395316,2011-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1279,3231,2023-11-21 00:00:00.000000,Betaferon® Regulatory Post-Marketing Surveillance,,http://clinicaltrials.gov/show/NCT01414816,2011-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1280,3230,2023-11-21 00:00:00.000000,Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01396343,2011-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1281,3229,2023-11-21 00:00:00.000000,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01462318,2011-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1282,3228,2023-11-21 00:00:00.000000,TREating FAtigue in Multiple Sclerosis: Cognitive behavioural therapy,,http://isrctn.com/ISRCTN58583714,2011-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1283,3227,2023-11-21 00:00:00.000000,Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01399957,2011-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1284,3226,2023-11-21 00:00:00.000000,TREating FAtigue in Multiple Sclerosis: Energy conservation management,,http://isrctn.com/ISRCTN82353628,2011-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1285,3225,2023-11-21 00:00:00.000000,TREating FAtigue in Multiple Sclerosis: Aerobic training,,https://www.isrctn.com/ISRCTN69520623,2011-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1286,3224,2023-11-21 00:00:00.000000,Evaluation the effect of adding methylprednisolone to mitoxantrone on progressive multiple sclerosis treatment,,http://en.irct.ir/trial/6421,2011-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1287,3223,2023-11-21 00:00:00.000000,"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability",,http://clinicaltrials.gov/show/NCT01404117,2011-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1288,3222,2023-11-21 00:00:00.000000,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",,http://clinicaltrials.gov/show/NCT01405872,2011-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1289,3221,2023-11-21 00:00:00.000000,Does Fampridine improve fatigue in patients with Multiple Sclerosis.,,https://anzctr.org.au/ACTRN12611000799954.aspx,2011-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1290,3220,2023-11-21 00:00:00.000000,Core Stability Training in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01414725,2011-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1291,3219,2023-11-21 00:00:00.000000,Effect of Q10 on multiple sclerosis patients,,http://en.irct.ir/trial/2375,2011-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1292,3218,2023-11-21 00:00:00.000000,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01412333,2011-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1293,3217,2023-11-21 00:00:00.000000,"Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells",,https://clinicaltrials.gov/show/NCT01414634,2011-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1294,3216,2023-11-21 00:00:00.000000,Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT01413243,2011-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1295,3215,2023-11-21 00:00:00.000000,Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate,,https://clinicaltrials.gov/show/NCT01454791,2011-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1296,3214,2023-11-21 00:00:00.000000,Plasma Exchanges in Multiple Sclerosis (MS) Relapses,,https://clinicaltrials.gov/show/NCT01442233,2011-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1297,3213,2023-11-21 00:00:00.000000,"The efficacy of low-power laser in amelioration of pain , dysesthesia and Lhermitte’s sign in multiple sclerosis patients",,https://anzctr.org.au/ACTRN12611000841976.aspx,2011-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1298,3212,2023-11-21 00:00:00.000000,Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers,,https://clinicaltrials.gov/show/NCT01431937,2011-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1299,3211,2023-11-21 00:00:00.000000,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002785-20,2011-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1300,3210,2023-11-21 00:00:00.000000,Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01417312,2011-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1301,3209,2023-11-21 00:00:00.000000,Fingolimod -Response According to Coping - Evaluation,,https://clinicaltrials.gov/show/NCT01420055,2011-08-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1302,3208,2023-11-21 00:00:00.000000,Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities,,http://clinicaltrials.gov/show/NCT01456416,2011-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1303,3207,2023-11-21 00:00:00.000000,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,,https://clinicaltrials.gov/show/NCT01442194,2011-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1304,3206,2023-11-21 00:00:00.000000,Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01435993,2011-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1305,3205,2023-11-21 00:00:00.000000,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01433250,2011-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1306,3204,2023-11-21 00:00:00.000000,The Effect of Acupressure on Severity of Fatigue and Pain of Multiple Sclerosis (MS) disease in female members of MS Association.,,http://en.irct.ir/trial/6670,2011-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1307,3203,2023-11-21 00:00:00.000000,A Phase IIa Study of NT-KO-003 for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01428726,2011-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1308,3202,2023-11-21 00:00:00.000000,Clinicopathological study of neuro-glial damage biomarkers in central nervous system diseases,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007301,2011-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1309,3201,2023-11-21 00:00:00.000000,Multicenter Randomized control study of Immunoadsorption therapy (IAPP) for acute attacks relapsing-remitting Multiple Sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007116,2011-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1310,3200,2023-11-21 00:00:00.000000,[18F]PBR111 and Microglial Activation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01428505,2011-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1311,3199,2023-11-21 00:00:00.000000,Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002333-19,2011-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1312,3198,2023-11-21 00:00:00.000000,Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01433497,2011-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1313,3197,2023-11-21 00:00:00.000000,Robot-assisted Gait Training in Multiple Sclerosis Subjects,,http://clinicaltrials.gov/show/NCT01435694,2011-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1314,3196,2023-11-21 00:00:00.000000,"Prevalence of CCSVI (Chronic cerebrospinal venous insufficiency) in patients with multiple sclerosis, other central nervous system disorders, and healthy controls in Japan",,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007555,2011-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1315,3195,2023-11-21 00:00:00.000000,"Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)",,https://clinicaltrials.gov/show/NCT01450124,2011-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1316,3194,2023-11-21 00:00:00.000000,Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS),,https://clinicaltrials.gov/show/NCT01440062,2011-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1317,3193,2023-11-21 00:00:00.000000,"China Betaferon Adherence, Coping and Nurse Support Study",,https://clinicaltrials.gov/show/NCT01436838,2011-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1318,3192,2023-11-21 00:00:00.000000,Dalfampridine for Imbalance in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01444300,2011-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1319,3191,2023-11-21 00:00:00.000000,Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01453764,2011-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1320,3190,2023-11-21 00:00:00.000000,T Cell Vaccination in Patients With Progressive Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01448252,2011-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1321,3189,2023-11-21 00:00:00.000000,Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01450488,2011-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1322,3188,2023-11-21 00:00:00.000000,Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE,,https://clinicaltrials.gov/show/NCT01450072,2011-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1323,3187,2023-11-21 00:00:00.000000,The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01455220,2011-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1324,3186,2023-11-21 00:00:00.000000,Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II,,https://clinicaltrials.gov/show/NCT01451723,2011-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1325,3185,2023-11-21 00:00:00.000000,Neuroprotection With Phenytoin in Optic Neuritis,,https://clinicaltrials.gov/show/NCT01451593,2011-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1326,3184,2023-11-21 00:00:00.000000,Efficacy and Safety of SPARC0921 in Subjects With Spasticity,,https://clinicaltrials.gov/show/NCT01457352,2011-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1327,3183,2023-11-21 00:00:00.000000,"MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",,http://clinicaltrials.gov/show/NCT01556685,2011-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1328,3182,2023-11-21 00:00:00.000000,Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01457924,2011-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1329,3181,2023-11-21 00:00:00.000000,Long-Term Prolonged-Release Fampridine Treatment and Quality of Life,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003507-38,2011-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1330,3180,2023-11-21 00:00:00.000000,Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples,,https://clinicaltrials.gov/show/NCT01465087,2011-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1331,3179,2023-11-21 00:00:00.000000,Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),,http://clinicaltrials.gov/show/NCT01464905,2011-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1332,3178,2023-11-21 00:00:00.000000,Task-oriented Circuit Class Training in Multiple Sclerosis Subjects,,http://clinicaltrials.gov/show/NCT01464749,2011-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1333,3177,2023-11-21 00:00:00.000000,"A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.",,https://clinicaltrials.gov/show/NCT01466322,2011-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1334,3176,2023-11-21 00:00:00.000000,"The Comparison of the Effect of Eccentric and Concentric Exercises to improve Function, Balance and Muscle Strength in Patients with Multiple Sclerosis",,http://en.irct.ir/trial/483,2011-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1335,3175,2023-11-21 00:00:00.000000,Worms for Immune Regulation of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01470521,2011-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1336,3174,2023-11-21 00:00:00.000000,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01658384,2011-10-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1337,3173,2023-11-21 00:00:00.000000,Cerebral venous drainage in multiple sclerosis,,http://isrctn.com/ISRCTN75786983,2011-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1338,3172,2023-11-21 00:00:00.000000,A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery,,https://clinicaltrials.gov/ct2/show/NCT01592552,2011-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1339,3171,2023-11-21 00:00:00.000000,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01480076,2011-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1340,3170,2023-11-21 00:00:00.000000,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,,https://clinicaltrials.gov/show/NCT01480063,2011-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1341,3169,2023-11-21 00:00:00.000000,Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants,,https://clinicaltrials.gov/show/NCT01485003,2011-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1342,3168,2023-11-21 00:00:00.000000,Canadian Avonex PEN Productivity Study,,http://clinicaltrials.gov/show/NCT01489748,2011-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1343,3167,2023-11-21 00:00:00.000000,The Effects of Attention Retraining in MS,,http://clinicaltrials.gov/show/NCT01492023,2011-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1344,3166,2023-11-21 00:00:00.000000,Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,,http://clinicaltrials.gov/show/NCT01487096,2011-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1345,3165,2023-11-21 00:00:00.000000,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01497262,2011-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1346,3164,2023-11-21 00:00:00.000000,Vitamin D Supplementation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01490502,2011-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1347,3163,2023-11-21 00:00:00.000000,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01491100,2011-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1348,3162,2023-11-21 00:00:00.000000,"Aerobic exercise to improve fitness, walking ability and cognitive function in multiple sclerosis: a randomized controlled trial",,http://isrctn.com/ISRCTN76467492,2011-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1349,3161,2023-11-21 00:00:00.000000,"A clinical trial to study the pharmacokinetics and pharmacodynamics of Interferon beta 1 b compared with Betaferon, in healthy, adult, male, human subjects.",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=404,2011-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1350,3160,2023-11-21 00:00:00.000000,To determine if BIIB017 is safe and tolerable enough in patients with Relapsing Multiple Sclerosis on a long term duration.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3498,2011-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1351,3159,2023-11-21 00:00:00.000000,Fampridine Pregnancy Exposure Registry,,https://clinicaltrials.gov/show/NCT01532154,2011-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1352,3158,2023-11-21 00:00:00.000000,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,,https://clinicaltrials.gov/show/NCT01498887,2011-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1353,3157,2023-11-21 00:00:00.000000,Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers,,http://clinicaltrials.gov/show/NCT01500408,2011-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1354,3156,2023-11-21 00:00:00.000000,aquaporin-4 water channel and Multiple Sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=7718,2011-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1355,3155,2023-11-21 00:00:00.000000,Occupational Therapy in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01507636,2012-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1356,3154,2023-11-21 00:00:00.000000,Multiple Sclerosis and Progressive Resistance Training,,http://clinicaltrials.gov/show/NCT01518660,2012-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1357,3153,2023-11-21 00:00:00.000000,Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01517282,2012-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1358,3152,2023-11-21 00:00:00.000000,Pacing Activity Self-management for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01512329,2012-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1359,3151,2023-11-21 00:00:00.000000,The Comparison of ReciGen and Rebif in patients with Relapsing Multiple Sclerosis,,http://en.irct.ir/trial/1450,2012-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1360,3150,2023-11-21 00:00:00.000000,Effect of co-administration of Amantadine and Aspirin on fatigue in patients with multiple sclerosis,,http://en.irct.ir/trial/8890,2012-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1361,3149,2023-11-21 00:00:00.000000,Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a,,https://clinicaltrials.gov/show/NCT01514370,2012-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1362,3148,2023-11-21 00:00:00.000000,Self Help for Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01532037,2012-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1363,3147,2023-11-21 00:00:00.000000,Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01516554,2012-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1364,3146,2023-11-21 00:00:00.000000,"Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as ""responders"" and ""not responders"" under treatment with Sativex",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000985-36,2012-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1365,3145,2023-11-21 00:00:00.000000,The Direct Benefit of Neuropsychological Assessment with Feedback in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12612000161820.aspx,2012-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1366,3144,2023-11-21 00:00:00.000000,"An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)",,https://clinicaltrials.gov/show/NCT01535664,2012-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1367,3143,2023-11-21 00:00:00.000000,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),,https://clinicaltrials.gov/show/NCT01534182,2012-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1368,3142,2023-11-21 00:00:00.000000,A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001437-16,2012-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1369,3141,2023-11-21 00:00:00.000000,Trial on the effectiveness of Fampridine medication for upper limb function in people with MS.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002561-38,2012-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1370,3140,2023-11-21 00:00:00.000000,"An initial, short-duration study of vitamin D versus an inactive therapy on the ability of the human immune system to counteract the effects of Multiple Sclerosis on the brain and the effects of vitamin D on the immune system in healthy individuals.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000635-68,2012-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1371,3139,2023-11-21 00:00:00.000000,"A clinical study in patients with multiple sclerosis to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml (experimental drug).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005550-57,2012-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1372,3138,2023-11-21 00:00:00.000000,A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01538355,2012-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1373,3137,2023-11-21 00:00:00.000000,"FAME - a study of the effect of Fampyra on muscle strength in the lower extremities, walking capacity, coordination in the upper extremitties and cognition in multiple sclerosis patients.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-006151-10,2012-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1374,3136,2023-11-21 00:00:00.000000,Study to evaluate the effect of oral BAF312 on a monophasic oral contraceptive in healthy female volunteers,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-006043-30,2012-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1375,3135,2023-11-21 00:00:00.000000,Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity,,http://clinicaltrials.gov/show/NCT01538225,2012-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1376,3134,2023-11-21 00:00:00.000000,A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01541618,2012-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1377,3133,2023-11-21 00:00:00.000000,A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01539395,2012-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1378,3132,2023-11-21 00:00:00.000000,Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01547234,2012-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1379,3131,2023-11-21 00:00:00.000000,Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire,,https://clinicaltrials.gov/show/NCT01547351,2012-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1380,3130,2023-11-21 00:00:00.000000,Virtual reality augmented exercise in multiple sclerosis patients,,http://isrctn.com/ISRCTN13924231,2012-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1381,3129,2023-11-21 00:00:00.000000,Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01555684,2012-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1382,3128,2023-11-21 00:00:00.000000,Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01564511,2012-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1383,3127,2023-11-21 00:00:00.000000,"?Post-authorization safety study to check the potential association between the safety
profile of beta interferon 1a and the body mass index or pharmacodynamics during the
titration phase",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000606-23,2012-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1384,3126,2023-11-21 00:00:00.000000,"A randomised, blinded, controlled study of percutaneous transluminal angioplasty (PTA) for extracranial vein stenoses in patients with multiple sclerosis (MS)",,https://anzctr.org.au/ACTRN12612000302853.aspx,2012-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1385,3125,2023-11-21 00:00:00.000000,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",,https://clinicaltrials.gov/show/NCT01578330,2012-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1386,3124,2023-11-21 00:00:00.000000,Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01576354,2012-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1387,3123,2023-11-21 00:00:00.000000,Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA),,http://clinicaltrials.gov/show/NCT01563900,2012-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1388,3122,2023-11-21 00:00:00.000000,Study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3897,2012-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1389,3121,2023-11-21 00:00:00.000000,Promoting Physical Activity Behavior in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01572207,2012-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1390,3120,2023-11-21 00:00:00.000000,Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate,,https://clinicaltrials.gov/show/NCT01569451,2012-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1391,3119,2023-11-21 00:00:00.000000,The effect of exercise on fatigue level,,http://en.irct.ir/trial/9806,2012-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1392,3118,2023-11-21 00:00:00.000000,Preventing patients with multiple sclerosis from developing side effects following treatment with alemtuzumab (Campath-1H).,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005606-30,2012-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1393,3117,2023-11-21 00:00:00.000000,Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01572714,2012-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1394,3116,2023-11-21 00:00:00.000000,"Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01585766,2012-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1395,3115,2023-11-21 00:00:00.000000,"A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004475-36,2012-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1396,3114,2023-11-21 00:00:00.000000,A study to explore heart function during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000653-32,2012-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1397,3113,2023-11-21 00:00:00.000000,Acupuncture in Multiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-58yq52,2012-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1398,3112,2023-11-21 00:00:00.000000,Group Balance Training for People With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01582126,2012-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1399,3111,2023-11-21 00:00:00.000000,Neuroimmunology Branch Repository,,https://clinicaltrials.gov/show/NCT01581567,2012-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1400,3110,2023-11-21 00:00:00.000000,NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness,,http://clinicaltrials.gov/show/NCT01591551,2012-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1401,3109,2023-11-21 00:00:00.000000,STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START),,https://clinicaltrials.gov/show/NCT01585298,2012-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1402,3108,2023-11-21 00:00:00.000000,ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon,,https://clinicaltrials.gov/show/NCT01621269,2012-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1403,3107,2023-11-21 00:00:00.000000,Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells,,http://clinicaltrials.gov/show/NCT01587690,2012-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1404,3106,2023-11-21 00:00:00.000000,Balance training in multiple sclerosis,,http://en.irct.ir/trial/4970,2012-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1405,3105,2023-11-21 00:00:00.000000,"A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000674-31,2012-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1406,3104,2023-11-21 00:00:00.000000,Does treatment initiated by a Continence Nurse help to improve bladder and bowel problems in people with Multiple Sclerosis?,,https://anzctr.org.au/ACTRN12612000471886.aspx,2012-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1407,3103,2023-11-21 00:00:00.000000,Pathogenesis of multiple sclerosis by proteome analysis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008267,2012-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1408,3102,2023-11-21 00:00:00.000000,Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS,,https://clinicaltrials.gov/show/NCT01592097,2012-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1409,3101,2023-11-21 00:00:00.000000,Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study,,https://clinicaltrials.gov/show/NCT01628315,2012-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1410,3100,2023-11-21 00:00:00.000000,Evaluation of Brain Atrophy in CIS Patients on Avonex,,http://clinicaltrials.gov/show/NCT01592474,2012-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1411,3099,2023-11-21 00:00:00.000000,"The impacts of core stability exercise (Pilates) on posture, pain, function and quality of life in wheelchair users with Multiple Sclerosis",,http://isrctn.com/ISRCTN58085997,2012-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1412,3098,2023-11-21 00:00:00.000000,Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01596881,2012-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1413,3097,2023-11-21 00:00:00.000000,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT01597297,2012-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1414,3096,2023-11-21 00:00:00.000000,A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01599234,2012-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1415,3095,2023-11-21 00:00:00.000000,Applying Speed of Processing Training to Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01838824,2012-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1416,3094,2023-11-21 00:00:00.000000,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT01600716,2012-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1417,3093,2023-11-21 00:00:00.000000,"An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device",,http://clinicaltrials.gov/show/NCT01601080,2012-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1418,3092,2023-11-21 00:00:00.000000,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,,http://clinicaltrials.gov/show/NCT01601119,2012-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1419,3091,2023-11-21 00:00:00.000000,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01606215,2012-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1420,3090,2023-11-21 00:00:00.000000,A Study of the Long-term Safety of Sativex Use,,https://clinicaltrials.gov/show/NCT01606137,2012-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1421,3089,2023-11-21 00:00:00.000000,A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01604265,2012-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1422,3088,2023-11-21 00:00:00.000000,A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin,,https://clinicaltrials.gov/show/NCT01606176,2012-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1423,3087,2023-11-21 00:00:00.000000,The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01611987,2012-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1424,3086,2023-11-21 00:00:00.000000,Long-term Extension Study to Evaluate the Safety and Efficacy of Daclizumab High Yield Process,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3908,2012-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1425,3085,2023-11-21 00:00:00.000000,Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination,,http://clinicaltrials.gov/show/NCT01627938,2012-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1426,3084,2023-11-21 00:00:00.000000,Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers,,http://clinicaltrials.gov/show/NCT01610310,2012-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1427,3083,2023-11-21 00:00:00.000000,An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01610700,2012-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1428,3082,2023-11-21 00:00:00.000000,A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01610687,2012-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1429,3081,2023-11-21 00:00:00.000000,An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01610713,2012-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1430,3080,2023-11-21 00:00:00.000000,Effects of Dalfampridine on Cognition in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02006160,2012-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1431,3079,2023-11-21 00:00:00.000000,Effects of highly specialized rehabilitation of patients with multiple sclerosis,,https://www.isrctn.com/ISRCTN05245917,2012-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1432,3078,2023-11-21 00:00:00.000000,Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility,,https://clinicaltrials.gov/ct2/show/NCT01617395,2012-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1433,3077,2023-11-21 00:00:00.000000,"Influence of two different concepts for positioning on passive range of motion, comfort and vital parameters in severely affected patients with CNS lesion",,http://drks.de/search/en/trial/DRKS00004163,2012-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1434,3076,2023-11-21 00:00:00.000000,The effects peer group education on psychological symptoms in multiple sclerosis patients,,http://en.irct.ir/trial/9756,2012-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1435,3075,2023-11-21 00:00:00.000000,Proposing a new method in treatment of patients with Multiple Sclerosis,,http://en.irct.ir/trial/2470,2012-06-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1436,3074,2023-11-21 00:00:00.000000,Evaluation of adjustment groups for people with Multiple Sclerosis: a pilot study,,http://isrctn.com/ISRCTN13272820,2012-06-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1437,3073,2023-11-21 00:00:00.000000,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT01623596,2012-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1438,3072,2023-11-21 00:00:00.000000,Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects,,http://clinicaltrials.gov/show/NCT01624714,2012-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1439,3071,2023-11-21 00:00:00.000000,Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study,,http://clinicaltrials.gov/show/NCT01628276,2012-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1440,3070,2023-11-21 00:00:00.000000,Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control,,http://clinicaltrials.gov/show/NCT01626248,2012-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1441,3069,2023-11-21 00:00:00.000000,Own mesenchymal stem cells for multiple sclerosis patients,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000518-13,2012-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1442,3068,2023-11-21 00:00:00.000000,Evaluating Intervention Responsiveness in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01632293,2012-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1443,3067,2023-11-21 00:00:00.000000,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,,https://clinicaltrials.gov/show/NCT01633112,2012-06-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1444,3066,2023-11-21 00:00:00.000000,Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01649050,2012-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1445,3065,2023-11-21 00:00:00.000000,Assessing Tolerability of Avonex Intramuscular Injections,,https://clinicaltrials.gov/show/NCT01641120,2012-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1446,3064,2023-11-21 00:00:00.000000,Safety Study of GNbAC1 in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01639300,2012-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1447,3063,2023-11-21 00:00:00.000000,Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004787-30,2012-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1448,3062,2023-11-21 00:00:00.000000,Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01647321,2012-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1449,3061,2023-11-21 00:00:00.000000,MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study),,https://clinicaltrials.gov/show/NCT01647880,2012-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1450,3060,2023-11-21 00:00:00.000000,Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01651520,2012-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1451,3059,2023-11-21 00:00:00.000000,Bone marrow stem cells to treat multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002357-35,2012-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1452,3058,2023-11-21 00:00:00.000000,A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse,,http://isrctn.com/ISRCTN66678006,2012-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1453,3057,2023-11-21 00:00:00.000000,FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra,,https://clinicaltrials.gov/show/NCT01656148,2012-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1454,3056,2023-11-21 00:00:00.000000,Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001965-34,2012-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1455,3055,2023-11-21 00:00:00.000000,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,,https://clinicaltrials.gov/show/NCT01705236,2012-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1456,3054,2023-11-21 00:00:00.000000,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,,https://clinicaltrials.gov/show/NCT01667796,2012-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1457,3053,2023-11-21 00:00:00.000000,Adderall XR and Processing Speed in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01667484,2012-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1458,3052,2023-11-21 00:00:00.000000,Study of the effects of therapeutic plasmapheresis  in comparison with corticosteroid therapy on the immune system of MS patients,,http://en.irct.ir/trial/10872,2012-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1459,3051,2023-11-21 00:00:00.000000,High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment,,http://clinicaltrials.gov/show/NCT01679041,2012-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1460,3050,2023-11-21 00:00:00.000000,A study to assess safety and effectiveness of the study drug MT-1303 at different dosage strengths,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002470-31,2012-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1461,3049,2023-11-21 00:00:00.000000,Alternative Treatment Paradigm for Natalizumab Trial,,https://clinicaltrials.gov/show/NCT01710228,2012-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1462,3048,2023-11-21 00:00:00.000000,Implementation of the Sapere Migliora Information aid for newly diagnosed multiple sclerosis (MS) patients in routine clinical Practice (SIMS-Practice),,http://isrctn.com/ISRCTN78940214,2012-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1463,3047,2023-11-21 00:00:00.000000,"Randomized, open labeled, multicenter study evaluating safety Fingolide® in patients with Relapsing- Remitting Multiple Sclerosis",,http://en.irct.ir/trial/7881,2012-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1464,3046,2023-11-21 00:00:00.000000,Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE),,https://clinicaltrials.gov/show/NCT01706055,2012-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1465,3045,2023-11-21 00:00:00.000000,Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003627-38,2012-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1466,3044,2023-11-21 00:00:00.000000,Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01684761,2012-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1467,3043,2023-11-21 00:00:00.000000,Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS),,http://isrctn.com/ISRCTN27232902,2012-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1468,3042,2023-11-21 00:00:00.000000,Acupressure and sleep quality in women with multiple sclerosis (MS),,http://en.irct.ir/trial/6671,2012-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1469,3041,2023-11-21 00:00:00.000000,Optical Coherence Tomography in Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01774123,2012-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1470,3040,2023-11-21 00:00:00.000000,A comparison between the effects of Hip Flexion Assist Orthosis and conventional Ankle Foot Orthosis on walking in multiple sclerosis patients,,http://en.irct.ir/trial/5926,2012-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1471,3039,2023-11-21 00:00:00.000000,Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01701856,2012-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1472,3038,2023-11-21 00:00:00.000000,Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial),,https://clinicaltrials.gov/show/NCT01698086,2012-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1473,3037,2023-11-21 00:00:00.000000,A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months,,http://clinicaltrials.gov/show/NCT01695434,2012-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1474,3036,2023-11-21 00:00:00.000000,First-in-Human Study With GNbAC1 in Healthy Volunteers,,https://clinicaltrials.gov/show/NCT01699555,2012-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1475,3035,2023-11-21 00:00:00.000000,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",,https://clinicaltrials.gov/show/NCT01707992,2012-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1476,3034,2023-11-21 00:00:00.000000,"A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000835-18,2012-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1477,3033,2023-11-21 00:00:00.000000,Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01704183,2012-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1478,3032,2023-11-21 00:00:00.000000,The Comparison of effects of Cinnaferon with Betaferon in Relapsing- Remitting Multiple  Sclerosis,,http://en.irct.ir/trial/1451,2012-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1479,3031,2023-11-21 00:00:00.000000,"A 6 months, multicenter study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002637-11,2012-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1480,3030,2023-11-21 00:00:00.000000,"A randomized, controlled trial of mindful meditation in people with Multiple Sclerosis: Effects on mood, inflammation and volume of the hippocampus.",,https://anzctr.org.au/ACTRN12612001083886.aspx,2012-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1481,3029,2023-11-21 00:00:00.000000,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,,https://clinicaltrials.gov/show/NCT01706107,2012-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1482,3028,2023-11-21 00:00:00.000000,Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS,,http://clinicaltrials.gov/show/NCT01709812,2012-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1483,3027,2023-11-21 00:00:00.000000,An extension trial of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000721-53,2012-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1484,3026,2023-11-21 00:00:00.000000,Evaluation of Coagulation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01711255,2012-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1485,3025,2023-11-21 00:00:00.000000,Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01712945,2012-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1486,3024,2023-11-21 00:00:00.000000,Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01714089,2012-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1487,3023,2023-11-21 00:00:00.000000,"Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity",,https://clinicaltrials.gov/show/NCT01718392,2012-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1488,3022,2023-11-21 00:00:00.000000,Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT01717664,2012-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1489,3021,2023-11-21 00:00:00.000000,The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort,,https://clinicaltrials.gov/show/NCT01723709,2012-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1490,3020,2023-11-21 00:00:00.000000,Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01719159,2012-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1491,3019,2023-11-21 00:00:00.000000,"OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01779934,2012-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1492,3018,2023-11-21 00:00:00.000000,Balance Exercise for multiple sclerosis,,https://anzctr.org.au/ACTRN12612001139864.aspx,2012-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1493,3017,2023-11-21 00:00:00.000000,"Relapse Escalation treatment trial in Optic Neuritis (RESCON):
Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004807-10,2012-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1494,3016,2023-11-21 00:00:00.000000,"Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Trial to determine the safety and efficacy of Vitamin D3 in preventing the risk of MS in Patients with a first demyelinating event.",,https://anzctr.org.au/ACTRN12612001160820.aspx,2012-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1495,3015,2023-11-21 00:00:00.000000,Effect of zinc on the treatment of depression and multiple sclerosis,,http://en.irct.ir/trial/11043,2012-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1496,3014,2023-11-21 00:00:00.000000,Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01723631,2012-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1497,3013,2023-11-21 00:00:00.000000,Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01780792,2012-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1498,3012,2023-11-21 00:00:00.000000,Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT01728922,2012-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1499,3011,2023-11-21 00:00:00.000000,Mesenchymal Stem Cells for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01730547,2012-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1500,3010,2023-11-21 00:00:00.000000,Methylphenidate modified release as treatment of MS-associated fatigue.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003418-15,2012-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1501,3009,2023-11-21 00:00:00.000000,Exercise in Severely Disabled Patients With MS,,http://clinicaltrials.gov/show/NCT01752660,2012-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1502,3008,2023-11-21 00:00:00.000000,"?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial?",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004602-97,2012-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1503,3007,2023-11-21 00:00:00.000000,Efficacy of combined use of Low Intensity Laser Therapy and Ultraviolet Radiation in the treatment of Relapsing-Remitting Multiple Sclerosis patients,,https://anzctr.org.au/ACTRN12612001186842.aspx,2012-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1504,3006,2023-11-21 00:00:00.000000,"Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).",,https://clinicaltrials.gov/show/NCT01738347,2012-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1505,3005,2023-11-21 00:00:00.000000,Effects of different types of balance training in neurological rehabilitation of patients with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00004520,2012-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1506,3004,2023-11-21 00:00:00.000000,The evaluation of therapeutic effects and adverse effects of Imatinib in Secondary Progressive Multiple Sclerosis,,http://en.irct.ir/trial/997,2012-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1507,3003,2023-11-21 00:00:00.000000,A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002639-27,2012-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1508,3002,2023-11-21 00:00:00.000000,Exploratory Phase Trial of OCH-NCNP1 in Healthy Subjects and Patients with Multiple Sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011008,2012-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1509,3001,2023-11-21 00:00:00.000000,Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01749943,2012-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1510,3000,2023-11-21 00:00:00.000000,A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01737372,2012-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1511,2999,2023-11-21 00:00:00.000000,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01743651,2012-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1512,2998,2023-11-21 00:00:00.000000,Mindfulness Intervention for Multiple Sclerosis (MIMS),,http://isrctn.com/ISRCTN93263909,2012-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1513,2997,2023-11-21 00:00:00.000000,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01744444,2012-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1514,2996,2023-11-21 00:00:00.000000,Dose-finding Study of MT-1303,,https://clinicaltrials.gov/show/NCT01742052,2012-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1515,2995,2023-11-21 00:00:00.000000,"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01745783,2012-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1516,2994,2023-11-21 00:00:00.000000,Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000411-91,2012-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1517,2993,2023-11-21 00:00:00.000000,Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial,,https://clinicaltrials.gov/show/NCT01746342,2012-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1518,2992,2023-11-21 00:00:00.000000,"Depression, Anxiety and stress in Multiple Sclerosis patients",,http://en.irct.ir/trial/10774,2012-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1519,2991,2023-11-21 00:00:00.000000,"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon",,https://clinicaltrials.gov/show/NCT01766063,2012-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1520,2990,2023-11-21 00:00:00.000000,Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients,,https://clinicaltrials.gov/show/NCT01767493,2012-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1521,2989,2023-11-21 00:00:00.000000,Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003176-39,2012-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1522,2988,2023-11-21 00:00:00.000000,Melatonin for Nocturia in patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004183-21,2012-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1523,2987,2022-03-17 12:44:43.883950,Famciclovir in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Famciclovir<br /><b>Sponsor</b>:    Queen Mary University of London<br /><b>Recruiting</b>,https://clinicaltrials.gov/show/NCT05283551,2022-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1524,2986,2023-11-21 00:00:00.000000,INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004847-61,2012-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1525,2985,2023-11-21 00:00:00.000000,Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation,,https://clinicaltrials.gov/show/NCT01758224,2012-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1526,2984,2023-11-21 00:00:00.000000,Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01755871,2012-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1527,2983,2023-11-21 00:00:00.000000,Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG),,https://clinicaltrials.gov/show/NCT01765361,2012-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1528,2982,2023-11-21 00:00:00.000000,Effects of exposure to a pulsetile magnetic field  on the treatment of Multiple Sclerotic patients with paresthesia,,http://en.irct.ir/trial/11782,2013-01-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1529,2981,2023-11-21 00:00:00.000000,"Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS",,http://clinicaltrials.gov/show/NCT01764737,2013-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1530,2980,2023-11-21 00:00:00.000000,GSK239512 DDI Study,,https://clinicaltrials.gov/show/NCT01802931,2013-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1531,2979,2023-11-21 00:00:00.000000,Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01763983,2013-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1532,2978,2023-11-21 00:00:00.000000,Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction,,https://clinicaltrials.gov/show/NCT01768910,2013-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1533,2977,2023-11-21 00:00:00.000000,Prospective Evaluation of the Clinical Utility of Ketamine in Pain Desensitisation in Chronic Pain,,https://anzctr.org.au/ACTRN12613000022763.aspx,2013-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1534,2976,2023-11-21 00:00:00.000000,Vitamine D in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01768039,2013-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1535,2975,2023-11-21 00:00:00.000000,AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. - AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005773-35,2013-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1536,2974,2023-11-21 00:00:00.000000,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01772199,2013-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1537,2973,2023-11-21 00:00:00.000000,Respiratory Function and Walking Capacity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01774201,2013-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1538,2972,2023-11-21 00:00:00.000000,Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple Sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial,,http://drks.de/search/en/trial/DRKS00004368,2013-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1539,2971,2023-11-21 00:00:00.000000,Health Promotion and Wellness Program for Adults With Disabling Conditions,,https://clinicaltrials.gov/show/NCT01776034,2013-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1540,2970,2023-11-21 00:00:00.000000,Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study,,https://clinicaltrials.gov/show/NCT01776060,2013-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1541,2969,2023-11-21 00:00:00.000000,Imaging of Intracerebral Inflammation in MS,,https://clinicaltrials.gov/show/NCT02305264,2013-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1542,2968,2023-11-21 00:00:00.000000,Effect of Thyroid hormones on imaging findings of patients with multiple sclerosis,,http://en.irct.ir/trial/1453,2013-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1543,2967,2023-11-21 00:00:00.000000,The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01783665,2013-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1544,2966,2023-11-21 00:00:00.000000,Saffron in treatment of Multiple Sclerosis,,http://en.irct.ir/trial/1448,2013-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1545,2965,2023-11-21 00:00:00.000000,Power Over Pain (POP) Study,,https://clinicaltrials.gov/show/NCT01800604,2013-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1546,2964,2023-11-21 00:00:00.000000,Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod,,https://clinicaltrials.gov/show/NCT01790269,2013-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1547,2963,2023-11-21 00:00:00.000000,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,,https://clinicaltrials.gov/show/NCT01791244,2013-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1548,2962,2023-11-21 00:00:00.000000,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,,https://clinicaltrials.gov/show/NCT01808885,2013-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1549,2961,2023-11-21 00:00:00.000000,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,,https://clinicaltrials.gov/show/NCT01797965,2013-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1550,2960,2023-11-21 00:00:00.000000,"A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005082-13,2013-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1551,2959,2023-11-21 00:00:00.000000,Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01796860,2013-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1552,2958,2023-11-21 00:00:00.000000,The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients,,https://clinicaltrials.gov/ct2/show/NCT01816100,2013-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1553,2957,2023-11-21 00:00:00.000000,"Study to provide access to fingolimod to Multiple Sclerosis patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005507-40,2013-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1554,2956,2023-11-21 00:00:00.000000,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01803867,2013-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1555,2955,2023-11-21 00:00:00.000000,Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality,,https://clinicaltrials.gov/show/NCT01805336,2013-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1556,2954,2023-11-21 00:00:00.000000,Amiloride Clinical Trial In Optic Neuritis,,https://clinicaltrials.gov/show/NCT01802489,2013-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1557,2953,2023-11-21 00:00:00.000000,Self-management and Multiple Sclerosis: The impact of a community-based exercise and education program,,https://anzctr.org.au/ACTRN12613000245796.aspx,2013-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1558,2952,2023-11-21 00:00:00.000000,"RETRAP - A study of the effect of combination of resistance training and prolonged-release fampridine on muscle strength in the legs, walking capacity and quality of life in multiple sclerosis patients.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002959-34,2013-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1559,2951,2023-11-21 00:00:00.000000,Effect of self care education on  quality of life of MS patient,,http://en.irct.ir/trial/11864,2013-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1560,2950,2023-11-21 00:00:00.000000,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease,,https://clinicaltrials.gov/show/NCT01804647,2013-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1561,2949,2023-11-21 00:00:00.000000,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population,,https://clinicaltrials.gov/show/NCT01804660,2013-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1562,2948,2023-11-21 00:00:00.000000,Effect of Tai Chi Chuan on balance and quality of life in MS patients,,http://en.irct.ir/trial/12555,2013-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1563,2947,2023-11-21 00:00:00.000000,"A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",,https://clinicaltrials.gov/show/NCT01808482,2013-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1564,2946,2023-11-21 00:00:00.000000,A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01811290,2013-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1565,2945,2023-11-21 00:00:00.000000,MINERAL (Magnetic-resonance Image of Nutraceutical Efficacy on Relapsing-ms Autoimmune Lesions) study: a novel nutraceutical formula NEUROASPIS PLP10® for the treatment of relapsing-remitting multiple sclerosis,,https://www.isrctn.com/ISRCTN06166891,2013-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1566,2944,2023-11-21 00:00:00.000000,Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT01817166,2013-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1567,2943,2023-11-21 00:00:00.000000,"A placebo-controlled, randomized, double-blind trial of the effects of modified release 4-aminopyridine on upper limb impairment in Multiple Sclerosis",,https://anzctr.org.au/ACTRN12613000331730.aspx,2013-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1568,2942,2023-11-21 00:00:00.000000,Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,,https://clinicaltrials.gov/show/NCT01954875,2013-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1569,2941,2023-11-21 00:00:00.000000,Effect of relaxation on Patients with multiple sclerosis,,http://en.irct.ir/trial/10292,2013-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1570,2940,2023-11-21 00:00:00.000000,Home Exercise Intervention in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01824550,2013-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1571,2939,2023-11-21 00:00:00.000000,Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications,,https://clinicaltrials.gov/show/NCT01834586,2013-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1572,2938,2023-11-21 00:00:00.000000,Acupuncture or MBSR for Patients With Fatigue and MS,,https://clinicaltrials.gov/show/NCT01864707,2013-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1573,2937,2023-11-21 00:00:00.000000,Melatonin for nocturia in multiple sclerosis (MS),,http://isrctn.com/ISRCTN38687869,2013-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1574,2936,2023-11-21 00:00:00.000000,A study to assess the safety and efficacy of BIIB033 in patients with relapsing forms of multiple sclerosis when used concurrently with Avonex®,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-006262-40,2013-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1575,2935,2023-11-21 00:00:00.000000,Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist,,http://clinicaltrials.gov/show/NCT01836055,2013-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1576,2934,2023-11-21 00:00:00.000000,Pilot Study of Free From Falls Program in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01829776,2013-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1577,2933,2023-11-21 00:00:00.000000,Resistant MS Spasticity Treatment with Sativex and Driving,,http://drks.de/search/en/trial/DRKS00004877,2013-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1578,2932,2023-11-21 00:00:00.000000,Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior,,http://clinicaltrials.gov/show/NCT01956227,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1579,2931,2023-11-21 00:00:00.000000,Project FARMS: Fall Risk Reduction in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01837017,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1580,2930,2023-11-21 00:00:00.000000,Study to be conducted only in Italy to evaluate the effect of the treatment with BG00012 on cognitive function in patients with Relapsing Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001422-25,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1581,2929,2023-11-21 00:00:00.000000,the effect of tibial nerve stimulation on urinary symptoms in multiple sclerosis,,http://en.irct.ir/trial/12825,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1582,2928,2023-11-21 00:00:00.000000,"A clinical and electrophysiological study of the effects of 
4-aminopyridine on upper limb impairment in Multiple Sclerosis",,https://anzctr.org.au/ACTRN12613000439741.aspx,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1583,2927,2023-11-21 00:00:00.000000,A Trial of Neuroprotection With ACTH in Acute Optic Neuritis,,https://clinicaltrials.gov/show/NCT01838174,2013-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1584,2926,2023-11-21 00:00:00.000000,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT01838668,2013-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1585,2925,2023-11-21 00:00:00.000000,Effect of rituximab in secondary progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004436-36,2013-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1586,2924,2023-11-21 00:00:00.000000,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity",,https://clinicaltrials.gov/show/NCT01844232,2013-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1587,2923,2023-11-21 00:00:00.000000,MIA-MS: The effectiveness of an online mindfulness based cognitive therapy intervention programme in improving well-being in people with multiple sclerosis,,http://isrctn.com/ISRCTN11615285,2013-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1588,2922,2023-11-21 00:00:00.000000,Efficacy of Fish Oil in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01842191,2013-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1589,2921,2023-11-21 00:00:00.000000,Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.,,https://clinicaltrials.gov/show/NCT01866878,2013-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1590,2920,2023-11-21 00:00:00.000000,"Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis",,http://clinicaltrials.gov/show/NCT01845896,2013-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1591,2919,2023-11-21 00:00:00.000000,A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years,,http://clinicaltrials.gov/show/NCT01847287,2013-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1592,2918,2023-11-21 00:00:00.000000,Sodium Intake in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01846234,2013-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1593,2917,2023-11-21 00:00:00.000000,Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005086-12,2013-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1594,2916,2023-11-21 00:00:00.000000,Natural History of Optic Neuritis,,https://clinicaltrials.gov/show/NCT01851434,2013-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1595,2915,2023-11-21 00:00:00.000000,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,,https://clinicaltrials.gov/show/NCT01873417,2013-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1596,2914,2023-11-21 00:00:00.000000,Idebenone for Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01854359,2013-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1597,2913,2023-11-21 00:00:00.000000,Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01864941,2013-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1598,2912,2023-11-21 00:00:00.000000,Detecting and Addressing Preclinical Disability,,https://clinicaltrials.gov/show/NCT01979081,2013-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1599,2911,2023-11-21 00:00:00.000000,"Open-label study to assess how the pharmacokinetics (i.e. the way the body absorbs, distributes and gets rid of a drug), safety, and tolerability of the drug siponimod are influenced by the presence of specific genetic characteristics (namely CYP2C9 genotypes).",,https://anzctr.org.au/ACTRN12613000545763.aspx,2013-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1600,2910,2023-11-21 00:00:00.000000,Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations,,http://clinicaltrials.gov/show/NCT01888354,2013-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1601,2909,2023-11-21 00:00:00.000000,EXPERT: EXPerience of a health website Evaluated in a Research Study,,http://isrctn.com/ISRCTN29549695,2013-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1602,2908,2023-11-21 00:00:00.000000,"Avonex®: Safety, Blood Levels and Effects",,http://clinicaltrials.gov/show/NCT01863069,2013-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1603,2907,2023-11-21 00:00:00.000000,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005324-16,2013-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1604,2906,2023-11-21 00:00:00.000000,A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01871818,2013-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1605,2905,2023-11-21 00:00:00.000000,Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI,,https://clinicaltrials.gov/show/NCT01865357,2013-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1606,2904,2023-11-21 00:00:00.000000,"Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.",,https://clinicaltrials.gov/show/NCT01868048,2013-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1607,2903,2023-11-21 00:00:00.000000,The effect of collaborative care model on lifestyle of multiple sclerosis patients,,http://en.irct.ir/trial/12340,2013-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1608,2902,2023-11-21 00:00:00.000000,Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001055-12,2013-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1609,2901,2023-11-21 00:00:00.000000,Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT01871337,2013-04-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1610,2900,2023-11-21 00:00:00.000000,Safety and Tolerability of Glatiramer Acetate,,https://clinicaltrials.gov/show/NCT01874145,2013-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1611,2899,2023-11-21 00:00:00.000000,The effect of collaborative care model on self-efficacy of  MS patients.,,http://en.irct.ir/trial/12341,2013-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1612,2898,2023-11-21 00:00:00.000000,Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months,,https://clinicaltrials.gov/show/NCT01881191,2013-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1613,2897,2023-11-21 00:00:00.000000,Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects,,https://clinicaltrials.gov/show/NCT01883310,2013-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1614,2896,2023-11-21 00:00:00.000000,Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01895439,2013-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1615,2895,2023-11-21 00:00:00.000000,The effect of continuous care  on lifestyle and quality of life in multiple sclerosis patients,,http://en.irct.ir/trial/12513,2013-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1616,2894,2023-11-21 00:00:00.000000,Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop,,https://clinicaltrials.gov/show/NCT01914016,2013-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1617,2893,2023-11-21 00:00:00.000000,To investigate the ability of the Heidelberg Assay Panel (HAP) score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis,,http://isrctn.com/ISRCTN82177408,2013-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1618,2892,2023-11-21 00:00:00.000000,Extension Study of MT-1303,,https://clinicaltrials.gov/show/NCT01890655,2013-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1619,2891,2023-11-21 00:00:00.000000,Decision-making impairment in patients with Multiple Sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011796,2013-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1620,2890,2023-11-21 00:00:00.000000,"A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis",,https://jrct.niph.go.jp/latest-detail/jRCT2080222132,2013-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1621,2889,2023-11-21 00:00:00.000000,study of transcranial magnetic stimulation effect on motor imagery rehabilitation and movement improvment in multiple sclerosis patients,,http://en.irct.ir/trial/13034,2013-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1622,2888,2023-11-21 00:00:00.000000,The effect of yoga and exercise on quality of life in patients with multiple sclerosis,,http://en.irct.ir/trial/13539,2013-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1623,2887,2023-11-21 00:00:00.000000,Methylphenidate to Improve Balance and Walking in MS,,https://clinicaltrials.gov/show/NCT01896700,2013-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1624,2886,2023-11-21 00:00:00.000000,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,,https://clinicaltrials.gov/show/NCT01903291,2013-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1625,2885,2023-11-21 00:00:00.000000,Adherence Trial With MS LifeLines ® Services,,http://clinicaltrials.gov/show/NCT01905527,2013-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1626,2884,2023-11-21 00:00:00.000000,Comprehensive Analysis of Relapse in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01906684,2013-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1627,2883,2023-11-21 00:00:00.000000,The effect of massage and Exercise Therapy  in Multiple Sclerosis,,http://en.irct.ir/trial/13209,2013-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1628,2882,2023-11-21 00:00:00.000000,Biogen Multiple Sclerosis Pregnancy Exposure Registry,,https://clinicaltrials.gov/show/NCT01911767,2013-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1629,2881,2023-11-21 00:00:00.000000,Wahls Paleo Diet and Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01915433,2013-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1630,2880,2023-11-21 00:00:00.000000,A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01917019,2013-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1631,2879,2023-11-21 00:00:00.000000,A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01918800,2013-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1632,2878,2023-11-21 00:00:00.000000,Treatment Of chronic Fatigue in patients with multiple sclerosis by paramedical disciplines,,http://isrctn.com/ISRCTN05017507,2013-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1633,2877,2023-11-21 00:00:00.000000,Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001409-10,2013-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1634,2876,2023-11-21 00:00:00.000000,Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01932593,2013-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1635,2875,2023-11-21 00:00:00.000000,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,,https://clinicaltrials.gov/show/NCT01930708,2013-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1636,2874,2023-11-21 00:00:00.000000,"Switch To RItuXimab in MS extension
An extension study of an ongoing clinical trial where people with multiple sclerosis switch therapy from interferon or glatiramere injections to rituximab, a monoclonal antibody that eliminate B lymphocytes",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002378-26,2013-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1637,2873,2023-11-21 00:00:00.000000,Development of a Motivational Intervention to Improve Treatment Adherence in MS,,https://clinicaltrials.gov/show/NCT01925690,2013-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1638,2872,2023-11-21 00:00:00.000000,Effect of Bosweilia serrata  in prevention of cognitive impairment  progression in multiple sclerosis,,http://en.irct.ir/trial/13643,2013-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1639,2871,2023-11-21 00:00:00.000000,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01933802,2013-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1640,2870,2023-11-21 00:00:00.000000,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-ß) Therapies to Peginterferon Beta-1a (BIIB017),,https://clinicaltrials.gov/show/NCT01939002,2013-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1641,2869,2023-11-21 00:00:00.000000,Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns,,https://clinicaltrials.gov/show/NCT01930799,2013-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1642,2868,2023-11-21 00:00:00.000000,ACTH in Progressive Forms of MS,,https://clinicaltrials.gov/show/NCT01950234,2013-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1643,2867,2023-11-21 00:00:00.000000,The effect of erythropoetin on Multiple Sclerosis,,http://en.irct.ir/trial/14055,2013-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1644,2866,2023-11-21 00:00:00.000000,Safety and Efficacy of Fingolimod in MS Patients in China,,https://clinicaltrials.gov/show/NCT01941004,2013-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1645,2865,2023-11-21 00:00:00.000000,Effects of tDCS and tRNS on attention and pain in multiple sclerosis,,http://drks.de/search/en/trial/DRKS00005296,2013-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1646,2864,2023-11-21 00:00:00.000000,Ireland Natalizumab (TYSABRI) Observational Program,,https://clinicaltrials.gov/show/NCT01943526,2013-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1647,2863,2023-11-21 00:00:00.000000,"A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared to Interferon ß-1a (Avonex, authorised drug) administered once weekly.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002082-19,2013-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1648,2862,2023-11-21 00:00:00.000000,Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design,,https://clinicaltrials.gov/show/NCT01945359,2013-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1649,2861,2023-11-21 00:00:00.000000,"The assessment of effect of Cinnovex, Rebif and Betaferon on serum level of brain-derived neurotrophic factor in multiple sclerosis patients referring to neurology department of Ahwaz Golestan hospital.",,http://en.irct.ir/trial/13874,2013-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1650,2860,2023-11-21 00:00:00.000000,Alemtuzumab in Multiple Sclerosis Safety System development,,https://anzctr.org.au/ACTRN12613001027707.aspx,2013-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1651,2859,2023-11-21 00:00:00.000000,T and B Cell Responses in Autoimmune Diseases,,https://clinicaltrials.gov/show/NCT01947036,2013-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1652,2858,2023-11-21 00:00:00.000000,The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT01947582,2013-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1653,2857,2023-11-21 00:00:00.000000,The effect of psycho-education on caregiver burden,,http://en.irct.ir/trial/12014,2013-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1654,2856,2023-11-21 00:00:00.000000,Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients,,https://clinicaltrials.gov/show/NCT01952483,2013-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1655,2855,2023-11-21 00:00:00.000000,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,,https://clinicaltrials.gov/show/NCT01895335,2013-03-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1656,2854,2023-11-21 00:00:00.000000,Use of an Electronic Diary by People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01954823,2013-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1657,2853,2023-11-21 00:00:00.000000,Comparing the effects of fish liver oil and Boswellia Serrata with placebo on multiple sclerosis  patients,,http://en.irct.ir/trial/12466,2013-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1658,2852,2023-11-21 00:00:00.000000,"A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002283-25,2013-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1659,2851,2023-11-21 00:00:00.000000,"Study on the evaluation of hippotherapy in the course of treatment for multiple sclerosis - a prospective, randomized controlled and multicenter study",,http://drks.de/search/en/trial/DRKS00005289,2013-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1660,2850,2023-11-21 00:00:00.000000,A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01964547,2013-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1661,2849,2023-11-21 00:00:00.000000,High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases,,https://clinicaltrials.gov/show/NCT01973517,2013-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1662,2848,2023-11-21 00:00:00.000000,improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002558-64,2013-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1663,2847,2023-11-21 00:00:00.000000,Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake,,https://clinicaltrials.gov/show/NCT01994018,2013-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1664,2846,2023-11-21 00:00:00.000000,FlexToBa for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01993095,2013-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1665,2845,2023-11-21 00:00:00.000000,Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01968902,2013-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1666,2844,2023-11-21 00:00:00.000000,MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV,,https://clinicaltrials.gov/show/NCT01970410,2013-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1667,2843,2023-11-21 00:00:00.000000,Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain,,https://clinicaltrials.gov/show/NCT02012439,2013-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1668,2842,2023-11-21 00:00:00.000000,A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT01975298,2013-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1669,2841,2023-11-21 00:00:00.000000,"Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01982942,2013-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1670,2840,2023-11-21 00:00:00.000000,Walking With FES or AFO in People With MS With Foot Drop,,https://clinicaltrials.gov/show/NCT01977287,2013-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1671,2839,2023-11-21 00:00:00.000000,Intellectual Enrichment to Build Cognitive Reserve in MS,,https://clinicaltrials.gov/show/NCT01978574,2013-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1672,2838,2023-11-21 00:00:00.000000,Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01981161,2013-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1673,2837,2023-11-21 00:00:00.000000,Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01992679,2013-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1674,2836,2023-11-21 00:00:00.000000,Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells,,https://clinicaltrials.gov/show/NCT01993004,2013-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1675,2835,2023-11-21 00:00:00.000000,JC Virus Reactivation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02004444,2013-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1676,2834,2023-11-21 00:00:00.000000,Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004626-28,2013-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1677,2833,2023-11-21 00:00:00.000000,Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion,,https://clinicaltrials.gov/ct2/show/NCT02043964,2013-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1678,2832,2023-11-21 00:00:00.000000,Tear Analysis in the Diagnosis of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02016222,2013-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1679,2831,2023-11-21 00:00:00.000000,The effect of amantadine and Q10 in fatigue of the Multiple Sclerosis patients,,http://en.irct.ir/trial/14303,2013-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1680,2830,2023-11-21 00:00:00.000000,Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02008669,2013-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1681,2829,2023-11-21 00:00:00.000000,Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity,,https://clinicaltrials.gov/show/NCT02005237,2013-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1682,2828,2023-11-21 00:00:00.000000,Study of Electrical Impedance Myography (EIM) in ALS,,https://clinicaltrials.gov/show/NCT02011204,2013-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1683,2827,2023-11-21 00:00:00.000000,Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months,,http://clinicaltrials.gov/show/NCT02017808,2013-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1684,2826,2023-11-21 00:00:00.000000,Calorie Restriction in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02411838,2013-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1685,2825,2023-11-21 00:00:00.000000,Effects of the Cross-Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02010398,2013-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1686,2824,2023-11-21 00:00:00.000000,Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS,,https://clinicaltrials.gov/show/NCT02010554,2013-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1687,2823,2023-11-21 00:00:00.000000,Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02011451,2013-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1688,2822,2023-11-21 00:00:00.000000,"study to evaluate whether the administration of Rebif ® 44 three times a week in the morning can reduce the severity of flu-like symptoms compared to administration in the evening, in patients with relapsing multiple sclerosis not yet treated.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004450-21,2013-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1689,2821,2023-11-21 00:00:00.000000,Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02035514,2013-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1690,2820,2023-11-21 00:00:00.000000,Electric Stimulation of the Eye to Improve Vision After Trauma,,https://clinicaltrials.gov/show/NCT02019927,2013-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1691,2819,2023-11-21 00:00:00.000000,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,,https://clinicaltrials.gov/show/NCT02019550,2013-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1692,2818,2023-11-21 00:00:00.000000,Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02021162,2013-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1693,2817,2023-11-21 00:00:00.000000,Testing the Efficacy of Self-Generation Treatment Protocol,,http://clinicaltrials.gov/show/NCT02032589,2013-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1694,2816,2023-11-21 00:00:00.000000,Effect of cinnamon supplement on multiple sclerosis patients,,http://en.irct.ir/trial/4923,2013-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1695,2815,2023-11-21 00:00:00.000000,"Impact of CRISP on Self-Efficacy, Loneliness, and Depression",,http://clinicaltrials.gov/show/NCT02030197,2014-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1696,2814,2023-11-21 00:00:00.000000,Treatment of stress in MS,,http://en.irct.ir/trial/14518,2014-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1697,2813,2023-11-21 00:00:00.000000,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02034188,2014-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1698,2812,2023-11-21 00:00:00.000000,Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02040298,2014-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1699,2811,2023-11-21 00:00:00.000000,Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases,,https://clinicaltrials.gov/show/NCT02040116,2014-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1700,2810,2023-11-21 00:00:00.000000,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02038049,2014-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1701,2809,2023-11-21 00:00:00.000000,"Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients",,http://clinicaltrials.gov/show/NCT02048358,2014-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1702,2808,2023-11-21 00:00:00.000000,Neuroretinal Biomarkers in Neurodegenerative Diseases,,https://clinicaltrials.gov/show/NCT02047760,2014-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1703,2807,2023-11-21 00:00:00.000000,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02045732,2014-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1704,2806,2023-11-21 00:00:00.000000,"Cytokine State, Cognitive Decline and Cortical Degeneration in MS-Patients (Multiple Sclerosis)",,http://drks.de/search/en/trial/DRKS00005625,2014-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1705,2805,2023-11-21 00:00:00.000000,A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers,,http://clinicaltrials.gov/show/NCT02046629,2014-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1706,2804,2023-11-21 00:00:00.000000,Dimethyl Fumarate (DMF) Observational Study,,https://clinicaltrials.gov/show/NCT02047097,2014-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1707,2803,2023-11-21 00:00:00.000000,Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study),,https://clinicaltrials.gov/show/NCT02047734,2014-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1708,2802,2023-11-21 00:00:00.000000,Upper Limbs Intervention in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02047825,2014-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1709,2801,2023-11-21 00:00:00.000000,Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS,,https://clinicaltrials.gov/show/NCT02048072,2014-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1710,2800,2023-11-21 00:00:00.000000,PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002419-87,2014-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1711,2799,2023-11-21 00:00:00.000000,Cognitive rehabilitation in multiple sclerosis,,http://isrctn.com/ISRCTN54901925,2014-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1712,2798,2023-11-21 00:00:00.000000,Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02065284,2014-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1713,2797,2023-11-21 00:00:00.000000,A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02064816,2014-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1714,2796,2023-11-21 00:00:00.000000,Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya,,https://clinicaltrials.gov/show/NCT02141022,2014-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1715,2795,2023-11-21 00:00:00.000000,Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02141386,2014-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1716,2794,2023-11-21 00:00:00.000000,Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002660-17,2014-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1717,2793,2023-11-21 00:00:00.000000,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),,https://jrct.niph.go.jp/latest-detail/jRCT2080222397,2014-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1718,2792,2023-11-21 00:00:00.000000,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,,https://clinicaltrials.gov/show/NCT02076841,2014-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1719,2791,2023-11-21 00:00:00.000000,Narrow band ultraviolet-B (UVB) light for patients with Clinically Isolated Syndrome,,https://anzctr.org.au/ACTRN12614000185662.aspx,2014-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1720,2790,2023-11-21 00:00:00.000000,An Observational Post-Marketing Safety Registry of Sativex®,,https://clinicaltrials.gov/show/NCT02073474,2014-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1721,2789,2023-11-21 00:00:00.000000,The study of ALS biomarker based on molecular dynamics of oxidative stress regulatory factor,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015091,2014-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1722,2788,2023-11-21 00:00:00.000000,Effect of  pentoxifylline on multiple sclerosis treatment,,http://en.irct.ir/trial/8893,2014-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1723,2787,2023-11-21 00:00:00.000000,N/A,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000296-12,2014-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1724,2786,2023-11-21 00:00:00.000000,"The Effectiveness, Safety and Tolerability of Actorif® Compared to Rebif® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)",,http://en.irct.ir/trial/12463,2014-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1725,2785,2023-11-21 00:00:00.000000,"The Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)",,http://en.irct.ir/trial/12462,2014-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1726,2784,2023-11-21 00:00:00.000000,"The Effectiveness, Safety and Tolerability of Actovex® Compared to Avonex® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)",,http://en.irct.ir/trial/12461,2014-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1727,2783,2023-11-21 00:00:00.000000,Consolidation & Interference in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02081508,2014-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1728,2782,2023-11-21 00:00:00.000000,TOLERATE - A Study that evaluates the Gastrointestinal Tolerability of DMF in Multiple Sclerosis Patients,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001486-17,2014-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1729,2781,2023-11-21 00:00:00.000000,Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino,,https://clinicaltrials.gov/show/NCT02082002,2014-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1730,2780,2023-11-21 00:00:00.000000,A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001895-40,2014-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1731,2779,2023-11-21 00:00:00.000000,Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02086188,2014-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1732,2778,2023-11-21 00:00:00.000000,Safety and Tolerability of Quetiapine in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02087631,2014-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1733,2777,2023-11-21 00:00:00.000000,Assesment of the effect of supplemental aqueous extracts of Achillea milefolium  in  Multiple sclerosis patients,,http://en.irct.ir/trial/15000,2014-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1734,2776,2023-11-21 00:00:00.000000,Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02106052,2014-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1735,2775,2023-11-21 00:00:00.000000,Study of Effects of Vitamin D on expression of some of genes in MS patient,,http://en.irct.ir/trial/15228,2014-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1736,2774,2023-11-21 00:00:00.000000,Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate,,https://clinicaltrials.gov/show/NCT02090348,2014-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1737,2773,2023-11-21 00:00:00.000000,Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,,https://clinicaltrials.gov/show/NCT02457091,2014-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1738,2772,2023-11-21 00:00:00.000000,Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02099370,2014-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1739,2771,2023-11-21 00:00:00.000000,Vitamin D3 and the Stress-axis in MS,,https://clinicaltrials.gov/show/NCT02096133,2014-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1740,2770,2023-11-21 00:00:00.000000,Implementing Physical Activity Guidelines for Adults With MS,,https://clinicaltrials.gov/show/NCT02100020,2014-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1741,2769,2023-11-21 00:00:00.000000,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT02097849,2014-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1742,2768,2023-11-21 00:00:00.000000,Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02104492,2014-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1743,2767,2023-11-21 00:00:00.000000,"A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005249-12,2014-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1744,2766,2023-11-21 00:00:00.000000,Protective Role of Oxcarbazepine in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02104661,2014-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1745,2765,2023-11-21 00:00:00.000000,"The effect of rhythmic cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis",,http://isrctn.com/ISRCTN67054113,2014-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1746,2764,2023-11-21 00:00:00.000000,"The long-term effects of textured shoe insoles on balance, walking ability and function in people with multiple sclerosis",,http://isrctn.com/ISRCTN85766784,2014-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1747,2763,2023-11-21 00:00:00.000000,Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002324-16,2014-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1748,2762,2023-11-21 00:00:00.000000,Description ofchanges in that part of the nervous sstem that is processing visual information over an extended perion of time in patients with relapsing remitting multiple sclerosis who take Tecfidera,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000395-26,2014-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1749,2761,2023-11-21 00:00:00.000000,EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02117375,2014-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1750,2760,2023-11-21 00:00:00.000000,RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate,,https://clinicaltrials.gov/show/NCT02117050,2014-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1751,2759,2023-11-21 00:00:00.000000,Allocentric Memory in MS and Resting State Functional MRI,,https://clinicaltrials.gov/show/NCT02118298,2014-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1752,2758,2023-11-21 00:00:00.000000,"This is an open label extension study of an on-going study where same subjects will be treated with drug - Daclizumab, to further evaluate the long term safety and efficacy of the drug.",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5860,2014-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1753,2757,2023-11-21 00:00:00.000000,Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study,,https://clinicaltrials.gov/show/NCT02137044,2014-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1754,2756,2023-11-21 00:00:00.000000,"BAY86-5046 (Betaseron), Non Interventional Studies",,https://clinicaltrials.gov/show/NCT02121444,2014-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1755,2755,2023-11-21 00:00:00.000000,Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients,,https://clinicaltrials.gov/show/NCT02146534,2014-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1756,2754,2023-11-21 00:00:00.000000,Speed of Processing Training to Improve Cognition in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02301260,2014-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1757,2753,2023-11-21 00:00:00.000000,Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation,,https://clinicaltrials.gov/show/NCT02123537,2014-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1758,2752,2023-11-21 00:00:00.000000,Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02131285,2014-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1759,2751,2023-11-21 00:00:00.000000,"The therapeutic effect of Avonex, Rebif and Betaferon on disability and quality of life in multiple sclerosis: A Randomized Clinical Trial",,http://en.irct.ir/trial/5641,2014-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1760,2750,2023-11-21 00:00:00.000000,Mindfulness-based Stress Reduction in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02136485,2014-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1761,2749,2023-11-21 00:00:00.000000,Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri,,https://clinicaltrials.gov/show/NCT02137109,2014-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1762,2748,2023-11-21 00:00:00.000000,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02133664,2014-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1763,2747,2023-11-21 00:00:00.000000,Physical Telerehabilitation in Veterans With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02346734,2014-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1764,2746,2023-11-21 00:00:00.000000,Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation,,https://clinicaltrials.gov/show/NCT02139696,2014-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1765,2745,2023-11-21 00:00:00.000000,"Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003600-40,2014-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1766,2744,2023-11-21 00:00:00.000000,Resistance Training and Amino Pyridine in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02143167,2014-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1767,2743,2023-11-21 00:00:00.000000,Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya,,https://clinicaltrials.gov/show/NCT02137707,2014-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1768,2742,2023-11-21 00:00:00.000000,Effects of eccentric exercise on calf muscle contracture in people with multiple sclerosis,,https://anzctr.org.au/ACTRN12614000490673.aspx,2014-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1769,2741,2023-11-21 00:00:00.000000,Long-term Follow-up of Fingolimod Phase II Study Patients,,https://clinicaltrials.gov/show/NCT02307838,2014-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1770,2740,2023-11-21 00:00:00.000000,Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02651545,2014-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1771,2739,2023-11-21 00:00:00.000000,Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02142764,2014-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1772,2738,2023-11-21 00:00:00.000000,"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",,http://clinicaltrials.gov/show/NCT02142205,2014-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1773,2737,2023-11-21 00:00:00.000000,Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02152085,2014-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1774,2736,2023-11-21 00:00:00.000000,Natalizumab Subcutaneous Immunogenicity and Safety Study,,https://clinicaltrials.gov/show/NCT02142192,2014-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1775,2735,2023-11-21 00:00:00.000000,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",,https://clinicaltrials.gov/show/NCT02159573,2014-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1776,2734,2023-11-21 00:00:00.000000,A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS,,https://clinicaltrials.gov/show/NCT02208050,2014-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1777,2733,2023-11-21 00:00:00.000000,Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02166021,2014-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1778,2732,2023-11-21 00:00:00.000000,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02149706,2014-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1779,2731,2023-11-21 00:00:00.000000,Effect of Traditional Medicine Product on MS-related Fatigue,,http://en.irct.ir/trial/16106,2014-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1780,2730,2023-11-21 00:00:00.000000,Nurse-led immunotherapy decision coaching in persons with relapsing-remitting multiple sclerosis (DECIMS),,http://isrctn.com/ISRCTN37929939,2014-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1781,2729,2023-11-21 00:00:00.000000,Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02157064,2014-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1782,2728,2023-11-21 00:00:00.000000,Fluxetine AND Multiple Sclerosis,,http://en.irct.ir/trial/16298,2014-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1783,2727,2023-11-21 00:00:00.000000,Comparative assessment of the absorption of a generic formulation of fingolimod capsule against the innovator fingolimod capsule conducted under fasting conditions in healthy male and female volunteers,,https://anzctr.org.au/ACTRN12614000600640.aspx,2014-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1784,2726,2023-11-21 00:00:00.000000,Comparative assessment of the absorption of a generic formulation of fingolimod capsule against the innovator fingolimod capsule conducted under fed conditions in healthy male and female volunteers,,https://anzctr.org.au/ACTRN12614000599673.aspx,2014-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1785,2725,2023-11-21 00:00:00.000000,Online therapy programme for fatigue in multiple sclerosis,,http://isrctn.com/ISRCTN25692173,2014-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1786,2724,2023-11-21 00:00:00.000000,Developing and Testing a Comprehensive MS Spasticity Management Program,,https://clinicaltrials.gov/show/NCT02170779,2014-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1787,2723,2023-11-21 00:00:00.000000,Management of the infusion-associated reactions in RRMS patients treated with Lemtrada,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000092-62,2014-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1788,2722,2023-11-21 00:00:00.000000,PeNSAMI Phase 2: a multicenter Italian trial of home-based palliative care for people with severe multiple sclerosis and their carers,,http://isrctn.com/ISRCTN73082124,2014-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1789,2721,2023-11-21 00:00:00.000000,fluoxetine AND Multiple sclerosis,,http://en.irct.ir/trial/16299,2014-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1790,2720,2023-11-21 00:00:00.000000,Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000221-20,2014-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1791,2719,2023-11-21 00:00:00.000000,CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS,,https://clinicaltrials.gov/show/NCT02543788,2014-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1792,2718,2023-11-21 00:00:00.000000,Mobility Enhancing Nursing Intervention,,http://clinicaltrials.gov/show/NCT02198599,2014-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1793,2717,2023-11-21 00:00:00.000000,Abdominal massage for bowel dysfunction in people with multiple sclerosis,,http://isrctn.com/ISRCTN85007023,2014-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1794,2716,2023-11-21 00:00:00.000000,Compare the effects of reflexology and relaxation on physical and mental symptom multiple sclerosis,,http://en.irct.ir/trial/16000,2014-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1795,2715,2023-11-21 00:00:00.000000,Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02184494,2014-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1796,2714,2023-11-21 00:00:00.000000,Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases,,https://clinicaltrials.gov/show/NCT02308579,2014-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1797,2713,2023-11-21 00:00:00.000000,Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02252666,2014-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1798,2712,2023-11-21 00:00:00.000000,A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303,,http://clinicaltrials.gov/show/NCT02193217,2014-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1799,2711,2023-11-21 00:00:00.000000,Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?,,https://clinicaltrials.gov/show/NCT02588053,2014-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1800,2710,2023-11-21 00:00:00.000000,"Effects of Endurance Training under Normobaric, Hypoxic Conditions on Fatigue in
Patients with Multiple Sclerosis: Results of a Randomized, Prospective Pilot Study.",,http://drks.de/search/en/trial/DRKS00006307,2014-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1801,2709,2023-11-21 00:00:00.000000,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02200718,2014-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1802,2708,2023-11-21 00:00:00.000000,"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT02201108,2014-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1803,2707,2023-11-21 00:00:00.000000,"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults",,https://clinicaltrials.gov/show/NCT02201849,2014-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1804,2706,2023-11-21 00:00:00.000000,"Treatment of fatigue,depression and paresthesia in Multiple Sclerosis patients",,http://en.irct.ir/trial/8798,2014-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1805,2705,2023-11-21 00:00:00.000000,The effect of Fampyra on visual function following previous optic neuritis.,,https://anzctr.org.au/ACTRN12614000782639.aspx,2014-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1806,2704,2023-11-21 00:00:00.000000,Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02308670,2014-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1807,2703,2023-11-21 00:00:00.000000,Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation,,https://clinicaltrials.gov/show/NCT02217982,2014-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1808,2702,2023-11-21 00:00:00.000000,Measuring Active Microglia in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02207075,2014-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1809,2701,2023-11-21 00:00:00.000000,Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif,,https://clinicaltrials.gov/show/NCT02377323,2014-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1810,2700,2023-11-21 00:00:00.000000,Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course,,https://clinicaltrials.gov/show/NCT02301572,2014-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1811,2699,2023-11-21 00:00:00.000000,Balance and Falls in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02209467,2014-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1812,2698,2023-11-21 00:00:00.000000,"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS",,https://clinicaltrials.gov/ct2/show/NCT02212886,2014-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1813,2697,2023-11-21 00:00:00.000000,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02294058,2014-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1814,2696,2023-11-21 00:00:00.000000,Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004622-29,2014-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1815,2695,2023-11-21 00:00:00.000000,"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=024-14,2014-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1816,2694,2023-11-21 00:00:00.000000,Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS,,https://clinicaltrials.gov/show/NCT02218879,2014-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1817,2693,2023-11-21 00:00:00.000000,Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis (MS),,http://isrctn.com/ISRCTN09697576,2014-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1818,2692,2023-11-21 00:00:00.000000,Effect of MD1003 in Spinal Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02220933,2014-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1819,2691,2023-11-21 00:00:00.000000,Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001643-20,2014-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1820,2690,2023-11-21 00:00:00.000000,Trekking Poles to Aid Multiple Sclerosis Gait Impairment,,https://clinicaltrials.gov/show/NCT02227524,2014-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1821,2689,2023-11-21 00:00:00.000000,Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02228213,2014-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1822,2688,2023-11-21 00:00:00.000000,Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.,,https://clinicaltrials.gov/show/NCT02225977,2014-08-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1823,2687,2023-11-21 00:00:00.000000,"Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate",,https://clinicaltrials.gov/show/NCT02307877,2014-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1824,2686,2023-11-21 00:00:00.000000,Plegridy Observational Program,,https://clinicaltrials.gov/show/NCT02230969,2014-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1825,2685,2023-11-21 00:00:00.000000,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod",,https://clinicaltrials.gov/show/NCT02232061,2014-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1826,2684,2023-11-21 00:00:00.000000,A safety study for patients with Relapsing Forms of Multiple Sclerosis who participated STRATA.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003669-97,2014-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1827,2683,2023-11-21 00:00:00.000000,Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-005586-39,2014-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1828,2682,2023-11-21 00:00:00.000000,Adherence in Pediatric Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02234713,2014-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1829,2681,2023-11-21 00:00:00.000000,Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy,,http://clinicaltrials.gov/show/NCT02234869,2014-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1830,2680,2023-11-21 00:00:00.000000,Efficacy of dual task on multiple    sclerosis,,http://en.irct.ir/trial/8909,2014-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1831,2679,2023-11-21 00:00:00.000000,Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?,,https://clinicaltrials.gov/show/NCT02236624,2014-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1832,2678,2023-11-21 00:00:00.000000,"A Phase 2 clinical study in subjects with Progressive Multiple Sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as
                compared to placebo",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001579-30,2014-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1833,2677,2023-11-21 00:00:00.000000,Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study,,https://clinicaltrials.gov/show/NCT02239393,2014-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1834,2676,2023-11-21 00:00:00.000000,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,,https://clinicaltrials.gov/show/NCT02247310,2014-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1835,2675,2023-11-21 00:00:00.000000,The Impact of Phototherapy on the modification of Fatigue and Cognitive functions for patients with Relapsing Remitting Multiple Sclerosis.,,https://anzctr.org.au/ACTRN12614001025628.aspx,2014-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1836,2674,2023-11-21 00:00:00.000000,Study of effects of vitamin D on some   genes  expression  in multiple sclerosis patients,,http://en.irct.ir/trial/16966,2014-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1837,2673,2023-11-21 00:00:00.000000,Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™,,https://clinicaltrials.gov/show/NCT02254304,2014-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1838,2672,2023-11-21 00:00:00.000000,A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02253264,2014-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1839,2671,2023-11-21 00:00:00.000000,Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS,,http://clinicaltrials.gov/show/NCT02259361,2014-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1840,2670,2023-11-21 00:00:00.000000,Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial,,https://clinicaltrials.gov/show/NCT02257606,2014-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1841,2669,2023-11-21 00:00:00.000000,Exercise & Brain Health in MS,,https://clinicaltrials.gov/show/NCT02263339,2014-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1842,2668,2023-11-21 00:00:00.000000,Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS),,https://clinicaltrials.gov/show/NCT02258217,2014-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1843,2667,2023-11-21 00:00:00.000000,"Efficacy Study of ""Imaginative Distention"", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS",,https://clinicaltrials.gov/show/NCT02290990,2014-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1844,2666,2023-11-21 00:00:00.000000,Exercise Intensity and Immune Function in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02264704,2014-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1845,2665,2023-11-21 00:00:00.000000,Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02266121,2014-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1846,2664,2023-11-21 00:00:00.000000,Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02280096,2014-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1847,2663,2023-11-21 00:00:00.000000,Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000709-10,2014-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1848,2662,2023-11-21 00:00:00.000000,The study of amyotrophic lateral sclerosis biomarker,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017962,2014-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1849,2661,2023-11-21 00:00:00.000000,Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk,,https://clinicaltrials.gov/show/NCT02440126,2014-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1850,2660,2023-11-21 00:00:00.000000,Testing the Effects of Methylphenidate on Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02286557,2014-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1851,2659,2023-11-21 00:00:00.000000,Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers,,http://clinicaltrials.gov/show/NCT02269930,2014-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1852,2658,2023-11-21 00:00:00.000000,Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02280876,2014-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1853,2657,2023-11-21 00:00:00.000000,Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02287454,2014-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1854,2656,2023-11-21 00:00:00.000000,Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02275741,2014-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1855,2655,2023-11-21 00:00:00.000000,Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02274935,2014-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1856,2654,2023-11-21 00:00:00.000000,Effects of Acthar on Recovery From Cognitive Relapses in MS,,https://clinicaltrials.gov/show/NCT02290444,2014-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1857,2653,2023-11-21 00:00:00.000000,Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod,,https://clinicaltrials.gov/show/NCT02277964,2014-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1858,2652,2023-11-21 00:00:00.000000,Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B,,https://clinicaltrials.gov/show/NCT02283671,2014-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1859,2651,2023-11-21 00:00:00.000000,"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo",,https://clinicaltrials.gov/show/NCT02284568,2014-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1860,2650,2023-11-21 00:00:00.000000,The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02282878,2014-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1861,2649,2023-11-21 00:00:00.000000,"A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02282826,2014-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1862,2648,2023-11-21 00:00:00.000000,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT02283853,2014-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1863,2647,2023-11-21 00:00:00.000000,Training caregivers of patients with brain damage,,http://en.irct.ir/trial/13235,2014-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1864,2646,2023-11-21 00:00:00.000000,Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02290587,2014-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1865,2645,2023-11-21 00:00:00.000000,Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects,,https://clinicaltrials.gov/show/NCT02287948,2014-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1866,2644,2023-11-21 00:00:00.000000,Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes,,https://clinicaltrials.gov/show/NCT02297932,2014-10-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1867,2643,2023-11-21 00:00:00.000000,Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02301442,2014-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1868,2642,2023-11-21 00:00:00.000000,Comparative Oral Bioavailability Study of MT-1303,,http://clinicaltrials.gov/show/NCT02310048,2014-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1869,2641,2023-11-21 00:00:00.000000,Mass Balance Study of MT-1303,,http://clinicaltrials.gov/show/NCT02293967,2014-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1870,2640,2023-11-21 00:00:00.000000,Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02301247,2014-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1871,2639,2023-11-21 00:00:00.000000,Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02296346,2014-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1872,2638,2023-11-21 00:00:00.000000,Stem Cell injection in Multiple Sclerosis  patients,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=10099,2014-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1873,2637,2023-11-21 00:00:00.000000,German Tysabri-Data-Register,,http://drks.de/search/en/trial/DRKS00007127,2014-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1874,2636,2023-11-21 00:00:00.000000,Imaging of inflammation in the cortex of the brain in progressive MS patients,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002547-17,2014-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1875,2635,2023-11-21 00:00:00.000000,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,,https://clinicaltrials.gov/show/NCT02306811,2014-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1876,2634,2023-11-21 00:00:00.000000,PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod,,https://clinicaltrials.gov/show/NCT02335892,2014-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1877,2633,2023-11-21 00:00:00.000000,Domperidone in Secondary Progressive Multiple Sclerosis (SPMS),,https://clinicaltrials.gov/show/NCT02308137,2014-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1878,2632,2023-11-21 00:00:00.000000,A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02317263,2014-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1879,2631,2023-11-21 00:00:00.000000,A first in human trial for evaluating both safety and preliminary efficacy of a single infusion of stimulated autologous CD4+ cells in patients with Relapsing- Remitting multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001081-99,2014-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1880,2630,2023-11-21 00:00:00.000000,A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668,,https://clinicaltrials.gov/show/NCT02313285,2014-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1881,2629,2023-11-21 00:00:00.000000,Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02904876,2014-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1882,2628,2023-11-21 00:00:00.000000,ACTH for Fatigue in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02315872,2014-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1883,2627,2023-11-21 00:00:00.000000,Computerized Cognition Testing and Cognitive Motor Interference in MS,,https://clinicaltrials.gov/show/NCT02318576,2014-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1884,2626,2023-11-21 00:00:00.000000,Psychometric Properties Mobility Measures MS,,https://clinicaltrials.gov/show/NCT02339688,2014-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1885,2625,2023-11-21 00:00:00.000000,"Exercise, chronic fatigue syndrome and multiple sclerosis",,https://anzctr.org.au/ACTRN12614001309673.aspx,2014-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1886,2624,2023-11-21 00:00:00.000000,Psychometric Properties Upper Limb Function Measures Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02339675,2014-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1887,2623,2023-11-21 00:00:00.000000,"A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada",,https://clinicaltrials.gov/show/NCT02367222,2014-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1888,2622,2023-11-21 00:00:00.000000,Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02326935,2014-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1889,2621,2023-11-21 00:00:00.000000,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),,https://clinicaltrials.gov/show/NCT02323269,2014-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1890,2620,2023-11-21 00:00:00.000000,Carnitine for the Treatment of Fatigue in Multiple Sclerosis,,http://en.irct.ir/trial/11303,2014-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1891,2619,2023-11-21 00:00:00.000000,Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02330965,2014-12-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1892,2618,2023-11-21 00:00:00.000000,The evaluation of the efficacy and safety of oral fingolimod in relapsing remitting multiple sclerosis,,http://en.irct.ir/trial/8799,2015-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1893,2617,2023-11-21 00:00:00.000000,Effect of individual empowerment program on self efficacy and quality of life in patients with multiple sclerosis referring to shiraz multiple sclerosis   society-1392,,http://en.irct.ir/trial/16978,2015-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1894,2616,2023-11-21 00:00:00.000000,Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series,,https://clinicaltrials.gov/show/NCT02335450,2015-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1895,2615,2023-11-21 00:00:00.000000,Effects of Rapamycin on multiple Sclerosis treatment,,http://en.irct.ir/trial/11339,2015-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1896,2614,2023-11-21 00:00:00.000000,Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.,,https://clinicaltrials.gov/show/NCT02343159,2015-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1897,2613,2023-11-21 00:00:00.000000,Mindfulness-based Stress Reduction for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02340754,2015-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1898,2612,2023-11-21 00:00:00.000000,Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden,,https://clinicaltrials.gov/show/NCT03778333,2015-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1899,2611,2023-11-21 00:00:00.000000,Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02421731,2015-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1900,2610,2023-11-21 00:00:00.000000,A Task-oriented Circuit Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02421744,2015-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1901,2609,2023-11-21 00:00:00.000000,A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003145-99,2015-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1902,2608,2023-11-21 00:00:00.000000,Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists,,http://clinicaltrials.gov/show/NCT02346279,2015-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1903,2607,2023-11-21 00:00:00.000000,A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers,,https://clinicaltrials.gov/show/NCT02364505,2015-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1904,2606,2023-11-21 00:00:00.000000,Fingolimod Effect on Cytokine and Chemokine Levels,,https://clinicaltrials.gov/show/NCT02373098,2015-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1905,2605,2023-11-21 00:00:00.000000,Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab,,https://clinicaltrials.gov/show/NCT02386566,2015-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1906,2604,2023-11-21 00:00:00.000000,"The effect of Self Care on fatigue, motor function and body balance in patients with MS",,http://en.irct.ir/trial/18025,2015-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1907,2603,2023-11-21 00:00:00.000000,Rouxbe Pilot for MS,,https://clinicaltrials.gov/show/NCT02424825,2015-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1908,2602,2023-11-21 00:00:00.000000,Transcranial Doppler in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02389426,2015-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1909,2601,2023-11-21 00:00:00.000000,A safety and efficacy study of BG00012 in slowing the progression of disability in patients with Secondary Progressive Multiple Sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003021-18,2015-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1910,2600,2023-11-21 00:00:00.000000,Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003481-25,2015-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1911,2599,2023-11-21 00:00:00.000000,Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics,,https://clinicaltrials.gov/show/NCT02369224,2015-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1912,2598,2023-11-21 00:00:00.000000,Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS),,https://clinicaltrials.gov/show/NCT02391064,2015-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1913,2597,2023-11-21 00:00:00.000000,"A study of BG00012 on MRI lesions and Pharmacokinetics in children from 10 to less than 18 years old with a type of Multiple Sclerosis called 'Relapsing, Remitting Multiple Sclerosis'",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005003-24,2015-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1914,2596,2023-11-21 00:00:00.000000,Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02398149,2015-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1915,2595,2023-11-21 00:00:00.000000,Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02391961,2015-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1916,2594,2023-11-21 00:00:00.000000,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension,,https://clinicaltrials.gov/show/NCT02383550,2015-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1917,2593,2023-11-21 00:00:00.000000,Comparison study of PF530 and Betaferon in healthy subjects,,https://anzctr.org.au/ACTRN12615000218594.aspx,2015-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1918,2592,2023-11-21 00:00:00.000000,Lakeshore Examination of Activity and Disability Exercise Response Study,,https://clinicaltrials.gov/show/NCT02533882,2015-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1919,2591,2023-11-21 00:00:00.000000,"The effect of cognitive behavioral therapy on stress, anxiety and depression",,http://en.irct.ir/trial/18405,2015-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1920,2590,2023-11-21 00:00:00.000000,Falls Prevention and Balance Rehabilitation in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02390830,2015-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1921,2589,2023-11-21 00:00:00.000000,An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02391298,2015-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1922,2588,2023-11-21 00:00:00.000000,Impact of Multiple Sclerosis From the Viewpoint of the Caregivers,,http://clinicaltrials.gov/show/NCT02388334,2015-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1923,2587,2023-11-21 00:00:00.000000,Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy,,https://clinicaltrials.gov/show/NCT02466165,2015-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1924,2586,2023-11-21 00:00:00.000000,Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02403570,2015-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1925,2585,2023-11-21 00:00:00.000000,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse,,https://clinicaltrials.gov/show/NCT02398461,2015-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1926,2584,2023-11-21 00:00:00.000000,VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02427997,2015-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1927,2583,2023-11-21 00:00:00.000000,Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL),,https://clinicaltrials.gov/show/NCT02394782,2015-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1928,2582,2023-11-21 00:00:00.000000,Comparison Study of PF530 and Betaferon in Healthy Subjects,,https://clinicaltrials.gov/show/NCT02474134,2015-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1929,2581,2023-11-21 00:00:00.000000,Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS,,https://clinicaltrials.gov/show/NCT02606604,2015-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1930,2580,2023-11-21 00:00:00.000000,Effects of motivational interviewing on health-promoting behaviors,,http://en.irct.ir/trial/18292,2015-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1931,2579,2023-11-21 00:00:00.000000,"Longitudinal neuropsychological and neuroradiological investigation of cognitive Impairment in early versus late MS and its
correlation to hippocampal dysfunction (HIPPOCOMS2)",,http://drks.de/search/en/trial/DRKS00007905,2015-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1932,2578,2023-11-21 00:00:00.000000,tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis,,https://clinicaltrials.gov/show/NCT02538094,2015-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1933,2577,2023-11-21 00:00:00.000000,Assistive Device Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02408718,2015-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1934,2576,2023-11-21 00:00:00.000000,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,,https://clinicaltrials.gov/show/NCT02419378,2015-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1935,2575,2023-11-21 00:00:00.000000,"Experimental clinical trial  regarding relapsing-remitTing Multiple Sclerosis  newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000303-21,2015-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1936,2574,2023-11-21 00:00:00.000000,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,,https://clinicaltrials.gov/show/NCT02410278,2015-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1937,2573,2023-11-21 00:00:00.000000,"The effect of  fordyse happiness model on depression, stress, anxiety and fatigue of multiple sclerosis patients",,http://en.irct.ir/trial/17816,2015-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1938,2572,2023-11-21 00:00:00.000000,A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02427776,2015-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1939,2571,2023-11-21 00:00:00.000000,Hyaluronic acid and chondroitin sulphate versus placebo in the prevention of urinary infections in female patients with multiple sclerosis.,,http://isrctn.com/ISRCTN10530863,2015-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1940,2570,2023-11-21 00:00:00.000000,Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02418897,2015-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1941,2569,2023-11-21 00:00:00.000000,Study to evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004562-22,2015-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1942,2568,2023-11-21 00:00:00.000000,Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS,,https://clinicaltrials.gov/show/NCT02419638,2015-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1943,2567,2023-11-21 00:00:00.000000,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02424396,2015-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1944,2566,2023-11-21 00:00:00.000000,Retinal scanning for biomarker discovery in multiple sclerosis,,http://isrctn.com/ISRCTN77452114,2015-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1945,2565,2023-11-21 00:00:00.000000,Oral Guanabenz for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02423083,2015-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1946,2564,2023-11-21 00:00:00.000000,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,,https://clinicaltrials.gov/show/NCT02425644,2015-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1947,2563,2023-11-21 00:00:00.000000,Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT02428218,2015-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1948,2562,2023-11-21 00:00:00.000000,"TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004483-38,2015-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1949,2561,2023-11-21 00:00:00.000000,Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02440516,2015-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1950,2560,2023-11-21 00:00:00.000000,A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02442570,2015-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1951,2559,2023-11-21 00:00:00.000000,Safety and Dose-finding Study of DC-TAB in Healthy Subjects,,http://clinicaltrials.gov/show/NCT02442557,2015-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1952,2558,2023-11-21 00:00:00.000000,The effects of prolonged wear of textured shoe insoles on walking in people with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12615000421538.aspx,2015-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1953,2557,2023-11-21 00:00:00.000000,Phase I clinical trial of autologous Epstein–Barr virus-specific T cell therapy as treatment of progressive multiple sclerosis,,https://anzctr.org.au/ACTRN12615000422527.aspx,2015-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1954,2556,2023-11-21 00:00:00.000000,Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS,,https://clinicaltrials.gov/show/NCT02446886,2015-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1955,2555,2023-11-21 00:00:00.000000,Effect of combined training exercises on fatigue and gait pattern in persons with relapsing-remitting multiple sclerosis,,https://anzctr.org.au/ACTRN12615000449538.aspx,2015-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1956,2554,2023-11-21 00:00:00.000000,Effect of Effleurage  Massage on Sleep Quality and Self-efficacy of  Multiple Sclerosis Patients,,http://en.irct.ir/trial/14913,2015-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1957,2553,2023-11-21 00:00:00.000000,Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02472938,2015-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1958,2552,2023-11-21 00:00:00.000000,Baseline Cortical Haemodynamics in MS,,https://clinicaltrials.gov/show/NCT02481882,2015-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1959,2551,2023-11-21 00:00:00.000000,Effect of Boswellia Serrata on Cognitive impairment in Multiple Sclerosis,,http://en.irct.ir/trial/19018,2015-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1960,2550,2023-11-21 00:00:00.000000,Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions,,https://clinicaltrials.gov/show/NCT02454465,2015-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1961,2549,2023-11-21 00:00:00.000000,MS Symptom Management Study,,https://clinicaltrials.gov/show/NCT02474940,2015-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1962,2548,2023-11-21 00:00:00.000000,The Use of Technology to Improve MS Clinical Trials and Patient Care,,https://clinicaltrials.gov/ct2/show/NCT02454907,2015-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1963,2547,2023-11-21 00:00:00.000000,Itolizumab for Relapsing Remitting Multiple Sclerosis,,https://rpcec.sld.cu/en/trials/RPCEC00000197-En,2015-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1964,2546,2023-11-21 00:00:00.000000,Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects,,https://clinicaltrials.gov/show/NCT02459821,2015-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1965,2545,2023-11-21 00:00:00.000000,CPAP to Treat Cognitive Dysfunction in MS,,https://clinicaltrials.gov/show/NCT02544373,2015-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1966,2544,2023-11-21 00:00:00.000000,Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02461069,2015-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1967,2543,2023-11-21 00:00:00.000000,Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02727907,2015-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1968,2542,2023-11-21 00:00:00.000000,The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects,,https://clinicaltrials.gov/show/NCT02463318,2015-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1969,2541,2023-11-21 00:00:00.000000,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02466074,2015-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1970,2540,2023-11-21 00:00:00.000000,Autologous Mesenchymal Stromal Cells for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02495766,2015-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1971,2539,2023-11-21 00:00:00.000000,"TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR:
A CONTROLED OPEN-LABEL STUDY",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005548-17,2015-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1972,2538,2023-11-21 00:00:00.000000,The effect of collaborative care model on happiness of multiple sclerosis (M.S) patients and their caregivers,,http://en.irct.ir/trial/18810,2015-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1973,2537,2023-11-21 00:00:00.000000,"Comprehension of confidence intervals in audio-visual patient information materials for people with multiple sclerosis:
a web-based randomised controlled, parallel group trial.",,http://drks.de/search/en/trial/DRKS00008561,2015-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1974,2536,2023-11-21 00:00:00.000000,The effect of collaborative care model on hope of multiple sclerosis (M.S) patients and their caregivers,,http://en.irct.ir/trial/18809,2015-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1975,2535,2023-11-21 00:00:00.000000,Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02529839,2015-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1976,2534,2023-11-21 00:00:00.000000,Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,,https://clinicaltrials.gov/show/NCT02471222,2015-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1977,2533,2023-11-21 00:00:00.000000,Tecfidera and the Gut Microbiota,,https://clinicaltrials.gov/show/NCT02471560,2015-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1978,2532,2023-11-21 00:00:00.000000,The effect of mindfulness on executive function and psychological symptoms of multiple sclerosis patients,,http://en.irct.ir/trial/18959,2015-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1979,2531,2023-11-21 00:00:00.000000,Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon,,https://clinicaltrials.gov/ct2/show/NCT02486640,2015-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1980,2530,2023-11-21 00:00:00.000000,Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus,,https://clinicaltrials.gov/show/NCT02489877,2015-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1981,2529,2023-11-21 00:00:00.000000,Teriflunomide Observational Effectiveness Study,,https://clinicaltrials.gov/show/NCT02490982,2015-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1982,2528,2023-11-21 00:00:00.000000,"CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily",,https://clinicaltrials.gov/show/NCT02499900,2015-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1983,2527,2023-11-21 00:00:00.000000,Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT02493049,2015-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1984,2526,2023-11-21 00:00:00.000000,Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02493166,2015-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1985,2525,2023-11-21 00:00:00.000000,"The safety and efficacy of combination treatment using adipose derived adult stem cells, platelet-rich-plasma and peptides on patients with Multiple Sclerosis.",,https://anzctr.org.au/ACTRN12615000687594.aspx,2015-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1986,2524,2023-11-21 00:00:00.000000,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,,https://clinicaltrials.gov/show/NCT02525874,2015-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1987,2523,2023-11-21 00:00:00.000000,Open-label Study of Liothyronine in MS,,https://clinicaltrials.gov/show/NCT02506751,2015-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1988,2522,2023-11-21 00:00:00.000000,Effect of self hypnosis on pain in multiple sclerosis patients,,http://en.irct.ir/trial/15473,2015-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1989,2521,2023-11-21 00:00:00.000000,Single-Dose Study of a New Formulation of BIIB061,,https://clinicaltrials.gov/show/NCT02521545,2015-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1990,2520,2023-11-21 00:00:00.000000,Tecfidera Lymphocyte Chart Review,,https://clinicaltrials.gov/show/NCT02519413,2015-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1991,2519,2023-11-21 00:00:00.000000,Natural History of Multiple Sclerosis and Its Mimickers,,https://clinicaltrials.gov/show/NCT02504840,2015-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1992,2518,2023-11-21 00:00:00.000000,WEB-Based Physiotherapy for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02508961,2015-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1993,2517,2023-11-21 00:00:00.000000,The effects of core stability training on balance and quality of life in female with Multiple Sclerosis with emphasis on Expanded Disability Status Scale.,,http://en.irct.ir/trial/19197,2015-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1994,2516,2023-11-21 00:00:00.000000,Phase I BP Interferon (IFN) Beta-001,,https://clinicaltrials.gov/show/NCT02515695,2015-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1995,2515,2023-11-21 00:00:00.000000,"In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",,https://clinicaltrials.gov/ct2/show/NCT02511028,2015-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1996,2514,2023-11-21 00:00:00.000000,The effect of self-care education on sleep quality for patients with multiple sclerosis in Jahrom,,http://en.irct.ir/trial/19485,2015-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1997,2513,2023-11-21 00:00:00.000000,Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02519244,2015-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1998,2512,2023-11-21 00:00:00.000000,Phase I BP Interferon (IFN) Beta-004,,https://clinicaltrials.gov/show/NCT02517788,2015-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
1999,2511,2023-11-21 00:00:00.000000,"Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003735-32,2015-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2000,2510,2023-11-21 00:00:00.000000,"Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy",,https://clinicaltrials.gov/show/NCT02525367,2015-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2001,2509,2023-11-21 00:00:00.000000,"Effectiveness of Mindfulness Based Stress Reduction on psychological Symptom, Sleep and Quality of Life in Women with Multiple Sclerosis",,http://en.irct.ir/trial/7666,2015-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2002,2508,2023-11-21 00:00:00.000000,The effect of atorvastatin on patients with multiple sclerosis,,http://en.irct.ir/trial/19821,2015-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2003,2507,2023-11-21 00:00:00.000000,The Impact of Positive Mental Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02524093,2015-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2004,2506,2023-11-21 00:00:00.000000,Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study,,https://clinicaltrials.gov/show/NCT02522962,2015-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2005,2505,2023-11-21 00:00:00.000000,Influence of Exercise on the Mobility and Balance of Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT02524483,2015-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2006,2504,2023-11-21 00:00:00.000000,"A clinical trial to study the effects of two drugs, Relibeta and Avonex in the treatment of patients with remitting multiple sclerosis and open after treatment with Interferon Î²1Ð°.",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=10784,2015-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2007,2503,2023-11-21 00:00:00.000000,Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study,,https://clinicaltrials.gov/show/NCT02523703,2015-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2008,2502,2023-11-21 00:00:00.000000,"Comparing the effect of high dose vitamin D3 intake on interleukin-10, 17 and quality of life in Multiple Sclerosis patients",,http://en.irct.ir/trial/11304,2015-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2009,2501,2023-11-21 00:00:00.000000,Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002159-89,2015-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2010,2500,2023-11-21 00:00:00.000000,Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02542787,2015-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2011,2499,2023-11-21 00:00:00.000000,PHASE 3 CLINICAL TRIAL OF RPC1063 FOR PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS,,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=024-15,2015-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2012,2498,2023-11-21 00:00:00.000000,Intrathecal Rituximab in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02545959,2015-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2013,2497,2023-11-21 00:00:00.000000,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02545868,2015-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2014,2496,2023-11-21 00:00:00.000000,Effects of muscle relaxation technique on fatigue and sleep in multiple sclerosis,,http://en.irct.ir/trial/20110,2015-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2015,2495,2023-11-21 00:00:00.000000,Mitochondrial Dysfunction and Disease Progression,,https://clinicaltrials.gov/show/NCT02549703,2015-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2016,2494,2023-11-21 00:00:00.000000,"Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases",,https://clinicaltrials.gov/show/NCT02967380,2015-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2017,2493,2023-11-21 00:00:00.000000,Frankincense effect on urinary disorders in multiple sclerosis,,http://en.irct.ir/trial/19806,2015-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2018,2492,2023-11-21 00:00:00.000000,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT02555215,2015-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2019,2491,2023-11-21 00:00:00.000000,"Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.",,https://clinicaltrials.gov/show/NCT02559765,2015-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2020,2490,2023-11-21 00:00:00.000000,A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period,,https://clinicaltrials.gov/show/NCT02587195,2015-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2021,2489,2023-11-21 00:00:00.000000,Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS,,https://clinicaltrials.gov/show/NCT02571335,2015-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2022,2488,2023-11-21 00:00:00.000000,Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02580669,2015-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2023,2487,2023-11-21 00:00:00.000000,Long-Term Effects of Torso-Weighting,,https://clinicaltrials.gov/show/NCT02743312,2015-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2024,2486,2023-11-21 00:00:00.000000,Comparative bioequivalence study of a generic formulation of fingolimod capsule against the innovator fingolimod capsule in fasting healthy subjects,,https://anzctr.org.au/ACTRN12615001055594.aspx,2015-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2025,2485,2023-11-21 00:00:00.000000,Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden,,https://clinicaltrials.gov/show/NCT02592265,2015-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2026,2484,2023-11-21 00:00:00.000000,A trial to determine bexarotene's safety and tolerability and its ability to promote brain repair in patients with multiple sclerosis,,https://www.isrctn.com/ISRCTN14265371,2015-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2027,2483,2023-11-21 00:00:00.000000,TMP001 in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02686788,2015-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2028,2482,2023-11-21 00:00:00.000000,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02583594,2015-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2029,2481,2023-11-21 00:00:00.000000,A RCT of Telephone-supported ACT in MS,,https://clinicaltrials.gov/show/NCT02596633,2015-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2030,2480,2023-11-21 00:00:00.000000,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,,https://clinicaltrials.gov/show/NCT02579681,2015-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2031,2479,2023-11-21 00:00:00.000000,Relationship between serum level of vitamin-D3 and Expanded Disability Status Scale (EDSS) changes before and 8 weeks after methylprednisolone pulse therapy in multiple sclerosis (MS) patients,,http://en.irct.ir/trial/1454,2015-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2032,2478,2023-11-21 00:00:00.000000,Deciphering the Role of the Gut Microbiota in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02580435,2015-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2033,2477,2023-11-21 00:00:00.000000,Comprehensive Fall Prevention and Detection in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02583386,2015-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2034,2476,2023-11-21 00:00:00.000000,"A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004116-38,2015-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2035,2475,2023-11-21 00:00:00.000000,Cognitive and Emotion Regulation Training in MS,,https://clinicaltrials.gov/show/NCT02717429,2015-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2036,2474,2023-11-21 00:00:00.000000,Plegridy Satisfaction Study in Participants,,https://clinicaltrials.gov/show/NCT02587065,2015-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2037,2473,2023-11-21 00:00:00.000000,Post-transfusion Platelet Count,,https://clinicaltrials.gov/show/NCT02601131,2015-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2038,2472,2023-11-21 00:00:00.000000,Sertraline effectiveness in prevention of depression in MS patients.,,http://en.irct.ir/trial/20319,2015-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2039,2471,2023-11-21 00:00:00.000000,Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition,,https://clinicaltrials.gov/show/NCT02598167,2015-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2040,2470,2023-11-21 00:00:00.000000,A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02601885,2015-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2041,2469,2023-11-21 00:00:00.000000,Acute Effect of Fascial Mobilization on Gait in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02628834,2015-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2042,2468,2023-11-21 00:00:00.000000,Use of Well Known Drugs for New Destination - MS Improvement (MSNT),,https://clinicaltrials.gov/show/NCT02606929,2015-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2043,2467,2023-11-21 00:00:00.000000,Comparison of Ziferon and Betaferon in  multiple sclerosis management,,http://en.irct.ir/trial/2092,2015-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2044,2466,2023-11-21 00:00:00.000000,Exercise effect on patients with multiple sclerosis,,http://en.irct.ir/trial/20590,2015-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2045,2465,2023-11-21 00:00:00.000000,[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02606630,2015-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2046,2464,2023-11-21 00:00:00.000000,Treating Anorectal Dysfunction in MS,,https://clinicaltrials.gov/show/NCT02609607,2015-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2047,2463,2023-11-21 00:00:00.000000,Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis,,https://clinicaltrials.gov/show/NCT02636829,2015-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2048,2462,2023-11-21 00:00:00.000000,Efficacy of MBI for Depressive Symptoms in Patients With MS,,https://clinicaltrials.gov/show/NCT02611401,2015-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2049,2461,2023-11-21 00:00:00.000000,"A ""Negative""Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial",,https://clinicaltrials.gov/show/NCT02618902,2015-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2050,2460,2023-11-21 00:00:00.000000,An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02612935,2015-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2051,2459,2023-11-21 00:00:00.000000,MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02614989,2015-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2052,2458,2023-11-21 00:00:00.000000,Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02623946,2015-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2053,2457,2023-11-21 00:00:00.000000,Clinical Disease Activity With Long Term Natalizumab Treatment,,https://clinicaltrials.gov/show/NCT02677077,2015-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2054,2456,2023-11-21 00:00:00.000000,Effectiveness of simvastatin on multiple sclerosis (MS),,http://en.irct.ir/trial/21170,2015-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2055,2455,2023-11-21 00:00:00.000000,MSPT Device Usability Study,,https://clinicaltrials.gov/show/NCT02664324,2015-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2056,2454,2023-11-21 00:00:00.000000,Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training,,https://clinicaltrials.gov/show/NCT02634567,2015-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2057,2453,2023-11-21 00:00:00.000000,"The effect of different types of motor imagery on walking, tiredness, quality of life, motor imagery ability and gait adaption with music beat in people with multiple sclerosis",,http://isrctn.com/ISRCTN92351899,2015-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2058,2452,2023-11-21 00:00:00.000000,The Effect Metacognitive Therapy on patient with Multiple Sclerosis,,http://en.irct.ir/trial/20398,2015-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2059,2451,2023-11-21 00:00:00.000000,Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment,,https://clinicaltrials.gov/show/NCT02632591,2015-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2060,2450,2023-11-21 00:00:00.000000,Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse,,https://clinicaltrials.gov/show/NCT02633033,2015-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2061,2449,2023-11-21 00:00:00.000000,This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for = 3 Years,,https://clinicaltrials.gov/show/NCT02638038,2015-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2062,2448,2023-11-21 00:00:00.000000,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,,https://clinicaltrials.gov/show/NCT02634307,2015-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2063,2447,2023-11-21 00:00:00.000000,SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004451-40,2015-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2064,2446,2023-11-21 00:00:00.000000,Tecfidera and MRI for Brain Energy in MS,,https://clinicaltrials.gov/show/NCT02644083,2015-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2065,2445,2023-11-21 00:00:00.000000,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",,https://clinicaltrials.gov/show/NCT02641041,2015-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2066,2444,2023-11-21 00:00:00.000000,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02647502,2015-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2067,2443,2023-11-21 00:00:00.000000,Natalizumab Temporary Discontinuation Study,,https://clinicaltrials.gov/show/NCT02775110,2015-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2068,2442,2023-11-21 00:00:00.000000,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,,https://clinicaltrials.gov/show/NCT02652091,2016-05-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2069,2441,2023-11-21 00:00:00.000000,Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02652013,2016-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2070,2440,2023-11-21 00:00:00.000000,Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS,,https://clinicaltrials.gov/show/NCT02675413,2016-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2071,2439,2023-11-21 00:00:00.000000,Multiple Sclerosis Patients' Attitudes Regarding Medical Rehabilitation,,http://drks.de/search/en/trial/DRKS00009811,2016-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2072,2438,2023-11-21 00:00:00.000000,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2,,https://clinicaltrials.gov/show/NCT02660359,2016-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2073,2437,2023-11-21 00:00:00.000000,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1,,https://clinicaltrials.gov/show/NCT02660138,2016-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2074,2436,2023-11-21 00:00:00.000000,Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers,,https://clinicaltrials.gov/show/NCT02683863,2016-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2075,2435,2023-11-21 00:00:00.000000,Aerobic Exercise and Brain Health in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02661555,2016-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2076,2434,2022-03-15 19:19:40.664680,A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers,<b>Condition</b>:    Amyotrophic Lateral Sclerosis<br /><b>Interventions</b>:    Drug: prosetin;   Drug: placebo<br /><b>Sponsors</b>:    ProJenX;   Worldwide Clinical Trials<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05279755?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-15 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
2077,2433,2023-11-21 00:00:00.000000,Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002820-20,2016-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2078,2432,2023-11-21 00:00:00.000000,The effect of balance training on balance in people with multiple sclerosis using a virtual reality system,,http://isrctn.com/ISRCTN14425615,2016-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2079,2431,2023-11-21 00:00:00.000000,An immune therapy register for the improvement of drug safety and treatment of patients with Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00007190,2016-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2080,2430,2023-11-21 00:00:00.000000,Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02687919,2016-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2081,2429,2023-11-21 00:00:00.000000,Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02671682,2016-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2082,2428,2023-11-21 00:00:00.000000,"Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY",,https://clinicaltrials.gov/show/NCT02665221,2016-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2083,2427,2023-11-21 00:00:00.000000,The evaluation of the Effect of Fingolimod  on Fatigue and depression in patients with M.S,,http://en.irct.ir/trial/8800,2016-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2084,2426,2023-11-21 00:00:00.000000,"Relaxing effect on sleep quality, depression and stress in people with multiple sclerosis",,http://ensaiosclinicos.gov.br/rg/RBR-95xmrb,2016-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2085,2425,2023-11-21 00:00:00.000000,The effect of evening primrose oil in the treatment of multiple sclerosis,,http://en.irct.ir/trial/20674,2016-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2086,2424,2023-11-21 00:00:00.000000,"Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02673827,2016-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2087,2423,2023-11-21 00:00:00.000000,New treatment for fear of the future in MS patients,,https://www.onderzoekmetmensen.nl/en/trial/28790,2016-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2088,2422,2023-11-21 00:00:00.000000,Teriflunomide Male Transmission Study,,https://clinicaltrials.gov/show/NCT02679885,2016-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2089,2421,2023-11-21 00:00:00.000000,SUMS: Standing up in people with multiple sclerosis,,https://www.isrctn.com/ISRCTN69614598,2016-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2090,2420,2023-11-21 00:00:00.000000,Does the alpha blocker Silodosin improve the bladder emptying in patients with MS?,,https://www.onderzoekmetmensen.nl/en/trial/26059,2016-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2091,2419,2023-11-21 00:00:00.000000,A study looking at the safety and effect of two kinds of Itolizumab in Normal Healthy Subjects.,,https://anzctr.org.au/ACTRN12616000138482.aspx,2016-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2092,2418,2023-11-21 00:00:00.000000,"Clinical study to assess efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004059-29,2016-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2093,2417,2023-11-21 00:00:00.000000,Task-oriented Upper Limb Training in MS,,https://clinicaltrials.gov/show/NCT02688231,2016-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2094,2416,2023-11-21 00:00:00.000000,Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study,,https://clinicaltrials.gov/show/NCT02695394,2016-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2095,2415,2023-11-21 00:00:00.000000,Clozapine and risperidone for the treatment of progressive multiple sclerosis (CRISP),,https://anzctr.org.au/ACTRN12616000178448.aspx,2016-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2096,2414,2023-11-21 00:00:00.000000,Tecfidera Diffusion Tensor Imaging,,https://clinicaltrials.gov/show/NCT02686684,2016-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2097,2413,2023-11-21 00:00:00.000000,Short-term effect of intensive physiotherapy rehabilitation on Parkinson&#39;s disease and neurodegenerative disorders,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023723,2016-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2098,2412,2023-11-21 00:00:00.000000,High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study,,https://clinicaltrials.gov/show/NCT02702804,2016-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2099,2411,2023-11-21 00:00:00.000000,comparison of Fingolimode and Betaferon(high dose) in M.S treatment,,http://en.irct.ir/trial/21071,2016-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2100,2410,2023-11-21 00:00:00.000000,High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02696590,2016-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2101,2409,2023-11-21 00:00:00.000000,Tryptophan immunoadsorption as escalation therapy for multiple sclerosis relapse - documentation of efficacy,,http://drks.de/search/en/trial/DRKS00010099,2016-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2102,2408,2023-11-21 00:00:00.000000,Impact of multivitamin on fatigue and inflammatory cytokines in multiple sclerosis,,http://en.irct.ir/trial/22026,2016-02-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2103,2407,2023-11-21 00:00:00.000000,Robot-based Rehabilitation of Upper Limb Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02711566,2016-02-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2104,2406,2023-11-21 00:00:00.000000,The effect of vitamin B12 and folic acid supplementation on the treatment of multiple sclerosis,,http://en.irct.ir/trial/13462,2016-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2105,2405,2023-11-21 00:00:00.000000,"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®",,https://clinicaltrials.gov/show/NCT02823951,2016-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2106,2404,2023-11-21 00:00:00.000000,The effectiveness of commitment and acceptance based therapy on adjustment psychological and well-being of women with MS,,http://en.irct.ir/trial/21271,2016-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2107,2403,2023-11-21 00:00:00.000000,Exercise in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02716701,2016-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2108,2402,2023-11-21 00:00:00.000000,"Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02708927,2016-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2109,2401,2023-11-21 00:00:00.000000,A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02710214,2016-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2110,2400,2023-11-21 00:00:00.000000,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),,https://clinicaltrials.gov/show/NCT02739542,2016-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2111,2399,2023-11-21 00:00:00.000000,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),,https://clinicaltrials.gov/show/NCT02720107,2016-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2112,2398,2023-11-21 00:00:00.000000,Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02726672,2016-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2113,2397,2023-11-21 00:00:00.000000,Comparison of Intermittent vs. Continuous Walking in MS,,https://clinicaltrials.gov/show/NCT02726373,2016-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2114,2396,2023-11-21 00:00:00.000000,Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02805634,2016-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2115,2395,2023-11-21 00:00:00.000000,"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02744222,2016-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2116,2394,2023-11-21 00:00:00.000000,Pilot Study of Transcranial Direct Current Stimulation (tDCS),,https://clinicaltrials.gov/show/NCT02746705,2016-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2117,2393,2023-11-21 00:00:00.000000,Effect of Active-Passive Trainer Cycling on Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02737904,2016-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2118,2392,2023-11-21 00:00:00.000000,Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study,,https://clinicaltrials.gov/show/NCT02760056,2016-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2119,2391,2023-11-21 00:00:00.000000,Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,,https://clinicaltrials.gov/show/NCT02790307,2016-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2120,2390,2023-11-21 00:00:00.000000,Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02738775,2016-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2121,2389,2023-11-21 00:00:00.000000,The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000464-42,2016-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2122,2388,2023-11-21 00:00:00.000000,Effect of emotional intelligence education program on self-efficacy and quality of life for women with MS,,http://en.irct.ir/trial/16002,2016-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2123,2387,2023-11-21 00:00:00.000000,Depression and Immune Function in Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02740296,2016-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2124,2386,2023-11-21 00:00:00.000000,Effectiveness of self-care education on  Multiple Sclerosis patients` adaptation,,http://en.irct.ir/trial/20540,2016-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2125,2385,2023-11-21 00:00:00.000000,Online Program to Reduce Depression in MS,,https://clinicaltrials.gov/show/NCT02740361,2016-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2126,2384,2023-11-21 00:00:00.000000,Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03134716,2016-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2127,2383,2023-11-21 00:00:00.000000,effects of Physical and psychological interventions on sexual function in MS patients,,http://en.irct.ir/trial/22145,2016-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2128,2382,2023-11-21 00:00:00.000000,RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT02746744,2016-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2129,2381,2023-11-21 00:00:00.000000,Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02753088,2016-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2130,2380,2023-11-21 00:00:00.000000,EPID Multiple Sclerosis Pregnancy Study,,https://clinicaltrials.gov/show/NCT02749396,2016-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2131,2379,2023-11-21 00:00:00.000000,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",,https://clinicaltrials.gov/show/NCT02750982,2016-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2132,2378,2023-11-21 00:00:00.000000,Effectiveness of a Multiple Sclerosis (MS) specific psychological intervention for depression and anxiety in those newly diagnosed with MS,,http://isrctn.com/ISRCTN10423371,2016-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2133,2377,2023-11-21 00:00:00.000000,Effect of exercise on leptin in patients with MS,,http://en.irct.ir/trial/22266,2016-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2134,2376,2023-11-21 00:00:00.000000,Telerehabilitation Upper Extremity for Neurological Disorders,,https://clinicaltrials.gov/show/NCT02764372,2016-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2135,2375,2023-11-21 00:00:00.000000,"Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients",,https://clinicaltrials.gov/show/NCT02771652,2016-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2136,2374,2023-11-21 00:00:00.000000,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,,https://clinicaltrials.gov/show/NCT02767609,2016-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2137,2373,2023-11-21 00:00:00.000000,A study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing remitting multiple sclerosis (RRMS),,http://isrctn.com/ISRCTN69897291,2016-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2138,2372,2023-11-21 00:00:00.000000,Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect,,https://clinicaltrials.gov/show/NCT02772666,2016-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2139,2371,2023-11-21 00:00:00.000000,"What is the safety and effectiveness, acceptability and cost of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by nurses for people with multiple sclerosis?",,https://anzctr.org.au/ACTRN12616000617460.aspx,2016-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2140,2370,2023-11-21 00:00:00.000000,Effects of rehabilitation interventions on balance and fatigue in MS patients,,http://en.irct.ir/trial/22270,2016-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2141,2369,2023-11-21 00:00:00.000000,Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02789670,2016-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2142,2368,2023-11-21 00:00:00.000000,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/show/NCT02776072,2016-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2143,2367,2023-11-21 00:00:00.000000,Motor Imagery Training in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02781142,2016-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2144,2366,2023-11-21 00:00:00.000000,Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS,,https://clinicaltrials.gov/show/NCT02782858,2016-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2145,2365,2023-11-21 00:00:00.000000,Abdominal Massage for Bowel Dysfunction,,https://clinicaltrials.gov/show/NCT03166007,2016-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2146,2364,2023-11-21 00:00:00.000000,Standardized cognitive training for MS patients,,http://isrctn.com/ISRCTN57222203,2016-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2147,2363,2023-11-21 00:00:00.000000,Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS,,https://clinicaltrials.gov/show/NCT02797015,2016-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2148,2362,2023-11-21 00:00:00.000000,Fingolimod Real World Experience: the French Grand-Est Cohort,,https://clinicaltrials.gov/show/NCT02799199,2016-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2149,2361,2023-11-21 00:00:00.000000,The effects of  oral nanocurcumin  in Multiple Sclerosis patients,,http://en.irct.ir/trial/22520,2016-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2150,2360,2023-11-21 00:00:00.000000,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT02792231,2016-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2151,2359,2023-11-21 00:00:00.000000,"Comparative Investigation efficacy of cognitive rehabilitation and  donepezil on memory, attention, quality of life and depression in patients with multiple sclerosis.",,http://en.irct.ir/trial/22528,2016-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2152,2358,2023-11-21 00:00:00.000000,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02792218,2016-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2153,2357,2023-11-21 00:00:00.000000,A Study of Oxidative Pathways in MS Fatigue,,https://clinicaltrials.gov/show/NCT02804594,2016-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2154,2356,2023-11-21 00:00:00.000000,"A 96-WEEK, PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB 4.5 MG/KG/DAY VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE OR RELAPSE-FREE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=003-16,2016-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2155,2355,2023-11-21 00:00:00.000000,Efficacy of persian carrot in multiple sclrosis patients'fatigue,,http://en.irct.ir/trial/22252,2016-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2156,2354,2023-11-21 00:00:00.000000,Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02807285,2016-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2157,2353,2023-11-21 00:00:00.000000,Effect of slow-stroke back massage on fatigue in  elderly with multiple sclerosis,,http://en.irct.ir/trial/20482,2016-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2158,2352,2023-11-21 00:00:00.000000,Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT02833714,2016-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2159,2351,2023-11-21 00:00:00.000000,Enhance Wellness for Individuals With Long-Term Physical Disabilities,,https://clinicaltrials.gov/show/NCT02815878,2016-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2160,2350,2023-11-21 00:00:00.000000,MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.,,https://clinicaltrials.gov/show/NCT02814487,2016-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2161,2349,2023-11-21 00:00:00.000000,Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients,,https://clinicaltrials.gov/show/NCT03092544,2016-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2162,2348,2023-11-21 00:00:00.000000,Improved involvement of multiple sclerosis patients in discussions about treatment,,https://www.isrctn.com/ISRCTN42739508,2016-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2163,2347,2023-11-21 00:00:00.000000,Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000283-41,2016-06-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2164,2346,2023-11-21 00:00:00.000000,"The effect of physical educational  program on Mental toughness, cognitive function, symptoms of related to MS and sleeping among ill people to MS",,http://en.irct.ir/trial/20210,2016-06-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2165,2345,2023-11-21 00:00:00.000000,Role of Virtual Reality in MS Rehabilitation,,https://clinicaltrials.gov/show/NCT02834533,2016-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2166,2344,2023-11-21 00:00:00.000000,"A prospective, open-label, non-interventional phase IV study  to investigate the COgnitive status, MOod, fatigue and quality of life in relapsing remitting multiple sclerosis patients treated with teriflunomide (Aubagio®) in Daily routine Observational Setting.",,https://www.onderzoekmetmensen.nl/en/trial/25460,2016-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2167,2343,2023-11-21 00:00:00.000000,Treatment of Sleep-disordered Breathing in Patients With SCI,,https://clinicaltrials.gov/show/NCT02830074,2016-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2168,2342,2023-11-21 00:00:00.000000,Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005418-31,2016-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2169,2341,2023-11-21 00:00:00.000000,Integrating Caregiver Support Into MS Care,,https://clinicaltrials.gov/show/NCT02835677,2016-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2170,2340,2023-11-21 00:00:00.000000,e-Mobile Tablet for People With Chronic Conditions,,https://clinicaltrials.gov/show/NCT02833311,2016-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2171,2339,2023-11-21 00:00:00.000000,"Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes",,https://clinicaltrials.gov/show/NCT02833142,2016-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2172,2338,2023-11-21 00:00:00.000000,MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02845635,2016-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2173,2337,2023-11-21 00:00:00.000000,Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder,,https://clinicaltrials.gov/show/NCT03033355,2016-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2174,2336,2023-11-21 00:00:00.000000,Urinary Markers of Detrusor Overactivity in Spina Bifida Patients,,https://clinicaltrials.gov/show/NCT02852317,2016-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2175,2335,2023-11-21 00:00:00.000000,Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life,,https://clinicaltrials.gov/show/NCT02848976,2016-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2176,2334,2023-11-21 00:00:00.000000,The effect of kinesiotaping of gastrocnemius on function of patients with multiple sclerosis in balance test,,http://en.irct.ir/trial/20462,2016-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2177,2333,2023-11-21 00:00:00.000000,A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02846558,2016-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2178,2332,2023-11-21 00:00:00.000000,Timing of Acute Palliative Care Consultation in Critically Ill Patients,,https://clinicaltrials.gov/show/NCT02858778,2016-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2179,2331,2023-11-21 00:00:00.000000,The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02848898,2016-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2180,2330,2023-11-21 00:00:00.000000,Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.,,https://clinicaltrials.gov/show/NCT02849782,2016-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2181,2329,2023-11-21 00:00:00.000000,GTA-MEG as a Biomarker for Cognition in MS,,https://clinicaltrials.gov/show/NCT02851342,2016-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2182,2328,2023-11-21 00:00:00.000000,Quantitative Fatigue and Muscle Performance in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02913209,2016-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2183,2327,2023-11-21 00:00:00.000000,Evaluate the effectiveness of the intervention of a physiotherapy program of sensory motor stimulation in multiple sclerosis.,,https://anzctr.org.au/ACTRN12616001025426.aspx,2016-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2184,2326,2023-11-21 00:00:00.000000,To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS,,https://clinicaltrials.gov/show/NCT02869425,2016-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2185,2325,2023-11-21 00:00:00.000000,The effects of exercise therapy  on improvement of symptoms of multiple sclerosis patients,,http://en.irct.ir/trial/19198,2016-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2186,2324,2023-11-21 00:00:00.000000,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),,https://clinicaltrials.gov/show/NCT02637856,2015-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2187,2323,2023-11-21 00:00:00.000000,How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?,,https://clinicaltrials.gov/show/NCT02870023,2016-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2188,2322,2023-11-21 00:00:00.000000,Test a new physiotherapy intervention to encourage people with multiple sclerosis to do more physical activity,,https://anzctr.org.au/ACTRN12616001070426.aspx,2016-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2189,2321,2023-11-21 00:00:00.000000,Correlation Between PET and Advanced MRI in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02869360,2016-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2190,2320,2023-11-21 00:00:00.000000,Effect of Cinnamon on the treatment of Multiple Sclerosis,,http://en.irct.ir/trial/23434,2016-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2191,2319,2023-11-21 00:00:00.000000,"Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training",,https://clinicaltrials.gov/show/NCT02882724,2016-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2192,2318,2023-11-21 00:00:00.000000,Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02885233,2016-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2193,2317,2023-11-21 00:00:00.000000,"Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02880553,2016-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2194,2316,2023-11-21 00:00:00.000000,Effect of peer educational program versus no education on self-efficacy in patients with multiple sclerosis,,http://en.irct.ir/trial/9550,2016-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2195,2315,2023-11-21 00:00:00.000000,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,,https://clinicaltrials.gov/show/NCT02881567,2016-08-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2196,2314,2023-11-21 00:00:00.000000,French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02887352,2016-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2197,2313,2023-11-21 00:00:00.000000,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),,https://clinicaltrials.gov/show/NCT02907177,2016-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2198,2312,2023-11-21 00:00:00.000000,"Effect of vitamin D pills on Menstrual pattern, levels of Sexual hormones and Sexual function in women with Multiple sclerosis",,http://en.irct.ir/trial/23091,2016-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2199,2311,2023-11-21 00:00:00.000000,Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02893683,2016-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2200,2310,2023-11-21 00:00:00.000000,Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02896179,2016-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2201,2309,2023-11-21 00:00:00.000000,Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization,,https://clinicaltrials.gov/show/NCT02889419,2016-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2202,2308,2023-11-21 00:00:00.000000,The Effect of Peer Educational Program on Multiple Sclerosis Patient’s Self- Efficacy,,http://en.irct.ir/trial/21578,2016-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2203,2307,2023-11-21 00:00:00.000000,Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02898974,2016-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2204,2306,2023-11-21 00:00:00.000000,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,,https://clinicaltrials.gov/show/NCT02901106,2016-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2205,2305,2023-11-21 00:00:00.000000,Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02896933,2016-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2206,2304,2023-11-21 00:00:00.000000,3D Phase Sensitive Inversion Recuperation MRI to Detect and Characterize Multiple Sclerosis Spinal Cord Lesions,,https://clinicaltrials.gov/show/NCT02896647,2016-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2207,2303,2023-11-21 00:00:00.000000,"Bimanual coordination in young adults, older adults and MS patients",,https://www.onderzoekmetmensen.nl/en/trial/25379,2016-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2208,2302,2023-11-21 00:00:00.000000,"2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib versus placebo in the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=15790,2016-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2209,2301,2023-11-21 00:00:00.000000,"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02937285,2016-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2210,2300,2023-11-21 00:00:00.000000,The evaluation of rehabilitation effects using exoskeleton EKSO GT in patients with multiple sclerosis,,https://anzctr.org.au/ACTRN12616001284459.aspx,2016-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2211,2299,2023-11-21 00:00:00.000000,Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study,,https://clinicaltrials.gov/ct2/show/NCT02914964,2016-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2212,2298,2023-11-21 00:00:00.000000,"A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003073-18,2016-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2213,2297,2023-11-21 00:00:00.000000,The effect of Lavender planet in the treatment on tremor of  Multipl Sclerosis patients.,,http://en.irct.ir/trial/23706,2016-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2214,2296,2023-11-21 00:00:00.000000,Hydroxychloroquine in Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02913157,2016-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2215,2295,2023-11-21 00:00:00.000000,Balance right in multiple sclerosis,,https://www.isrctn.com/ISRCTN13587999,2016-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2216,2294,2023-11-21 00:00:00.000000,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),,https://clinicaltrials.gov/show/NCT02921035,2016-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2217,2293,2023-11-21 00:00:00.000000,Effects of a 12&#45;Week Respiratory Muscle Training Program (RMTP) on Respiratory and Peripheral Muscle Strength in Patients with Multiple Sclerosis (PwMS),,https://www.thaiclinicaltrials.org/show/TCTR20160930001,2016-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2218,2292,2023-11-21 00:00:00.000000,"Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions",,https://clinicaltrials.gov/show/NCT02939859,2016-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2219,2291,2023-11-21 00:00:00.000000,Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02939079,2016-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2220,2290,2023-11-21 00:00:00.000000,Effect of MD1003 in Progressive Multiple Sclerosis (SPI2),,https://clinicaltrials.gov/show/NCT02936037,2016-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2221,2289,2023-11-21 00:00:00.000000,MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT02949908,2016-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2222,2288,2023-11-21 00:00:00.000000,Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/),,https://clinicaltrials.gov/show/NCT02992847,2016-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2223,2287,2023-11-21 00:00:00.000000,Study of Utilization Patterns of Dimethyl Fumarate in Germany,,https://clinicaltrials.gov/show/NCT02969304,2016-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2224,2286,2023-11-21 00:00:00.000000,Plantar Pressure Distribution in Patient With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02947906,2016-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2225,2285,2023-11-21 00:00:00.000000,Benefit and risk information for medications in multiple sclerosis,,http://isrctn.com/ISRCTN17318966,2016-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2226,2284,2023-11-21 00:00:00.000000,The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT02950454,2016-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2227,2283,2023-11-21 00:00:00.000000,Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study,,https://clinicaltrials.gov/show/NCT02952911,2016-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2228,2282,2023-11-21 00:00:00.000000,Clinical Importance of Glucose Regulation in Relapsing MS,,https://clinicaltrials.gov/show/NCT03004079,2016-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2229,2281,2023-11-21 00:00:00.000000,Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting,,https://clinicaltrials.gov/show/NCT03047460,2016-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2230,2280,2023-11-21 00:00:00.000000,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02959658,2016-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2231,2279,2023-11-21 00:00:00.000000,Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS,,https://clinicaltrials.gov/show/NCT02965170,2016-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2232,2278,2023-11-21 00:00:00.000000,Neurorehabilitation on Upper Limb and on Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02960984,2016-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2233,2277,2023-11-21 00:00:00.000000,Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02980042,2016-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2234,2276,2023-11-21 00:00:00.000000,Effects of a 12&#45;Week Respiratory Muscle Training Program (RMTP) on Respiratory Muscle Strength&#44; fatigue and quality of life in Patients with Multiple Sclerosis (PwMS),,https://www.thaiclinicaltrials.org/show/TCTR20161113002,2016-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2235,2275,2023-11-21 00:00:00.000000,Evaluating  the effect of parsnip syrup on sexual function in women with multiple sclerosis.,,http://en.irct.ir/trial/22253,2016-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2236,2274,2023-11-21 00:00:00.000000,The effect of personalized comprehensive rehabilitation training,,http://en.irct.ir/trial/17750,2016-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2237,2273,2023-11-21 00:00:00.000000,"Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt",,https://clinicaltrials.gov/show/NCT02970370,2016-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2238,2272,2023-11-21 00:00:00.000000,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02977533,2016-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2239,2271,2023-11-21 00:00:00.000000,Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?,,https://clinicaltrials.gov/show/NCT02987621,2016-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2240,2270,2023-11-21 00:00:00.000000,Pilot Diet Study for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02986893,2016-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2241,2269,2023-11-21 00:00:00.000000,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02988401,2016-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2242,2268,2023-11-21 00:00:00.000000,Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction,,https://clinicaltrials.gov/show/NCT03001284,2016-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2243,2267,2023-11-21 00:00:00.000000,"The effect of Group Therapy Based on metacognitive Model of Detached Mindfulness on
Cognitive functions in  patients with Multiple sclerosis",,http://en.irct.ir/trial/22879,2016-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2244,2266,2023-11-21 00:00:00.000000,Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03000647,2016-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2245,2265,2023-11-21 00:00:00.000000,Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort,,https://clinicaltrials.gov/show/NCT03004794,2016-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2246,2264,2023-11-21 00:00:00.000000,Testosterone for Fatigue in Men With MS,,https://clinicaltrials.gov/show/NCT03000127,2016-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2247,2263,2023-11-21 00:00:00.000000,The effect of education program Self-Care to control physical complications resulted from multiple sclerosis,,http://en.irct.ir/trial/23382,2016-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2248,2262,2023-11-21 00:00:00.000000,Effectiveness of Cognitive Rehabilitation in Multiple Sclerosis.,,http://en.irct.ir/trial/23815,2016-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2249,2261,2023-11-21 00:00:00.000000,Physiotherapist-guided Home Exercise in Moderate to Severe MS,,https://clinicaltrials.gov/show/NCT03039400,2016-12-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2250,2260,2023-11-21 00:00:00.000000,"Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms",,https://clinicaltrials.gov/show/NCT03005119,2016-12-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2251,2259,2023-11-21 00:00:00.000000,Multiple Sclerosis and Pilates,,https://clinicaltrials.gov/show/NCT03006900,2016-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2252,2258,2023-11-21 00:00:00.000000,Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes,,https://clinicaltrials.gov/show/NCT03066752,2017-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2253,2257,2023-11-21 00:00:00.000000,"Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03067025,2017-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2254,2256,2023-11-21 00:00:00.000000,ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study,,https://clinicaltrials.gov/show/NCT03137602,2017-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2255,2255,2023-11-21 00:00:00.000000,Effects of Memantine on fatigue in patients with Multiple sclerosis,,http://en.irct.ir/trial/24696,2017-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2256,2254,2023-11-21 00:00:00.000000,Physical Telerehabilitation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03230903,2017-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2257,2253,2023-11-21 00:00:00.000000,The effects of Spiritual-Religious care on Depression intensity,,http://en.irct.ir/trial/24551,2017-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2258,2252,2023-11-21 00:00:00.000000,Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses,,https://clinicaltrials.gov/show/NCT03021317,2017-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2259,2251,2023-11-21 00:00:00.000000,Efficacy and safety of peginterferon beta-1a (CinnaGen) in relapsing-remitting multiple sclerosis patients.,,http://en.irct.ir/trial/6574,2017-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2260,2250,2023-11-21 00:00:00.000000,Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03025269,2017-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2261,2249,2023-11-21 00:00:00.000000,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS),,https://clinicaltrials.gov/ct2/show/NCT03073603,2017-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2262,2248,2023-11-21 00:00:00.000000,pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress,,https://clinicaltrials.gov/show/NCT03028675,2017-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2263,2247,2023-11-21 00:00:00.000000,E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03029897,2017-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2264,2246,2023-11-21 00:00:00.000000,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,,https://clinicaltrials.gov/show/NCT03177083,2017-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2265,2245,2023-11-21 00:00:00.000000,A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004935-18,2017-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2266,2244,2023-11-21 00:00:00.000000,Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03045380,2017-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2267,2243,2023-11-21 00:00:00.000000,Three-week inpatient energy management education (IEME) for persons with multiple sclerosis–related fatigue. A feasibility study,,http://drks.de/search/en/trial/DRKS00011634,2017-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2268,2242,2023-11-21 00:00:00.000000,"The effect of cycling using active-passive trainers on spasticity, cardiovascular fitness, function and quality of life in people with multiple sclerosis",,http://isrctn.com/ISRCTN15999892,2017-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2269,2241,2023-11-21 00:00:00.000000,Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),,https://clinicaltrials.gov/show/NCT03049969,2017-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2270,2240,2023-11-21 00:00:00.000000,Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance,,https://clinicaltrials.gov/show/NCT03052595,2017-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2271,2239,2023-11-21 00:00:00.000000,Light Therapy as Treatment for Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03060759,2017-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2272,2238,2023-11-21 00:00:00.000000,Medical Education for Better Multiple Sclerosis Outcomes,,https://clinicaltrials.gov/show/NCT03134794,2017-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2273,2237,2023-11-21 00:00:00.000000,The effect of crocin in multiple sclerosis patients,,http://en.irct.ir/trial/13140,2017-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2274,2236,2023-11-21 00:00:00.000000,the effect of Melatonin on sphincter disorder in multiple sclerosis,,http://en.irct.ir/trial/17973,2017-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2275,2235,2023-11-21 00:00:00.000000,A clinical trial to study the safety and efficacy of Botox for arm tremor in people with multiple sclerosis (MS),,https://anzctr.org.au/ACTRN12617000379314.aspx,2017-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2276,2234,2023-11-21 00:00:00.000000,Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study,,https://clinicaltrials.gov/show/NCT03151941,2017-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2277,2233,2023-11-21 00:00:00.000000,Study of myMS in Participants With a Diagnosis of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03111394,2017-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2278,2232,2023-11-21 00:00:00.000000,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,,https://clinicaltrials.gov/show/NCT03093324,2017-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2279,2231,2023-11-21 00:00:00.000000,Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS),,https://clinicaltrials.gov/show/NCT03091400,2017-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2280,2230,2023-11-21 00:00:00.000000,Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters,,https://clinicaltrials.gov/show/NCT03108573,2017-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2281,2229,2023-11-21 00:00:00.000000,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,,https://clinicaltrials.gov/show/NCT03091569,2017-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2282,2228,2023-11-21 00:00:00.000000,"Study of efficacy and safety of ofatumumab compared to teriflunomide in
patients with relapsing multiple sclerosis",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16236,2017-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2283,2227,2023-11-21 00:00:00.000000,Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03094364,2017-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2284,2226,2023-11-21 00:00:00.000000,Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity,,https://clinicaltrials.gov/show/NCT03096977,2017-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2285,2225,2023-11-21 00:00:00.000000,Comparison of the efficacy of rehabilitation robotics in gait rehabilitation in patients with multiple sclerosis.,,http://www.anzctr.org.au/ACTRN12617000447358.aspx,2017-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2286,2224,2023-11-21 00:00:00.000000,The effects of caffeine on walking and balance in patients with multiple sclerosis,,http://en.irct.ir/trial/25120,2017-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2287,2223,2023-11-21 00:00:00.000000,A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia,,https://clinicaltrials.gov/show/NCT03110315,2017-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2288,2222,2023-11-21 00:00:00.000000,The effect of vitamin D in the prevention of MS disease in first degree relatives of MS patients.,,http://en.irct.ir/trial/3735,2016-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2289,2221,2023-11-21 00:00:00.000000,"Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis",,https://clinicaltrials.gov/show/NCT03164018,2017-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2290,2220,2023-11-21 00:00:00.000000,Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS,,https://clinicaltrials.gov/show/NCT03114293,2017-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2291,2219,2023-11-21 00:00:00.000000,Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03177785,2017-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2292,2218,2023-11-21 00:00:00.000000,Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach,,https://clinicaltrials.gov/show/NCT03198598,2017-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2293,2217,2023-11-21 00:00:00.000000,Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03126760,2017-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2294,2216,2023-11-21 00:00:00.000000,Tele-Exercise and Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03117881,2017-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2295,2215,2023-11-21 00:00:00.000000,From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings,,https://clinicaltrials.gov/show/NCT03108950,2017-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2296,2214,2023-11-21 00:00:00.000000,Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03122873,2017-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2297,2213,2023-11-21 00:00:00.000000,The impact of marital relationship enrichment program in patients with MS,,http://en.irct.ir/trial/24691,2017-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2298,2212,2023-11-21 00:00:00.000000,Feasibility and Acceptability of Orthotic Shorts for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03164031,2017-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2299,2211,2023-11-21 00:00:00.000000,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03135249,2017-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2300,2210,2023-11-21 00:00:00.000000,"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome",,https://clinicaltrials.gov/show/NCT03122652,2017-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2301,2209,2023-11-21 00:00:00.000000,Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03219073,2017-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2302,2208,2023-11-21 00:00:00.000000,Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?,,https://clinicaltrials.gov/show/NCT03136744,2017-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2303,2207,2023-11-21 00:00:00.000000,Collection of neurophysiological parameters during tension- vs. electrical current based electromyography,,http://drks.de/search/en/trial/DRKS00011892,2017-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2304,2206,2023-11-21 00:00:00.000000,Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study,,https://clinicaltrials.gov/show/NCT03134573,2017-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2305,2205,2023-11-21 00:00:00.000000,Examining the Feasibility of an Online Cognitive Behaviour Therapy (CBT) - based self-management Program for Adults with Neurological Conditions.,,https://anzctr.org.au/ACTRN12617000581369.aspx,2017-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2306,2204,2023-11-21 00:00:00.000000,The effect of Melatonin on Fatigue in Multiple sclerosis patients,,http://en.irct.ir/trial/17974,2017-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2307,2203,2023-11-21 00:00:00.000000,The effect of crocin on  MS,,http://en.irct.ir/trial/13139,2017-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2308,2202,2023-11-21 00:00:00.000000,Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03138525,2017-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2309,2201,2023-11-21 00:00:00.000000,Central Pain Study for ABX-1431,,https://clinicaltrials.gov/show/NCT03138421,2017-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2310,2200,2023-11-21 00:00:00.000000,"Effectiveness of Acceptance and Commitment Therapy on death and health anxiety, cognitive and somatic symptoms of anxiety, and component of acceptance and commitment in patients with multiple sclerosis",,http://en.irct.ir/trial/25610,2017-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2311,2199,2023-11-21 00:00:00.000000,Changing physical activity behaviour in people with MS: the iStep-MS trial,,https://www.isrctn.com/ISRCTN15343862,2017-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2312,2198,2023-11-21 00:00:00.000000,Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03148938,2017-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2313,2197,2023-11-21 00:00:00.000000,Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX),,https://clinicaltrials.gov/show/NCT03154801,2017-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2314,2196,2023-11-21 00:00:00.000000,Improving cognitive performance in MS by transcranial alternating current brain stimulation (tACS); a pilot study,,https://www.onderzoekmetmensen.nl/en/trial/28830,2017-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2315,2195,2023-11-21 00:00:00.000000,Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03183869,2017-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2316,2194,2023-11-21 00:00:00.000000,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,,https://clinicaltrials.gov/show/NCT03326505,2017-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2317,2193,2023-11-21 00:00:00.000000,STUDY OF EFFICACY AND SAFETY OF OFATUMUMAB COMPARED TO TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS.,,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=049-16,2017-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2318,2192,2023-11-21 00:00:00.000000,Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab,,https://clinicaltrials.gov/show/NCT03157830,2017-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2319,2191,2023-11-21 00:00:00.000000,Understanding Evaluation of Patient Information Sheets by User Testing Method,,https://clinicaltrials.gov/show/NCT03155334,2017-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2320,2190,2023-11-21 00:00:00.000000,Lipoic Acid for Progressive Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03161028,2017-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2321,2189,2023-11-21 00:00:00.000000,The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative,,https://clinicaltrials.gov/show/NCT03480854,2017-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2322,2188,2023-11-21 00:00:00.000000,Promoting job-seeking behaviour in adults with a physical disability,,http://www.anzctr.org.au/ACTRN12617000728336.aspx,2017-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2323,2187,2023-11-21 00:00:00.000000,ZEUS - ZINBRYTA real world use study in Germany,,http://isrctn.com/ISRCTN11671729,2017-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2324,2186,2023-11-21 00:00:00.000000,Strength Training to Improve Gait in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03175133,2017-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2325,2185,2023-11-21 00:00:00.000000,MitoQ for Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03166800,2017-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2326,2184,2023-11-21 00:00:00.000000,The benefits of exercising in a group vs at home independently for ambulatory people with multiple sclerosis,,http://www.anzctr.org.au/ACTRN12617000764336.aspx,2017-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2327,2183,2023-11-21 00:00:00.000000,"Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.",,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027997,2017-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2328,2182,2023-11-21 00:00:00.000000,The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03172741,2017-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2329,2181,2023-11-21 00:00:00.000000,Rehabilitation in Multiple Sclerosis - Sometimes Too Much?,,https://clinicaltrials.gov/show/NCT03187847,2017-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2330,2180,2023-11-21 00:00:00.000000,A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03174379,2017-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2331,2179,2023-11-21 00:00:00.000000,Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03177655,2017-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2332,2178,2023-11-21 00:00:00.000000,Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients with recurrent forms of multiple sclerosis,,http://en.irct.ir/trial/8804,2017-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2333,2177,2023-11-21 00:00:00.000000,Effect  of Cognitive hypnotherapy in multiple sclerosis patients,,http://en.irct.ir/trial/23630,2017-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2334,2176,2023-11-21 00:00:00.000000,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03185065,2017-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2335,2175,2023-11-21 00:00:00.000000,Relationship between performance in vigilance tasks and fatigue in patients with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00012392,2017-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2336,2174,2023-11-21 00:00:00.000000,"Comparison the efficacy of eight weeks resistance, balance and combined (resistance- balance) training program on balance, gait and quality of life in patients with Multiple Sclerosis",,http://en.irct.ir/trial/26219,2017-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2337,2173,2023-11-21 00:00:00.000000,Cognitive Impairment in Pediatric Onset Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03190902,2017-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2338,2172,2023-11-21 00:00:00.000000,Vaccine Exposure in Patients With MS,,https://clinicaltrials.gov/show/NCT03191669,2017-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2339,2171,2023-11-21 00:00:00.000000,The effect of Ex-PLISSIT model based sexual counseling  on the intimacy and sexuality of married women with multiple sclerosis: a randomized controlled trial,,http://en.irct.ir/trial/26004,2017-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2340,2170,2023-11-21 00:00:00.000000,To Evaluate the Effectiveness of Whole Body Vibration on Strength and Endurance of Core muscles in Ambulant Individuals with Multiple Sclerosis,,http://en.irct.ir/trial/23086,2017-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2341,2169,2023-11-21 00:00:00.000000,Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03200899,2017-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2342,2168,2023-11-21 00:00:00.000000,An Observational Study on Teriflunomide-exposed Pregnancies,,https://clinicaltrials.gov/ct2/show/NCT03198351,2017-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2343,2167,2023-11-21 00:00:00.000000,Project Y: searching for the cause of differences in disease course in MS,,https://www.onderzoekmetmensen.nl/en/trial/25188,2017-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2344,2166,2023-11-21 00:00:00.000000,Study of Biomarkers of the Response to Biotine,,https://clinicaltrials.gov/show/NCT03215433,2017-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2345,2165,2023-11-21 00:00:00.000000,Effect of Need to Void on Gait Speed in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03204747,2017-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2346,2164,2023-11-21 00:00:00.000000,Stylistic Memory Enhancement,,https://clinicaltrials.gov/show/NCT03206034,2017-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2347,2163,2023-11-21 00:00:00.000000,Clinical Decision Support System (CADIMS) for MS Diagnostic,,https://clinicaltrials.gov/show/NCT03205280,2017-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2348,2162,2023-11-21 00:00:00.000000,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,,https://clinicaltrials.gov/show/NCT03266965,2017-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2349,2161,2023-11-21 00:00:00.000000,"A long term follow up study to look at the progress of patients with
symptoms suggestive of MS who took part in previous studies with
Betaferon®/Betaseron®",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001176-31,2017-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2350,2160,2023-11-21 00:00:00.000000,"The impact of two different-home based physical training interventions to reduce fatigue and improve, strength, dexterity, and activities of daily living in adults with Multiple Sclerosis.",,http://www.anzctr.org.au/ACTRN12617000984392.aspx,2017-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2351,2159,2023-11-21 00:00:00.000000,Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03239860,2017-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2352,2158,2023-11-21 00:00:00.000000,The Impact of Exercise Training on Living Quality in Multiple Sclerosis Individuals,,https://clinicaltrials.gov/show/NCT03222596,2017-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2353,2157,2023-11-21 00:00:00.000000,"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT03232073,2017-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2354,2156,2023-11-21 00:00:00.000000,A Phase 1 Study of ARN-6039,,https://clinicaltrials.gov/show/NCT03237832,2017-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2355,2155,2023-11-21 00:00:00.000000,Targeted ballet program for people with multiple sclerosis,,https://www.isrctn.com/ISRCTN67916624,2017-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2356,2154,2023-11-21 00:00:00.000000,"A long term follow up study to look at the progress of patients with
                symptoms suggestive of MS who took part in previous studies with
                Betaferon®/Betaseron®",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001176-31,2017-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2357,2153,2023-11-21 00:00:00.000000,Effects of Melatonin on? radiological changes  of multiple sclerosis patient ?,,http://en.irct.ir/trial/17995,2017-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2358,2152,2023-11-21 00:00:00.000000,Gilenya's Impact on Cognitive Function and Thalamic Volumes,,https://clinicaltrials.gov/show/NCT03243721,2017-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2359,2151,2023-11-21 00:00:00.000000,Obstetric Anesthesia and Analgesia and Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03247894,2017-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2360,2150,2023-11-21 00:00:00.000000,Behavior and Activity Monitoring in MS,,https://clinicaltrials.gov/show/NCT03244696,2017-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2361,2149,2023-11-21 00:00:00.000000,The effect of Melatonin on the disability of multiple sclerosis patients,,http://en.irct.ir/trial/17994,2017-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2362,2148,2023-11-21 00:00:00.000000,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,,https://clinicaltrials.gov/show/NCT03269175,2017-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2363,2147,2023-11-21 00:00:00.000000,Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03282760,2017-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2364,2146,2023-11-21 00:00:00.000000,The effect of exercise training on women with multiple sclerosis,,http://en.irct.ir/trial/25648,2017-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2365,2145,2023-11-21 00:00:00.000000,The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03255460,2017-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2366,2144,2023-11-21 00:00:00.000000,Telephone-Delivered Exercise for Multiple Sclerosis Fatigue,,https://clinicaltrials.gov/show/NCT03256851,2017-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2367,2143,2023-11-21 00:00:00.000000,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,,https://clinicaltrials.gov/show/NCT03257358,2017-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2368,2142,2023-11-21 00:00:00.000000,Strength and resistance training in Multiple Sclerosis patients,,http://en.irct.ir/trial/25649,2017-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2369,2141,2023-11-21 00:00:00.000000,Impact of self-management program on MS patients,,http://en.irct.ir/trial/26534,2017-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2370,2140,2023-11-21 00:00:00.000000,Gut Microbiota and Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03262870,2017-08-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2371,2139,2023-11-21 00:00:00.000000,"Is there a relationship between pain, cognitive functioning, mood and motor activity in patients 
suffering from  multiple sclerosis",,https://www.onderzoekmetmensen.nl/en/trial/29634,2017-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2372,2138,2023-11-21 00:00:00.000000,Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions,,https://clinicaltrials.gov/show/NCT03268239,2017-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2373,2137,2023-11-21 00:00:00.000000,"Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination",,https://clinicaltrials.gov/show/NCT03268096,2017-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2374,2136,2023-11-21 00:00:00.000000,Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.,,https://clinicaltrials.gov/show/NCT03268187,2017-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2375,2135,2023-11-21 00:00:00.000000,Neural Stem Cell Transplantation in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03269071,2017-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2376,2134,2023-11-21 00:00:00.000000,Intensive Multimodal Training for Persons With MS,,https://clinicaltrials.gov/show/NCT03271125,2017-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2377,2133,2023-11-21 00:00:00.000000,"Impact of telephone counseling and follow-up on fatigue, pain and quality of life in  Multiple Sclerosis patients",,http://en.irct.ir/trial/26177,2017-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2378,2132,2023-11-21 00:00:00.000000,"A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)",,https://clinicaltrials.gov/show/NCT03277248,2017-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2379,2131,2023-11-21 00:00:00.000000,"A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)",,https://clinicaltrials.gov/show/NCT03277261,2017-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2380,2130,2023-11-21 00:00:00.000000,Effect of cognitive-behavioral group on fatigue and depression,,http://en.irct.ir/trial/21855,2017-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2381,2129,2023-11-21 00:00:00.000000,Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS),,https://clinicaltrials.gov/show/NCT03281330,2017-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2382,2128,2023-11-21 00:00:00.000000,Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03283826,2017-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2383,2127,2023-11-21 00:00:00.000000,Determining the merits of a lower limb robotic exoskeleton (HELLEN) in patients with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12617001316392.aspx,2017-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2384,2126,2023-11-21 00:00:00.000000,Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes,,https://clinicaltrials.gov/show/NCT03284970,2017-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2385,2125,2023-11-21 00:00:00.000000,The Effectiveness of Psychological Therapy on Improving Psychological Symptoms in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/24540,2017-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2386,2124,2023-11-21 00:00:00.000000,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,,https://clinicaltrials.gov/show/NCT03249714,2017-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2387,2123,2023-11-21 00:00:00.000000,"Feasability, Validty and Reliability of Inertial Sensors",,https://clinicaltrials.gov/show/NCT03668990,2017-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2388,2122,2023-11-21 00:00:00.000000,"Reliability, Validity and Clinical Utility of a Robotic Assessment for Proprioception",,https://clinicaltrials.gov/show/NCT03619642,2017-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2389,2121,2023-11-21 00:00:00.000000,Early Mobility Protocol to neurological inpatients,,http://ensaiosclinicos.gov.br/rg/RBR-9n35t4,2017-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2390,2120,2023-11-21 00:00:00.000000,Effect of supplementation in treatment of patients with multiple sclerosis,,http://en.irct.ir/trial/6089,2015-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2391,2119,2023-11-21 00:00:00.000000,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,,https://clinicaltrials.gov/show/NCT03290131,2017-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2392,2118,2023-11-21 00:00:00.000000,The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS,,https://clinicaltrials.gov/show/NCT03451955,2017-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2393,2117,2023-11-21 00:00:00.000000,Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03306875,2017-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2394,2116,2023-11-21 00:00:00.000000,Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03302442,2017-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2395,2115,2023-11-21 00:00:00.000000,Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression,,https://clinicaltrials.gov/show/NCT03368677,2017-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2396,2114,2023-11-21 00:00:00.000000,Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03302806,2017-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2397,2113,2023-11-21 00:00:00.000000,Study to Assess OCT: RNFL and GCL in MS Patients,,https://clinicaltrials.gov/show/NCT03313843,2017-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2398,2112,2023-11-21 00:00:00.000000,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,,https://clinicaltrials.gov/show/NCT03319732,2017-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2399,2111,2023-11-21 00:00:00.000000,Exercise and Learning and Memory in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03319771,2017-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2400,2110,2023-11-21 00:00:00.000000,Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03322748,2017-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2401,2109,2023-11-21 00:00:00.000000,Early Exercise Efforts in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03322761,2017-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2402,2108,2023-11-21 00:00:00.000000,Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response,,https://clinicaltrials.gov/show/NCT03316404,2017-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2403,2107,2023-11-21 00:00:00.000000,Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03315923,2017-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2404,2106,2023-11-21 00:00:00.000000,Behavior Cognitive Therapy on Fatigue Impact in MS Patients,,https://clinicaltrials.gov/show/NCT03758820,2017-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2405,2105,2023-11-21 00:00:00.000000,Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study,,https://clinicaltrials.gov/show/NCT03335618,2017-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2406,2104,2023-11-21 00:00:00.000000,The effect of counseling on sexual function and satisfaction in women with MS,,http://en.irct.ir/trial/27351,2017-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2407,2103,2023-11-21 00:00:00.000000,Group-based multidisciplinary rehabilitation for outpatient clients with multiple sclerosis,,http://isrctn.com/ISRCTN72556817,2017-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2408,2102,2023-11-21 00:00:00.000000,Effects of a Persian Herbal Extract in treatment of Multiple Sclerosis Patients,,http://en.irct.ir/trial/15337,2017-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2409,2101,2023-11-21 00:00:00.000000,Gaze and Postural Stability in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03521557,2017-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2410,2100,2023-11-21 00:00:00.000000,Videofluoroscopic Swallowing Study (VFSS),,https://clinicaltrials.gov/show/NCT03387267,2017-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2411,2099,2023-11-21 00:00:00.000000,Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03369171,2017-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2412,2098,2023-11-21 00:00:00.000000,Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère,,https://clinicaltrials.gov/show/NCT03339817,2017-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2413,2097,2023-11-21 00:00:00.000000,MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamous Cell Carcinoma),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011470-15,2017-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2414,2096,2023-11-21 00:00:00.000000,"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT",,https://clinicaltrials.gov/ct2/show/NCT03368664,2017-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2415,2095,2023-11-21 00:00:00.000000,Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03548974,2017-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2416,2094,2023-11-21 00:00:00.000000,Stress Urinary Incontinence in Women With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03332654,2017-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2417,2093,2023-11-21 00:00:00.000000,MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03356366,2017-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2418,2092,2023-11-21 00:00:00.000000,Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.,,https://clinicaltrials.gov/show/NCT03336424,2017-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2419,2091,2023-11-21 00:00:00.000000,Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03339908,2017-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2420,2090,2023-11-21 00:00:00.000000,Maximizing Outcome of Multiple Sclerosis Transplantation,,https://clinicaltrials.gov/show/NCT03342638,2017-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2421,2089,2023-11-21 00:00:00.000000,Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03345199,2017-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2422,2088,2023-11-21 00:00:00.000000,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03355365,2017-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2423,2087,2023-11-21 00:00:00.000000,Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT03357887,2017-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2424,2086,2023-11-21 00:00:00.000000,Comparison of different gait training methods in Muliple sclerosis,,http://drks.de/search/en/trial/DRKS00012324,2017-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2425,2085,2023-11-21 00:00:00.000000,A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03347370,2017-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2426,2084,2023-11-21 00:00:00.000000,Effect of combined omega-3 and vitamin D supplementation in treatment of multiple sclerosis,,http://en.irct.ir/trial/26062,2017-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2427,2083,2023-11-21 00:00:00.000000,Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:,,https://clinicaltrials.gov/show/NCT03360487,2017-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2428,2082,2023-11-21 00:00:00.000000,Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS,,https://clinicaltrials.gov/show/NCT03372187,2017-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2429,2081,2023-11-21 00:00:00.000000,A Multi-Site Trial of MS INFoRm (Fatigue Management Resource),,https://clinicaltrials.gov/show/NCT03362541,2017-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2430,2080,2023-11-21 00:00:00.000000,A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology,,https://clinicaltrials.gov/show/NCT03458767,2017-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2431,2079,2023-11-21 00:00:00.000000,Supervised Perturbation Training Results in Changes in Balance and Falling in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04132167,2017-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2432,2078,2023-11-21 00:00:00.000000,Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study,,https://clinicaltrials.gov/show/NCT03369106,2017-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2433,2077,2023-11-21 00:00:00.000000,Pediatric Onset Multiple Sclerosis in Egyptians,,https://clinicaltrials.gov/show/NCT03360188,2017-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2434,2076,2023-11-21 00:00:00.000000,Tecfidera and Fatigue and fatigability in RRMS,,https://www.onderzoekmetmensen.nl/en/trial/25337,2017-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2435,2075,2023-11-21 00:00:00.000000,App Based Dexterity Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03369470,2017-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2436,2074,2023-11-21 00:00:00.000000,Remediation of Emotional Processing Deficits in MS,,https://clinicaltrials.gov/show/NCT03373344,2017-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2437,2073,2023-11-21 00:00:00.000000,Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy,,https://clinicaltrials.gov/show/NCT03375541,2017-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2438,2072,2023-11-21 00:00:00.000000,Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03436927,2017-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2439,2071,2023-11-21 00:00:00.000000,"Evaluation The Effect Of  The  Fordyce  Happiness Program On sleep Quality,Spiritual Well-Being ,and Pain In Peoples With Multiple Sclerosis",,http://en.irct.ir/trial/2740,2017-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2440,2070,2023-11-21 00:00:00.000000,Muscle Vibration in MS to Improve Walking,,https://clinicaltrials.gov/show/NCT03403413,2017-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2441,2069,2023-11-21 00:00:00.000000,An Extension of the TG1101-RMS201 Trial,,https://clinicaltrials.gov/show/NCT03381170,2017-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2442,2068,2023-11-21 00:00:00.000000,Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03385356,2017-12-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2443,2067,2023-11-21 00:00:00.000000,LEAP a New Overground Body Weight Support Robot: Usability Trial,,https://clinicaltrials.gov/show/NCT03458169,2017-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2444,2066,2023-11-21 00:00:00.000000,Nutritional Approaches in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03508414,2017-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2445,2065,2023-11-21 00:00:00.000000,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),,https://clinicaltrials.gov/show/NCT03387046,2017-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2446,2064,2023-11-21 00:00:00.000000,Development of a device for physically challenged people for independent indoor & outdoor mobility.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21923,2017-12-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2447,2063,2023-11-21 00:00:00.000000,Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03396822,2018-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2448,2062,2023-11-21 00:00:00.000000,Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03401307,2018-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2449,2061,2023-11-21 00:00:00.000000,Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b,,https://clinicaltrials.gov/show/NCT03408093,2018-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2450,2060,2023-11-21 00:00:00.000000,Carnosine Loading and Periodized Training in MS and HC,,https://clinicaltrials.gov/show/NCT03418376,2018-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2451,2059,2023-11-21 00:00:00.000000,CLEVER: CLadribine tablets - EValuation of therapy satisfaction,,http://drks.de/search/en/trial/DRKS00013587,2018-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2452,2058,2023-11-21 00:00:00.000000,"The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients",,https://clinicaltrials.gov/show/NCT03424538,2018-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2453,2057,2023-11-21 00:00:00.000000,Evaluation   the relationship between cognitive function and inflammatory factors in patients with MS,,http://en.irct.ir/trial/1100,2018-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2454,2056,2023-11-21 00:00:00.000000,Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03490240,2018-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2455,2055,2023-11-21 00:00:00.000000,The effect of Emotional Freedom Technique on fatigue and pain,,http://en.irct.ir/trial/28223,2018-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2456,2054,2023-11-21 00:00:00.000000,Effects of Core Stability Training on Gait in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03442049,2018-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2457,2053,2023-11-21 00:00:00.000000,The SEMS Project: Staying Employed With MS,,https://clinicaltrials.gov/show/NCT03647904,2018-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2458,2052,2023-11-21 00:00:00.000000,Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI,,https://clinicaltrials.gov/show/NCT03438357,2018-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2459,2051,2023-11-21 00:00:00.000000,Effect of Motor Cortex Versus Sacral Magnetic Stimulation in Multiple Sclerosis Patients With Urinary Tract Dysfunction,,https://clinicaltrials.gov/show/NCT03434873,2018-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2460,2050,2023-11-21 00:00:00.000000,New Service Delivery Model for Augmentative and Alternative Communication (AAC) Devices and Intervention,,http://drks.de/search/en/trial/DRKS00013628,2018-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2461,2049,2022-03-14 13:19:41.179332,Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis,<b>Conditions</b>:    Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Device: Eye-tracking<br /><b>Sponsors</b>:    McGill University;   Innodem Neurosciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05277740,2022-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2462,2048,2023-11-21 00:00:00.000000,nd,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001515-20,2018-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2463,2047,2023-11-21 00:00:00.000000,Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004100-22,2018-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2464,2046,2023-11-21 00:00:00.000000,Reproductibility of Cystometry in Multiple Sclerosis Patient,,https://clinicaltrials.gov/show/NCT03451175,2018-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2465,2045,2023-11-21 00:00:00.000000,Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment,,https://clinicaltrials.gov/show/NCT03436199,2018-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2466,2044,2023-11-21 00:00:00.000000,"Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03551275,2018-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2467,2043,2023-11-21 00:00:00.000000,"Validating a self-administered, language-independent iPad-based test for assessment and monitoring of cognitive impairment in patients with multiple sclerosis (MS)",,http://isrctn.com/ISRCTN17924218,2018-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2468,2042,2023-11-21 00:00:00.000000,Effect of nano formulation of saffron crocin in patients with multiple sclerosis,,http://en.irct.ir/trial/29602,2018-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2469,2041,2023-11-21 00:00:00.000000,Effect of oral curcuden on multiple sclerosis patients,,http://en.irct.ir/trial/25165,2018-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2470,2040,2023-11-21 00:00:00.000000,CLADQoL: CLADribine tablets –evaluation of Quality of Life,,http://drks.de/search/en/trial/DRKS00013934,2018-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2471,2039,2023-11-21 00:00:00.000000,"Chronic Inflammatory Disease, Lifestyle and Risk of Disease",,https://clinicaltrials.gov/show/NCT03456206,2018-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2472,2038,2023-11-21 00:00:00.000000,Radiotherapy in Multiple sclerosis patients,,http://en.irct.ir/trial/28302,2018-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2473,2037,2023-11-21 00:00:00.000000,Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II,,https://clinicaltrials.gov/show/NCT03797937,2018-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2474,2036,2023-11-21 00:00:00.000000,Comparative Effectiveness Study Telerehab Versus Conventional,,https://clinicaltrials.gov/ct2/show/NCT03468868,2018-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2475,2035,2023-11-21 00:00:00.000000,Mechanistic Studies of Teriflunomide in RRMS,,https://clinicaltrials.gov/show/NCT03464448,2018-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2476,2034,2023-11-21 00:00:00.000000,"quality of sleep, life and fatigue in patient with multiple sclerosis",,http://en.irct.ir/trial/29075,2018-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2477,2033,2023-11-21 00:00:00.000000,Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03889327,2018-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2478,2032,2023-11-21 00:00:00.000000,Digital Cognition in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03569618,2018-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2479,2031,2023-11-21 00:00:00.000000,Ozone Therapy Effect on Multiple sclerosis,,http://en.irct.ir/trial/27913,2018-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2480,2030,2023-11-21 00:00:00.000000,Difficulty retrieving words (anomia) in people with relapsing-remitting multiple sclerosis (RR-MS),,https://www.isrctn.com/ISRCTN54123111,2018-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2481,2029,2023-11-21 00:00:00.000000,"Study the action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action in patients with Progressive Multiple Sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005493-11,2018-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2482,2028,2023-11-21 00:00:00.000000,""" Treating MS Patients With Lower Extremity Spasticity Using Dysport""",,https://clinicaltrials.gov/show/NCT03585569,2018-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2483,2027,2023-11-21 00:00:00.000000,Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.,,https://clinicaltrials.gov/show/NCT03486665,2018-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2484,2026,2023-11-21 00:00:00.000000,Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03493841,2018-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2485,2025,2023-11-21 00:00:00.000000,effect of Transcranial Direct current Stimulation on fatigue and quality of life in multiple sclerosis,,http://en.irct.ir/trial/30200,2018-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2486,2024,2023-11-21 00:00:00.000000,Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03508089,2018-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2487,2023,2023-11-21 00:00:00.000000,Effect of exercise training in women patients with multiple sclerosis,,http://en.irct.ir/trial/29984,2018-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2488,2022,2023-11-21 00:00:00.000000,Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587),,https://clinicaltrials.gov/ct2/show/NCT03486873,2018-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2489,2021,2023-11-21 00:00:00.000000,Abdominal Functional Electrical Stimulation to improve bowel and bladder function in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12618000464268.aspx,2018-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2490,2020,2023-11-21 00:00:00.000000,"STUDY TO ASSESS OCRELIZUMAB EFFICACY, SAFETY AND IMPACT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS
(PRO-MSACTIVE)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000780-91,2018-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2491,2019,2023-11-21 00:00:00.000000,Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03497468,2018-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2492,2018,2023-11-21 00:00:00.000000,Lipid Mediators in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03492606,2018-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2493,2017,2023-11-21 00:00:00.000000,Unraveling Early Walking Dysfunction in Non-disabled MS People: Assessment and Potential Therapeutic Interventions,,https://clinicaltrials.gov/show/NCT03492450,2018-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2494,2016,2023-11-21 00:00:00.000000,Ketamine for Treatment of MS Fatigue,,https://clinicaltrials.gov/show/NCT03500289,2018-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2495,2015,2023-11-21 00:00:00.000000,Evaluation of the biometric value of observational gait scales - Wisconsin Gait Scale and Gait Abnormality Rating Scale – modified in neurological diseases,,http://www.anzctr.org.au/ACTRN12618000494235.aspx,2018-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2496,2014,2023-11-21 00:00:00.000000,"Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics",,https://clinicaltrials.gov/show/NCT03854123,2018-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2497,2013,2023-11-21 00:00:00.000000,Melatonin in Patients With Multiple Sclerosis (MS).,,https://clinicaltrials.gov/ct2/show/NCT03498131,2018-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2498,2012,2023-11-21 00:00:00.000000,Effectiveness of magnetic fields in treating fatigue in patients with multiple sclerosis.,,https://anzctr.org.au/ACTRN12618000515291.aspx,2018-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2499,2011,2023-11-21 00:00:00.000000,A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03499314,2018-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2500,2010,2023-11-21 00:00:00.000000,"Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03501342,2018-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2501,2009,2023-11-21 00:00:00.000000,Clinical Pilates Training for Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03502772,2018-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2502,2008,2023-11-21 00:00:00.000000,Towards Personalized Dosing of Natalizumab in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03516526,2018-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2503,2007,2023-11-21 00:00:00.000000,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03523858,2018-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2504,2006,2023-11-21 00:00:00.000000,Dual-Task Performance in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03508284,2018-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2505,2005,2023-11-21 00:00:00.000000,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury,,https://clinicaltrials.gov/show/NCT04408274,2018-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2506,2004,2023-11-21 00:00:00.000000,The Effect of Multiple-Task Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03512886,2018-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2507,2003,2023-11-21 00:00:00.000000,The Effect of Task-Oriented Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03505294,2018-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2508,2002,2023-11-21 00:00:00.000000,Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03552211,2018-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2509,2001,2023-11-21 00:00:00.000000,Intermittent Fasting in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03539094,2018-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2510,2000,2023-11-21 00:00:00.000000,"The influence that physical exercise Tai-Geiko provides in people with multiple sclerosis regarding muscle strength, balance and performing two tasks at the same time.",,http://ensaiosclinicos.gov.br/rg/RBR-4sty47,2018-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2511,1999,2023-11-21 00:00:00.000000,Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03536559,2018-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2512,1998,2023-11-21 00:00:00.000000,What is the relation of Severity of Disability with Function and Balance in Multiple Sclerosis?,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=24102,2018-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2513,1997,2023-11-21 00:00:00.000000,Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies,,https://clinicaltrials.gov/show/NCT03552185,2018-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2514,1996,2023-11-21 00:00:00.000000,Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03555253,2018-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2515,1995,2023-11-21 00:00:00.000000,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,,https://clinicaltrials.gov/show/NCT03560739,2018-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2516,1994,2023-11-21 00:00:00.000000,Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers,,https://clinicaltrials.gov/show/NCT03574428,2018-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2517,1993,2023-11-21 00:00:00.000000,Effects of Low-intensity Interval Walking With Blood Flow Restriction on Functional Capacity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03544177,2018-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2518,1992,2023-11-21 00:00:00.000000,Finding the Right Words in Neurogenic Communication Disorders,,https://clinicaltrials.gov/show/NCT03568760,2018-05-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2519,1991,2023-11-21 00:00:00.000000,A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,,https://clinicaltrials.gov/show/NCT03567057,2018-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2520,1990,2023-11-21 00:00:00.000000,Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus,,https://clinicaltrials.gov/show/NCT03562975,2018-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2521,1989,2023-11-21 00:00:00.000000,Robot-assisted Arm Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03561155,2018-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2522,1988,2023-11-21 00:00:00.000000,Fatigue Management Programs for People With MS,,https://clinicaltrials.gov/show/NCT03550170,2018-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2523,1987,2023-11-21 00:00:00.000000,Preventing Falls and Participation Restrictions in Neurological Diseases,,https://clinicaltrials.gov/show/NCT03570268,2018-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2524,1986,2023-11-21 00:00:00.000000,Massage therapy and MS,,http://en.irct.ir/trial/31271,2018-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2525,1985,2023-11-21 00:00:00.000000,"READY for MS, a group intervention to promote resilience in people with multiple sclerosis in Italy",,https://www.isrctn.com/ISRCTN38971970,2018-04-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2526,1984,2023-11-21 00:00:00.000000,Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03594487,2018-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2527,1983,2023-11-21 00:00:00.000000,Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio),,https://clinicaltrials.gov/show/NCT03561402,2018-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2528,1982,2023-11-21 00:00:00.000000,The Effect of TRX Suspension Training on Functional Capacity in Patients With Multiple Sclerosis,,http://en.irct.ir/trial/31370,2018-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2529,1981,2023-11-21 00:00:00.000000,APPS MS: smartphone monitoring in MS,,https://www.onderzoekmetmensen.nl/en/trial/27724,2018-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2530,1980,2023-11-21 00:00:00.000000,Compare the effectiveness of two psychological treatment methods on the symptoms of MS patients,,http://en.irct.ir/trial/29569,2018-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2531,1979,2023-11-21 00:00:00.000000,Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With MS,,https://clinicaltrials.gov/show/NCT03603691,2018-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2532,1978,2023-11-21 00:00:00.000000,Brain Targets in Patients With Bladder Emptying Difficulties,,https://clinicaltrials.gov/ct2/show/NCT03574610,2018-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2533,1977,2023-11-21 00:00:00.000000,E-Support Groups in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03574961,2018-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2534,1976,2023-11-21 00:00:00.000000,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),,https://clinicaltrials.gov/ct2/show/NCT03599245,2018-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2535,1975,2023-11-21 00:00:00.000000,Betaferon Use in Children and Adolescents With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03577977,2018-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2536,1974,2023-11-21 00:00:00.000000,"""Investigating the Self-care Effect on MS""",,http://en.irct.ir/trial/31158,2018-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2537,1973,2023-11-21 00:00:00.000000,OFSEP High Definition Cohort,,https://clinicaltrials.gov/ct2/show/NCT03603457,2018-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2538,1972,2023-11-21 00:00:00.000000,"The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.",,https://clinicaltrials.gov/show/NCT03584672,2018-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2539,1971,2023-11-21 00:00:00.000000,Neurodynamic Interventions for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03595631,2018-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2540,1970,2023-11-21 00:00:00.000000,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",,https://clinicaltrials.gov/show/NCT03589105,2018-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2541,1969,2023-11-21 00:00:00.000000,The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03597451,2018-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2542,1968,2023-11-21 00:00:00.000000,Cognitive Functions in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03594357,2018-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2543,1967,2023-11-21 00:00:00.000000,Combined Exercise Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03591809,2018-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2544,1966,2023-11-21 00:00:00.000000,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03593590,2018-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2545,1965,2023-11-21 00:00:00.000000,"LSFG-SKIN, Laser Speckle Flowgraphy",,https://clinicaltrials.gov/show/NCT03660618,2018-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2546,1964,2023-11-21 00:00:00.000000,Mindfulness for Newly Diagnosed Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03607773,2018-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2547,1963,2023-11-21 00:00:00.000000,Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03608527,2018-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2548,1962,2023-11-21 00:00:00.000000,The effect of M1 transcranial direct current stimulation on implicit motor learning in the patients with multiple sclerosis,,http://en.irct.ir/trial/29365,2018-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2549,1961,2023-11-21 00:00:00.000000,Advanced MRI Sequences in Multiple Sclerosis and Its Mimics,,https://clinicaltrials.gov/show/NCT03608605,2018-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2550,1960,2023-11-21 00:00:00.000000,"The effectiveness of mindfulness-based stress reduction on fatigue severity, functional disability and emotion dysregulation among patients with multiple sclerosis",,http://en.irct.ir/trial/29800,2018-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2551,1959,2023-11-21 00:00:00.000000,A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/show/NCT03606460,2018-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2552,1958,2023-11-21 00:00:00.000000,"Effects of equine therapy on postural balance, gait, performance and functional mobility and quality of life in healthy people and people with disability",,http://ensaiosclinicos.gov.br/rg/RBR-3zs6g9,2018-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2553,1957,2023-11-21 00:00:00.000000,Evaluation of a Mindfulness-Based program for people with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12618001260213.aspx,2018-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2554,1956,2023-11-21 00:00:00.000000,Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03632473,2018-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2555,1955,2023-11-21 00:00:00.000000,Environmental challenges towards participation of persons with neurological disabilities with walking difficulties in an urban city,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=24961,2018-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2556,1954,2023-11-21 00:00:00.000000,Validation of a Smartwatch in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03750097,2018-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2557,1953,2023-11-21 00:00:00.000000,Exercise and Brain Health in MS,,https://clinicaltrials.gov/show/NCT03638739,2018-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2558,1952,2023-11-21 00:00:00.000000,Assessment of Walking-related Fatigability in Patients With Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT03860675,2018-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2559,1951,2023-11-21 00:00:00.000000,Effect of corrective movements and Saffron on Multiple Sclerosis,,http://en.irct.ir/trial/31315,2018-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2560,1950,2023-11-21 00:00:00.000000,"Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue",,https://clinicaltrials.gov/show/NCT03621761,2018-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2561,1949,2023-11-21 00:00:00.000000,A Positive Psychology Intervention for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03637699,2018-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2562,1948,2023-11-21 00:00:00.000000,Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study,,https://clinicaltrials.gov/show/NCT03624296,2018-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2563,1947,2023-11-21 00:00:00.000000,The effects of balance training using the Homebalance instrument in people with multiple sclerosis,,https://www.isrctn.com/ISRCTN11744221,2018-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2564,1946,2023-11-21 00:00:00.000000,MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03692975,2018-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2565,1945,2023-11-21 00:00:00.000000,The Effect of Cervical Mobilization on Balance and Spasticity in Multiple Sclerosis Individuals,,https://clinicaltrials.gov/show/NCT03706131,2018-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2566,1944,2023-11-21 00:00:00.000000,A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004702-17,2018-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2567,1943,2023-11-21 00:00:00.000000,High-intensity Training and Its Effects on Neuroplasticity,,https://clinicaltrials.gov/show/NCT03652519,2018-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2568,1942,2023-11-21 00:00:00.000000,Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome,,https://clinicaltrials.gov/show/NCT03636789,2018-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2569,1941,2023-11-21 00:00:00.000000,Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000001-23,2018-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2570,1940,2023-11-21 00:00:00.000000,A study to evaluate the safety and pharmacokinetics (the measure of how the human body processes a substance) of EHP-101 when administered orally to healthy participants,,https://anzctr.org.au/ACTRN12618001390279.aspx,2018-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2571,1939,2023-11-21 00:00:00.000000,Motor Evoked Potentials With Modified Facilitation Technique,,https://clinicaltrials.gov/show/NCT03646929,2018-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2572,1938,2023-11-21 00:00:00.000000,Cortical Lesions in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03653585,2018-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2573,1937,2023-11-21 00:00:00.000000,Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation,,https://clinicaltrials.gov/ct2/show/NCT03679468,2018-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2574,1936,2023-11-21 00:00:00.000000,Improving Mobility and Reducing Fatigue in People With Multiple Sclerosis by Electrical Stimulation Therapy,,https://clinicaltrials.gov/show/NCT03684369,2018-08-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2575,1935,2023-11-21 00:00:00.000000,Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03656055,2018-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2576,1934,2023-11-21 00:00:00.000000,Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037594,2018-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2577,1933,2023-11-21 00:00:00.000000,A randomized controlled clinical trial of fecal bacteria transplantation for multiple sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=28380,2018-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2578,1932,2023-11-21 00:00:00.000000,MS-SAFE: Stepping to Avoid Fall Events in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12618001436268.aspx,2018-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2579,1931,2023-11-21 00:00:00.000000,Home Exercise Telerehabiliation for MS,,https://clinicaltrials.gov/show/NCT03655431,2018-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2580,1930,2023-11-21 00:00:00.000000,Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03655093,2018-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2581,1929,2023-11-21 00:00:00.000000,Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease,,https://clinicaltrials.gov/show/NCT03656627,2018-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2582,1928,2023-11-21 00:00:00.000000,Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T MRI Study,,https://clinicaltrials.gov/ct2/show/NCT03659981,2018-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2583,1927,2023-11-21 00:00:00.000000,A Study for Testing Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior,,https://clinicaltrials.gov/show/NCT03671499,2018-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2584,1926,2023-11-21 00:00:00.000000,"A Phase 1, Randomized, Open-Label Study of the Relative Bioavailability and Effect of Food on the Pharmacokinetics of a Novel Formulation of PRN2246 Compared to a Reference Formulation in Healthy Adult Participants",,https://anzctr.org.au/ACTRN12618001523291.aspx,2018-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2585,1925,2023-11-21 00:00:00.000000,"Aspirin, Cooling and Exercise in Multiple Sclerosis",,https://anzctr.org.au/ACTRN12618001534279.aspx,2018-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2586,1924,2023-11-21 00:00:00.000000,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,,https://clinicaltrials.gov/ct2/show/NCT03677440,2018-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2587,1923,2023-11-21 00:00:00.000000,Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging,,https://clinicaltrials.gov/show/NCT03706118,2018-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2588,1922,2023-11-21 00:00:00.000000,Validation of [11C]MeDAS PET imaging for myelin quantification in multiple sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/26325,2018-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2589,1921,2023-11-21 00:00:00.000000,Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03679806,2018-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2590,1920,2023-11-21 00:00:00.000000,The PrEliMS Feasibility Trial,,https://clinicaltrials.gov/show/NCT03735056,2018-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2591,1919,2023-11-21 00:00:00.000000,"Evaluation of the correlation of MRT based brain volume, OCT (optical coherence tomography), neuropsychology and VEP (visual evoked potentials) in MS patients with high and moderate activity.",,http://drks.de/search/en/trial/DRKS00015506,2018-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2592,1918,2023-11-21 00:00:00.000000,VEstibular Rehabilitation in MultIple Sclerosis,,https://www.isrctn.com/ISRCTN27374299,2018-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2593,1917,2023-11-21 00:00:00.000000,Influence of Cognitive Function Software Therapy on the Improvement of Manual Skills in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03693118,2018-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2594,1916,2023-11-21 00:00:00.000000,Feasibility and Reliability of Multimodal Evoked Potentials,,https://clinicaltrials.gov/show/NCT03686826,2018-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2595,1915,2023-11-21 00:00:00.000000,Effect of Spiritual Training on MS Patients.,,http://en.irct.ir/trial/23162,2018-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2596,1914,2023-11-21 00:00:00.000000,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",,https://clinicaltrials.gov/ct2/show/NCT03689972,2018-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2597,1913,2023-11-21 00:00:00.000000,Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03723356,2018-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2598,1912,2023-11-21 00:00:00.000000,Photobiomodulation Therapy in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03691766,2018-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2599,1911,2023-11-21 00:00:00.000000,Effect of royal Jelly and Omega-3 in multiple sclerosis,,http://en.irct.ir/trial/32379,2018-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2600,1910,2023-11-21 00:00:00.000000,Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS,,https://clinicaltrials.gov/show/NCT03696485,2018-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2601,1909,2023-11-21 00:00:00.000000,Correlation between cortisol concentration in saliva and cognitive fatigue in patients afflicted with multiple sclerosis (MS),,http://drks.de/search/en/trial/DRKS00015651,2018-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2602,1908,2023-11-21 00:00:00.000000,Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03783585,2018-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2603,1907,2023-11-21 00:00:00.000000,Multi-joint Muscle Fatigability and Gait Performance in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03735654,2018-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2604,1906,2023-11-21 00:00:00.000000,Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03740295,2018-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2605,1905,2023-11-21 00:00:00.000000,Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients,,https://clinicaltrials.gov/show/NCT03710655,2018-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2606,1904,2023-11-21 00:00:00.000000,Exercise-based Therapy for Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03735524,2018-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2607,1903,2023-11-21 00:00:00.000000,My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03708276,2018-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2608,1902,2023-11-21 00:00:00.000000,Interoception and Sense of Movement in the Patient With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03711968,2018-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2609,1901,2023-11-21 00:00:00.000000,Cerebrovascular Changes in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03709290,2018-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2610,1900,2023-11-21 00:00:00.000000,Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS,,https://clinicaltrials.gov/show/NCT03718247,2018-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2611,1899,2023-11-21 00:00:00.000000,Effects of Exercises in MS on Postural Control With Dual Task,,https://clinicaltrials.gov/show/NCT03718819,2018-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2612,1898,2023-11-21 00:00:00.000000,The effect of mental training in multiple sclerosis patients,,http://en.irct.ir/trial/33766,2018-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2613,1897,2023-11-21 00:00:00.000000,The effect of reflexology on constipation,,http://en.irct.ir/trial/31363,2018-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2614,1896,2023-11-21 00:00:00.000000,The effect of training protocol on multiple sclerosis,,http://en.irct.ir/trial/34101,2018-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2615,1895,2023-11-21 00:00:00.000000,Physiology of Interregional Connectivity in the Human Brain,,https://clinicaltrials.gov/show/NCT03723434,2018-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2616,1894,2023-11-21 00:00:00.000000,"The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03718026,2018-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2617,1893,2023-11-21 00:00:00.000000,"The Effect of NLP Individual Psychotherapy On The Reduction Of Symptom Of Depression, Anxiety, Stress and Improving Quality of Life and Control of proceeding Disease on RRMS Patients",,http://en.irct.ir/trial/28711,2018-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2618,1892,2023-11-21 00:00:00.000000,Views on Physical Activity Following a Relapse in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03736902,2018-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2619,1891,2023-11-21 00:00:00.000000,Aerobic Exercise and Transcranial Low Laser Therapy in Patients With Central Nervous System Injury,,https://clinicaltrials.gov/show/NCT03751306,2018-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2620,1890,2023-11-21 00:00:00.000000,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03737851,2018-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2621,1889,2023-11-21 00:00:00.000000,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03737812,2018-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2622,1888,2023-11-21 00:00:00.000000,Computerized Cognitive Training in MS,,https://clinicaltrials.gov/show/NCT03737825,2018-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2623,1887,2023-11-21 00:00:00.000000,Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS,,https://clinicaltrials.gov/show/NCT03808545,2018-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2624,1886,2023-11-21 00:00:00.000000,The effect of exercise and royal jelly on total antioxidant capacity and glutathione peroxidase in multiple sclerosis patients,,http://en.irct.ir/trial/33324,2018-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2625,1885,2023-11-21 00:00:00.000000,"Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study",,https://clinicaltrials.gov/ct2/show/NCT03797378,2018-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2626,1884,2023-11-21 00:00:00.000000,Effects of Cladribine Tablets on the PK of Microgynon®,,https://clinicaltrials.gov/show/NCT03745144,2018-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2627,1883,2023-11-21 00:00:00.000000,"Effectiveness of group consultation on intimacy, sexuality and   satisfaction in married women of multiple sclerosis",,http://en.irct.ir/trial/34118,2018-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2628,1882,2023-11-21 00:00:00.000000,Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses,,https://clinicaltrials.gov/show/NCT03752307,2018-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2629,1881,2023-11-21 00:00:00.000000,"Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With MS",,https://clinicaltrials.gov/show/NCT03753698,2018-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2630,1880,2023-11-21 00:00:00.000000,The effect of dietary modification on multiple sclerosis.,,http://en.irct.ir/trial/35185,2018-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2631,1879,2023-11-21 00:00:00.000000,Effects of Ondansetron versus Amantadine on fatigability in patients with multiple sclerosis,,http://en.irct.ir/trial/35109,2018-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2632,1878,2023-11-21 00:00:00.000000,BX-1 in Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03756974,2018-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2633,1877,2023-11-21 00:00:00.000000,Functional near-infrared spectroscopy in multiple sclerosis: gait automaticity with and without fatigability,,http://drks.de/search/en/trial/DRKS00015190,2018-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2634,1876,2023-11-21 00:00:00.000000,The Effectiveness of Acceptance and Commitment Therapy on Cognitive Flexibility and Emotional Regulation of Patients with Spinal Cord Injury and MS Patients,,http://en.irct.ir/trial/32431,2018-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2635,1875,2023-11-21 00:00:00.000000,Comparing the effect of groups reminiscence therapy on loneliness and spiritual well-being of elderly men,,http://en.irct.ir/trial/31858,2018-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2636,1874,2023-11-21 00:00:00.000000,Mindful or mind-full? An eight-week program on mental health and quality of life in people with multiple sclerosis,,https://anzctr.org.au/ACTRN12618001922268.aspx,2018-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2637,1873,2023-11-21 00:00:00.000000,Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03756142,2018-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2638,1872,2023-11-21 00:00:00.000000,Cell Surface Marker Expression in Autoimmune Diseases,,https://clinicaltrials.gov/show/NCT03757065,2018-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2639,1871,2023-11-21 00:00:00.000000,Sleep Medical Treatment in MS Patients Suffering From Fatigue,,https://clinicaltrials.gov/show/NCT03759249,2018-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2640,1870,2023-11-21 00:00:00.000000,Effects of fingolimod in treatment of multiple sclerosis,,http://en.irct.ir/trial/33624,2018-11-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2641,1869,2023-11-21 00:00:00.000000,The effect of exercise and royal jelly on inflammatory factors in multiple sclerosis patients,,http://en.irct.ir/trial/33323,2018-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2642,1868,2023-11-21 00:00:00.000000,Cognition and MRI Markers in MS Patients With Aubagio® Treatment,,https://clinicaltrials.gov/show/NCT03768648,2018-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2643,1867,2023-11-21 00:00:00.000000,Muscle Architecture of Lower Extremity In Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03766698,2018-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2644,1866,2023-11-21 00:00:00.000000,MBCT and CBT for Chronic Pain in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03782246,2018-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2645,1865,2023-11-21 00:00:00.000000,Vaginal Estriol in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03774407,2018-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2646,1864,2023-11-21 00:00:00.000000,"Impact of Exercise on ""Invisible"" Symptoms and Quality of Life in Multiple Sclerosis Individuals",,https://clinicaltrials.gov/show/NCT03768830,2018-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2647,1863,2023-11-21 00:00:00.000000,SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03783416,2018-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2648,1862,2023-11-21 00:00:00.000000,LEMTRADA Pregnancy Registry in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03774914,2018-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2649,1861,2023-11-21 00:00:00.000000,Isokinetic Exercises in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03779724,2018-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2650,1860,2023-11-21 00:00:00.000000,The effect of exercise and royal jelly on liver enzymes in multiple sclerosis patients,,http://en.irct.ir/trial/33321,2018-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2651,1859,2023-11-21 00:00:00.000000,A study to evaluate the safety and tolerability of an investigational transdermal patch containing Fingolimod in healthy volunteers.,,https://anzctr.org.au/ACTRN12618002016213.aspx,2018-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2652,1858,2023-11-21 00:00:00.000000,Mind-body interventions in patients with multiple sclerosis,,https://anzctr.org.au/ACTRN12618002024224.aspx,2018-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2653,1857,2023-11-21 00:00:00.000000,Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique,,https://clinicaltrials.gov/show/NCT03847545,2018-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2654,1856,2023-11-21 00:00:00.000000,Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada,,https://clinicaltrials.gov/show/NCT03784898,2018-12-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2655,1855,2023-11-21 00:00:00.000000,Effects of Aerobic and Isokinetic Exercise in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03805061,2018-12-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2656,1854,2023-11-21 00:00:00.000000,Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03949296,2018-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2657,1853,2023-11-21 00:00:00.000000,"German translation, cultural adaption and validation of the Unidimensional Self-Efficacy scale for Multiple Sclerosis and validation of the Neurological Fatigue Index for Multiple Sclerosis",,https://www.isrctn.com/ISRCTN14843579,2019-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2658,1852,2023-11-21 00:00:00.000000,Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03796611,2019-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2659,1851,2023-11-21 00:00:00.000000,Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event,,https://clinicaltrials.gov/show/NCT03796247,2019-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2660,1850,2023-11-21 00:00:00.000000,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,,https://clinicaltrials.gov/show/NCT03799718,2019-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2661,1849,2023-11-21 00:00:00.000000,Assessing Fatiguability of Tongue Muscles in MS,,https://clinicaltrials.gov/show/NCT03817073,2019-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2662,1848,2023-11-21 00:00:00.000000,Aspirin for Exercise in Multiple Sclerosis (ASPIRE),,https://clinicaltrials.gov/show/NCT03824938,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2663,1847,2023-11-21 00:00:00.000000,Effectiveness of a long term training program through a wearable exoskeleton in persons with multiple sclerosis on gait velocity,,https://anzctr.org.au/ACTRN12619000014156.aspx,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2664,1846,2023-11-21 00:00:00.000000,Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03801473,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2665,1845,2023-11-21 00:00:00.000000,Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment,,https://clinicaltrials.gov/ct2/show/NCT03806387,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2666,1844,2023-11-21 00:00:00.000000,Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03803800,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2667,1843,2023-11-21 00:00:00.000000,PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon,,https://clinicaltrials.gov/show/NCT03808142,2019-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2668,1842,2023-11-21 00:00:00.000000,Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products,,https://clinicaltrials.gov/show/NCT03886753,2019-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2669,1841,2023-11-21 00:00:00.000000,The effect of self-care education on self-concept and self-efficacy in patients with multiple sclerosis,,http://en.irct.ir/trial/34064,2019-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2670,1840,2023-11-21 00:00:00.000000,PET With [18F]Flumazenil as an Index of Neurodegeneration in MS,,https://clinicaltrials.gov/show/NCT03825601,2019-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2671,1839,2023-11-21 00:00:00.000000,LoveYourBrain Yoga for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03827928,2019-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2672,1838,2023-11-21 00:00:00.000000,Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03822858,2019-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2673,1837,2023-11-21 00:00:00.000000,Evaluation of serum-biomarkers as a surrogate marker for florid MS lesions (contrast enhancement) in patients with multiple sclerosis.,,http://drks.de/search/en/trial/DRKS00016029,2019-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2674,1836,2023-11-21 00:00:00.000000,Understanding Magnetic Resonance Imaging in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03872583,2019-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2675,1835,2023-11-21 00:00:00.000000,Effect of progressive muscle relaxation technique on self-esteem and self-efficacy.,,http://en.irct.ir/trial/35061,2019-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2676,1834,2023-11-21 00:00:00.000000,Effectiveness of Mindfulness-Integrated Cognitive Behaviour Therapy and Schema Therapy on the Emotional States and the Quality of life of People with Multiple Sclerosis,,http://en.irct.ir/trial/36533,2019-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2677,1833,2023-11-21 00:00:00.000000,Inspiratory Muscle Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03887546,2019-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2678,1832,2023-11-21 00:00:00.000000,Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03825055,2019-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2679,1831,2023-11-21 00:00:00.000000,Neurology Inpatient Clinical Education Trial,,https://clinicaltrials.gov/show/NCT03826056,2019-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2680,1830,2023-11-21 00:00:00.000000,eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS,,https://clinicaltrials.gov/show/NCT03829267,2019-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2681,1829,2023-11-21 00:00:00.000000,Comparison the Effectiveness of Mindfulness Based Cognitive Therapy and Short-Term Axis-based treatment as Therapeutic Supplements with Drug Therapy in Improving the Quality of Life in Multiple Sclerosis Patients .____________________________________________________________________________,,http://en.irct.ir/trial/35938,2019-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2682,1828,2023-11-21 00:00:00.000000,Exergaming in Persons With Multiple Sclerosis With Restless Legs Syndrome,,https://clinicaltrials.gov/show/NCT03878810,2019-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2683,1827,2023-11-21 00:00:00.000000,Exploring the Comorbidity Between Mental Disorders and General Medical Conditions,,https://clinicaltrials.gov/show/NCT03847753,2019-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2684,1826,2023-11-21 00:00:00.000000,The effect of spiritual care versus without spiritual care on death anxiety and self-esteem in multiple sclerosis patients,,http://en.irct.ir/trial/37132,2019-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2685,1825,2023-11-21 00:00:00.000000,Spinal Cord Analysis in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03841903,2019-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2686,1824,2023-11-21 00:00:00.000000,"Turkish Version of Mini-BESTest, Validity and Reliability for Adult Participants With Sensoriomotor Impairments",,https://clinicaltrials.gov/show/NCT03839381,2019-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2687,1823,2023-11-21 00:00:00.000000,Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03856801,2019-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2688,1822,2023-11-21 00:00:00.000000,Community Exercise for persons with multiple sclerosis,,https://anzctr.org.au/ACTRN12619000228189.aspx,2019-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2689,1821,2023-11-21 00:00:00.000000,Adherence in neurogeriatric patients,,http://drks.de/search/en/trial/DRKS00016774,2019-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2690,1820,2023-11-21 00:00:00.000000,Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS,,https://clinicaltrials.gov/show/NCT03849001,2019-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2691,1819,2023-11-21 00:00:00.000000,Long term monitoring of multiple sclerosis patients on cladribine treatment,,https://anzctr.org.au/ACTRN12619000257167.aspx,2019-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2692,1818,2023-11-21 00:00:00.000000,Short-term B-cell Depletion in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03853746,2019-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2693,1817,2023-11-21 00:00:00.000000,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03856619,2019-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2694,1816,2023-11-21 00:00:00.000000,G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03980145,2019-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2695,1815,2023-11-21 00:00:00.000000,Sarcopenic Obesity in Neurodisabilities,,https://clinicaltrials.gov/show/NCT03863379,2019-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2696,1814,2023-11-21 00:00:00.000000,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03889639,2019-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2697,1813,2023-11-21 00:00:00.000000,A study on TeriFlunomidE for multiple sclerosis patients to understand the safety and clinical profile.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27726,2019-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2698,1812,2023-11-21 00:00:00.000000,tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03870048,2019-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2699,1811,2023-11-21 00:00:00.000000,Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients,,https://clinicaltrials.gov/show/NCT03887065,2019-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2700,1810,2023-11-21 00:00:00.000000,Open-label randomized controlled trials on the superiority of ultrasonic instruments in peripheral vascular access procedures in apheresis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041091,2019-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2701,1809,2023-11-21 00:00:00.000000,"Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) study with ENX-201",,https://www.onderzoekmetmensen.nl/en/trial/23997,2019-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2702,1808,2023-11-21 00:00:00.000000,Ocrelizumab Effects on the Metabolome in MS,,https://clinicaltrials.gov/show/NCT03873389,2019-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2703,1807,2023-11-21 00:00:00.000000,The effect of cognitive-behavioral intervention in MS patients,,http://en.irct.ir/trial/31068,2019-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2704,1806,2023-11-21 00:00:00.000000,Multi-center Database Registry to Study Thalamus Changes Using AI in MS,,https://clinicaltrials.gov/show/NCT03920995,2019-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2705,1805,2023-11-21 00:00:00.000000,"An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS",,https://jrct.niph.go.jp/latest-detail/jRCT2080224590,2019-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2706,1804,2023-11-21 00:00:00.000000,The effects of electrical stimulation treatment on adults with MS with swallowing problems,,https://anzctr.org.au/ACTRN12619000414112.aspx,2019-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2707,1803,2023-11-21 00:00:00.000000,The effect of bromelain on patients with Multiple sclerosis,,http://en.irct.ir/trial/38051,2019-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2708,1802,2023-11-21 00:00:00.000000,The impacts of a peer-led and a nurse-led self-management program on the subject well-being,,http://en.irct.ir/trial/38049,2019-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2709,1801,2023-11-21 00:00:00.000000,Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosis,,https://jrct.niph.go.jp/latest-detail/jRCTs031180346,2019-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2710,1800,2023-11-21 00:00:00.000000,Vojta Therapy in Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT03887507,2019-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2711,1799,2023-11-21 00:00:00.000000,Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.,,https://clinicaltrials.gov/show/NCT04095377,2019-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2712,1798,2023-11-21 00:00:00.000000,STAT4 in Multiple Sclerosis by PCR and Flow Cytometry,,https://clinicaltrials.gov/show/NCT03893344,2019-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2713,1797,2023-11-21 00:00:00.000000,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,,https://clinicaltrials.gov/show/NCT03941184,2019-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2714,1796,2023-11-21 00:00:00.000000,Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS,,https://clinicaltrials.gov/show/NCT03906370,2019-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2715,1795,2023-11-21 00:00:00.000000,"Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients",,https://clinicaltrials.gov/show/NCT04115930,2019-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2716,1794,2023-11-21 00:00:00.000000,Comparative assessment of the absorption of a generic formulation of dimethyl fumarate capsule  against the innovator dimethyl fumarate capsule  conducted under fasting condition in healthy male and female volunteers.,,https://anzctr.org.au/ACTRN12619000576123.aspx,2019-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2717,1793,2023-11-21 00:00:00.000000,Sit Less or Exercise More: Impact on Cardiometabolic Health in MS,,https://clinicaltrials.gov/show/NCT03919058,2019-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2718,1792,2023-11-21 00:00:00.000000,Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS),,https://clinicaltrials.gov/show/NCT03917589,2019-12-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2719,1791,2023-11-21 00:00:00.000000,Balance in MS patients,,http://en.irct.ir/trial/35940,2019-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2720,1790,2023-11-21 00:00:00.000000,Measuring Gait Variability in Multiple Sclerosis (MS): exploring new markers for clinical monitoring,,http://drks.de/search/en/trial/DRKS00016156,2019-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2721,1789,2023-11-21 00:00:00.000000,Comparative study of effects and tolerability of Solifenacin and Oxybutynin on the urinary symptoms of multiple sclerosis patients.,,http://en.irct.ir/trial/38532,2019-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2722,1788,2023-11-21 00:00:00.000000,Behavioural Activation for Low Mood in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03935529,2019-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2723,1787,2023-11-21 00:00:00.000000,PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.,,https://clinicaltrials.gov/ct2/show/NCT03942952,2019-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2724,1786,2023-11-21 00:00:00.000000,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03926637,2019-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2725,1785,2023-11-21 00:00:00.000000,Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire,,https://clinicaltrials.gov/show/NCT03927092,2019-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2726,1784,2023-11-21 00:00:00.000000,Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-Onset Multiple Sclerosis (POMS),,https://clinicaltrials.gov/show/NCT03933020,2019-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2727,1783,2023-11-21 00:00:00.000000,Sonification Embodied Associations,,https://clinicaltrials.gov/show/NCT03931278,2019-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2728,1782,2023-11-21 00:00:00.000000,"""Effect of Acceptance and Commitment Treatment in MS Patients""",,http://en.irct.ir/trial/35450,2019-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2729,1781,2023-11-21 00:00:00.000000,The effect of mobile-based self-care program on motor disorders and activity daily living of people with MS,,http://en.irct.ir/trial/38546,2019-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2730,1780,2023-11-21 00:00:00.000000,Emotion Regulation Skills Training for Individuals With MS and Their Support Partners,,https://clinicaltrials.gov/show/NCT03934489,2019-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2731,1779,2023-11-21 00:00:00.000000,A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2),,https://clinicaltrials.gov/ct2/show/NCT03933202,2019-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2732,1778,2023-11-21 00:00:00.000000,A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS),,https://clinicaltrials.gov/ct2/show/NCT03933215,2019-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2733,1777,2023-11-21 00:00:00.000000,Art for MS - Controlled Trial,,https://clinicaltrials.gov/show/NCT03938558,2019-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2734,1776,2023-11-21 00:00:00.000000,Physical Activity Intervention for Improving Vascular Comorbidity Risk in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03944538,2019-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2735,1775,2023-11-21 00:00:00.000000,Exergames Balance Program in Neurorehabilitation,,https://clinicaltrials.gov/show/NCT03993275,2019-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2736,1774,2023-11-21 00:00:00.000000,Life-Style Exercise and Activity Package for People Living With Progressive MS,,https://clinicaltrials.gov/show/NCT03951181,2019-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2737,1773,2023-11-21 00:00:00.000000,"Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence",,https://clinicaltrials.gov/show/NCT03945006,2019-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2738,1772,2023-11-21 00:00:00.000000,Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program,,https://clinicaltrials.gov/ct2/show/NCT03954717,2019-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2739,1771,2023-11-21 00:00:00.000000,Interactive Web Platform for EmPOWERment in Early Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03968172,2019-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2740,1770,2023-11-21 00:00:00.000000,Intermittent vs Continuous Walking in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03963492,2019-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2741,1769,2023-11-21 00:00:00.000000,Effect Reflexology and  Ef?eurage   on  fatigue and insomnia,,http://en.irct.ir/trial/39022,2019-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2742,1768,2023-11-21 00:00:00.000000,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),,https://clinicaltrials.gov/ct2/show/NCT03961204,2019-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2743,1767,2023-11-21 00:00:00.000000,Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03963375,2019-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2744,1766,2023-11-21 00:00:00.000000,"AN OPEN-LABEL EXTENSION STUDY EVALUATING LONG-TERM SAFETY, TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RMS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=003-19,2019-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2745,1765,2023-11-21 00:00:00.000000,Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03975413,2019-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2746,1764,2023-11-21 00:00:00.000000,"RIPC on Activity, Fatigue and Gait in MS",,https://clinicaltrials.gov/show/NCT03967106,2019-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2747,1763,2023-11-21 00:00:00.000000,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT03972306,2019-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2748,1762,2023-11-21 00:00:00.000000,Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03983252,2019-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2749,1761,2023-11-21 00:00:00.000000,Endurance and Walking Training by Nordic Walking in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03976128,2019-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2750,1760,2023-11-21 00:00:00.000000,RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS,,https://clinicaltrials.gov/show/NCT03979456,2019-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2751,1759,2023-11-21 00:00:00.000000,Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03974997,2019-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2752,1758,2023-11-21 00:00:00.000000,A Pilot Nutrition Program for Spinal Cord Injury and MS,,https://clinicaltrials.gov/show/NCT03977922,2019-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2753,1757,2023-11-21 00:00:00.000000,Comparison of effectiveness and complication of rituximab and fingolimod in  improvement disability motion,,http://en.irct.ir/trial/38158,2019-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2754,1756,2023-11-21 00:00:00.000000,Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03995810,2019-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2755,1755,2023-11-21 00:00:00.000000,"The effect of ajwain, viper’s bugloss and cinnamon product on  multiple sclerosis patients",,http://en.irct.ir/trial/37120,2019-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2756,1754,2023-11-21 00:00:00.000000,Open-Label Placebos to Treat Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04002102,2019-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2757,1753,2023-11-21 00:00:00.000000,3 Meter Backwards Walk Test and Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04004026,2019-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2758,1752,2023-11-21 00:00:00.000000,Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04009005,2019-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2759,1751,2023-11-21 00:00:00.000000,A Wheelchair Propulsion Training Program,,https://clinicaltrials.gov/show/NCT04009187,2019-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2760,1750,2023-11-21 00:00:00.000000,Investigation for immune response against JC virus in Multiple Sclerosis patients on treatment with fingolimod,,https://jrct.niph.go.jp/latest-detail/jRCT1080224761,2019-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2761,1749,2023-11-21 00:00:00.000000,The effect of salimarin in patients with multiple sclerosis,,http://en.irct.ir/trial/35513,2019-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2762,1748,2023-11-21 00:00:00.000000,tDCS and Glucose Uptake in Leg Muscles,,https://clinicaltrials.gov/show/NCT04016844,2019-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2763,1747,2023-11-21 00:00:00.000000,Efficacy of transcranial direct current stimulation (tDCS) on the treatment of neurological diseases,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042544,2019-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2764,1746,2023-11-21 00:00:00.000000,Individualized Physiotherapy and Activity Coaching for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04027114,2019-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2765,1745,2023-11-21 00:00:00.000000,Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers,,https://clinicaltrials.gov/show/NCT04022473,2019-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2766,1744,2023-11-21 00:00:00.000000,Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04024085,2019-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2767,1743,2023-11-21 00:00:00.000000,Upper Limb Telerehabilitation With Virtual Reality in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04032431,2019-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2768,1742,2023-11-21 00:00:00.000000,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04025554,2019-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2769,1741,2023-11-21 00:00:00.000000,Cerebral Blood Flow and tDCS,,https://clinicaltrials.gov/show/NCT04033133,2019-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2770,1740,2023-11-21 00:00:00.000000,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04032171,2019-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2771,1739,2023-11-21 00:00:00.000000,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/show/NCT04032158,2019-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2772,1738,2023-11-21 00:00:00.000000,Prospective Stratification of Infectious Risks in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04036097,2019-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2773,1737,2023-11-21 00:00:00.000000,Melatonin for Sleep in MS,,https://clinicaltrials.gov/show/NCT04035889,2019-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2774,1736,2023-11-21 00:00:00.000000,Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04062331,2019-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2775,1735,2023-11-21 00:00:00.000000,Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04096443,2019-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2776,1734,2023-11-21 00:00:00.000000,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis (Feasibility Study),,https://clinicaltrials.gov/show/NCT04057066,2019-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2777,1733,2023-11-21 00:00:00.000000,"The effects of postural trainingwith cerebellar a-tDCS on balance, static and dynamic postural stability and fear of falling in patients with Multiple Sclerosis",,http://en.irct.ir/trial/40794,2019-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2778,1732,2023-11-21 00:00:00.000000,The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS,,https://clinicaltrials.gov/show/NCT04075968,2019-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2779,1731,2023-11-21 00:00:00.000000,The effect of training on MS,,http://en.irct.ir/trial/40054,2019-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2780,1730,2023-11-21 00:00:00.000000,Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04056897,2019-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2781,1729,2023-11-21 00:00:00.000000,Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04057222,2019-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2782,1728,2023-11-21 00:00:00.000000,The quality of life of multiple sclerosis patients in Europe,,http://isrctn.com/ISRCTN78466206,2019-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2783,1727,2023-11-21 00:00:00.000000,Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study,,https://clinicaltrials.gov/show/NCT04061681,2019-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2784,1726,2023-11-21 00:00:00.000000,"bioequivalence study of Fampiridine 10mg tablet of AlborzDarou Pharm Co., IRAN",,http://en.irct.ir/trial/41499,2019-08-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2785,1725,2023-11-21 00:00:00.000000,PTNS on Urinary and Global Quality of Life in MS Patients,,https://clinicaltrials.gov/show/NCT04063852,2019-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2786,1724,2023-11-21 00:00:00.000000,Vigorous Cool Room Treadmill Training,,https://clinicaltrials.gov/show/NCT04066972,2019-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2787,1723,2023-11-21 00:00:00.000000,Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04074629,2019-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2788,1722,2023-11-21 00:00:00.000000,Magnetic brain stimulation for multiple sclerosis trial,,https://anzctr.org.au/ACTRN12619001196134.aspx,2019-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2789,1721,2023-11-21 00:00:00.000000,The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04113135,2019-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2790,1720,2023-11-21 00:00:00.000000,Effects of stretching exercises in patients with Multiple Sclerosis,,http://en.irct.ir/trial/40523,2019-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2791,1719,2023-11-21 00:00:00.000000,Effect of Ankle-foot Orthoses on Balance Confidence,,https://clinicaltrials.gov/show/NCT04080687,2019-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2792,1718,2023-11-21 00:00:00.000000,The effect of sexual health education on sexual dysfunction and sexual quality of life in women with multiple sclerosis,,http://en.irct.ir/trial/41014,2019-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2793,1717,2023-11-21 00:00:00.000000,Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/show/NCT04079088,2019-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2794,1716,2023-11-21 00:00:00.000000,"A cognitive, occupation-based programme for people with multiple sclerosis (COB-MS)",,https://www.isrctn.com/ISRCTN11462710,2019-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2795,1715,2023-11-21 00:00:00.000000,VALIDATE: Factor VIII Trending for MS Relapse,,https://clinicaltrials.gov/show/NCT04082468,2019-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2796,1714,2023-11-21 00:00:00.000000,Impaired Glucose Tolerance and Cognition in MS,,https://clinicaltrials.gov/show/NCT04748302,2019-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2797,1713,2023-11-21 00:00:00.000000,Evaluation of Therapeutic and safety of clemastine fumarate in symptoms and quality of life in secondry Relapsing MS patients,,http://en.irct.ir/trial/32708,2019-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2798,1712,2023-11-21 00:00:00.000000,Improving wellbeing after acquired brain injury with a group program to enhance participation in valued activities,,https://anzctr.org.au/ACTRN12619001243101.aspx,2019-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2799,1711,2023-11-21 00:00:00.000000,Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®,,https://clinicaltrials.gov/show/NCT04115488,2019-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2800,1710,2023-11-21 00:00:00.000000,Detection of Pattern of Some Unusual Signs and Symptoms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04100343,2019-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2801,1709,2023-11-21 00:00:00.000000,Intervention for Employed Women With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04100525,2019-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2802,1708,2023-11-21 00:00:00.000000,Scan-Rescan Sub-Study of MS PATHS,,https://clinicaltrials.gov/show/NCT04123353,2019-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2803,1707,2023-11-21 00:00:00.000000,Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04120675,2019-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2804,1706,2023-11-21 00:00:00.000000,Relationship Between the Nutritional Habits and Relapsing and Disability Rates in Patient With Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT04110171,2019-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2805,1705,2023-11-21 00:00:00.000000,Effectiveness of an emotion-focused behavioral treatment program for adults with multiple sclerosis,,https://www.isrctn.com/ISRCTN95459505,2019-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2806,1704,2023-11-21 00:00:00.000000,Compare the effect of acupressure and aromatherapy on pain of knee in patients with multiple sclerosis (MS),,http://en.irct.ir/trial/35033,2019-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2807,1703,2023-11-21 00:00:00.000000,M-health app for rehabilitation of patients with Multiple Sclerosis.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36870,2019-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2808,1702,2023-11-21 00:00:00.000000,"Arts & Health Education to Improve Health, Resilience, and Well-Being",,https://clinicaltrials.gov/show/NCT04154579,2019-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2809,1701,2023-11-21 00:00:00.000000,VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study,,https://clinicaltrials.gov/show/NCT04116424,2019-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2810,1700,2023-11-21 00:00:00.000000,Observational Study on Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04133779,2019-04-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2811,1699,2023-11-21 00:00:00.000000,"An Eight-week RCT of Home-based Pilates for Symptoms of Anxiety, Depression, and Fatigue Among People With MS",,https://clinicaltrials.gov/show/NCT04120207,2019-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2812,1698,2023-11-21 00:00:00.000000,Exercise on Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04125628,2019-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2813,1697,2023-11-21 00:00:00.000000,To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT04121637,2019-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2814,1696,2023-11-21 00:00:00.000000,Validation of a Shared Decision-Making Tool for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04122989,2019-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2815,1695,2023-11-21 00:00:00.000000,An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04132037,2019-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2816,1694,2023-11-21 00:00:00.000000,Video Game-based Physical Activity Training in People With Multiple Sclerosis During Relapse Treatment,,https://clinicaltrials.gov/show/NCT04125823,2019-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2817,1693,2023-11-21 00:00:00.000000,FMT for MS Patients,,https://clinicaltrials.gov/show/NCT04150549,2019-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2818,1692,2023-11-21 00:00:00.000000,MS and NMOSD in African-Americans,,https://clinicaltrials.gov/show/NCT04131673,2019-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2819,1691,2023-11-21 00:00:00.000000,Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04129736,2019-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2820,1690,2023-11-21 00:00:00.000000,Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04130256,2019-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2821,1689,2023-11-21 00:00:00.000000,Diagnosis of ON With or Without MS or NMOSD,,https://clinicaltrials.gov/show/NCT04131764,2019-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2822,1688,2023-11-21 00:00:00.000000,Advancing Understanding of Transportation Options,,https://clinicaltrials.gov/show/NCT04141891,2019-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2823,1687,2023-11-21 00:00:00.000000,Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04265092,2019-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2824,1686,2023-11-21 00:00:00.000000,The effect of lavender on balance a persons with multiple sclerosis,,http://en.irct.ir/trial/42133,2019-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2825,1685,2023-11-21 00:00:00.000000,Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063),,https://clinicaltrials.gov/ct2/show/NCT04140305,2019-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2826,1684,2023-11-21 00:00:00.000000,"Underlying Causes and Related Factors, and Rehabilitation Approaches",,https://clinicaltrials.gov/show/NCT04142853,2019-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2827,1683,2023-11-21 00:00:00.000000,Walk With Me: a Mobile Application to Improve Walking in Persons With MS,,https://clinicaltrials.gov/show/NCT04142008,2019-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2828,1682,2023-11-21 00:00:00.000000,iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04147052,2019-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2829,1681,2023-11-21 00:00:00.000000,Pilates training improved functional balance of male patients with Multiple Sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043791,2019-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2830,1680,2023-11-21 00:00:00.000000,Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS,,https://clinicaltrials.gov/show/NCT04145284,2019-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2831,1679,2023-11-21 00:00:00.000000,A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS,,https://clinicaltrials.gov/show/NCT04145934,2019-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2832,1678,2023-11-21 00:00:00.000000,Effects of Activity Based Interventions on  Performance  in People with Multiple Sclerosis,,http://en.irct.ir/trial/36554,2019-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2833,1677,2023-11-21 00:00:00.000000,Effectiveness of  a cost effective cognitive behavioural program on improvement mentall health in MS,,http://en.irct.ir/trial/40779,2019-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2834,1676,2023-11-21 00:00:00.000000,OCT and Early Cognitive Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04153773,2019-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2835,1675,2023-11-21 00:00:00.000000,Cognitive-motor Interference in Persons With MS,,https://clinicaltrials.gov/show/NCT04158063,2019-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2836,1674,2023-11-21 00:00:00.000000,MS JobSeek: harnessing peer support to help job-seekers with multiple sclerosis find employment.,,https://anzctr.org.au/ACTRN12619001537145.aspx,2019-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2837,1673,2023-11-21 00:00:00.000000,Emotion-focused cost-effective cognitive behavioral intervention for multiple sclerosis,,http://isrctn.com/ISRCTN16135866,2019-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2838,1672,2023-11-21 00:00:00.000000,"Detecting Multiple Sclerosis via breath analysis using an eNose, a pilot study",,https://www.onderzoekmetmensen.nl/en/trial/28252,2019-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2839,1671,2023-11-21 00:00:00.000000,Semi-inmersive Virtual Reality on Upper Limb in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04171908,2019-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2840,1670,2023-11-21 00:00:00.000000,Effect of exercise on immune and inflammatory factors in MS patients,,http://en.irct.ir/trial/42785,2019-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2841,1669,2023-11-21 00:00:00.000000,Minocycline in MS: Confirmation of Benefit,,https://clinicaltrials.gov/show/NCT04291456,2019-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2842,1668,2023-11-21 00:00:00.000000,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,,https://clinicaltrials.gov/show/NCT04171310,2019-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2843,1667,2023-11-21 00:00:00.000000,Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04175054,2019-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2844,1666,2023-11-21 00:00:00.000000,The Effects of Two Different Types of Exercise Programs to Increase Physical Activity in Patients With MS,,https://clinicaltrials.gov/show/NCT04175418,2019-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2845,1665,2023-11-21 00:00:00.000000,Cladribine Tablets After Treatment With Natalizumab (CLADRINA),,https://clinicaltrials.gov/ct2/show/NCT04178005,2019-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2846,1664,2023-11-21 00:00:00.000000,Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab,,https://clinicaltrials.gov/show/NCT04175834,2019-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2847,1663,2023-11-21 00:00:00.000000,Comparing the Effects of Two High-Intensity Functional Exercise Protocols (HIFT) and Aerobic Exercise on Functional Fitness and Psychological Factors in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/39613,2019-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2848,1662,2023-11-21 00:00:00.000000,Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04178980,2019-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2849,1661,2023-11-21 00:00:00.000000,Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04182269,2019-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2850,1660,2023-11-21 00:00:00.000000,The safety and cost-effectiveness of discontinuing disease-modifying therapies in relapsing-onset multiple sclerosis (DOT-MS): a randomized rater-blinded multicenter trial.,,https://www.onderzoekmetmensen.nl/en/trial/21462,2019-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2851,1659,2023-11-21 00:00:00.000000,A study of biosimilar Natalizumab in comparision to Tysabri in Patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004751-20,2019-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2852,1658,2023-11-21 00:00:00.000000,The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04185688,2019-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2853,1657,2023-11-21 00:00:00.000000,HD-tDCS to Enhance Cognitive Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04261556,2019-04-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2854,1656,2023-11-21 00:00:00.000000,The Impact of Training on Sitting Time and Brain Volumes in Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT04191772,2019-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2855,1655,2023-11-21 00:00:00.000000,Patient Experiences of Multiple Sclerosis (PExMS),,https://clinicaltrials.gov/show/NCT04236544,2019-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2856,1654,2023-11-21 00:00:00.000000,Acceptance Based Telephone Support When Transitioning to SPMS,,https://clinicaltrials.gov/show/NCT04239664,2019-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2857,1653,2023-11-21 00:00:00.000000,Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study,,https://clinicaltrials.gov/show/NCT04386863,2019-09-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2858,1652,2023-11-21 00:00:00.000000,Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04201470,2019-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2859,1651,2023-11-21 00:00:00.000000,"Effect of Manuel Therapy on Tonus, Proprioseption and Balance in Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04201691,2019-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2860,1650,2023-11-21 00:00:00.000000,Association Between Fatigue and Balance in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04215354,2019-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2861,1649,2023-11-21 00:00:00.000000,Efficacy and Safety of OCH-NCNP1 in patients with Relapsing Multiple Sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044202,2019-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2862,1648,2023-11-21 00:00:00.000000,Immunologic Biomarker Profile of Cerebrospinal Fluid,,https://clinicaltrials.gov/show/NCT04202055,2019-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2863,1647,2023-11-21 00:00:00.000000,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,,https://clinicaltrials.gov/ct2/show/NCT04306939,2019-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2864,1646,2023-11-21 00:00:00.000000,Phase II Clinical Trial of OCH-NCNP1,,https://clinicaltrials.gov/ct2/show/NCT04211740,2019-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2865,1645,2023-11-21 00:00:00.000000,"The Effect of a Cognitive-motor program on balance and gait, quality of life, and stress management in patients with multiple sclerosis",,http://en.irct.ir/trial/41241,2019-12-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2866,1644,2023-11-21 00:00:00.000000,Multiple Sclerosis: Chi3L1 and Treatment Efficacy,,https://clinicaltrials.gov/show/NCT04289675,2019-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2867,1643,2023-11-21 00:00:00.000000,Nutritional Counselling for Patients at Kasr AlAiny Multiple Sclerosis Clinic: an Intervention Study,,https://clinicaltrials.gov/show/NCT04217564,2019-12-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2868,1642,2023-11-21 00:00:00.000000,Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04233970,2020-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2869,1641,2023-11-21 00:00:00.000000,"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP",,https://clinicaltrials.gov/ct2/show/NCT04221191,2020-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2870,1640,2023-11-21 00:00:00.000000,Metacognition Assessment in Patient With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04240379,2020-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2871,1639,2023-11-21 00:00:00.000000,Exercise in Progressive Multiple Sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/29122,2020-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2872,1638,2023-11-21 00:00:00.000000,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,,https://clinicaltrials.gov/show/NCT04237337,2020-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2873,1637,2023-11-21 00:00:00.000000,The Comparison of the Effect of Self-Care Education Based on Team Members Teaching Design and lecture on Quality of Life and Self-efficacy in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/37221,2020-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2874,1636,2023-11-21 00:00:00.000000,""" Return to Work? Effectiveness of medico-occupational rehabilitation and health care costs after the use of occupational-oriented concepts in neurological rehabilitation"".",,http://drks.de/search/en/trial/DRKS00019915,2020-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2875,1635,2023-11-21 00:00:00.000000,"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",,https://clinicaltrials.gov/show/NCT04239521,2020-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2876,1634,2023-11-21 00:00:00.000000,"Effect of ""Jollab-e-monzej"" for the treatment of MS-related fatigue",,http://en.irct.ir/trial/41920,2020-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2877,1633,2023-11-21 00:00:00.000000,MUltiple Sclerosis : T Cell / B Cell Exploration,,https://clinicaltrials.gov/show/NCT04231253,2020-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2878,1632,2023-11-21 00:00:00.000000,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,,https://clinicaltrials.gov/show/NCT04230174,2020-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2879,1631,2023-11-21 00:00:00.000000,Transcranial direct current stimulation in neurological disorders,,https://jrct.niph.go.jp/latest-detail/jRCTs042190106,2020-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2880,1630,2023-11-21 00:00:00.000000,A Dyadic Approach for Promoting Physical Activity Among People With MS and Their Support Partners,,https://clinicaltrials.gov/show/NCT04267185,2020-01-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2881,1629,2023-11-21 00:00:00.000000,A Clinical Trial Examining the Effects of Temelimab Following Rituximab Treatment in Patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004822-15,2020-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2882,1628,2023-11-21 00:00:00.000000,Effect of Fingolimod with and without probiotic and vitamin E on the liver complications of in patients with relapsing-remitting multiple sclerosis,,http://en.irct.ir/trial/44877,2020-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2883,1627,2023-11-21 00:00:00.000000,Effect of Cladribine Treatment on Microglial Activation in the CNS,,https://clinicaltrials.gov/show/NCT04239820,2020-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2884,1626,2023-11-21 00:00:00.000000,To Study the Pathophysiological Features of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04242056,2020-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2885,1625,2023-11-21 00:00:00.000000,Pilot Study for the Evaluation of the More Stamina in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04244214,2020-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2886,1624,2023-11-21 00:00:00.000000,Investigating of Silybum marianum fruit extract on MS fatigue,,http://en.irct.ir/trial/44864,2020-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2887,1623,2023-11-21 00:00:00.000000,Studying the Effect of Cinnamon Oral Drop on Balance and Fear of Falling in Patients with Multiple Sclerosis (MS),,http://en.irct.ir/trial/39673,2020-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2888,1622,2023-11-21 00:00:00.000000,The Effects of Pilates-Based Core Stabilization Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04252053,2020-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2889,1621,2023-11-21 00:00:00.000000,Finding the right balance with participation in exercise and sport for individuals with multiple sclerosis,,https://anzctr.org.au/ACTRN12620000076976.aspx,2020-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2890,1620,2023-11-21 00:00:00.000000,The Effect Of Spiritual Counseling On Happiness And Hope Among M.S Patients,,http://en.irct.ir/trial/41672,2020-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2891,1619,2023-11-21 00:00:00.000000,Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS,,https://clinicaltrials.gov/show/NCT04255953,2020-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2892,1618,2023-11-21 00:00:00.000000,Out of Pocket Cost Communication in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04257071,2020-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2893,1617,2023-11-21 00:00:00.000000,Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04261790,2020-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2894,1616,2023-11-21 00:00:00.000000,Functional Exercise in Virtual Environment for Persons With Multiple Sclerosis or Parkinson's Disease,,https://clinicaltrials.gov/show/NCT04266444,2020-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2895,1615,2023-11-21 00:00:00.000000,The Effectiveness of Acceptance and Commitment Therapy for Reducing Interference and improving Verbal and Visual Working Memory in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/45234,2020-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2896,1614,2023-11-21 00:00:00.000000,Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).,,https://clinicaltrials.gov/show/NCT04295616,2020-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2897,1613,2023-11-21 00:00:00.000000,bupropion therapy in multiple sclerosis patient,,http://en.irct.ir/trial/38591,2020-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2898,1612,2023-11-21 00:00:00.000000,Examining the efficacy of an Online Cognitive Behaviour Therapy (CBT) - based self-management Program for Adults with Neurological Disorders.,,https://anzctr.org.au/ACTRN12620000165987.aspx,2020-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2899,1611,2023-11-21 00:00:00.000000,"Effects of Ten-Weeks Power Training on Neuromuscular Performance, Heart Rate Variability, Sleep Quality and Mobility in Persons With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04276324,2020-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2900,1610,2023-11-21 00:00:00.000000,Acute Intermittent Hypoxia in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04280484,2020-02-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2901,1609,2023-11-21 00:00:00.000000,"Position Sense, Balance, and Dual Task Performance at the Menstrual Cycle in Females With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04286828,2020-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2902,1608,2023-11-21 00:00:00.000000,Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS),,https://clinicaltrials.gov/show/NCT04289909,2020-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2903,1607,2023-11-21 00:00:00.000000,Evaluation of exercise plus brain stimulation on gait of patients with multiple sclerosis,,http://en.irct.ir/trial/44745,2020-02-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2904,1606,2023-11-21 00:00:00.000000,Coping and Adjusting to Living With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04300816,2020-04-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2905,1605,2023-11-21 00:00:00.000000,Effects of Ba-Duan-Jin exercise and Yoga intervention programs on physical and mental health of patients with MS.,,http://www.chictr.org.cn/showproj.aspx?proj=49886,2020-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2906,1604,2023-11-21 00:00:00.000000,MicroRNA-150 and microRNA-155 in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04300543,2020-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2907,1603,2023-11-21 00:00:00.000000,Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms,,https://clinicaltrials.gov/show/NCT04303143,2020-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2908,1602,2023-11-21 00:00:00.000000,Rhythmic Auditory Stimulation & Gait Training,,https://clinicaltrials.gov/show/NCT04314076,2020-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2909,1601,2023-11-21 00:00:00.000000,Effect of peer education method on life expectancy and quality of life in patients with multiple sclerosis,,http://en.irct.ir/trial/46293,2020-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2910,1600,2023-11-21 00:00:00.000000,Functional near infrared spectroscopy in a rehabilitative context - gait and fatigability in patients with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00021057,2020-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2911,1599,2023-11-21 00:00:00.000000,Mental Practice and Manipulative Skills Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04325074,2020-03-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2912,1598,2023-11-21 00:00:00.000000,A Self-management Program to Prevent Falls in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04317716,2020-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2913,1597,2023-11-21 00:00:00.000000,Validating digital mobility assessment using wearable technology,,https://www.isrctn.com/ISRCTN12246987,2020-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2914,1596,2023-11-21 00:00:00.000000,The Effectiveness of Strengthening Respiratory Muscles and their Relationship with Fatigue in Patients with Multiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-8rkrr3,2020-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2915,1595,2023-11-21 00:00:00.000000,Effects of othoses on the gait of people with multiple sclerosis,,http://en.irct.ir/trial/42788,2020-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2916,1594,2023-11-21 00:00:00.000000,Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04338646,2020-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2917,1593,2023-11-21 00:00:00.000000,Comparison of stress system in patients with multiple sclerosis before and after TSST intervention,,http://en.irct.ir/trial/46226,2020-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2918,1592,2023-11-21 00:00:00.000000,The effect of spine stabilizing exercises on balance and falling in people with multiple sclerosis,,http://en.irct.ir/trial/46429,2020-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2919,1591,2023-11-21 00:00:00.000000,Training and Energy Management Education to Improve Quality of Life in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04356248,2020-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2920,1590,2023-11-21 00:00:00.000000,Bioequivalence study of Teriflunomide 14 mg tablets produced by Zahravi Pharmaceutical Co. versus Aubagio® tablets of Sanofi Genzyme Co. in 14 healthy male under fasting conditions,,http://en.irct.ir/trial/47145,2020-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2921,1589,2023-11-21 00:00:00.000000,"Neuroproprioceptive ""Facilitation, Inhibition"" and Brain Plasticity",,https://clinicaltrials.gov/show/NCT04355663,2020-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2922,1588,2023-11-21 00:00:00.000000,US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector,,https://clinicaltrials.gov/ct2/show/NCT04356339,2020-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2923,1587,2023-11-21 00:00:00.000000,The Effect of PLISSIT Model on sexual Quality of Life of Women with Multiple Sclerosis,,http://en.irct.ir/trial/40147,2020-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2924,1586,2023-11-21 00:00:00.000000,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04367389,2020-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2925,1585,2023-11-21 00:00:00.000000,The Effectiveness of Acceptance and Commitment-Based Treatment in Multiple Sclerosis,,http://en.irct.ir/trial/46929,2020-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2926,1584,2023-11-21 00:00:00.000000,Sensor-based Technology for Upper Limb Rehabilitation,,https://clinicaltrials.gov/show/NCT04367285,2020-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2927,1583,2023-11-21 00:00:00.000000,Myotonometer Analyses of Muscles in Multiple Sclerosis Patients With Dysphagia,,https://clinicaltrials.gov/show/NCT04369092,2020-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2928,1582,2023-11-21 00:00:00.000000,The effectiveness of Sexual counseling on Family Function and Sexual Quality of Life in patients with MS,,http://en.irct.ir/trial/47158,2020-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2929,1581,2023-11-21 00:00:00.000000,Comparison of the effects of functional electrical stimulation in multiple sclerosis,,http://en.irct.ir/trial/46640,2020-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2930,1580,2023-11-21 00:00:00.000000,Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients,,https://clinicaltrials.gov/show/NCT04371575,2020-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2931,1579,2023-11-21 00:00:00.000000,Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04380220,2020-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2932,1578,2023-11-21 00:00:00.000000,Effect of occupation-based practice on upper extremity function of people with Multiple sclerosis,,http://en.irct.ir/trial/41493,2020-05-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2933,1577,2023-11-21 00:00:00.000000,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.,,https://clinicaltrials.gov/ct2/show/NCT04377555,2020-01-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2934,1576,2023-11-21 00:00:00.000000,Safety and effectiveness of Satinex buccal spray,,http://en.irct.ir/trial/46998,2020-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2935,1575,2023-11-21 00:00:00.000000,Ocrelizumab in Breastmilk,,https://clinicaltrials.gov/show/NCT04387110,2020-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2936,1574,2023-11-21 00:00:00.000000,Experiences of patients receiving medicinal cannabis: effects of different doses and formulations on symptoms and side effects.,,https://anzctr.org.au/ACTRN12620000543987.aspx,2020-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2937,1573,2023-11-21 00:00:00.000000,Physical Therapy and Neuroactive Steroids Therapy Does Not Modulate Serum Level of Neuroactive Steroids,,https://clinicaltrials.gov/show/NCT04379193,2020-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2938,1572,2023-11-21 00:00:00.000000,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,,https://clinicaltrials.gov/show/NCT04379661,2020-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2939,1571,2023-11-21 00:00:00.000000,Time Restricted Eating Outcomes in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04389970,2020-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2940,1570,2023-11-21 00:00:00.000000,The Effect of Nurse Practitioner (NP-led) Care Upon Mood in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04388592,2020-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2941,1569,2023-11-21 00:00:00.000000,Waking Hypnosis in the Treatment of MS-related Fatigue,,https://clinicaltrials.gov/show/NCT04429789,2020-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2942,1568,2023-11-21 00:00:00.000000,Cerebellar tDCS and Balance Training in PwMS,,https://clinicaltrials.gov/ct2/show/NCT04391023,2020-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2943,1567,2023-11-21 00:00:00.000000,DreaMS - Digital Biomarkers for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04413032,2020-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2944,1566,2023-11-21 00:00:00.000000,Intervention for Young Adults With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04431323,2020-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2945,1565,2023-11-21 00:00:00.000000,Functional Intermuscular Reduction of Spasticity,,https://clinicaltrials.gov/show/NCT04403594,2020-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2946,1564,2023-11-21 00:00:00.000000,COVID-19 Related Lockdown Effects On Chronic Diseases,,https://clinicaltrials.gov/show/NCT04390126,2020-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2947,1563,2023-11-21 00:00:00.000000,Characteristics of INTESTINAL DYSFUNCTION in Patients With MULTIPLE SCLEROSIS,,https://clinicaltrials.gov/show/NCT04599595,2020-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2948,1562,2023-11-21 00:00:00.000000,"Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04408742,2020-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2949,1561,2023-11-21 00:00:00.000000,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,,https://clinicaltrials.gov/show/NCT04410965,2020-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2950,1560,2023-11-21 00:00:00.000000,Feasibility of a High-intensity Interval Training Program in Persons With Multiple Sclerosis Who Have Walking Disability,,https://clinicaltrials.gov/show/NCT04416243,2020-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2951,1559,2023-11-21 00:00:00.000000,Telerehabilitation vs Supervised Exercises in MS,,https://clinicaltrials.gov/show/NCT04413682,2020-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2952,1558,2023-11-21 00:00:00.000000,Immunodeficiency in MS,,https://clinicaltrials.gov/show/NCT04447937,2020-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2953,1557,2023-11-21 00:00:00.000000,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",,https://clinicaltrials.gov/show/NCT04438954,2020-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2954,1556,2023-11-21 00:00:00.000000,Brain Activity Changes Following Neuroproprioceptive Physiotherapy in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04448444,2020-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2955,1555,2023-11-21 00:00:00.000000,Mobile Attentional Bias Modification Training in Pediatric MS,,https://clinicaltrials.gov/show/NCT04441229,2020-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2956,1554,2023-11-21 00:00:00.000000,Comparison of the effect of TRX and aerophytic exercises on MS patients,,http://en.irct.ir/trial/47679,2020-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2957,1553,2023-11-21 00:00:00.000000,Endeavor™ in Pediatric MS,,https://clinicaltrials.gov/show/NCT04445116,2020-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2958,1552,2023-11-21 00:00:00.000000,A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research,,http://www.chictr.org.cn/showproj.aspx?proj=49539,2020-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2959,1551,2023-11-21 00:00:00.000000,"Effects of Ten-Weeks Progressive Resistance Training on Neuromuscular Performance, Mobility, Heart Rate Variability and Sleep Quality in Persons With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04452760,2020-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2960,1550,2023-11-21 00:00:00.000000,Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04450030,2020-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2961,1549,2023-11-21 00:00:00.000000,The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04478591,2020-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2962,1548,2023-11-21 00:00:00.000000,Investigation of the effect of curcumin in Multiple Sclerosis,,http://en.irct.ir/trial/48888,2020-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2963,1547,2023-11-21 00:00:00.000000,"Functional neurological symptoms, psychological aspects, life events and their interaction in patients with multiple sclerosis",,http://drks.de/search/en/trial/DRKS00022105,2020-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2964,1546,2023-11-21 00:00:00.000000,Cannabinoid Medicine Observational Study (CMOS): Observation of cannabinoid prescribing and dosage patterns in Australian clinical practice,,https://anzctr.org.au/ACTRN12620000718943.aspx,2020-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2965,1545,2023-11-21 00:00:00.000000,Prescription Drug Safety and Effectiveness in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04472975,2020-03-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2966,1544,2023-11-21 00:00:00.000000,Non-invasive Transcranial Electrical Stimulation in MS,,https://clinicaltrials.gov/show/NCT04466228,2020-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2967,1543,2023-11-21 00:00:00.000000,Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset,,https://clinicaltrials.gov/ct2/show/NCT04466150,2020-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2968,1542,2023-11-21 00:00:00.000000,"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region",,https://clinicaltrials.gov/ct2/show/NCT04468165,2020-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2969,1541,2023-11-21 00:00:00.000000,An Open Label Observational Study of Safety and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis™-CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different Indications,,https://anzctr.org.au/ACTRN12620000741987.aspx,2020-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2970,1540,2023-11-21 00:00:00.000000,The Effectiveness of Reality Therapy & Positive psychotherapy on Emotional Reactions and the Quality of Life and Sleep of Patients with Multiple Sclerosis,,http://en.irct.ir/trial/49389,2020-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2971,1539,2023-11-21 00:00:00.000000,Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04486209,2020-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2972,1538,2023-11-21 00:00:00.000000,Conventional Vestibular Training Versus Immersive Virtual Reality- Based Vestibular in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04497025,2020-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2973,1537,2023-11-21 00:00:00.000000,Under and Over Rehabilitation Study,,https://clinicaltrials.gov/show/NCT04490044,2020-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2974,1536,2023-11-21 00:00:00.000000,SF-QUALIVEEN Turkish Validity and Reliability Study,,https://clinicaltrials.gov/show/NCT04483609,2020-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2975,1535,2023-11-21 00:00:00.000000,"Designing, implementation and evaluation of an intervention based on PRECEDE-PROCEED model to promote quality of life in patients with multiple sclerosis",,http://en.irct.ir/trial/49778,2020-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2976,1534,2023-11-21 00:00:00.000000,Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04495556,2020-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2977,1533,2023-11-21 00:00:00.000000,SPINCOMS Biomarker Study,,https://clinicaltrials.gov/show/NCT04496830,2020-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2978,1532,2023-11-21 00:00:00.000000,Reducing Symptoms of Multiple Sclerosis Using Non-invasive Neuromodulation,,https://clinicaltrials.gov/show/NCT04498039,2020-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2979,1531,2023-11-21 00:00:00.000000,Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04496804,2020-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2980,1530,2023-11-21 00:00:00.000000,Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04496531,2020-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2981,1529,2023-11-21 00:00:00.000000,The Energetic Origin of Neurodegeneration in MS,,https://clinicaltrials.gov/show/NCT04532944,2020-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2982,1528,2023-11-21 00:00:00.000000,iTBS Study for Depression in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04524039,2020-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2983,1527,2023-11-21 00:00:00.000000,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04498286,2020-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2984,1526,2023-11-21 00:00:00.000000,Improved care for mental and neurological diseases,,http://drks.de/search/en/trial/DRKS00022754,2020-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2985,1525,2023-11-21 00:00:00.000000,Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO),,https://clinicaltrials.gov/show/NCT04510350,2020-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2986,1524,2023-11-21 00:00:00.000000,Accurate Diagnosis of Multiple Sclerosis Using PET/MR,,https://clinicaltrials.gov/show/NCT04521439,2020-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2987,1523,2023-11-21 00:00:00.000000,The Effect of Combined Vibration-Stretching Exercises Patients with Multiple Sclerosis,,http://en.irct.ir/trial/46757,2020-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2988,1522,2023-11-21 00:00:00.000000,Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04528784,2020-08-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2989,1521,2023-11-21 00:00:00.000000,The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04533971,2020-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2990,1520,2023-11-21 00:00:00.000000,Effect of probiotic in patients with Multiple Sclerosis,,http://en.irct.ir/trial/50321,2020-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2991,1519,2023-11-21 00:00:00.000000,Comparison of the effectiveness of treatment methods on psychological problems of Multiple Sclerosis (M.S) Patients.,,http://en.irct.ir/trial/48835,2020-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2992,1518,2023-11-21 00:00:00.000000,Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04528121,2020-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2993,1517,2023-11-21 00:00:00.000000,The Effect of High Tone Power Therapy on Fatigue and Functional Outcomes in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04530669,2020-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2994,1516,2023-11-21 00:00:00.000000,Aerobic Exercises for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04545372,2020-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2995,1515,2023-11-21 00:00:00.000000,Prediction of recurrence of multiple sclerosis using medical imaging,,http://www.chictr.org.cn/showproj.aspx?proj=59967,2020-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2996,1514,2023-11-21 00:00:00.000000,"""The effect of dual-task training on cognitive and motor rehabilitation of MS patients""",,http://en.irct.ir/trial/50300,2020-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2997,1513,2023-11-21 00:00:00.000000,Effect of pelvic floor muscle exercise on Multiple Sclerosis,,http://en.irct.ir/trial/48227,2020-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2998,1512,2023-11-21 00:00:00.000000,To study the effect of microbial flora of the gut on brain (gut-brain axis) in Multiple Sclerosis patients,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46586,2020-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
2999,1511,2023-11-21 00:00:00.000000,Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease,,https://clinicaltrials.gov/ct2/show/NCT04540861,2020-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3000,1510,2023-11-21 00:00:00.000000,5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04546698,2020-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3001,1509,2023-11-21 00:00:00.000000,Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04538872,2020-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3002,1508,2023-11-21 00:00:00.000000,My MS Toolkit + Coaching: A Guided Web-based Symptom Self-Management Program for People With MS,,https://clinicaltrials.gov/show/NCT04552561,2020-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3003,1507,2023-11-21 00:00:00.000000,Qigong for Multiple Sclerosis: A Feasibility Study,,https://clinicaltrials.gov/show/NCT04585659,2020-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3004,1506,2023-11-21 00:00:00.000000,Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04543448,2020-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3005,1505,2023-11-21 00:00:00.000000,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",,https://clinicaltrials.gov/ct2/show/NCT04544436,2020-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3006,1504,2023-11-21 00:00:00.000000,Dynamic Balance Training in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04719494,2020-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3007,1503,2023-11-21 00:00:00.000000,Proximal Resistance Training for People With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04548154,2020-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3008,1502,2023-11-21 00:00:00.000000,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",,https://clinicaltrials.gov/ct2/show/NCT04548999,2020-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3009,1501,2023-11-21 00:00:00.000000,Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients,,https://clinicaltrials.gov/show/NCT04550650,2020-10-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3010,1500,2023-11-21 00:00:00.000000,The Effect of Cooperative Care Model on Mental Health of MS Patients,,http://en.irct.ir/trial/29934,2020-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3011,1499,2023-11-21 00:00:00.000000,Making it Personal: Identifying Personalised Triggers of Fatigue in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12620000908932.aspx,2020-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3012,1498,2023-11-21 00:00:00.000000,haMSter: a Novel Smartphone Communication Tool for People With MS,,https://clinicaltrials.gov/show/NCT04555863,2020-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3013,1497,2023-11-21 00:00:00.000000,Study of Royal jelly effect on serum levels of cytokines and antioxidant capacity on Multiple sclerosis patients in comparison with Omega-3,,http://en.irct.ir/trial/50483,2020-09-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3014,1496,2023-11-21 00:00:00.000000,Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo,,https://clinicaltrials.gov/show/NCT04578262,2020-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3015,1495,2023-11-21 00:00:00.000000,Randomized-controlled trial investigating the effectiveness of a digital life-style intervention to improve quality of life in people with multiple sclerosis.,,http://drks.de/search/en/trial/DRKS00023023,2020-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3016,1494,2023-11-21 00:00:00.000000,Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects,,https://clinicaltrials.gov/show/NCT04570670,2020-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3017,1493,2023-11-21 00:00:00.000000,Home Based Tele-exercise for People With Chronic Neurological Impairments,,https://clinicaltrials.gov/show/NCT04564495,2020-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3018,1492,2023-11-21 00:00:00.000000,"Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT04567264,2020-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3019,1491,2023-11-21 00:00:00.000000,Phase III Study of Evobrutinib in Relapsing Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46964,2020-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3020,1490,2023-11-21 00:00:00.000000,TRPMS to Improve Mobility and Depression in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04578041,2020-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3021,1489,2023-11-21 00:00:00.000000,Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort,,https://clinicaltrials.gov/show/NCT04580381,2020-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3022,1488,2023-11-21 00:00:00.000000,Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04601233,2020-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3023,1487,2023-11-21 00:00:00.000000,Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04602390,2020-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3024,1486,2023-11-21 00:00:00.000000,Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System,,https://clinicaltrials.gov/show/NCT04599023,2020-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3025,1485,2023-11-21 00:00:00.000000,"Effect of Guided Imagery on fatigue, stigma, and mood in patients with Multiple Sclerosis",,http://en.irct.ir/trial/46899,2020-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3026,1484,2023-11-21 00:00:00.000000,Intermittent Hypoxia Intervention in MS Patients,,https://clinicaltrials.gov/show/NCT04635033,2020-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3027,1483,2023-11-21 00:00:00.000000,Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.,,https://clinicaltrials.gov/show/NCT04633967,2020-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3028,1482,2023-11-21 00:00:00.000000,Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04619953,2020-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3029,1481,2023-11-21 00:00:00.000000,"A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT04626921,2020-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3030,1480,2023-11-21 00:00:00.000000,Effect of rocker shoes on balance and gait parameters in subjects with multiple sclerosis,,http://en.irct.ir/trial/51015,2020-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3031,1479,2023-11-21 00:00:00.000000,"The influence of whole-body cryotherapy on physiological blood indicators, oxidative stress and selected disease markers in people with multiple sclerosis",,https://anzctr.org.au/ACTRN12620001142921.aspx,2020-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3032,1478,2023-11-21 00:00:00.000000,Can acupuncture affect cytokine levels in multiple sclerosis?,,https://www.isrctn.com/ISRCTN34352011,2020-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3033,1477,2023-11-21 00:00:00.000000,"A PHASE III MULTICENTER, RANDOMIZED,
				DOUBLE-BLIND, DOUBLE-DUMMY,
				PARALLEL-GROUP STUDY TO EVALUATE THE
				EFFICACY AND SAFETY OF FENEBRUTINIB
				COMPARED WITH OCRELIZUMAB IN ADULT
				PATIENTS WITH PRIMARY PROGRESSIVE
				MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=028-20,2020-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3034,1476,2023-11-21 00:00:00.000000,"A PHASE IIIB MULTICENTER, RANDOMIZED,
				DOUBLE-BLIND, CONTROLLED STUDY TO
				EVALUATE THE EFFICACY, SAFETY AND
				PHARMACOKINETICS OF A HIGHER DOSE OF
				OCRELIZUMAB IN ADULTS WITH PRIMARY
				PROGRESSIVE MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=068-20,2020-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3035,1475,2023-11-21 00:00:00.000000,Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® dose,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003874-30,2020-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3036,1474,2023-11-21 00:00:00.000000,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04657666,2020-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3037,1473,2023-11-21 00:00:00.000000,Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04633759,2020-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3038,1472,2023-11-21 00:00:00.000000,The Effects of Anodal tDCS on Incontinency in Patients with Multiple Sclerosis (MS),,http://en.irct.ir/trial/52036,2020-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3039,1471,2023-11-21 00:00:00.000000,Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04635709,2020-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3040,1470,2023-11-21 00:00:00.000000,Effectiveness of Hippotherapy Simulator in PwMS,,https://clinicaltrials.gov/show/NCT04651725,2020-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3041,1469,2023-11-21 00:00:00.000000,Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor SAR442168,,https://jrct.niph.go.jp/latest-detail/jRCT2021200028,2020-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3042,1468,2023-11-21 00:00:00.000000,Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy,,https://clinicaltrials.gov/show/NCT04640818,2020-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3043,1467,2023-11-21 00:00:00.000000,Relapsing forms of multiple sclerosis (RMS) study of BTK inhibitor SAR442168 (GEMINI 2),,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45462,2020-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3044,1466,2023-11-21 00:00:00.000000,Effect of Jadwar  capsules in multiple sclerosis patients,,http://en.irct.ir/trial/52171,2020-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3045,1465,2023-11-21 00:00:00.000000,Preventive Program in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04667130,2020-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3046,1464,2023-11-21 00:00:00.000000,Exercise Training in Pediatric-Onset Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04660227,2020-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3047,1463,2023-11-21 00:00:00.000000,Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program,,https://clinicaltrials.gov/show/NCT04655222,2020-11-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3048,1462,2023-11-21 00:00:00.000000,Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04662008,2020-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3049,1461,2023-11-21 00:00:00.000000,The evaluation of the additive value of cognitive task on whole body vibration on balance and cognition in multiple sclerosis,,http://en.irct.ir/trial/50974,2020-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3050,1460,2023-11-21 00:00:00.000000,Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04667221,2020-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3051,1459,2023-11-21 00:00:00.000000,Clinical validation of a mobility monitor to measure and predict health outcomes,,https://www.isrctn.com/ISRCTN12051706,2020-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3052,1458,2023-11-21 00:00:00.000000,Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168,,https://jrct.niph.go.jp/latest-detail/jRCT2031200240,2020-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3053,1457,2023-11-21 00:00:00.000000,Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.,,https://clinicaltrials.gov/show/NCT04674163,2020-12-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3054,1456,2023-11-21 00:00:00.000000,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04676555,2020-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3055,1455,2023-11-21 00:00:00.000000,Ellagic acid in multiple sclerosis,,http://en.irct.ir/trial/48599,2020-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3056,1454,2023-11-21 00:00:00.000000,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,,https://clinicaltrials.gov/show/NCT04682548,2020-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3057,1453,2023-11-21 00:00:00.000000,Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebrutinib (SAR442168),,https://jrct.niph.go.jp/latest-detail/jRCT2021200035,2020-12-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3058,1452,2023-11-21 00:00:00.000000,Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: a multicentre study,,http://drks.de/search/en/trial/DRKS00023978,2020-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3059,1451,2023-11-21 00:00:00.000000,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
				DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE
				THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED
				WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=076-20,2020-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3060,1450,2023-11-21 00:00:00.000000,IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04697407,2021-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3061,1449,2023-11-21 00:00:00.000000,"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography",,https://clinicaltrials.gov/show/NCT04705610,2021-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3062,1448,2023-11-21 00:00:00.000000,Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04702763,2021-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3063,1447,2023-11-21 00:00:00.000000,"Long-term management of spasticity in patients with multiple sclerosis using a software application (APP) based hometraining: a prospective, randomized-controlled multicenter study",,http://drks.de/search/en/trial/DRKS00023960,2021-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3064,1446,2023-11-21 00:00:00.000000,A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04711148,2021-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3065,1445,2023-11-21 00:00:00.000000,"Communication, Coordination und Security for People with Multiple Sclerosis",,http://drks.de/search/en/trial/DRKS00022771,2021-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3066,1444,2023-11-21 00:00:00.000000,"The effect of Cladribine on iron rims around lesions, lesion expansion, brain
atrophy and disease progression in multiple sclerosis patients - an
observational exploratory study",,http://drks.de/search/en/trial/DRKS00023841,2021-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3067,1443,2023-11-21 00:00:00.000000,Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04705870,2021-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3068,1442,2023-11-21 00:00:00.000000,Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T,,https://clinicaltrials.gov/ct2/show/NCT04707144,2021-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3069,1441,2023-11-21 00:00:00.000000,Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers,,https://clinicaltrials.gov/show/NCT04725175,2021-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3070,1440,2023-11-21 00:00:00.000000,The Minnesota Manual Dexterity Test As A Measure Of Hand Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04721340,2021-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3071,1439,2023-11-21 00:00:00.000000,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04749667,2021-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3072,1438,2023-11-21 00:00:00.000000,Effect of probiotic and zinc supplementation separately and in combination on reducing the complication of influenza-like syndrome during therapy by beta-interferon in patients with relapsing-remitting multiple sclerosis,,http://en.irct.ir/trial/53804,2021-01-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3073,1437,2023-11-21 00:00:00.000000,Barriers to Physical Activity in People With MS,,https://clinicaltrials.gov/show/NCT04746807,2021-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3074,1436,2023-11-21 00:00:00.000000,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study,,https://clinicaltrials.gov/show/NCT04754542,2021-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3075,1435,2023-11-21 00:00:00.000000,Tele-Assessment and Face-to-Face Evaluation of Balance in MS,,https://clinicaltrials.gov/show/NCT04743284,2021-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3076,1434,2023-11-21 00:00:00.000000,"Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",,https://clinicaltrials.gov/ct2/show/NCT04742400,2021-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3077,1433,2023-11-21 00:00:00.000000,Quality of Life Assessment Between Stroke and Multiple Sclerosis Patients of the Same Age Range,,https://clinicaltrials.gov/show/NCT04758494,2021-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3078,1432,2023-11-21 00:00:00.000000,Effects of Telerehabilitation-Based Pelvic Floor Muscle Training in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04758468,2021-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3079,1431,2023-11-21 00:00:00.000000,Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera,,https://clinicaltrials.gov/ct2/show/NCT04756687,2021-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3080,1430,2023-11-21 00:00:00.000000,Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04756700,2021-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3081,1429,2023-11-21 00:00:00.000000,App-based investigation of patient-reported outcomes in TYSABRI therapy,,http://drks.de/search/en/trial/DRKS00024387,2021-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3082,1428,2023-11-21 00:00:00.000000,Effectiveness comparison of two methods of treatment based on acceptance and commitment therapy (ACT) and relationship enhancement couples therapy (RECT) on intimacy and sexual activity in women with multiple sclerosis in online consulting method,,http://en.irct.ir/trial/53305,2021-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3083,1427,2023-11-21 00:00:00.000000,Is there a circadian differential effect of fatigue in multiple sclerosis (MS) on sustained attention performance and EEG frequency patterns?,,http://drks.de/search/en/trial/DRKS00024516,2021-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3084,1426,2023-11-21 00:00:00.000000,Histaminergic Basis of Fatigue in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04764383,2021-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3085,1425,2023-11-21 00:00:00.000000,Transcranial Magnetic Stimulation ( rTMS ) add-on therapy to Standard treatment in Multiple sclerosis Patients with Depression Symptoms,,http://en.irct.ir/trial/54245,2021-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3086,1424,2023-11-21 00:00:00.000000,Neuropsychological evaluation and rehabilitation in multiple sclerosis – qualitative case study,,https://www.isrctn.com/ISRCTN15615992,2021-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3087,1423,2023-11-21 00:00:00.000000,The effect of garlic on fatigue and quality of life in MS patients,,http://en.irct.ir/trial/52817,2021-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3088,1422,2023-11-21 00:00:00.000000,The feasibility of an online lifestyle intervention for people with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12621000245897.aspx,2021-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3089,1421,2023-11-21 00:00:00.000000,Effects of Receptive Music Therapy with a Monochord in multiple sclerosis (MUTIMS) – a randomized controlled study,,http://drks.de/search/en/trial/DRKS00024549,2021-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3090,1420,2023-11-21 00:00:00.000000,The Effect of Clove Extract on Pain Caused by Copamer Injection in Patients with MS.,,http://en.irct.ir/trial/52271,2021-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3091,1419,2023-11-21 00:00:00.000000,The effectiveness of balance-sensory exercises on motor function in patients with MS,,http://en.irct.ir/trial/54922,2021-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3092,1418,2023-11-21 00:00:00.000000,To investigate calcium metabolism as a therapeutic target in multiple sclerosis (MS),,http://drks.de/search/en/trial/DRKS00024950,2021-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3093,1417,2023-11-21 00:00:00.000000,Transcutaneous spinal cord stimulation (tSCS) for the treatment of spasticity and gait disorders in multiple sclerosis,,http://drks.de/search/en/trial/DRKS00023357,2021-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3094,1416,2023-11-21 00:00:00.000000,Walking abilities and its treatment strategies in Multiple Sclerosis patients,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=55395,2021-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3095,1415,2023-11-21 00:00:00.000000,Observational Study on Sars CoV2 Vaccinations in Patients with MS,,http://drks.de/search/en/trial/DRKS00025221,2021-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3096,1414,2023-11-21 00:00:00.000000,Effect of Stress Management  in Multiple Sclerosis.,,http://en.irct.ir/trial/55705,2021-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3097,1413,2023-11-21 00:00:00.000000,A study of the impact of yoga and physical therapy on symptoms and quality of life in patients with multiple sclerosis,,https://www.isrctn.com/ISRCTN15486200,2021-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3098,1412,2023-11-21 00:00:00.000000,Changes to the immune system after vitamin D supplementation in healthy individuals and people with multiple sclerosis,,https://anzctr.org.au/ACTRN12621000597897.aspx,2021-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3099,1411,2023-11-21 00:00:00.000000,Development and Evaluation of A Digital Version of the REsilience Activities for every DaY (READY) Program for Adults with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12621000602820.aspx,2021-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3100,1410,2023-11-21 00:00:00.000000,Dutch Multiple sclerosis study (DMSS),,https://www.onderzoekmetmensen.nl/en/trial/22564,2021-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3101,1409,2023-11-21 00:00:00.000000,Association between brain atrophy and intestinal permeability in patients with multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049020,2021-01-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3102,1408,2023-11-21 00:00:00.000000,Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with rituximab,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001973-21,2021-04-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3103,1407,2023-11-21 00:00:00.000000,Efficacy of Dalfyra (extended release Fampridine) in fatigue in multiple sclerosis patients,,http://en.irct.ir/trial/55983,2021-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3104,1406,2023-11-21 00:00:00.000000,The role of mobility assistive devices for participation and subjective well-being of people with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00025532,2021-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3105,1405,2023-11-21 00:00:00.000000,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis,,https://lbctr.moph.gov.lb/Trials/Details/4795,2021-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3106,1404,2023-11-21 00:00:00.000000,Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting condition in healthy male and female volunteers.,,https://anzctr.org.au/ACTRN12621000775819.aspx,2021-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3107,1403,2023-11-21 00:00:00.000000,Comparison of Therapeutic Effect of Amantidine and Modafinil in Fatigue Related Multiple Sclerosis,,http://en.irct.ir/trial/56243,2021-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3108,1402,2023-11-21 00:00:00.000000,ND,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000708-26,2021-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3109,1401,2023-11-21 00:00:00.000000,Clinical trial of fecal bacteria transplantation in the treatment of multiple sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=129210,2021-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3110,1400,2023-11-21 00:00:00.000000,"Bioequivalence study of Dimethyl Fumarate 240mg capsule of Nanoalvand Co., IRAN",,http://en.irct.ir/trial/57165,2021-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3111,1399,2023-11-21 00:00:00.000000,Accelerated long-term forgetting in Multiple sclerosis patients with little disability,,http://drks.de/search/en/trial/DRKS00025791,2021-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3112,1398,2023-11-21 00:00:00.000000,Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fed conditions in healthy male and female volunteers.,,https://anzctr.org.au/ACTRN12621000887875.aspx,2021-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3113,1397,2023-11-21 00:00:00.000000,The effect of Oleoylethanolamide supplementation on oxidative stress parameters in multiple sclerosis patients,,http://en.irct.ir/trial/55860,2021-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3114,1396,2023-11-21 00:00:00.000000,ExerG: An innovative digital solution to individually improve physical and cognitive functions using an exergame (video game-based) training in an ecologically valid and safe setting for the geriatric population,,http://drks.de/search/en/trial/DRKS00025838,2021-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3115,1395,2023-11-21 00:00:00.000000,The effect of MSCs transplantation in the treatment of SPMS,,http://en.irct.ir/trial/57075,2021-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3116,1394,2023-11-21 00:00:00.000000,"Comparison of the effect of 8 weeks of CoDuSe training in water and on land on the fatigue, balance and physical disability in women with Multiple Sclerosis.",,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051500,2021-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3117,1393,2023-11-21 00:00:00.000000,Investigating the effect of education on Multiple Sclerosis patients' drug adherence,,http://en.irct.ir/trial/57994,2021-08-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3118,1392,2023-11-21 00:00:00.000000,Bioequivalence study of Cladribine 10 mg tablet in highly active relapsing multiple sclerosis patients,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=57619,2021-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3119,1391,2023-11-21 00:00:00.000000,The effect of effleurage massage and foot reflexology training on quality of life in patients with multiple sclerosis,,http://en.irct.ir/trial/57682,2021-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3120,1390,2023-11-21 00:00:00.000000,Testing a new ice vest that could help people experiencing Multiple Sclerosis exercise,,https://anzctr.org.au/ACTRN12621001226897.aspx,2021-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3121,1389,2023-11-21 00:00:00.000000,Immediate effect of trunk loading with a weighted jacket on balance in patients with Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49143,2021-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3122,1388,2023-11-21 00:00:00.000000,Validation of smartphone-based assessments in multiple sclerosis,,https://www.isrctn.com/ISRCTN15993728,2021-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3123,1387,2023-11-21 00:00:00.000000,"Comparison of therapeutic effectiveness based on the analysis of lived experiences of social stigma with positive psychotherapy method in mental toighness, cognitive flexibility, distress tolerance and feeling of entrapment in patients with multiple sclerosis.",,http://en.irct.ir/trial/58174,2021-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3124,1386,2023-11-21 00:00:00.000000,Acupuncture effect in MS Associated Fatigue,,http://en.irct.ir/trial/58164,2021-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3125,1385,2023-11-21 00:00:00.000000,A randomized controlled pilot and feasibility study of multimodal agility-based exercise training versus strength and endurance training to improve Multiple Sclerosis-related fatigue and fatigability during inpatient rehabilitation,,http://drks.de/search/en/trial/DRKS00023943,2021-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3126,1384,2023-11-21 00:00:00.000000,Evaluation of the effectiveness of hip flexion-assisted orthosis on reducing pain and improving the quality of life in patientswith MS,,http://en.irct.ir/trial/56396,2021-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3127,1383,2023-11-21 00:00:00.000000,"Effectiveness of dialectical behavior therapy for fatigue, depression, anxiety, stress and quality of life of patients with Multiple Sclerosis",,http://en.irct.ir/trial/57678,2021-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3128,1382,2023-11-21 00:00:00.000000,SISTER –Subcutaneous: Non-Interventional Study for Tysabri Patient Preference – Experience from Real World,,http://drks.de/search/en/trial/DRKS00026704,2021-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3129,1381,2023-11-21 00:00:00.000000,CANcer patients’ perspectives on coronavirus VACCination Survey (CANVACCS) research project,,https://anzctr.org.au/ACTRN12621001467820.aspx,2021-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3130,1380,2023-11-21 00:00:00.000000,A Study of Diroximel Fumarate (DRF) in Adult Participants from the Asia-Pacific Region with Relapsing Forms of Multiple Sclerosis (RMS),,https://jrct.niph.go.jp/latest-detail/jRCT2051210115,2021-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3131,1379,2023-11-21 00:00:00.000000,CancerCOVID - Allocating resources for cancer care in times of the Sars-CoV-2 outbreak. Evidence and ethical implications,,http://drks.de/search/en/trial/DRKS00026043,2021-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3132,1378,2023-11-21 00:00:00.000000,Effects of rTMS and tDCS in balance of MS patients,,http://en.irct.ir/trial/58852,2021-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3133,1377,2023-11-21 00:00:00.000000,the effects  of Sleep hygiene education and music  on sleep quality in clients with MS,,http://en.irct.ir/trial/59627,2021-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3134,1376,2023-11-21 00:00:00.000000,The effect of expressive writing on sexual and  marital satisfaction in women with multiple sclerosis,,https://www.thaiclinicaltrials.org/show/TCTR20211120004,2021-11-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3135,1375,2023-11-21 00:00:00.000000,The effectiveness of compassion focused acceptance and commitment therapy in patients with multiple sclerosis,,http://en.irct.ir/trial/57278,2021-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3136,1374,2023-11-21 00:00:00.000000,"Phase 3 Study to Evaluate Efficacy, Safety, PK, and PD of SC Natalizumab in Japanese Participants With RRMS",,https://jrct.niph.go.jp/latest-detail/jRCT2051210146,2021-12-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3137,1373,2023-11-21 00:00:00.000000,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=55485,2021-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3138,1372,2023-11-21 00:00:00.000000,Determinants of participation at working life with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00023963,2022-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3139,1371,2023-11-21 00:00:00.000000,Acupuncture and Cognitive Impairment in MS,,http://en.irct.ir/trial/60998,2022-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3140,1370,2023-11-21 00:00:00.000000,A survey on the actual situation of driving support by occupational therapists in Okinawa Prefecture,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053129,2022-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3141,1369,2023-11-21 00:00:00.000000,Robot-assisted gait training in patients with neurological disorders: a comparative multiple case study,,http://drks.de/search/en/trial/DRKS00027887,2022-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3142,1368,2023-11-21 00:00:00.000000,TANNE: Telemedicine responses to neuropalliative demands in real time,,http://drks.de/search/en/trial/DRKS00027436,2022-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3143,1367,2023-11-21 00:00:00.000000,Wheat-free diet in patients with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00027967,2022-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3144,1366,2023-11-21 00:00:00.000000,Developing and implementing an online nutrition education program for people with multiple sclerosis,,https://anzctr.org.au/ACTRN12622000276752.aspx,2022-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3145,1365,2023-11-21 00:00:00.000000,Effectiveness of the application of a TDCs treatment and combined exercise program on fragility in a population wtih Multiple Sclerosis,,https://anzctr.org.au/ACTRN12622000264785.aspx,2022-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3146,1364,2023-11-21 00:00:00.000000,Motor Improvement in Neurological Conditions (MINC): Feasibility of using a virtual dolphin to influence arm function and cognition in multiple sclerosis.,,https://anzctr.org.au/ACTRN12622000281796.aspx,2022-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3147,1363,2023-11-21 00:00:00.000000,MuSic Moves – Co-creating a music-supported exercise programme with people with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00027979,2022-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3148,1362,2023-11-21 00:00:00.000000,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,,https://lbctr.moph.gov.lb/Trials/Details/4915,2022-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3149,1361,2023-11-21 00:00:00.000000,A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Whose Current Treatment with Lipid-Modifying Therapies is not Sufficiently Effective.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005092-39,2022-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3150,1360,2023-11-21 00:00:00.000000,Electroneuromyography comparison between pre-elderly adults with and without MS; the potential role of a home-based exercise therapy in improving neurophysiological profile of MS during pandemic.,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053549,2022-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3151,1359,2023-11-21 00:00:00.000000,Comparison of the effect of cerebellum tDCS and prefrontal in patients with multiple sclerosis,,http://en.irct.ir/trial/61409,2022-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3152,1358,2023-11-21 00:00:00.000000,Investigate the effect of Crocin in Multiple Sclerosis patients,,http://en.irct.ir/trial/62257,2022-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3153,1357,2023-11-21 00:00:00.000000,Effect of intervention focused on intolerance of uncertainty in multiple sclerosis,,http://en.irct.ir/trial/59136,2022-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3154,1356,2023-11-21 00:00:00.000000,Profile of physical activity and depression in people with multiple sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-9bp2g4w,2022-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3155,1355,2023-11-21 00:00:00.000000,Effect of spiritual care based on Sound Heart Model on Spirituality Experience and tendency to Social Desirability in patients with Multiple Sclerosis,,http://en.irct.ir/trial/62457,2022-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3156,1354,2023-11-21 00:00:00.000000,The effect   Pilates Training on  multiple sclerosis,,http://en.irct.ir/trial/62583,2022-03-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3157,1353,2023-11-21 00:00:00.000000,Evaluation of modern MRI acceleration techniques for imaging of the brain and it's vascular supply at 1.5 T.,,http://drks.de/search/en/trial/DRKS00024403,2022-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3158,1352,2023-11-21 00:00:00.000000,Neurofilament light chain (NfL) levels in long term clinical course of patients with relapsing remitting multiple sclerosis,,http://drks.de/search/en/trial/DRKS00028507,2022-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3159,1351,2023-11-21 00:00:00.000000,The effect of transcranial direct current stimulation (tDCS) on cognition in people with MS,,http://en.irct.ir/trial/58217,2022-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3160,1350,2023-11-21 00:00:00.000000,Autologous Stem Cell Transplant in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12622000536763.aspx,2022-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3161,1349,2023-11-21 00:00:00.000000,Repetitive transcranial magnetic stimulation and working memory,,http://en.irct.ir/trial/63163,2022-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3162,1348,2023-11-21 00:00:00.000000,Effects of a probiotic intervention on cognitive symptoms and gut-brain biomarkers in multiple sclerosis (MS); a pilot study.,,https://anzctr.org.au/ACTRN12622000631707.aspx,2022-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3163,1347,2023-11-21 00:00:00.000000,Evaluation of protective effect of  Royal Jelly on Serum Oxidative Stress markers and Interleukin-1 Beta of Patients with Multiple Sclerosis.,,http://en.irct.ir/trial/61321,2022-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3164,1346,2023-11-21 00:00:00.000000,The effect of Pilates exercise on the treatment of multiple sclerosis,,http://en.irct.ir/trial/62634,2022-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3165,1345,2023-11-21 00:00:00.000000,Clinical Study on Beta Glucan N 163 to treat Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=69004,2022-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3166,1344,2023-11-21 00:00:00.000000,The effect of Jollab beverage on fatigue and happiness in patients with multiple sclerosis,,http://en.irct.ir/trial/63405,2022-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3167,1343,2023-11-21 00:00:00.000000,Multiple Sclerosis (MS) WorkSmart Feasibility Study,,https://anzctr.org.au/ACTRN12622000826741.aspx,2022-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3168,1342,2023-11-21 00:00:00.000000,Network to strengthen the participation in chronicall ilness using the example of multiple sclerosis,,http://drks.de/search/en/trial/DRKS00025451,2022-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3169,1341,2023-11-21 00:00:00.000000,Patients-Physicians Gap Survey,,https://jrct.niph.go.jp/latest-detail/jRCT1030220258,2022-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3170,1340,2023-11-21 00:00:00.000000,Multiple Sclerosis functional electrical stimulation cycling study,,https://anzctr.org.au/ACTRN12622001170718.aspx,2022-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3171,1339,2023-11-21 00:00:00.000000,Efficacy of Yoga Based Lifestyle  in Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=73652,2022-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3172,1338,2023-11-21 00:00:00.000000,Mobile application based intervention for individuals with relapsing Multiple Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=71800,2022-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3173,1337,2023-11-21 00:00:00.000000,The effects of face masks on walking adaptability in people with Parkinson’s disease and multiple sclerosis: A crossover study,,http://drks.de/search/en/trial/DRKS00030207,2022-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3174,1336,2023-11-21 00:00:00.000000,The effect of lavender tea on the ataxia and spasm in patients with multiple sclerosis,,http://en.irct.ir/trial/65516,2022-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3175,1335,2023-11-21 00:00:00.000000,Complementary Medicine in Multiple Sclerosis,,http://en.irct.ir/trial/62769,2022-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3176,1334,2023-11-21 00:00:00.000000,"An observational, non-interventional, multicenter, prospective study to explore the association of MS-related disability worsening and loss of thalamus volume",,http://drks.de/search/en/trial/DRKS00030403,2022-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3177,1333,2023-11-21 00:00:00.000000,"Retrospective investigation of the structure, efficiency and effectiveness of differential diagnostic measures in patients with multiple sclerosis",,http://drks.de/search/en/trial/DRKS00030651,2022-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3178,1332,2023-11-21 00:00:00.000000,The effect of Fennel flower and flax plants on MS,,http://en.irct.ir/trial/66482,2022-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3179,1331,2023-11-21 00:00:00.000000,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients on Disease-Modifying Drugs,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054698,2022-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3180,1330,2023-11-21 00:00:00.000000,The effect of Action Observation on gait of persons with multiple sclerosis (MS),,http://en.irct.ir/trial/64124,2022-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3181,1329,2023-11-21 00:00:00.000000,ASSESSING THE RELIABILITY OF THE MODIFIED MANUAL MUSCLE TEST (MMMT) IN PEOPLE WITH MULTIPLE SCLEROSIS AFTER EXAMINER TRAINING (MASTERARBEIT),,http://drks.de/search/en/trial/DRKS00029984,2022-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3182,1328,2023-11-21 00:00:00.000000,The effect of  family-centered training from distance on quality of life and sleep quality,,http://en.irct.ir/trial/67379,2022-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3183,1327,2023-11-21 00:00:00.000000,Proprioceptive Neuromuscular Facilitation Techniques On  Patients With  Multiple  Sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=76885,2022-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3184,1326,2023-11-21 00:00:00.000000,The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders,,http://en.irct.ir/trial/65313,2022-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3185,1325,2023-11-21 00:00:00.000000,Feasibility of hybrid-technology upper limb rehabilitation for people with neurological impairments in hospital.,,https://anzctr.org.au/ACTRN12622001564741.aspx,2022-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3186,1324,2023-11-21 00:00:00.000000,"Molecular, genetic and neuroimaging mechanisms of relapse recovery in multiple sclerosis: exploring the role of brain-derived neurotrophic factor",,http://drks.de/search/en/trial/DRKS00031011,2023-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3187,1323,2023-11-21 00:00:00.000000,effect of exercise treatment in patients with multiple sclerosis.,,http://en.irct.ir/trial/67036,2023-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3188,1322,2023-11-21 00:00:00.000000,Evaluating the effect of a simple cooling cap in heat-sensitive people with multiple sclerosis,,https://www.isrctn.com/ISRCTN56350227,2023-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3189,1321,2023-11-21 00:00:00.000000,Treatment (AMDR) and Positive Psychotherapy in Depression and Quality of Life in Men and Women with MS.,,http://en.irct.ir/trial/67669,2023-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3190,1320,2023-11-21 00:00:00.000000,The effect of Swedish massage on sleep quality in patients with multiple sclerosis,,http://en.irct.ir/trial/67080,2023-03-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3191,1319,2023-11-21 00:00:00.000000,Comparison of the effect of therapy based on acceptance and commitment with a focus on compassion and yoga exercises on MS patients,,http://en.irct.ir/trial/68777,2023-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3192,1318,2023-11-21 00:00:00.000000,"Effect of peer education and nurse education versus control group on the quality of life, resilience and anxiety of multiple sclerosis patients",,http://en.irct.ir/trial/69040,2023-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3193,1317,2023-11-21 00:00:00.000000,Effect of Bupropion versus placebo on the management of fatigue caused by multiple sclerosis,,http://en.irct.ir/trial/69041,2023-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3194,1316,2023-11-21 00:00:00.000000,Investigating the effect of carrot seed capsules on the sexual desire of female patients with multiple sclerosis,,http://en.irct.ir/trial/69083,2023-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3195,1315,2023-11-21 00:00:00.000000,Efficacy of Ankle Foot Orthosis on Multiple Sclerosis,,http://en.irct.ir/trial/69119,2023-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3196,1314,2023-11-21 00:00:00.000000,Exteroceptive Reflexes in Neurological Conditions and Healthy Controls,,https://anzctr.org.au/ACTRN12623000311651.aspx,2023-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3197,1313,2023-11-21 00:00:00.000000,"A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatment",,https://euclinicaltrials.eu/app/#/view/2023-504577-21-00?lang=en,2023-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3198,1312,2023-11-21 00:00:00.000000,The effects of eight weeks swing exercises on functional ability and quality of life in multiple sclerosis women with emphasis on Expanded disability Status Scale,,http://en.irct.ir/trial/65899,2023-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3199,1311,2023-11-21 00:00:00.000000,Investigating the effectiveness of Captain’s Log cognitive rehabilitation software on Perceptual Reasoning and Working Memory performance of patients with MS,,http://en.irct.ir/trial/69658,2023-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3200,1310,2023-11-21 00:00:00.000000,"For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial",,https://euclinicaltrials.eu/app/#/view/2023-505420-62-00?lang=en,2023-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3201,1309,2023-11-21 00:00:00.000000,Comparing the effectiveness of compassion-focused therapy with acceptance and commitment-based therapy on marital satisfaction and experiential avoidance.,,http://en.irct.ir/trial/67114,2023-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3202,1308,2023-11-21 00:00:00.000000,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,,https://lbctr.moph.gov.lb/Trials/Details/5355,2023-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3203,1307,2023-11-21 00:00:00.000000,"The Global QUEST initiative: QUality of life Evaluation STudy:
Assessing Health Related Quality of Life in patients receiving medicinal cannabis.",,https://anzctr.org.au/ACTRN12623000583640.aspx,2023-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3204,1306,2023-11-21 00:00:00.000000,Effectiveness of transdiagnostic treatment on psychological parameters in multiple sclerosis,,http://en.irct.ir/trial/68461,2023-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3205,1305,2023-11-21 00:00:00.000000,"Investigating the effect of oral magnesium supplementation on cognitive function, fatigue, depression, anxiety of multiple sclerosis patients",,http://en.irct.ir/trial/70631,2023-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3206,1304,2023-11-21 00:00:00.000000,The effect of Mediterranean diet and the traditional food recommendation on fatigue and depression in multiple sclerosis,,http://en.irct.ir/trial/65991,2023-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3207,1303,2023-11-21 00:00:00.000000,"The effect of 8 weeks of combined exercise training (aerobic-resistance) on microRNAs involved in pain, inflammation and fatigue in patients with MS.",,http://en.irct.ir/trial/70773,2023-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3208,1302,2023-11-21 00:00:00.000000,Supervised pelvic floor muscle training improves sexual function and diminishes sexual distress in women with multiple sclerosis,,https://www.isrctn.com/ISRCTN67646109,2023-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3209,1301,2023-11-21 00:00:00.000000,The Effect of Yoga on the Complications of MS.,,http://en.irct.ir/trial/70016,2023-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3210,1300,2023-11-21 00:00:00.000000,The effect of breathing yoga “Bhramary Pranayama” on fatigue and depression in patients with multiple sclerosis,,http://en.irct.ir/trial/70708,2023-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3211,1299,2023-11-21 00:00:00.000000,Investigation for biomarkers for &quot;silent progression&quot; in neuromyelitis optica spectrum disorders and multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058947,2023-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3212,1298,2023-11-21 00:00:00.000000,Investigating the effect of crocin in multiple sclerosis patients,,http://en.irct.ir/trial/71629,2023-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3213,1297,2023-11-21 00:00:00.000000,Clinical trial of anti-Epstein-Barr virus therapies for the prevention of progression in multiple sclerosis,,https://anzctr.org.au/ACTRN12623000849695.aspx,2023-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3214,1296,2023-11-21 00:00:00.000000,"Design, Manufacture and production of rehabilitation aid belt for Neurological Patients",,http://en.irct.ir/trial/71669,2023-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3215,1295,2023-11-21 00:00:00.000000,Consonance,,https://lbctr.moph.gov.lb/Trials/Details/5405,2023-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3216,1294,2023-11-21 00:00:00.000000,Neurofilament light chains (NFL) in serum in multiple sclerosis for the detection of high risk of disease progression,,http://drks.de/search/en/trial/DRKS00032567,2023-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3217,1293,2023-11-21 14:03:16.587594,Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Frexalimab; Drug: Teriflunomide; Drug: Placebo infusion; Drug: Placebo tablet; Drug: MRI contrast-enhancing agents; Drug: Cholestyramine; Drug: Activated charcoal
<br /><b>Sponsors</b>: Sanofi
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06141473,2023-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3218,1292,2023-11-21 14:03:16.576733,Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Frexalimab; Drug: Placebo; Drug: MRI contrast-enhancing agents
<br /><b>Sponsors</b>: Sanofi
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06141486,2023-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3219,1291,2023-11-21 00:00:00.000000,"Investigation the effect of progressive muscle relaxation on sexual dysfunction in women with multiple sclerosis in Rafsanjan, 2023",,http://en.irct.ir/trial/71197,2023-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3220,1290,2023-11-21 00:00:00.000000,Vitamin D supplementation in knee osteoarthritis,,https://www.thaiclinicaltrials.org/show/TCTR20230901001,2023-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3221,1289,2023-11-21 00:00:00.000000,Exchange of human material for diagnostics development and production,,http://drks.de/search/en/trial/DRKS00032367,2023-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3222,1288,2023-11-21 00:00:00.000000,Pregnancy Immunobiology Study,,https://anzctr.org.au/ACTRN12623000951651.aspx,2023-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3223,1287,2023-11-21 00:00:00.000000,Resistance Training and Multiple Sclerosis,,http://en.irct.ir/trial/71215,2023-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3224,1286,2022-03-12 06:20:41.569236,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,,https://clinicaltrials.gov/ct2/show/NCT04940065,2021-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3225,1285,2023-11-21 00:00:00.000000,Acceptability of a digital health application to empower persons with multiple sclerosis with moderate to severe disability: Single-arm prospective pilot study,,http://drks.de/search/en/trial/DRKS00032667,2023-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3226,1284,2023-11-21 00:00:00.000000,How does the NFL value change longitudinally after a change or start of disease modifying treatment?,,http://drks.de/search/en/trial/DRKS00032753,2023-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3227,1283,2023-11-21 00:00:00.000000,Homoeopathy in the treatment of multimorbidity in older adults,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=82099,2023-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3228,1282,2023-11-21 00:00:00.000000,The Effects of gain versus loss messages following adherence to the DASH diet and a low glycemic index diet in multiple sclerosis,,http://en.irct.ir/trial/72028,2023-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3229,1281,2023-11-21 00:00:00.000000,assessment of Fine motor ability and its relation to functional impairment in patients with Multiple Sclerosis.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=94284,2023-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3230,1280,2023-11-21 00:00:00.000000,The role of cholesterol metabolism and exosomes released from CD27hi p75NTR+ B cells in EBV-associated multiple sclerosis,,https://www.chictr.org.cn/showproj.html?proj=208249,2023-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3231,1279,2023-11-21 00:00:00.000000,Study of Effects of Group CFT on Social Isolation and Depression in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/73412,2023-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3232,1278,2023-11-21 00:00:00.000000,"Evaluation of the effect of vitamin B12, folic acid, and vitamin E on Multiple sclerosis amelioration",,http://en.irct.ir/trial/72559,2023-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3233,1277,2023-11-21 00:00:00.000000,OTAGO exercise program to improve the balance and reduce fear of falling in individuals with Multiple Sclerosis.,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=95009,2023-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3234,1276,2023-11-21 00:00:00.000000,Measurement of involuntary muscle contraction in adults with spasticity,,https://anzctr.org.au/ACTRN12623001135606.aspx,2023-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3235,1275,2023-11-21 00:00:00.000000,The Effect of Music on Pain Intensity and Sleep Quality,,http://en.irct.ir/trial/73177,2023-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3236,1274,2023-11-21 00:00:00.000000,Assessing the utility of BioEye eye-tracking technology in managing neurological conditions,,https://anzctr.org.au/ACTRN12623001151628.aspx,2023-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3237,1273,2023-11-21 00:00:00.000000,A validation study to evaluate performance and safety of the BioEye application,,https://anzctr.org.au/ACTRN12623001150639.aspx,2023-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3238,1272,2023-11-21 00:00:00.000000,Effect of aspirin in fatigue of multiple sclerosis,,http://en.irct.ir/trial/71779,2023-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3239,1271,2023-11-21 12:43:16.754060,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...","<p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT<br />Start Date: 2022-09-29<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/GR"">GR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2022-000049-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3240,1270,2023-11-20 07:23:14.534548,"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis","<p>EudraCT Number: 2010-020338-25<br />Sponsor Protocol Number: WA25046<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2010-11-02<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DK"">DK</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PL"">PL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2010-020338-25,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3241,1269,2023-11-18 14:43:11.636235,"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","<b>Conditions</b>: Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive
<br /><b>Interventions</b>: Biological: KYV-101 anti-CD19 CAR-T cell therapy; Drug: Standard lymphodepletion regimen
<br /><b>Sponsors</b>: Stanford University; Kyverna Therapeutics
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06138132,2023-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3242,1268,2023-11-18 14:43:11.625699,Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Dalfampridine 10 MG [Ampyra]; Behavioral: Physical therapy; Other: Dalfampridine plus physical therapy
<br /><b>Sponsors</b>: MGH Institute of Health Professions
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06136728,2023-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3243,1267,2023-11-18 14:43:11.615827,"An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer","<b>Conditions</b>: Multiple Sclerosis; Lung Cancer; Breast Cancer
<br /><b>Interventions</b>: Device: CT-100-D-004-A; Device: CT-100-D-004-B
<br /><b>Sponsors</b>: Click Therapeutics, Inc.
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06136923,2023-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3244,1266,2023-11-18 14:43:11.602574,Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities,"<b>Conditions</b>: Telomeric 22Q13 Monosomy Syndrome; Tuberous Sclerosis; Hamartoma Syndrome, Multiple; Fragile X Syndrome; Angelman Syndrome; Rett Syndrome; Chromosome 15Q, Partial Deletion; Creatine Deficiency, X-linked
<br /><b>Interventions</b>: Behavioral: Functional Behavioral Training (FBT); Other: Positive Parenting Strategies-Treatment as Usual
<br /><b>Sponsors</b>: Rush University Medical Center; Emory University
<br /><b>Enrolling by invitation</b>",https://clinicaltrials.gov/study/NCT06139172?cond=Multiple+Sclerosis,2023-11-18 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
3245,1265,2023-11-17 09:03:19.044307,"A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...","<p>EudraCT Number: 2020-005971-11<br />Sponsor Protocol Number: AP101-02<br />Sponsor Name: AL-S Pharma, AG<br />Start Date: 2021-12-22<br />Medical condition: Amyotrophic Lateral Sclerosis  (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005971-11/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-005971-11,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3246,1264,2023-11-16 09:03:17.560803,"Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...","<p>EudraCT Number: 2007-006338-32<br />Sponsor Protocol Number: WA21493<br />Sponsor Name: Hoffman La Roche Ltd<br />Start Date: 2008-05-06<br />Medical condition: Relapsing remitting multiple sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2007-006338-32,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3247,1263,2023-11-15 13:40:46.111844,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...","<p>EudraCT Number: 2020-004128-41<br />Sponsor Protocol Number: WN42086<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-08-24<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-004128-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3248,1262,2023-11-15 13:40:45.439441,A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Ozanimod; Drug: Select DMTs other than ozanimod; Drug: No DMTs
<br /><b>Sponsors</b>: Bristol-Myers Squibb
<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06133049,2023-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3249,1261,2023-11-15 12:23:13.131593,"A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the T...","<p>EudraCT Number: 2021-000639-30<br />Sponsor Protocol Number: AB20009<br />Sponsor Name: AB Science<br />Start Date: 2022-01-12<br />Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/NO"">NO</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000639-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3250,1260,2023-11-15 11:40:57.608722,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-004719-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3251,1259,2023-11-14 12:33:08.839590,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","<p>EudraCT Number: 2019-004857-10<br />Sponsor Protocol Number: GN41851<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-11-20<br />Medical condition: Relapsing multiple sclerosis (RMS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004857-10/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-004857-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3252,1258,2023-11-13 14:03:20.769891,A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments,"<b>Conditions</b>: Multiple Sclerosis, Relapsing-Remitting
<br /><b>Sponsors</b>: Biogen
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06127095,2023-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3253,1257,2023-11-13 14:03:20.757374,"The Effect of Yoga on Sleep Quality, Fatigue and Physical Activity Level of Multiple Sclerosis","<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Behavioral: Yoga
<br /><b>Sponsors</b>: Ataturk University
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06128668,2023-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3254,1256,2023-11-13 14:03:20.741665,"the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis","<b>Conditions</b>: Multiple Sclerosis, Relapsing-Remitting
<br /><b>Interventions</b>: Behavioral: Reiki
<br /><b>Sponsors</b>: Ataturk University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06129019,2023-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3255,1255,2023-11-13 11:03:15.061243,A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS),"<p>EudraCT Number: 2020-003995-42<br />Sponsor Protocol Number: MS700568_0157<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-12-18<br />Medical condition: Highly-active relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003995-42,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3256,1254,2023-11-12 14:53:11.759530,"Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T...","<p>EudraCT Number: 2020-003231-19<br />Sponsor Protocol Number: ViRap<br />Sponsor Name: The Children's Memorial Health Institute<br />Start Date: Information not available in EudraCT<br />Medical condition: Tuberous Sclerosis Complex
Epilepsy
Tumors associated with Tuberous Sclerosis Complex<br />Disease: <br />Population Age: Infants and toddlers, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003231-19/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003231-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3257,1253,2023-11-12 14:53:11.749585,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2017-004703-51<br />Sponsor Protocol Number: COMB157G2399<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-01-10<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-004703-51,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3258,1252,2023-11-12 14:53:11.737891,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...","<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV"">LV</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-001341-40,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3259,1251,2023-11-12 14:53:11.726822,"An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...","<p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE"">SE</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI"">FI</a> (Temporarily Halted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-000826-22,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3260,1250,2023-11-12 14:53:11.716618,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis","<p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000637-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3261,1249,2023-11-12 14:53:11.705785,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","<p>EudraCT Number: 2020-000645-14<br />Sponsor Protocol Number: EFC16035<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-10-13<br />Medical condition: Primary Progressive Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NO"">NO</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000645-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3262,1248,2023-11-12 14:53:11.695441,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-002700-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3263,1247,2023-11-12 14:53:11.682292,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","<p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2022-08-05<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-005746-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3264,1246,2023-11-11 20:40:46.985569,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","<p>EudraCT Number: 2020-000645-14<br />Sponsor Protocol Number: EFC16035<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-10-13<br />Medical condition: Primary Progressive Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NO"">NO</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000645-14,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
3265,1245,2023-11-11 20:31:42.184229,Verbanden tussen therapietrouw aan glatirameer acetaat (Copaxone) en ontvangen zorg bij patienten met aanvalsgewijze multipele sclerose.,,https://www.onderzoekmetmensen.nl/en/trial/26562,2010-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3266,1244,2023-11-11 20:31:42.184229,Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02220244,2014-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3267,1243,2023-11-11 20:31:42.184229,Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02485223,2015-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3268,1242,2023-11-11 20:31:42.184229,ASSESSMENT OF EARLY  CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003209-14,2015-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3269,1241,2023-11-11 20:31:42.184229,Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02496416,2015-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3270,1240,2023-11-11 20:31:42.184229,Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS,,https://clinicaltrials.gov/show/NCT02518776,2015-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3271,1239,2023-11-11 20:31:42.184229,Effects of Stimulation Patterns of Deep Brain Stimulation,,https://clinicaltrials.gov/show/NCT02553525,2015-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3272,1238,2023-11-11 20:31:42.184229,Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02607020,2015-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3273,1237,2023-11-11 20:31:42.184229,Adderall XR and Cognitive Impairment in MS,,https://clinicaltrials.gov/ct2/show/NCT02676739,2016-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3274,1236,2023-11-11 20:31:42.184229,Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers,,https://clinicaltrials.gov/show/NCT02760082,2016-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3275,1235,2023-11-11 20:31:42.184229,The effect of self-care program on quality of life and coping skills of multiple sclerosis patients,,http://en.irct.ir/trial/48056,2020-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3276,1234,2023-11-11 20:31:42.184229,Evaluation of the effect of Trazodone in hospitalized patients with MS,,http://en.irct.ir/trial/57418,2021-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3277,1233,2023-11-11 20:31:42.184229,The effect of Atomoxetine on Cognitive Function of Multiple Sclerosis,,http://en.irct.ir/trial/58215,2021-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3278,1232,2023-11-11 20:31:42.184229,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),,https://clinicaltrials.gov/ct2/show/NCT00001248,1999-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3279,1231,2023-11-11 20:31:42.184229,Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00006060,2000-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3280,1230,2023-11-11 20:31:42.184229,"Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004519-43,2005-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3281,1229,2023-11-11 20:31:42.184229,Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001008-37,2005-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3282,1228,2023-11-11 20:31:42.184229,Cannabinoids in progressive inflammatory brain disease (CUPID),,http://isrctn.com/ISRCTN62942668,2005-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3283,1227,2023-11-11 20:31:42.184229,BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001340-22,2005-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3284,1226,2023-11-11 20:31:42.184229,Rehabilitation and driving with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12605000121662.aspx,2005-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3285,1225,2023-11-11 20:31:42.184229,Sleep Disorders in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00137904,2005-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3286,1224,2023-11-11 20:31:42.184229,Effects of Spinal Cord Injury on Female Sexual Response,,http://clinicaltrials.gov/show/NCT00142714,2005-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3287,1223,2023-11-11 20:31:42.184229,Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients,,http://clinicaltrials.gov/show/NCT00151801,2005-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3288,1222,2023-11-11 20:31:42.184229,Use of Cannabinoids in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00202423,2005-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3289,1221,2023-11-11 20:31:42.184229,Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS,,http://clinicaltrials.gov/show/NCT00210301,2005-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3290,1220,2023-11-11 20:31:42.184229,Fatigue Treatment Using Provigil,,http://clinicaltrials.gov/show/NCT00220506,2005-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3291,1219,2023-11-11 20:31:42.184229,Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients,,http://clinicaltrials.gov/show/NCT00220493,2005-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3292,1218,2023-11-11 20:31:42.184229,T-Cell Vaccination in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00220428,2005-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3293,1217,2023-11-11 20:31:42.184229,A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00217295,2005-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3294,1216,2023-11-11 20:31:42.184229,MSBase- An international Registry dedicated to evaluating outcomes data in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12605000455662.aspx,2005-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3295,1215,2023-11-11 20:31:42.184229,TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00228228,2005-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3296,1214,2023-11-11 20:31:42.184229,Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00230204,2005-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3297,1213,2023-11-11 20:31:42.184229,"A Multi-Centre, Open label Study to Investigate the Recovery of Interferon-b Efficacy in Relapsing-Remitting Multiple Sclerosis Patients with Neutralising IFN-b Antibodies and Reduced Bioavailability.",,https://anzctr.org.au/ACTRN12605000657628.aspx,2005-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3298,1212,2023-11-11 20:31:42.184229,A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00242268,2005-10-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3299,1211,2023-11-11 20:31:42.184229,Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity. - Mitoxantrone in high activity multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001286-17,2006-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3300,1210,2023-11-11 20:31:42.184229,Fluoxetine in progressive multiple sclerosis: A placebo-controlled randomized trial.,,https://www.onderzoekmetmensen.nl/en/trial/23448,2006-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3301,1209,2023-11-11 20:31:42.184229,Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate,,http://clinicaltrials.gov/show/NCT00331747,2006-05-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3302,1208,2023-11-11 20:31:42.184229,Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit,,http://clinicaltrials.gov/show/NCT00338637,2006-06-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3303,1207,2023-11-11 20:31:42.184229,"An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005679-13,2006-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3304,1206,2023-11-11 20:31:42.184229,Dexamethason for the treatment of exacerbations in multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-003113-40,2006-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3305,1205,2023-11-11 20:31:42.184229,Influence on brain perfusion and metabolism through pharmacologic agents,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004318-42,2006-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3306,1204,2023-11-11 20:31:42.184229,Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001776-13,2006-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3307,1203,2023-11-11 20:31:42.184229,Correlation Between Cognitive Functions and MRI in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00423111,2007-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3308,1202,2023-11-11 20:31:42.184229,Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002562-19,2007-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3309,1201,2023-11-11 20:31:42.184229,Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00429442,2007-01-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3310,1200,2023-11-11 20:31:42.184229,A randomized controlled trial of progressive resistance strength training for people with multiple sclerosis who have difficulty walking,,https://anzctr.org.au/ACTRN12607000101482.aspx,2007-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3311,1199,2023-11-11 20:31:42.184229,Safety and Efficacy of BG00012 in Relapsing Remitting Multiple Sclerosis,,https://anzctr.org.au/ACTRN12607000124437.aspx,2007-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3312,1198,2023-11-11 20:31:42.184229,"MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON  REBIF 44 mcg X 3 TIMES WEEKLY  IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001601-10,2007-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3313,1197,2023-11-11 20:31:42.184229,"Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques

[Charakterisierung der Multiple Sklerose Pathologie durch “ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001337-17,2007-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3314,1196,2023-11-11 20:31:42.184229,"Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS   Neuroprotection by Memantine at Early Stage In Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000503-15,2007-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3315,1195,2023-11-11 20:31:42.184229,Evaluation of an Online Fatigue Self-management Group Intervention for Adults with Chronic Neurological Conditions,,https://anzctr.org.au/ACTRN12607000268448.aspx,2007-05-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3316,1194,2023-11-11 20:31:42.184229,"Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000590-37,2007-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3317,1193,2023-11-11 20:31:42.184229,multicentee randomized controlled study of azathioprine versus  iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004937-13,2007-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3318,1192,2023-11-11 20:31:42.184229,A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003086-40,2007-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3319,1191,2023-11-11 20:31:42.184229,Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-002179-15,2007-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3320,1190,2023-11-11 20:31:42.184229,EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006268-32,2007-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3321,1189,2023-11-11 20:31:42.184229,"Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005414-40,2007-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3322,1188,2023-11-11 20:31:42.184229,"Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohorte de 50 patients après un premier évènement (""CIS"" patients) à haut risque de développer une sclérose en plaques. - USPIO-CIS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005363-10,2007-11-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3323,1187,2023-11-11 20:31:42.184229,"Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres dosis de monoterapia con atacicept en sujetos con esclerosis múltiple recidivante (EMR) durante un periodo de tratamiento de 36 semanas.

A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003936-50,2008-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3324,1186,2023-11-11 20:31:42.184229,Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans. - USPIO-Mitox,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005362-12,2008-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3325,1185,2023-11-11 20:31:42.184229,"ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO,
PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE
METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA EN
PACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE
 - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis  Múltiple",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000888-15,2008-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3326,1184,2023-11-11 20:31:42.184229,"Randomized, single-blind, clinical and MRI study  for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000955-90,2008-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3327,1183,2023-11-11 20:31:42.184229,Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001940-38,2008-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3328,1182,2023-11-11 20:31:42.184229,Serum Auto-Antibodies in Neurological Diseases,,https://clinicaltrials.gov/show/NCT00704626,2008-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3329,1181,2023-11-11 20:31:42.184229,Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases,,https://clinicaltrials.gov/ct2/show/NCT00716066,2008-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3330,1180,2023-11-11 20:31:42.184229,"ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS 
- ETIMS -

 - ETIMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004408-29,2008-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3331,1179,2023-11-11 20:31:42.184229,Validation of an Obstacle Course Used in Patients With Muscle Tightness,,http://clinicaltrials.gov/show/NCT00776048,2008-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3332,1178,2023-11-11 20:31:42.184229,"POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiol
in Multiple sclerosis - POPART`MUS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005460-30,2008-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3333,1177,2023-11-11 20:31:42.184229,Evaluation of an Online Fatigue Self-management Group Intervention for Adults with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12608000553370.aspx,2008-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3334,1176,2023-11-11 20:31:42.184229,ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - RMaIDSM,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007162-32,2008-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3335,1175,2023-11-11 20:31:42.184229,Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System,,https://clinicaltrials.gov/ct2/show/NCT00794352,2008-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3336,1174,2023-11-11 20:31:42.184229,Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) - SHADOWTEP,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004174-40,2008-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3337,1173,2023-11-11 20:31:42.184229,Characteristic Study on Chinese Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00818103,2008-12-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3338,1172,2023-11-11 20:31:42.184229,"Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple recidivante

------------------------------------------------------------
A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosisA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis. - TENERE",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006226-34,2009-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3339,1171,2023-11-11 20:31:42.184229,Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005906-38,2009-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3340,1170,2023-11-11 20:31:42.184229,GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study).,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007447-14,2009-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3341,1169,2023-11-11 20:31:42.184229,"Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011516-37,2009-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3342,1168,2023-11-11 20:31:42.184229,Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00910598,2009-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3343,1167,2023-11-11 20:31:42.184229,Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT00914758,2009-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3344,1166,2023-11-11 20:31:42.184229,"A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCT",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013129-41,2009-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3345,1165,2023-11-11 20:31:42.184229,The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT00917839,2009-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3346,1164,2023-11-11 20:31:42.184229,Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms,,https://clinicaltrials.gov/ct2/show/NCT00919217,2009-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3347,1163,2023-11-11 20:31:42.184229,Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011585-28,2009-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3348,1162,2023-11-11 20:31:42.184229,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials,,https://clinicaltrials.gov/show/NCT01013350,2009-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3349,1161,2023-11-11 20:31:42.184229,NARCOMS Registry: A Multiple Sclerosis Registry,,https://clinicaltrials.gov/ct2/show/NCT01018537,2009-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3350,1160,2023-11-11 20:31:42.184229,Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct,,http://clinicaltrials.gov/show/NCT01024985,2009-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3351,1159,2023-11-11 20:31:42.184229,Novel Immune Markers in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01026272,2009-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3352,1158,2023-11-11 20:31:42.184229,"The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis:
A Phase 2 Randomized, double-blind, four–arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012716-40,2009-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3353,1157,2023-11-11 20:31:42.184229,"Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016442-74,2009-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3354,1156,2023-11-11 20:31:42.184229,Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012500-11,2010-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3355,1155,2023-11-11 20:31:42.184229,Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01065727,2010-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3356,1154,2023-11-11 20:31:42.184229,"An international study, which is an extension to protocol AC 058B201, with the aim to study how safe and efficacious is the long-term treatment with ponesimod in three different doses in patients with relapsing-remitting multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011470-15,2010-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3357,1153,2023-11-11 20:31:42.184229,Gabapentin as symptomatic therapy of cerebellar ataxia in degenerative and inflammatory CNS-disease,,http://drks.de/search/en/trial/DRKS00000269,2010-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3358,1152,2023-11-11 20:31:42.184229,Pharmacogenomics of Drug Safety in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01118130,2010-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3359,1151,2023-11-11 20:31:42.184229,low dose Aspirin for improving fatigue of multiple sclerosis patients,,https://anzctr.org.au/ACTRN12610000353099.aspx,2010-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3360,1150,2022-03-11 20:20:41.430654,"Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer&#39;s Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ...",,https://www.novartis.com//clinicaltrials/study/nct04795466,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3361,1149,2023-11-11 20:31:42.184229,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01194570,2010-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3362,1148,2023-11-11 20:31:42.184229,A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020338-25,2010-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3363,1147,2023-11-11 20:31:42.184229,Impact of Vitamin A on Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01417273,2010-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3364,1146,2023-11-11 20:31:42.184229,The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023996-25,2010-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3365,1145,2023-11-11 20:31:42.184229,"Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023560-40,2010-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3366,1144,2023-11-11 20:31:42.184229,"Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient",,http://clinicaltrials.gov/show/NCT01407211,2011-02-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3367,1143,2023-11-11 20:31:42.184229,Genes and Environment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01353547,2011-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3368,1142,2023-11-11 20:31:42.184229,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica,,http://clinicaltrials.gov/show/NCT01364246,2011-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3369,1141,2023-11-11 20:31:42.184229,Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01371071,2011-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3370,1140,2023-11-11 20:31:42.184229,Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023677-19,2011-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3371,1139,2023-11-11 20:31:42.184229,A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020337-99,2010-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3372,1138,2023-11-11 20:31:42.184229,Evaluación de masitinib en esclerosis múltiple,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021219-17,2011-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3373,1137,2023-11-11 20:31:42.184229,Fluoxetine therapy for multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003775-11,2011-07-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3374,1136,2023-11-11 20:31:42.184229,"A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002969-38,2011-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3375,1135,2023-11-11 20:31:42.184229,The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01453868,2011-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3376,1134,2023-11-11 20:31:42.184229,Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition,,https://clinicaltrials.gov/show/NCT01466114,2011-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3377,1133,2023-11-11 20:31:42.184229,The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003570-89,2011-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3378,1132,2023-11-11 20:31:42.184229,A clinical trial to test if NU100 is safe and can treat patient with relapsing types of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002683-24,2011-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3379,1131,2023-11-11 20:31:42.184229,"EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000150-31,2011-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3380,1130,2023-11-11 20:31:42.184229,Electrical stimulation for foot drop in people with multiple sclerosis (MS),,https://anzctr.org.au/ACTRN12612000201875.aspx,2012-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3381,1129,2023-11-11 20:31:42.184229,"Investigating Fatigue, Balance, Falls and Mobility in people with Multiple Sclerosis",,https://anzctr.org.au/ACTRN12612000218897.aspx,2012-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3382,1128,2023-11-11 20:31:42.184229,A Phase 1/2 study to test how effective different doses of MEDI-551 is for treating subjects with Relapsing-Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005475-16,2012-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3383,1127,2023-11-11 20:31:42.184229,Study of the relationship between pathophysiology of neurological disease including multiple sclerosis and function of LOTUS,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009254,2012-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3384,1126,2023-11-11 20:31:42.184229,Neutralizing antibody of Interferon beta on multiple sclerosis  (Multi-center clinical studies),,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009647,2012-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3385,1125,2023-11-11 20:31:42.184229,Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT01659593,2012-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3386,1124,2023-11-11 20:31:42.184229,Effect of cooling in aerobic exercise on fatigue and physical performance for people with Multiple Sclerosis: A preliminary crossover trial,,https://anzctr.org.au/ACTRN12612000862842.aspx,2012-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3387,1123,2023-11-11 20:31:42.184229,"Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36,2012-03-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3388,1122,2023-11-11 20:31:42.184229,"Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with BAF312",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36,2012-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3389,1121,2023-11-11 20:31:42.184229,Study of B cell functions in multiple sclerosis.,,https://www.onderzoekmetmensen.nl/en/trial/24833,2012-09-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3390,1120,2023-11-11 20:31:42.184229,Complementary and Alternative Care in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01703429,2012-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3391,1119,2023-11-11 20:31:42.184229,Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01705457,2012-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3392,1118,2023-11-11 20:31:42.184229,Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004019-29,2012-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3393,1117,2023-11-11 20:31:42.184229,"Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT01720849,2012-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3394,1116,2023-11-11 20:31:42.184229,Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01879202,2012-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3395,1115,2023-11-11 20:31:42.184229,The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01743664,2012-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3396,1114,2023-11-11 20:31:42.184229,A long term follow up study to look at the progress of patients with symptoms suggestive of MS who took part in previous studies with Betaferon®/Betaseron®,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005262-35,2013-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3397,1113,2023-11-11 20:31:42.184229,Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity,,http://clinicaltrials.gov/show/NCT01786005,2013-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3398,1112,2023-11-11 20:31:42.184229,Safety and efficacy of fingolimod in pediatric patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005677-23,2013-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3399,1111,2023-11-11 20:31:42.184229,Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005113-39,2013-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3400,1110,2023-11-11 20:31:42.184229,Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT01891071,2013-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3401,1109,2023-11-11 20:31:42.184229,Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner,,http://clinicaltrials.gov/show/NCT01805986,2013-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3402,1108,2023-11-11 20:31:42.184229,"Natalizumab de-escalation to interferon-beta-1b in patients with
relapsing-remitting multiple sclerosis: A multicenter study",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004040-30,2013-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3403,1107,2023-11-11 20:31:42.184229,A Single Centre Phase II Study Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Auto-Immune Diseases.,,https://anzctr.org.au/ACTRN12613000339752.aspx,2013-03-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3404,1106,2023-11-11 20:31:42.184229,MEsenchymal StEm Cells for Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT01854957,2013-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3405,1105,2023-11-11 20:31:42.184229,Safety and Efficacy of BMMNC in Multiple Sclerosis (MS),,http://clinicaltrials.gov/show/NCT01883661,2013-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3406,1104,2023-11-11 20:31:42.184229,Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients,,http://clinicaltrials.gov/show/NCT01918501,2013-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3407,1103,2023-11-11 20:31:42.184229,Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses,,https://clinicaltrials.gov/show/NCT01900093,2013-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3408,1102,2023-11-11 20:31:42.184229,Spinal blood flow and metabolism in neurological diseases,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013014,2013-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3409,1101,2023-11-11 20:31:42.184229,Measurement of Relaxin Peptide in Multiple Sclerosis (MS),,https://clinicaltrials.gov/ct2/show/NCT01909492,2013-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3410,1100,2023-11-11 20:31:42.184229,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,,http://clinicaltrials.gov/show/NCT01918748,2013-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3411,1099,2023-11-11 20:31:42.184229,"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",,https://clinicaltrials.gov/show/NCT01931644,2013-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3412,1098,2023-11-11 20:31:42.184229,"Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005450-30,2013-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3413,1097,2023-11-11 20:31:42.184229,The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014841,2014-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3414,1096,2023-11-11 20:31:42.184229,Bone marrow cell treatment as treatment of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000734-19,2014-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3415,1095,2023-11-11 20:31:42.184229,"A study to assess immune function and typical disease characteristics in patients with multiple sclerosis, when switching from the medication Natalizumab to the medication Gilenya.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004616-21,2014-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3416,1094,2023-11-11 20:31:42.184229,"A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT02057159,2014-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3417,1093,2023-11-11 20:31:42.184229,Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02059096,2014-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3418,1092,2023-11-11 20:31:42.184229,Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003126-83,2014-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3419,1091,2023-11-11 20:31:42.184229,Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMs).,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002318-11,2014-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3420,1090,2023-11-11 20:31:42.184229,"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005249-12,2014-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3421,1089,2023-11-11 20:31:42.184229,Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003884-71,2014-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3422,1088,2022-03-11 14:47:23.013971,Neuromodulation in MS Using Translingual Stimulation,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Combination Product: PT plus translingual stimulation device;   Combination Product: PT plus translingual stimulation control device<br /><b>Sponsors</b>:    University of Saskatchewan;   Memorial University of Newfoundland<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/show/NCT05275049,2021-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3423,1087,2023-11-11 20:31:42.184229,Development of novel biomarkers of neurodegenerative diseases-comprehensive analysis of the proteins and the RNAs in exosomes extracted from cerebrospinal fluid and urine,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017525,2014-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3424,1086,2023-11-11 20:31:42.184229,"Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS",,http://clinicaltrials.gov/show/NCT02273635,2014-03-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3425,1085,2023-11-11 20:31:42.184229,Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/24446,2014-06-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3426,1084,2023-11-11 20:31:42.184229,Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods,,https://clinicaltrials.gov/show/NCT02291107,2014-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3427,1083,2023-11-11 20:31:42.184229,"The purpose of this study is to examine the safety and efficacy of VSN16R and the performance in treating spasticity (tightness, stiffness or ""pull"" of muscles) in patients with Multiple Sclerosis (MS).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004412-11,2014-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3428,1082,2023-11-11 20:31:42.184229,Fall Risk Reduction in Multiple Sclerosis (FIRMS),,https://clinicaltrials.gov/show/NCT02314585,2014-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3429,1081,2023-11-11 20:31:42.184229,Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02364986,2014-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3430,1080,2023-11-11 20:31:42.184229,"Multiple Sclerosis, menopause and hormone replacement therapy",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005129-10,2014-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3431,1079,2023-11-11 20:31:42.184229,Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02331654,2014-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3432,1078,2023-11-11 20:31:42.184229,Swiss Multiple Sclerosis Cohort-Study,,https://clinicaltrials.gov/show/NCT02433028,2014-12-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3433,1077,2023-11-11 20:31:42.184229,Administration of Mirabegron 50mg in patients with neurogenic bladder,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002592-29,2014-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3434,1076,2023-11-11 20:31:42.184229,DTI in Children With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02361697,2015-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3435,1075,2023-11-11 20:31:42.184229,Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis,,http://clinicaltrials.gov/show/NCT02352194,2015-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3436,1074,2023-11-11 20:31:42.184229,Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000182-31,2015-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3437,1073,2023-11-11 20:31:42.184229,Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02369926,2015-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3438,1072,2023-11-11 20:31:42.184229,Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720),,http://clinicaltrials.gov/show/NCT02408380,2015-03-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3439,1071,2023-11-11 20:31:42.184229,Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study,,http://clinicaltrials.gov/show/NCT02408367,2015-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3440,1070,2022-03-11 11:30:24.347794,"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)",,https://www.novartis.com//clinicaltrials/study/nct04868968,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3441,1069,2023-11-11 20:31:42.184229,D-mannose for the Prevention of UTIs in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02490046,2015-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3442,1068,2023-11-11 20:31:42.184229,Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures,,https://clinicaltrials.gov/show/NCT02777060,2015-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3443,1067,2023-11-11 20:31:42.184229,Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02468765,2015-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3444,1066,2022-03-11 11:30:24.340166,"A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age",,https://www.novartis.com//clinicaltrials/study/nct04946318,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3445,1065,2023-11-11 20:31:42.184229,A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS,,https://clinicaltrials.gov/show/NCT02490943,2015-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3446,1064,2023-11-11 20:31:42.184229,iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02486562,2015-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3447,1063,2023-11-11 20:31:42.184229,11C-acetate PET for Multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021027,2015-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3448,1062,2022-03-11 11:30:24.331596,Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer),,https://www.novartis.com//clinicaltrials/study/nct04575025,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3449,1061,2023-11-11 20:31:42.184229,Can Do Training in relapsing MS,,https://www.onderzoekmetmensen.nl/en/trial/25770,2015-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3450,1060,2023-11-11 20:31:42.184229,Impact of a program of global exercises on balance and memory of subjects with Mutiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-9gh4km,2015-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3451,1059,2023-11-11 20:31:42.184229,Effects of dalfampridine on mobility in the context of daily life,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003498-41,2015-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3452,1058,2022-03-11 11:30:24.316439,"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema",,https://www.novartis.com//clinicaltrials/study/nct04058067,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3453,1057,2023-11-11 20:31:42.184229,Evaluation of upper limb motor performances using tablet-based tests,,http://drks.de/search/en/trial/DRKS00009022,2015-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3454,1056,2023-11-11 20:31:42.184229,"Improvement of walking ability, balance and coordination in patients with multiple sclerosis under PR Fampridine therapy",,http://drks.de/search/en/trial/DRKS00009228,2015-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3455,1055,2023-11-11 20:31:42.184229,Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells,,https://clinicaltrials.gov/ct2/show/NCT02674217,2015-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3456,1054,2022-03-11 11:30:24.307013,"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria",,https://www.novartis.com//clinicaltrials/study/nct04812548,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3457,1053,2023-11-11 20:31:42.184229,Mesenchymal stem cells therapy for patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000137-78,2015-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3458,1052,2023-11-11 20:31:42.184229,A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,,https://clinicaltrials.gov/show/NCT02418325,2015-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3459,1051,2023-11-11 20:31:42.184229,A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,,https://clinicaltrials.gov/show/NCT02418351,2015-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3460,1050,2022-03-11 11:30:24.300229,"A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan",,https://www.novartis.com//clinicaltrials/study/nct05114746,2022-03-11 11:30:24.300229,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3461,1049,2023-11-11 20:31:42.184229,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,,https://clinicaltrials.gov/show/NCT02649985,2016-06-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3462,1048,2023-11-11 20:31:42.184229,Pathological Basis of MRI Signal Changes in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT02659956,2016-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3463,1047,2023-11-11 20:31:42.184229,Quality Improvement and Practice Based Research in Neurology Using the EMR,,https://clinicaltrials.gov/ct2/show/NCT02670161,2016-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3464,1046,2022-03-11 11:30:24.290363,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04926818,2021-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3465,1045,2023-11-11 20:31:42.184229,"A Phase II  study:
Haematopoietic Stem Cell Transplantation for highly active
treatment resistant  multiple sclerosis .",,https://anzctr.org.au/ACTRN12616000151437.aspx,2016-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3466,1044,2023-11-11 20:31:42.184229,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),,https://clinicaltrials.gov/ct2/show/NCT02688985,2016-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3467,1043,2023-11-11 20:31:42.184229,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005597-38,2016-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3468,1042,2023-11-11 20:31:42.184229,Methylprednisolone During the Switch Between Natalizumab and Fingolimod,,https://clinicaltrials.gov/show/NCT02769689,2016-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3469,1041,2023-11-11 20:31:42.184229,Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02759211,2016-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3470,1040,2023-11-11 20:31:42.184229,Impact of Tecfidera on Gut Microbiota,,https://clinicaltrials.gov/show/NCT02736279,2016-03-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3471,1039,2023-11-11 20:31:42.184229,Interventions to improve gait and reduce falls in people with multiple sclerosis (MS),,https://anzctr.org.au/ACTRN12616000415404.aspx,2016-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3472,1038,2023-11-11 20:31:42.184229,Reduce the number of natalizumab infusions in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000345-31,2016-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3473,1037,2023-11-11 20:31:42.184229,Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients,,https://clinicaltrials.gov/ct2/show/NCT02747914,2016-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3474,1036,2023-11-11 20:31:42.184229,Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy,,https://clinicaltrials.gov/show/NCT03133403,2016-04-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3475,1035,2023-11-11 20:31:42.184229,"Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.",,https://clinicaltrials.gov/show/NCT02769767,2016-04-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3476,1034,2022-03-11 11:30:23.276296,"A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors",,https://www.novartis.com//clinicaltrials/study/nct04795427,,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
3477,1033,2023-11-11 20:31:42.184229,Impact of exercise on the urinary control muscles in women with Multiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-5ph2zw,2014-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3478,1032,2023-11-11 20:31:42.184229,"To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003147-19,2016-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3479,1031,2023-11-11 20:31:42.184229,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,,https://clinicaltrials.gov/ct2/show/NCT02784210,2016-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3480,1030,2023-11-11 20:31:42.184229,Default Mode Network in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02810314,2016-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3481,1029,2023-11-11 20:31:42.184229,Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000541-12,2016-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3482,1028,2023-11-11 20:31:42.184229,Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders,,https://clinicaltrials.gov/show/NCT02836327,2016-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3483,1027,2023-11-11 20:31:42.184229,Multiple sclerosis therapy with transdermal myelin peptide stimulation.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002180-33,2016-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3484,1026,2023-11-11 20:31:42.184229,Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS),,https://clinicaltrials.gov/ct2/show/NCT02903537,2016-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3485,1025,2023-11-11 20:31:42.184229,An interactive step training system to reduce falls in people with multiple sclerosis: a randomised controlled trial,,https://anzctr.org.au/ACTRN12616001053415.aspx,2016-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3486,1024,2023-11-11 20:31:42.184229,Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02876536,2016-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3487,1023,2023-11-11 20:31:42.184229,A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT02874677,2016-08-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3488,1022,2023-11-11 20:31:42.184229,Lorraine Registry of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02883335,2016-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3489,1021,2023-11-11 20:31:42.184229,The French Multiple Sclerosis Registry,,https://clinicaltrials.gov/show/NCT02889965,2016-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3490,1020,2023-11-11 20:31:42.184229,Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02912897,2016-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3491,1019,2023-11-11 20:31:42.184229,"PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000434-21,2016-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3492,1018,2023-11-11 20:31:42.184229,Does MS grey matter pathology progress faster in regions with more damage in connected white matter?,,https://www.onderzoekmetmensen.nl/en/trial/23313,2016-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3493,1017,2023-11-11 20:31:42.184229,A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001448-21,2016-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3494,1016,2023-11-11 20:31:42.184229,Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT02966808,2016-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3495,1015,2023-11-11 20:31:42.184229,Effect of vestibular rehablitation on fatigue,,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1853,2016-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3496,1014,2023-11-11 20:31:42.184229,The German Multiple Sclerosis Registry of the German MS Society,,http://drks.de/search/en/trial/DRKS00011257,2016-11-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3497,1013,2023-11-11 20:31:42.184229,"A research in patients with progressive multiple sclerosis, primary as well as the secondary form. Two groups of patients in which one group of patients receives IVIG medication and the patients of the other group do not receive medication for their progressive multiple sclerosis. 
With questionnaires we measure if there is a difference in quality of life and fatigue in these two groups of patients.",,https://www.onderzoekmetmensen.nl/en/trial/27216,2016-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3498,1012,2023-11-11 20:31:42.184229,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT02975349,2016-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3499,1011,2023-11-11 20:31:42.184229,Swiss Multiple Sclerosis Registry,,https://clinicaltrials.gov/show/NCT02980640,2016-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3500,1010,2023-11-11 20:31:42.184229,Prospective Investigation of Multiple Sclerosis in the Three Rivers Region,,https://clinicaltrials.gov/show/NCT02994121,2016-12-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3501,1009,2023-11-11 20:31:42.184229,Development of quantitative evaluation of walking disability for neurodegenerative diseases using an infrared depth-sensing camera,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028927,2016-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3502,1008,2023-11-11 20:31:42.184229,"The therapeutic effects of ß, D, Mannuronic acid in patients with multiple sclerosis",,http://en.irct.ir/trial/13521,2017-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3503,1007,2023-11-11 20:31:42.184229,Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training,,https://clinicaltrials.gov/show/NCT03057652,2017-02-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3504,1006,2023-11-11 20:31:42.184229,Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica relapses during pregnancy and breastfeeding,,http://drks.de/search/en/trial/DRKS00011770,2017-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3505,1005,2023-11-11 20:31:42.184229,Cellular immunity after alemtuzumab,,http://drks.de/search/en/trial/DRKS00011205,2017-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3506,1004,2023-11-11 20:31:42.184229,"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003100-30,2017-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3507,1003,2023-11-11 20:31:42.184229,Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT03069170,2017-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3508,1002,2023-11-11 20:31:42.184229,The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003622-16,2017-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3509,1001,2023-11-11 20:31:42.184229,Armergometry to Improve Mobility in MS,,https://clinicaltrials.gov/show/NCT03147105,2017-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3510,1000,2023-11-11 20:31:42.184229,A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil,,https://clinicaltrials.gov/show/NCT03087136,2017-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3511,999,2023-11-11 20:31:42.184229,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),,https://clinicaltrials.gov/ct2/show/NCT03085810,2017-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3512,998,2023-11-11 20:31:42.184229,"This is a long-term study of the safety, efficacy and patient satisfaction of the drug rituximab in comparison with other immunomodulatory treatments for multiple sclerosis. The study will use a national registry for both retrospective and prospective data retrieval.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003587-39,2017-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3513,997,2023-11-11 20:31:42.184229,Exploring the potential of Hybrid Electrical Stimulation Cycling for aerobic exercise in Persons with Advanced Multiple Sclerosis,,https://anzctr.org.au/ACTRN12617000415303.aspx,2017-03-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3514,996,2023-11-11 20:31:42.184229,Effects of whole body vibration in the elderly and in neurologic disorders,,http://drks.de/search/en/trial/DRKS00012265,2017-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3515,995,2023-11-11 20:31:42.184229,Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03113162,2017-10-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3516,994,2023-11-11 20:31:42.184229,"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)",,https://clinicaltrials.gov/ct2/show/NCT03109288,2017-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3517,993,2023-11-11 20:31:42.184229,Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy,,https://clinicaltrials.gov/show/NCT03213522,2017-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3518,992,2023-11-11 20:31:42.184229,Clinical Applications of Advanced Ophthalmic Imaging,,https://clinicaltrials.gov/ct2/show/NCT03135327,2017-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3519,991,2023-11-11 20:31:42.184229,Therapeutic effect of Guluronat  on disease severity in MS,,http://en.irct.ir/trial/13523,2017-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3520,990,2023-11-11 20:31:42.184229,"Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis",,https://clinicaltrials.gov/show/NCT03153553,2017-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3521,989,2023-11-11 20:31:42.184229,Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03345940,2017-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3522,988,2023-11-11 20:31:42.184229,A hybrid functional electrical stimulation training program for persons with advanced multiple sclerosis,,https://anzctr.org.au/ACTRN12617000784314.aspx,2017-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3523,987,2023-11-11 20:31:42.184229,Cognitive rehabilitation and mindfulness in multiple sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/27244,2017-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3524,986,2023-11-11 20:31:42.184229,COMBAT-MS (COgnitive reMediation and Behavioural Approaches to Treatment in Multiple Sclerosis),,https://anzctr.org.au/ACTRN12617000808347.aspx,2017-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3525,985,2023-11-11 20:31:42.184229,Improving Dynamic Balance and Gait Adaptability Using Treadmill Training,,https://clinicaltrials.gov/show/NCT03201692,2017-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3526,984,2023-11-11 20:31:42.184229,Virtual Reality and Manual Dexterity in in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03186612,2017-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3527,983,2023-11-11 20:31:42.184229,The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03193086,2017-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3528,982,2023-11-11 20:31:42.184229,Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03216915,2017-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3529,981,2023-11-11 20:31:42.184229,Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03207464,2017-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3530,980,2023-11-11 20:31:42.184229,"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) ""Prevention of Relapse of Multiple Sclerosis""",,https://jrct.niph.go.jp/latest-detail/jRCT1080223004,2015-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3531,979,2023-11-11 20:31:42.184229,A research study to look at the long term benefits and risks of ponesimod 20 mg treatment for patients with relapsing multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10,2017-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3532,978,2023-11-11 20:31:42.184229,MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002634-24,2017-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3533,977,2023-11-11 20:31:42.184229,Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ?,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001253-13,2017-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3534,976,2023-11-11 20:31:42.184229,Biomarkers of Synaptic Damage in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03217396,2017-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3535,975,2023-11-11 20:31:42.184229,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),,https://clinicaltrials.gov/show/NCT03222973,2017-07-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3536,974,2023-11-11 20:31:42.184229,The Effect of Transcranial Direct Current Stimulation on Fatigue in Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00012766,2017-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3537,973,2023-11-11 20:31:42.184229,Effect of vaginal contraction exercise in bladder control in women with multiple sclerosis and neurological disease caused by the virus HTLV1,,http://ensaiosclinicos.gov.br/rg/RBR-2hpkp3,2017-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3538,972,2023-11-11 20:31:42.184229,Neurofilaments for NEDA Assessing in MS,,https://clinicaltrials.gov/show/NCT03250169,2017-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3539,971,2023-11-11 20:31:42.184229,"Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002838-23,2017-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3540,970,2023-11-11 20:31:42.184229,Retinal Imaging in Neurodegenerative Disease,,https://clinicaltrials.gov/ct2/show/NCT03233646,2017-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3541,969,2023-11-11 20:31:42.184229,Treatment of urinary incontinence in subjects with multiple sclerosis using pelvic floor training based on intravaginal electrical stimulation: changes in urinary leakages and quality of life.,,http://www.anzctr.org.au/ACTRN12617001113347.aspx,2017-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3542,968,2023-11-11 20:31:42.184229,Effect of saffron syrup on fatigue severity,,http://en.irct.ir/trial/22033,2017-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3543,967,2023-11-11 20:31:42.184229,"Understanding problems with attention, memory and concentration in persons with multiple sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002636-16,2017-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3544,966,2023-11-11 20:31:42.184229,Corevitas Multiple Sclerosis (MS) Registry,,https://clinicaltrials.gov/show/NCT03291756,2017-08-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3545,965,2023-11-11 20:31:42.184229,Ublituximab In Multiple Sclerosis Treatment Effects,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000639-15,2017-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3546,964,2023-11-11 20:31:42.184229,UbLiTuximab In Multiple Sclerosis Treatment Effects,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000638-75,2017-06-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3547,963,2023-11-11 20:31:42.184229,Effect of Erhuang Decoction on Memory Disorder in Patients with Recurrent Mitigation Multiple Sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=21518,2017-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3548,962,2023-11-11 20:31:42.184229,"A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS",,https://clinicaltrials.gov/show/NCT03283397,2017-12-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3549,961,2023-11-11 20:31:42.184229,"Evaluation of the “specialist program” for care in the fields of neurology, psychiatry, psychosomatics and psychotherapy in Baden-Wuerttemberg in accordance with §73c SGB V",,http://drks.de/search/en/trial/DRKS00013114,2017-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3550,960,2023-11-11 20:31:42.184229,Mechanism of Action of Ocrelizumab in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03344094,2017-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3551,959,2023-11-11 20:31:42.184229,"Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribine or ocrelizumab in patients with relapsing remitting multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001362-25,2017-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3552,958,2023-11-11 20:31:42.184229,Data Sharing as a Challenge for the Response Rate in Health Care Research in Germany? Randomized-controlled Study to Examine the Impact of Different Data Sharing Statements on the Response Rate,,http://drks.de/search/en/trial/DRKS00013115,2017-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3553,957,2023-11-11 20:31:42.184229,Optic Neuritis Differential Diagnosis Study,,https://clinicaltrials.gov/show/NCT03370965,2017-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3554,956,2023-11-11 20:31:42.184229,Low Fat Diet for Fatigue in MS,,https://clinicaltrials.gov/show/NCT03322982,2017-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3555,955,2023-11-11 20:31:42.184229,MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003328-56,2017-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3556,954,2023-11-11 20:31:42.184229,Investigating of red grape seeds on MS fatigue,,http://en.irct.ir/trial/8450,2017-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3557,953,2023-11-11 20:31:42.184229,Immediate effects of dry needling Hamstring muscles spasticity in in MS subjects,,http://en.irct.ir/trial/27323,2017-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3558,952,2023-11-11 20:31:42.184229,Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS,,https://clinicaltrials.gov/ct2/show/NCT03362294,2017-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3559,951,2023-11-11 20:31:42.184229,Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.,,https://clinicaltrials.gov/ct2/show/NCT03353974,2017-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3560,950,2023-11-11 20:31:42.184229,Efficacy of tDCS on Pain in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03389217,2017-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3561,949,2023-11-11 20:31:42.184229,Effect of two types of exercises on balance performance in patients with multiple sclerosis,,http://en.irct.ir/trial/16242,2014-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3562,948,2023-11-11 20:31:42.184229,PREG-MS: New England MS Pregnancy Registry,,https://clinicaltrials.gov/show/NCT03368157,2017-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3563,947,2023-11-11 20:31:42.184229,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),,https://clinicaltrials.gov/show/NCT03364036,2017-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3564,946,2023-11-11 20:31:42.184229,Vitamin D supplementation in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004846-31,2017-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3565,945,2023-11-11 20:31:42.184229,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),,https://clinicaltrials.gov/show/NCT03369665,2017-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3566,944,2023-11-11 20:31:42.184229,Multiple Sclerosis Registry in Argentina (RelevarEM),,https://clinicaltrials.gov/show/NCT03375177,2017-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3567,943,2023-11-11 20:31:42.184229,Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=23655,2017-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3568,942,2023-11-11 20:31:42.184229,Efficacy of Broad-Band Ultraviolet B  versus Vitamin D3 supplementation in balance control and cognitive functions in Patients with Multiple Sclerosis,,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=2891,2017-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3569,941,2023-11-11 20:31:42.184229,Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004414-10,2018-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3570,940,2023-11-11 20:31:42.184229,Cognition Evolution and MRI Markers in PPMS Patients on 2 Years,,https://clinicaltrials.gov/show/NCT03455582,2018-04-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3571,939,2023-11-11 20:31:42.184229,Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03401879,2018-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3572,938,2023-11-11 20:31:42.184229,The effect of fat-derived stem cells in treatment of   multiple sclerosis,,http://en.irct.ir/trial/2617,2018-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3573,937,2023-11-11 20:31:42.184229,Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03404388,2018-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3574,936,2023-11-11 20:31:42.184229,The Effects of FES in a Variety of Walking Conditions in People With MS,,https://clinicaltrials.gov/ct2/show/NCT03410498,2018-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3575,935,2023-11-11 20:31:42.184229,e-TREFAMS-CBT: Blended CBT for MS-related fatigue,,https://www.onderzoekmetmensen.nl/en/trial/23922,2018-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3576,934,2023-11-11 20:31:42.184229,Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects,,https://clinicaltrials.gov/show/NCT03424733,2018-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3577,933,2023-11-11 20:31:42.184229,"RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab in MS",,https://clinicaltrials.gov/ct2/show/NCT03477500,2018-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3578,932,2023-11-11 20:31:42.184229,Effect of Spirituality Education Program on Depression and Anxiety,,http://en.irct.ir/trial/25692,2018-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3579,931,2023-11-11 20:31:42.184229,Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial,,https://clinicaltrials.gov/ct2/show/NCT03500328,2018-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3580,930,2023-11-11 20:31:42.184229,Improving Learning in Hispanics With TBI or MS,,https://clinicaltrials.gov/show/NCT03453125,2018-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3581,929,2023-11-11 20:31:42.184229,Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000635-13,2018-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3582,928,2023-11-11 20:31:42.184229,Fall Prevention Program for Non-ambulatory Wheeled Mobility Device Users Living With MS,,https://clinicaltrials.gov/show/NCT03705364,2018-02-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3583,927,2023-11-11 20:31:42.184229,A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001313-93,2018-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3584,926,2023-11-11 20:31:42.184229,Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme,,https://clinicaltrials.gov/ct2/show/NCT03471338,2018-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3585,925,2023-11-11 20:31:42.184229,An evaluation of an online mindfulness programme for people with multiple sclerosis,,http://isrctn.com/ISRCTN14675178,2018-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3586,924,2023-11-11 20:31:42.184229,"The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trial",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000426-35,2018-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3587,923,2023-11-11 20:31:42.184229,The Study Effectiveness of Mindfulness integrated Cognitive Behavior Group Therapy on patients with Multiple Sclerosis,,http://en.irct.ir/trial/29957,2018-03-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3588,922,2023-11-11 20:31:42.184229,Effect of Fingolimod in Multiple Sclerosis,,http://en.irct.ir/trial/29466,2018-03-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3589,921,2023-11-11 20:31:42.184229,"Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a),  injected once a week via intramuscolar (i.m.), and glatiramer-acetate (GA) in children/adolescent patients with multiple sclerosis.",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-005129-18,2018-03-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3590,920,2023-11-11 20:31:42.184229,The effect of probiotic  Saccharomyces Bulardi in Multiple Sclerosis (MS),,http://en.irct.ir/trial/29990,2018-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3591,919,2023-11-11 20:31:42.184229,Effect of MS14 on multiple sclerosis,,http://en.irct.ir/trial/28801,2018-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3592,918,2023-11-11 20:31:42.184229,A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000721-31,2018-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3593,917,2023-11-11 20:31:42.184229,Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03536299,2018-02-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3594,916,2023-11-11 20:31:42.184229,Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis,,https://clinicaltrials.gov/show/NCT03540485,2018-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3595,915,2023-11-11 20:31:42.184229,Effect of foot reflexology in MS,,http://en.irct.ir/trial/30525,2018-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3596,914,2023-11-11 20:31:42.184229,Effect of two types of exercises on reaction speed and coordination in patients with multiple sclerosis,,http://en.irct.ir/trial/30604,2018-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3597,913,2023-11-11 20:31:42.184229,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,,https://clinicaltrials.gov/ct2/show/NCT03535298,2018-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3598,912,2023-11-11 20:31:42.184229,Risk Factors in Early Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03586986,2018-05-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3599,911,2023-11-11 20:31:42.184229,"Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)",,https://clinicaltrials.gov/show/NCT03541226,2018-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3600,910,2023-11-11 20:31:42.184229,Impact of Custom Assistive and Adaptive Technology in Rehabilitation,,https://clinicaltrials.gov/show/NCT03567239,2018-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3601,909,2023-11-11 20:31:42.184229,Protective Stepping & MS,,https://clinicaltrials.gov/ct2/show/NCT03551665,2018-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3602,908,2023-11-11 20:31:42.184229,The effect of Roy Jelly on quality of life and health status,,http://en.irct.ir/trial/31331,2018-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3603,907,2023-11-11 20:31:42.184229,The effect of N-acetylcysteine in the treatment of multiple sclerosis,,http://en.irct.ir/trial/31309,2018-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3604,906,2023-11-11 20:31:42.184229,Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001292-21,2018-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3605,905,2023-11-11 20:31:42.184229,Myo-inositol - a new imaging biomarker for Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00014854,2018-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3606,904,2023-11-11 20:31:42.184229,Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI,,https://clinicaltrials.gov/ct2/show/NCT03564496,2018-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3607,903,2023-11-11 20:31:42.184229,Escalationtherapy of a MS-relapse by Methylprednisolone vs Immunoadsorption,,http://drks.de/search/en/trial/DRKS00014289,2018-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3608,902,2023-11-11 20:31:42.184229,"90/5000
Different devices to interact with virtual environment in people with Multiple Sclerosis",,http://ensaiosclinicos.gov.br/rg/RBR-8d8rj7,2018-06-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3609,901,2023-11-11 20:31:42.184229,NA,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004158-40,2018-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3610,900,2023-11-11 20:31:42.184229,Behavior of multiple sclerosis patients' view in computer use,,http://ensaiosclinicos.gov.br/rg/RBR-4m6zdh,2018-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3611,899,2023-11-11 20:31:42.184229,Application of ihMT MRI in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03600779,2018-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3612,898,2023-11-11 20:31:42.184229,"The  of aquatic exercise interventions on quality of sleep, mental toughness, cognitive function, fatigue, paresthesia and depression among patients with Multiple Sclerosis (MS)",,http://en.irct.ir/trial/32341,2018-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3613,897,2023-11-11 20:31:42.184229,The effect of cognitive rehabilitation based on information processing speed on occupational performance in people with Multiple Sclerosis,,http://en.irct.ir/trial/31305,2018-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3614,896,2023-11-11 20:31:42.184229,Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT03610139,2018-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3615,895,2023-11-11 20:31:42.184229,The optimalistion of neuromuscular electrical stimulation in the treatment of swallowing disorders in multiple sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/29473,2018-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3616,894,2023-11-11 20:31:42.184229,Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).,,https://clinicaltrials.gov/show/NCT03647722,2018-08-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3617,893,2023-11-11 20:31:42.184229,Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP),,https://clinicaltrials.gov/ct2/show/NCT03653273,2018-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3618,892,2023-11-11 20:31:42.184229,Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP),,https://clinicaltrials.gov/show/NCT03662347,2018-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3619,891,2023-11-11 20:31:42.184229,Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),,https://clinicaltrials.gov/show/NCT03888924,2018-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3620,890,2023-11-11 20:31:42.184229,Effect of diet on multiple sclerosis patient,,http://en.irct.ir/trial/31423,2018-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3621,889,2023-11-11 20:31:42.184229,CNS-reactive B cells in the blood are biomarkers for therapeutic responsiveness and disease activity in Lemtrada-treated MS patients,,http://drks.de/search/en/trial/DRKS00015528,2018-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3622,888,2023-11-11 20:31:42.184229,Imatinib for Multiple Sclerosis (MS) Relapses,,https://clinicaltrials.gov/show/NCT03674099,2018-09-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3623,887,2023-11-11 20:31:42.184229,EFFECTIVENESS OF REPEATED INJECTIONS OF BOTULINUM TOXIN IN THE GAIT AND QUALITY OF LIFE OF ADULT PATIENTS WITH WEAKNESS AND MUSCLE RIGIDITY DUE TO MULTIPLE ESCLEROSIS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003231-30,2018-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3624,886,2023-11-11 20:31:42.184229,Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714,,https://clinicaltrials.gov/ct2/show/NCT03691077,2018-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3625,885,2023-11-11 20:31:42.184229,Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS,,https://clinicaltrials.gov/show/NCT03703180,2018-04-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3626,884,2023-11-11 20:31:42.184229,"Effectiveness of acceptance and commitment therapy on the sense of coherence,Locus of Control and post-traumatic growth in patients with spinal cord injury and MS",,http://en.irct.ir/trial/33524,2018-10-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3627,883,2023-11-11 20:31:42.184229,The effect of tactile stimulation on multiple sclerosis patients,,http://en.irct.ir/trial/33668,2018-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3628,882,2023-11-11 20:31:42.184229,Simvastatin in Secondary Progressive Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003008-30,2018-05-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3629,881,2023-11-11 20:31:42.184229,Evaluation the effect of aerobic exercise with stationary bike with trans cranial direct current stimulation on gait improvement in multiple sclerosis patients,,http://en.irct.ir/trial/32581,2018-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3630,880,2023-11-11 20:31:42.184229,Safety and tolerability Phase I study of a new immunomodulatory drug in healthy participants after single and repeat doses.,,https://anzctr.org.au/ACTRN12618001769279.aspx,2018-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3631,879,2023-11-11 20:31:42.184229,Effects of exercises on balance and falls in  patients with multiple sclerosis,,http://en.irct.ir/trial/34786,2018-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3632,878,2023-11-11 20:31:42.184229,Computerized Cognitive Rehabilitation in MS Patients,,https://clinicaltrials.gov/show/NCT03729713,2018-01-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3633,877,2023-11-11 20:31:42.184229,Affecting of vitamin D administration on mRNA expression of Treg/Th17 axis.,,http://en.irct.ir/trial/34936,2018-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3634,876,2023-11-11 20:31:42.184229,Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in aggressive multiple sclerosis and neuromyelitis optica,,http://www.chictr.org.cn/showproj.aspx?proj=32563,2018-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3635,875,2023-11-11 20:31:42.184229,Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.,,https://clinicaltrials.gov/show/NCT03759522,2018-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3636,874,2023-11-11 20:31:42.184229,IL-11 in the Development of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03735823,2018-07-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3637,873,2023-11-11 20:31:42.184229,Enhancing balance and gait in patients with Multiple Sclerosis – combined use of balance training with non-invasive brain stimulation,,https://anzctr.org.au/ACTRN12618001836224.aspx,2018-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3638,872,2023-11-11 20:31:42.184229,Identification of a CSF- and blood biomarker fingerprint differentiating between highly active and moderate/mild forms of multiple sclerosis (MS),,http://drks.de/search/en/trial/DRKS00015761,2018-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3639,871,2023-11-11 20:31:42.184229,B Cell Differentiation in MS,,https://clinicaltrials.gov/show/NCT03744351,2018-11-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3640,870,2023-11-11 20:31:42.184229,Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM,,https://clinicaltrials.gov/show/NCT03784547,2018-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3641,869,2023-11-11 20:31:42.184229,The effect of probiotic supplement on some inflammatory markers in patients with multiple sclerosis,,http://en.irct.ir/trial/35841,2018-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3642,868,2023-11-11 20:31:42.184229,PET Study in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03787446,2018-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3643,867,2023-11-11 20:31:42.184229,"The evaluation of muscle strength, balance, gait and fatigue in patients with multiple sclerosis",,https://anzctr.org.au/ACTRN12618002052213.aspx,2018-12-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3644,866,2023-11-11 20:31:42.184229,"The Effect of Cognitive- Behavioral Group Therapy (CBGT) on Anxiety, Self- Esteem, Quality of Life, Pain Self-Efficacy and Hope in  Patients with Multiple Sclerosis (MS)",,http://en.irct.ir/trial/29048,2019-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3645,865,2023-11-11 20:31:42.184229,Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000516-22,2018-11-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3646,864,2023-11-11 20:31:42.184229,Fatigue treatment in multiple sclerosis patients,,http://ensaiosclinicos.gov.br/rg/RBR-5y5sm9,2019-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3647,863,2023-11-11 20:31:42.184229,KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis,,https://clinicaltrials.gov/show/NCT03804047,2019-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3648,862,2023-11-11 20:31:42.184229,Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.,,https://clinicaltrials.gov/show/NCT03807973,2019-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3649,861,2023-11-11 20:31:42.184229,investigating the effect of aromatherapy with lavender extract on fatigue and  working memory in women with multiple sclerosis,,http://en.irct.ir/trial/35466,2019-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3650,860,2023-11-11 20:31:42.184229,MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS),,https://clinicaltrials.gov/show/NCT03846219,2019-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3651,859,2023-11-11 20:31:42.184229,"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer",,https://clinicaltrials.gov/ct2/show/NCT03816345,2019-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3652,858,2023-11-11 20:31:42.184229,Follow-up of Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03878836,2019-01-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3653,857,2023-11-11 20:31:42.184229,The reduction in the number of attacks in multiple sclerosis patients,,http://en.irct.ir/trial/36976,2019-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3654,856,2023-11-11 20:31:42.184229,Observational study of changes in q-space Myelin Map (qMM) imaging in MS patients   treated with dimethyl fumarate (DMF),,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040760,2019-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3655,855,2023-11-11 20:31:42.184229,"The Effect of Group Therapy Based on Acceptance and Commitment on  Meaning Life,Distress Tolerance, Pain Self-Efficacy and Quality of Life in Patients whit Multiple Sclerosis (MS)",,http://en.irct.ir/trial/37206,2019-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3656,854,2023-11-11 20:31:42.184229,tDCS for the Management of Multiple Sclerosis Related Fatigue,,https://clinicaltrials.gov/show/NCT03838770,2019-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3657,853,2023-11-11 20:31:42.184229,Evaluation of a novel test to detect subtle cognitive deficits in relapsing-remitting Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00016600,2019-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3658,852,2023-11-11 20:31:42.184229,The effect of exercise on urinary incontinence,,http://en.irct.ir/trial/35875,2019-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3659,851,2023-11-11 20:31:42.184229,"Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation",,https://clinicaltrials.gov/show/NCT03869879,2019-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3660,850,2023-11-11 20:31:42.184229,The effect of vestibular rehabilitation in multiple sclerosis,,http://en.irct.ir/trial/37720,2019-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3661,849,2023-11-11 20:31:42.184229,Relationship between physical activity behavior and disease progression in persons with Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00016624,2019-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3662,848,2023-11-11 20:31:42.184229,Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis.,,https://anzctr.org.au/ACTRN12619000348156.aspx,2019-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3663,847,2023-11-11 20:31:42.184229,French Registry for Monitoring Pregnancies for Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03900221,2019-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3664,846,2023-11-11 20:31:42.184229,Thermal Cures in the Treatment of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03915028,2019-12-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3665,845,2023-11-11 20:31:42.184229,Decision Making in Multiple Sclerosis Care Under Uncertainty,,https://clinicaltrials.gov/show/NCT04035720,2019-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3666,844,2023-11-11 20:31:42.184229,"Effect of Curcumin, Vitamin D and herbal oil on  Multiple Sclerosis",,http://en.irct.ir/trial/38011,2019-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3667,843,2023-11-11 20:31:42.184229,TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03910738,2019-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3668,842,2023-11-11 20:31:42.184229,The Effect of Occupation-Based Interventions in Caregivers of People with Multiple Sclerosis,,http://en.irct.ir/trial/35552,2019-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3669,841,2023-11-11 20:31:42.184229,Functional training for persons with multiple sclerosis,,http://drks.de/search/en/trial/DRKS00017091,2019-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3670,840,2023-11-11 20:31:42.184229,"The effect of Group Therapy Based on meta-cognitive Model of Detached Mindfulness on stress, anxiety, depression, fatigue and well - being in patients with Multiple sclerosis",,http://en.irct.ir/trial/37506,2019-04-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3671,839,2023-11-11 20:31:42.184229,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003008-38,2019-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3672,838,2023-11-11 20:31:42.184229,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - ORATORIO HAND",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001511-73,2019-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3673,837,2023-11-11 20:31:42.184229,Long-term safety and efficacy study of SAR442168 in relapsing multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004731-76,2019-02-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3674,836,2023-11-11 20:31:42.184229,A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab,,https://clinicaltrials.gov/show/NCT04048577,2019-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3675,835,2023-11-11 20:31:42.184229,Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life,,https://clinicaltrials.gov/show/NCT03928990,2019-04-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3676,834,2023-11-11 20:31:42.184229,Aromatherapy Effects on Multiple Sclerosis,,http://en.irct.ir/trial/36965,2019-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3677,833,2023-11-11 20:31:42.184229,Outcomes Mandate National Integration With Cannabis as Medicine,,https://clinicaltrials.gov/show/NCT03944447,2019-03-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3678,832,2023-11-11 20:31:42.184229,Functional Electrical Stimulation Cycling for Managing Mobility Disability in People With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT03949387,2019-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3679,831,2023-11-11 20:31:42.184229,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,2019-07-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3680,830,2023-11-11 20:31:42.184229,A Social Emotion Regulation Intervention in MS,,https://clinicaltrials.gov/show/NCT03951974,2019-05-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3681,829,2023-11-11 20:31:42.184229,The effect of functional foods intervention on common symptoms such as fatigue and depression in patients with multiple sclerosis,,https://anzctr.org.au/ACTRN12619000765123.aspx,2019-05-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3682,828,2023-11-11 20:31:42.184229,Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03981003,2019-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3683,827,2023-11-11 20:31:42.184229,User-friendliness of a Portable Driving Simulator,,https://clinicaltrials.gov/show/NCT03969927,2019-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3684,826,2023-11-11 20:31:42.184229,A Clinical Study Comparing Rituximab and Cladribine for Relapsing Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001505-24,2019-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3685,825,2023-11-11 20:31:42.184229,Effects of a Circuit Training on Balance in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04006613,2019-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3686,824,2023-11-11 20:31:42.184229,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT03993171,2019-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3687,823,2023-11-11 20:31:42.184229,Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome,,https://clinicaltrials.gov/ct2/show/NCT03979391,2019-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3688,822,2023-11-11 20:31:42.184229,Clinical trial to determine the effect of Famciclovir on Epstein Barr virus levels in the saliva of patients with Multiple Sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000169-19,2019-05-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3689,821,2023-11-11 20:31:42.184229,Prebiotic vs Probiotic in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04038541,2019-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3690,820,2023-11-11 20:31:42.184229,Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?,,https://clinicaltrials.gov/ct2/show/NCT03983720,2019-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3691,819,2023-11-11 20:31:42.184229,Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS,,https://clinicaltrials.gov/show/NCT03983681,2019-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3692,818,2023-11-11 20:31:42.184229,"Evaluating the efficacy and safety of Ocrelizumab (CinnaGen, Iran) in comparison to Ocrevus® (Roche, Switzerland) in patients with relapsing multiple sclerosis",,http://en.irct.ir/trial/39481,2019-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3693,817,2023-11-11 20:31:42.184229,Pilates Training in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04011579,2019-11-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3694,816,2023-11-11 20:31:42.184229,DiagnosE Using the Central veIn SIgn,,https://clinicaltrials.gov/show/NCT04024969,2019-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3695,815,2023-11-11 20:31:42.184229,"Effect of dual task training on somatosensory, balance, Community participation and activity of daily living in Multiple sclerosis",,http://en.irct.ir/trial/31443,2019-06-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3696,814,2023-11-11 20:31:42.184229,Effects of a Weight Based Training Program on MS Patients,,https://clinicaltrials.gov/show/NCT04002492,2019-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3697,813,2023-11-11 20:31:42.184229,"Effectiveness of dry needling in perceived pain, quality of gait and spasticity in patients with multiple sclerosis",,https://anzctr.org.au/ACTRN12619000880145.aspx,2019-06-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3698,812,2023-11-11 20:31:42.184229,miR-142-3p as Potential Biomarker of Synaptopathy in MS,,https://clinicaltrials.gov/show/NCT03999788,2019-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3699,811,2023-11-11 20:31:42.184229,Safety and Efficacy of Fecal Microbiota Transplantation,,https://clinicaltrials.gov/show/NCT04014413,2019-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3700,810,2023-11-11 20:31:42.184229,XO as a Screening Test of Cognitive Impairment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT03999034,2019-06-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3701,809,2023-11-11 20:31:42.184229,Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04002934,2019-06-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3702,808,2023-11-11 20:31:42.184229,"Study of the clinical, biomechanical, and functional effects of dry needling on spastic gastronemius muscle in patients with multiple sclerosis",,http://en.irct.ir/trial/40413,2019-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3703,807,2023-11-11 20:31:42.184229,In Clinic Physical Activity in Persons With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04186910,2019-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3704,806,2023-11-11 20:31:42.184229,Effect of dry Cupping on fatigue and quality of life in patients with Multiple Sclerosis,,http://en.irct.ir/trial/40115,2019-07-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3705,805,2023-11-11 20:31:42.184229,Effect of cladribine treatment on microglial activation in the CNS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001960-31,2019-11-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3706,804,2023-11-11 20:31:42.184229,Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis,,https://clinicaltrials.gov/show/NCT04042363,2019-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3707,803,2023-11-11 20:31:42.184229,Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04027491,2019-07-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3708,802,2023-11-11 20:31:42.184229,Lee Silverman Voice Treatment Versus Standard Speech Therapy Versus Control in Hypophonia Rehabilitation in MS,,https://clinicaltrials.gov/show/NCT04034277,2019-07-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3709,801,2023-11-11 20:31:42.184229,Walking fatigue in persons with Multiple Sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/26405,2019-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3710,800,2023-11-11 20:31:42.184229,Investigating the effect of aromatherapy in abdominal surgery,,http://en.irct.ir/trial/33952,2019-08-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3711,799,2023-11-11 20:31:42.184229,Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS),,https://clinicaltrials.gov/ct2/show/NCT04047628,2019-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3712,798,2023-11-11 20:31:42.184229,Multimodal Imaging of MS Reveals the Smoldering Inflammation,,https://clinicaltrials.gov/show/NCT04126772,2019-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3713,797,2023-11-11 20:31:42.184229,Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04053374,2019-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3714,796,2023-11-11 20:31:42.184229,The effect of home care of people with multiple sclerosis,,http://en.irct.ir/trial/41089,2019-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3715,795,2023-11-11 20:31:42.184229,Effects of dimethyl fumarate (Tecfidera) on white matter integrity and functional brain adaptation and cognition in Multiple Sclerosis,,https://www.onderzoekmetmensen.nl/en/trial/21490,2019-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3716,794,2023-11-11 20:31:42.184229,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04054050,2019-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3717,793,2023-11-11 20:31:42.184229,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04075266,2019-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3718,792,2023-11-11 20:31:42.184229,Clinical and genetic studies of neuroimmune disease,,http://www.chictr.org.cn/showproj.aspx?proj=27584,2019-08-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3719,791,2023-11-11 20:31:42.184229,Determination of the Effect of Crude Oil on Erectile Dysfunction in Men with Multiple Sclerosis,,http://en.irct.ir/trial/40729,2019-08-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3720,790,2023-11-11 20:31:42.184229,Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04073940,2019-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3721,789,2023-11-11 20:31:42.184229,Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response,,https://clinicaltrials.gov/show/NCT04082260,2019-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3722,788,2023-11-11 20:31:42.184229,Efficacy of lavender in the treatment of fatigue in patients with multiple sclerosis,,http://en.irct.ir/trial/41799,2019-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3723,787,2023-11-11 20:31:42.184229,Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®,,https://clinicaltrials.gov/show/NCT04086225,2019-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3724,786,2023-11-11 20:31:42.184229,Effects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04090996,2019-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3725,785,2023-11-11 20:31:42.184229,Use of GLP-1 analogs in the treatment of multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003001-94,2019-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3726,784,2023-11-11 20:31:42.184229,Aerobic Training Effects on Motor and Cognitive Performances in MS: an Exploratory Study With Structural and Functional MRI,,https://clinicaltrials.gov/ct2/show/NCT04097418,2019-09-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3727,783,2023-11-11 20:31:42.184229,"A Personalised Radiosurgery Procedure for People With Trigeminal Neuralgia to Improve Pain, Quality of Life and Reduce Complications",,https://clinicaltrials.gov/show/NCT04117035,2019-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3728,782,2023-11-11 20:31:42.184229,Effects of shiatsu-associated physical therapy on pain and fatigue in patients with Multiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-2c6ymn,2019-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3729,781,2023-11-11 20:31:42.184229,Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS),,https://clinicaltrials.gov/show/NCT04121403,2019-09-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3730,780,2023-11-11 20:31:42.184229,Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/show/NCT04121065,2019-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3731,779,2023-11-11 20:31:42.184229,A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04121468,2019-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3732,778,2023-11-11 20:31:42.184229,Longitudinal Cognitive Assessment by BoCA,,https://clinicaltrials.gov/show/NCT04114994,2019-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3733,777,2023-11-11 20:31:42.184229,"A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000284-93,2019-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3734,776,2023-11-11 20:31:42.184229,The effect of tapering of prednisolone after pulse therapy in a MS attack,,http://en.irct.ir/trial/40311,2019-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3735,775,2023-11-11 20:31:42.184229,An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04130997,2019-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3736,774,2023-11-11 20:31:42.184229,Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue,,https://clinicaltrials.gov/show/NCT04144257,2019-10-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3737,773,2023-11-11 20:31:42.184229,Personalizing the treatment with natalizumab in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002566-13,2019-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3738,772,2023-11-11 20:31:42.184229,A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04148313,2019-10-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3739,771,2023-11-11 20:31:42.184229,Epidemiological study on Japanese patient with multiple sclerosis,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043385,2019-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3740,770,2023-11-11 20:31:42.184229,Home-based EXergames To impRove cognitivE Function in MUltiple Sclerosis,,https://clinicaltrials.gov/show/NCT04169750,2019-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3741,769,2023-11-11 20:31:42.184229,Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities,,https://clinicaltrials.gov/show/NCT04157283,2019-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3742,768,2023-11-11 20:31:42.184229,Imatinib treatment for Multiple Sclerosis (MS) Relapses,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000620-34,2018-03-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3743,767,2023-11-11 20:31:42.184229,Analysis of Intellectual Capabilities in People with Multiple Sclerosis in Virtual Games,,http://ensaiosclinicos.gov.br/rg/RBR-9xzsyx,2019-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3744,766,2023-11-11 20:31:42.184229,Quality of life therapy in multiple sclerosis patients,,http://en.irct.ir/trial/40792,2019-11-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3745,765,2023-11-11 20:31:42.184229,Local Vibration in Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04192786,2019-11-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3746,764,2023-11-11 20:31:42.184229,"The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients",,https://clinicaltrials.gov/show/NCT04183751,2019-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3747,763,2023-11-11 20:31:42.184229,"Effects of water-based exercises on balance, functional status, fatigue and quality of life among patients with multiple sclerosis: case series.",,https://anzctr.org.au/ACTRN12619001718134.aspx,2019-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3748,762,2023-11-11 20:31:42.184229,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR1-365",,https://anzctr.org.au/ACTRN12619001756112.aspx,2019-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3749,761,2023-11-11 20:31:42.184229,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04203498,2019-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3750,760,2023-11-11 20:31:42.184229,Explorative study of emerging blood biomarkers in progressive multiple sclerosis,,http://drks.de/search/en/trial/DRKS00020132,2019-12-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3751,759,2023-11-11 20:31:42.184229,Correlation of Serum Lactate and Activity of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04210960,2019-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3752,758,2023-11-11 20:31:42.184229,Virtual Reality Approach in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04212689,2019-12-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3753,757,2023-11-11 20:31:42.184229,The effect of  hEnSCs  transplantation in the treatment of SPMS,,http://en.irct.ir/trial/40732,2019-12-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3754,756,2023-11-11 20:31:42.184229,"The effect of expressive writing on sexual dysfunction, quality of life and body image of women with MS",,http://en.irct.ir/trial/43488,2019-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3755,755,2023-11-11 20:31:42.184229,The effect of education and telephone follow up on Family Caregivers burden of Patients with multiple scelorsis,,http://en.irct.ir/trial/39827,2019-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3756,754,2023-11-11 20:31:42.184229,Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04225312,2020-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3757,753,2023-11-11 20:31:42.184229,Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04220814,2020-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3758,752,2023-11-11 20:31:42.184229,Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04228328,2020-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3759,751,2023-11-11 20:31:42.184229,"Effect of relaxation technique versus control group on depression, stress and anxiety in patients with multiple sclerosis",,http://en.irct.ir/trial/44869,2020-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3760,750,2023-11-11 20:31:42.184229,Investigating the effect of the bone marrow-drived mesenchymal stem cells in MS patients under fingolimod therapy.,,http://en.irct.ir/trial/44197,2020-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3761,749,2023-11-11 20:31:42.184229,Postoperative Relapses in MS Patients,,https://clinicaltrials.gov/show/NCT04237675,2020-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3762,748,2023-11-11 20:31:42.184229,Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).,,https://clinicaltrials.gov/show/NCT04260711,2020-01-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3763,747,2023-11-11 20:31:42.184229,Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients.,,https://clinicaltrials.gov/show/NCT04252599,2020-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3764,746,2023-11-11 20:31:42.184229,Implementation of eccentric training in various clinical populations - a pilot study,,http://drks.de/search/en/trial/DRKS00020483,2020-01-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3765,745,2023-11-11 20:31:42.184229,MR-Guided Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04279912,2020-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3766,744,2023-11-11 20:31:42.184229,Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients with highly active relapsing remitting MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001549-42,2020-03-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3767,743,2023-11-11 20:31:42.184229,MitoQ for Fatigue in Multiple Sclerosis (MS),,https://clinicaltrials.gov/ct2/show/NCT04267926,2020-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3768,742,2023-11-11 20:31:42.184229,An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumab,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001341-40,2020-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3769,741,2023-11-11 20:31:42.184229,Deficit-specific Training in Spinal Disorders,,https://clinicaltrials.gov/ct2/show/NCT04292717,2020-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3770,740,2023-11-11 20:31:42.184229,Patient Centered Outcomes Analysis for MS Using a Mobile Application,,https://clinicaltrials.gov/show/NCT04281160,2020-02-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3771,739,2023-11-11 20:31:42.184229,Effectiveness of playing the instruments „Big Bom“ and “Temple Blocks” as a music therapy approach to improve gait function among patients with multiple sclerosis.,,http://drks.de/search/en/trial/DRKS00020469,2020-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3772,738,2023-11-11 20:31:42.184229,Kinematic Assessment In Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04283071,2020-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3773,737,2023-11-11 20:31:42.184229,Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04283747,2020-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3774,736,2023-11-11 20:31:42.184229,Validation of the BeCare Multiple Sclerosis Assessment App,,https://clinicaltrials.gov/show/NCT04288011,2020-02-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3775,735,2023-11-11 20:31:42.184229,Exercise Therapy in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04294979,2020-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3776,734,2023-11-11 20:31:42.184229,Immunisation Status and Safety of Vaccines in Italian MS Patients,,https://clinicaltrials.gov/show/NCT04300868,2020-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3777,733,2023-11-11 20:31:42.184229,Exercise to Manage Fatigue in Progressive Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04304027,2020-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3778,732,2023-11-11 20:31:42.184229,Deployment o the Multidisciplinary Prospective Cohort Imminent,,https://clinicaltrials.gov/show/NCT04334031,2020-10-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3779,731,2023-11-11 20:31:42.184229,Postural control analysis during head and eye motion during standing and walking in Adults with Sclerosis Multiple,,http://drks.de/search/en/trial/DRKS00018076,2020-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3780,730,2023-11-11 20:31:42.184229,Study on the Therapeutic Effect and Mechanism of Bushen Yisui Capsules Against Multiple Sclerosis with Depression Based on Multi-modality Analysis,,http://www.chictr.org.cn/showproj.aspx?proj=51394,2020-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3781,729,2023-11-11 20:31:42.184229,The effect of cocoa powder on fatigue in multiple sclerosis patients,,http://en.irct.ir/trial/46493,2020-03-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3782,728,2023-11-11 20:31:42.184229,Study of Evobrutinib in Participants With RMS (evolutionRMS 1),,https://clinicaltrials.gov/ct2/show/NCT04338022,2020-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3783,727,2023-11-11 20:31:42.184229,Study of Evobrutinib in Participants With RMS (evolutionRMS 2),,https://clinicaltrials.gov/ct2/show/NCT04338061,2020-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3784,726,2023-11-11 20:31:42.184229,The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,,https://clinicaltrials.gov/show/NCT04354519,2020-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3785,725,2023-11-11 20:31:42.184229,Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003127-38,2020-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3786,724,2023-11-11 20:31:42.184229,The effect of pelvic floor muscle exercises therapy program on the fatigue and quality of life in women with multiple sclerosis suffering from urinary disorders,,http://en.irct.ir/trial/44198,2020-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3787,723,2023-11-11 20:31:42.184229,Short Arm Human Centrifuge Therapeutic Training and Rehabilitation (GRACER1),,https://clinicaltrials.gov/show/NCT04369976,2020-04-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3788,722,2023-11-11 20:31:42.184229,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,,https://clinicaltrials.gov/show/NCT04355611,2020-04-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3789,721,2023-11-11 20:31:42.184229,Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential Diagnosis,,https://clinicaltrials.gov/show/NCT04369898,2020-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3790,720,2023-11-11 20:31:42.184229,Effectiveness of Yoga Comparing to Amantadine   and Commitment Group Therapy in Patients with Multiple Sclerosis,,http://en.irct.ir/trial/47463,2020-04-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3791,719,2023-11-11 20:31:42.184229,Effects of Ocrevus in Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04387734,2020-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3792,718,2023-11-11 20:31:42.184229,Entire-body PET Scans for Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04390009,2020-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3793,717,2023-11-11 20:31:42.184229,A resilience group training program for people with multiple sclerosis: multi-centre trial (Multi_READY for MS),,https://www.isrctn.com/ISRCTN67194859,2020-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3794,716,2023-11-11 20:31:42.184229,Resting Postural Tremor in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04405479,2020-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3795,715,2023-11-11 20:31:42.184229,Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with Relapsing Multiple Sclerosis (RMS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001967-58,2020-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3796,714,2023-11-11 20:31:42.184229,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),,https://clinicaltrials.gov/ct2/show/NCT04410991,2020-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3797,713,2023-11-11 20:31:42.184229,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),,https://clinicaltrials.gov/show/NCT04411641,2020-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3798,712,2023-11-11 20:31:42.184229,Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04415372,2020-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3799,711,2023-11-11 20:31:42.184229,"The effect of eight weeks of training in water on fatigue, balance and functional movement in men",,http://en.irct.ir/trial/45763,2020-06-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3800,710,2023-11-11 20:31:42.184229,The immediate effect of kinesio taping of quadriceps muscle on position sense of knee joint following full squat in patients with multiple sclerosis,,http://en.irct.ir/trial/45059,2020-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3801,709,2023-11-11 20:31:42.184229,Amantadine and dalfampiridine effects on multiple sclerosis,,http://en.irct.ir/trial/48735,2020-06-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3802,708,2023-11-11 20:31:42.184229,Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI,,https://clinicaltrials.gov/ct2/show/NCT04448977,2020-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3803,707,2023-11-11 20:31:42.184229,"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine
Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000644-55,2020-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3804,706,2022-03-09 00:29:14.458003,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05269004,2022-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3805,705,2023-11-11 20:31:42.184229,The effect of Benson relaxation  on fatigue and general health in multiple sclerosis patients,,http://en.irct.ir/trial/45350,2020-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3806,704,2023-11-11 20:31:42.184229,Effect of Mindfulness-Based Cognitive Therapy on swallowing in Multiple Sclerosis,,http://en.irct.ir/trial/48415,2020-06-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3807,703,2023-11-11 20:31:42.184229,Effect of combined training on breast cancer survivors,,http://en.irct.ir/trial/49108,2020-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3808,702,2023-11-11 20:31:42.184229,Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04458688,2020-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3809,701,2023-11-11 20:31:42.184229,Multiple Sclerosis - patient-oriented care in Lower Saxony,,http://drks.de/search/en/trial/DRKS00021741,2020-08-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3810,700,2023-11-11 20:31:42.184229,Evaluation of clarithromycin on IL-6 serum level in patients with multiple sclerosis,,http://en.irct.ir/trial/48412,2020-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3811,699,2023-11-11 20:31:42.184229,Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002981-15,2020-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3812,698,2023-11-11 20:31:42.184229,Assessment the effect of the health lifestyle education on the sexual function of womens with MS,,http://en.irct.ir/trial/45564,2020-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3813,697,2023-11-11 20:31:42.184229,The effects of locomotive exercise therapy on individuals with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12620000769987.aspx,2020-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3814,696,2023-11-11 20:31:42.184229,PPMS Study of Bruton's tyrosine kinase (BTK) inhibitor SAR442168 (PERSEUS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000645-14,2020-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3815,695,2023-11-11 20:31:42.184229,Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (PERSEUS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000645-14,2020-07-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3816,694,2023-11-11 20:31:42.184229,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher 
Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000893-69,2020-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3817,693,2023-11-11 20:31:42.184229,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher
Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000894-26,2020-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3818,692,2023-11-11 20:31:42.184229,9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04510220,2020-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3819,691,2023-11-11 20:31:42.184229,Motor Skill Acquisition Between Individuals With Neurological Disorders and Healthy Individuals,,https://clinicaltrials.gov/show/NCT04503187,2020-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3820,690,2023-11-11 20:31:42.184229,Cognitive assessment and patients with multiple sclerosis and their relationship with performance in virtual tasks,,http://ensaiosclinicos.gov.br/rg/RBR-8bt3hg,2020-05-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3821,689,2023-11-11 20:31:42.184229,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000893-69,2020-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3822,688,2023-11-11 20:31:42.184229,Evaluation of clarithromycin on TNF-a serum level in patients with multiple sclerosis,,http://en.irct.ir/trial/48443,2020-08-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3823,687,2023-11-11 20:31:42.184229,Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04518657,2020-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3824,686,2023-11-11 20:31:42.184229,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000894-26,2020-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3825,685,2023-11-11 20:31:42.184229,Preventing Job Loss Using Acceptance and Commitment Therapy in Vocational Rehabilitation,,https://clinicaltrials.gov/show/NCT04515355,2020-08-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3826,684,2023-11-11 20:31:42.184229,Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS),,https://clinicaltrials.gov/show/NCT04530955,2020-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3827,683,2023-11-11 20:31:42.184229,Effect of Emotion Regulation Training in MS patients,,http://en.irct.ir/trial/48854,2020-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3828,682,2023-11-11 20:31:42.184229,Examining Effects of Tysabri on Cognitive Fatigue Using fMRI,,https://clinicaltrials.gov/ct2/show/NCT04565431,2020-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3829,681,2023-11-11 20:31:42.184229,Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04530318,2020-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3830,680,2023-11-11 20:31:42.184229,Aerobic Exercise for Remyelination in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04539002,2020-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3831,679,2023-11-11 20:31:42.184229,A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets,,https://clinicaltrials.gov/show/NCT04550455,2020-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3832,678,2023-11-11 20:31:42.184229,Keep Control Validation study,,http://drks.de/search/en/trial/DRKS00022998,2020-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3833,677,2023-11-11 20:31:42.184229,RMS study of BTK inhibitor SAR442168 (GEMINI 2),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000644-55,2020-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3834,676,2023-11-11 20:31:42.184229,"Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosis",,https://www.isrctn.com/ISRCTN88667898,2020-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3835,675,2023-11-11 20:31:42.184229,Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit,,https://clinicaltrials.gov/show/NCT04563832,2020-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3836,674,2023-11-11 20:31:42.184229,HFP (High-Fiber Supplement) in MS (Multiple Sclerosis),,https://clinicaltrials.gov/ct2/show/NCT04574024,2020-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3837,673,2023-11-11 20:31:42.184229,Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease,,https://clinicaltrials.gov/ct2/show/NCT04578639,2020-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3838,672,2023-11-11 20:31:42.184229,Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT04573673,2020-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3839,671,2023-11-11 20:31:42.184229,A phase 2b study of Cladribine to halt deterioration in people with advanced multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-005038-39,2020-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3840,670,2023-11-11 20:31:42.184229,Investigation of Subclinical Markers of Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04604041,2020-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3841,669,2023-11-11 20:31:42.184229,Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.,,https://clinicaltrials.gov/show/NCT04595799,2020-07-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3842,668,2023-11-11 20:31:42.184229,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/ct2/show/NCT04586010,2020-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3843,667,2023-11-11 20:31:42.184229,Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/ct2/show/NCT04586023,2020-08-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3844,666,2023-11-11 20:31:42.184229,Primary progressive multiple sclerosis (PPMS) study of BTK inhibitor SAR442168 (PERSEUS),,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46809,2020-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3845,665,2023-11-11 20:31:42.184229,Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation,,https://clinicaltrials.gov/show/NCT04691102,2020-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3846,664,2023-11-11 20:31:42.184229,Obesity and Pediatric Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04593082,2020-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3847,663,2023-11-11 20:31:42.184229,Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS,,https://clinicaltrials.gov/show/NCT04621708,2020-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3848,662,2023-11-11 20:31:42.184229,Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04603196,2020-10-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3849,661,2023-11-11 20:31:42.184229,Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04707976,2020-10-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3850,660,2023-11-11 20:31:42.184229,Effect of Respiratory Muscle Training in Multiple Sclerosis,,http://en.irct.ir/trial/51280,2020-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3851,659,2023-11-11 20:31:42.184229,"A PHASE III MULTICENTER, RANDOMIZED,
			DOUBLE-BLIND, DOUBLE-DUMMY,
			PARALLEL-GROUP STUDY TO EVALUATE THE
			EFFICACY AND SAFETY OF FENEBRUTINIB
			COMPARED WITH OCRELIZUMAB IN ADULT
			PATIENTS WITH PRIMARY PROGRESSIVE
			MULTIPLE SCLEROSIS",,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=028-20,2020-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3852,658,2023-11-11 20:31:42.184229,Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04625049,2020-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3853,657,2023-11-11 20:31:42.184229,"New strategies for diagnostic, therapeutic and clinical care in neurological diseases",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004650-34,2020-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3854,656,2023-11-11 20:31:42.184229,RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial,,https://clinicaltrials.gov/ct2/show/NCT04625153,2020-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3855,655,2023-11-11 20:31:42.184229,ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04695080,2020-06-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3856,654,2023-11-11 20:31:42.184229,Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions,,https://clinicaltrials.gov/show/NCT04639401,2020-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3857,653,2023-11-11 20:31:42.184229,Novel Assessment of Synaptic Density in Progressive MS,,https://clinicaltrials.gov/show/NCT04634994,2020-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3858,652,2023-11-11 20:31:42.184229,Efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45641,2020-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3859,651,2023-11-11 20:31:42.184229,Optimization Research of Clinical treatment Scheme of traditional Chinese Medicine for multiple Sclerosis,,http://itmctr.ccebtcm.org.cn/en-US/Home/ProjectView?pid=7e68fc24-fd74-4e44-9dff-ae742bb598ea,2020-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3860,650,2023-11-11 20:31:42.184229,Home Based Infusions for Ocrelizumab,,https://clinicaltrials.gov/show/NCT04650321,2020-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3861,649,2023-11-11 20:31:42.184229,"A cognitive-behavioural approach for the treatment of fear of progression in patients wth Parkinson's disease and Multiple Sclerosis: 
A Mixed-Methods Study",,http://drks.de/search/en/trial/DRKS00020989,2020-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3862,648,2023-11-11 20:31:42.184229,Clinical study of cerebrospinal fluid immunoglobulin G oligoclonal band detection in Chinese patients with multiple sclerosis,,http://www.chictr.org.cn/showproj.aspx?proj=63373,2020-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3863,647,2023-11-11 20:31:42.184229,AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis,,https://clinicaltrials.gov/ct2/show/NCT04721717,2020-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3864,646,2023-11-11 20:31:42.184229,Studying the effect of multi-strain supplements on controlling the MS disease symptoms,,http://en.irct.ir/trial/52680,2020-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3865,645,2023-11-11 20:31:42.184229,Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects,,https://clinicaltrials.gov/ct2/show/NCT04699747,2020-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3866,644,2023-11-11 20:31:42.184229,"Remediation Program Via a ""Serious Game"" for the Cognitive Functions of Multiple Sclerosis Patients",,https://clinicaltrials.gov/show/NCT04694534,2020-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3867,643,2023-11-11 20:31:42.184229,Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis,,https://clinicaltrials.gov/ct2/show/NCT04688788,2020-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3868,642,2023-11-11 20:31:42.184229,Pilot trial of an online Acceptance and Commitment Therapy course to help People with Multiple Sclerosis who want to stay in work,,https://www.isrctn.com/ISRCTN14056874,2020-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3869,641,2023-11-11 20:31:42.184229,A ToM Training for People With Multiple Sclerosis: an Efficacy Study.,,https://clinicaltrials.gov/show/NCT04711941,2020-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3870,640,2023-11-11 20:31:42.184229,Comparison of the effects of omeprazole in prevention of gastrointestinal events in patients with multiple sclerosis receiving corticosteroid pulse therapy,,http://en.irct.ir/trial/52928,2020-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3871,639,2023-11-11 20:31:42.184229,An effectiveness and safety comparison study of N-acetylcysteine and amantadine on fatigue and Disability and quality of life of multiple sclerotic patients,,http://en.irct.ir/trial/53136,2020-12-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3872,638,2023-11-11 20:31:42.184229,Music-assisted treadmill training in the rehabilitation of patients with Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00023709,2021-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3873,637,2023-11-11 20:31:42.184229,The effect of nursing process based on the goal attainment theory  in individuals with multiple sclerosis,,http://en.irct.ir/trial/53168,2021-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3874,636,2023-11-11 20:31:42.184229,Monitoring procedures in primary progressive multiple sclerosis (PPMS): Cognitive parameters in routine clinical practice,,http://drks.de/search/en/trial/DRKS00023067,2021-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3875,635,2023-11-11 20:31:42.184229,LUNA-EMG to Enhance Motor Functions in Multiple Sclerosis,,https://clinicaltrials.gov/show/NCT04720898,2021-01-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3876,634,2023-11-11 20:31:42.184229,The MS-LINK™ Outcomes Study,,https://clinicaltrials.gov/ct2/show/NCT04735406,2021-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3877,633,2023-11-11 20:31:42.184229,"Does deep breathing significantly reduce fatigue in multiple sclerosis patients? A randomized, single-blind, controlled trial",,http://drks.de/search/en/trial/DRKS00024358,2021-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3878,632,2023-11-11 20:31:42.184229,Power Training in Older Multiple Sclerosis Patients,,https://clinicaltrials.gov/show/NCT04762342,2021-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3879,631,2023-11-11 20:31:42.184229,Neuropsychological evaluation and rehabilitation in multiple sclerosis – feasibility study,,https://www.isrctn.com/ISRCTN11203922,2021-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3880,630,2023-11-11 20:31:42.184229,Proof-of-concept study for SAR441344 in relapsing multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004785-19,2021-05-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3881,629,2023-11-11 20:31:42.184229,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,,https://clinicaltrials.gov/show/NCT04760990,2021-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3882,628,2023-11-11 20:31:42.184229,Protocol Number; CBAF312A1401,,https://jrct.niph.go.jp/latest-detail/jRCT2031200377,2021-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3883,627,2023-11-11 20:31:42.184229,"The effect of Drug therapy on the treatment of overactive Bladder in Multiple Sclerosis,  The effect of Physiotherapy on the treatment of overactive Bladder in Multiple Sclerosis",,http://en.irct.ir/trial/54196,2021-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3884,626,2023-11-11 20:31:42.184229,Humour and self-distance: Two associated coping resources in selected neurodegenerative disorders (Multiple sclerosis and Primary Parkinson's disease)?,,http://drks.de/search/en/trial/DRKS00024580,2021-03-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3885,625,2023-11-11 20:31:42.184229,A resource for advance care planning in multiple sclerosis,,https://www.isrctn.com/ISRCTN48527663,2021-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3886,624,2023-11-11 20:31:42.184229,Creation of a retrospective and prospective database for the evaluation of urodynamic measurement parameters in the diagnosis of bladder dysfunctions of all kinds.,,http://drks.de/search/en/trial/DRKS00024744,2021-03-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3887,623,2023-11-11 20:31:42.184229,Development of the measurement of the blood brain barrier breakdown and myelin damage by brain MRI in healthy controls abd patients with multiple sclerosis and neuromyelitis optica spectrum disorder.,,https://jrct.niph.go.jp/latest-detail/jRCT1031210006,2021-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3888,622,2023-11-11 20:31:42.184229,Yoga is useful in multiple sclerosis relapse and quality of life,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54421,2021-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3889,621,2023-11-11 20:31:42.184229,A trial to test how efficient Nabiximols is for treatment of spacticity in patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002625-29,2019-11-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3890,620,2023-11-11 20:31:42.184229,PrograMS,,https://www.onderzoekmetmensen.nl/en/trial/21916,2021-04-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3891,619,2023-11-11 20:31:42.184229,The effect of bupropion on impotence in female MS patients,,http://en.irct.ir/trial/54285,2021-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3892,618,2023-11-11 20:31:42.184229,Register study on neuroprognostics in patients with neurological / neurosurgical diseases in intensive care unit,,http://drks.de/search/en/trial/DRKS00025259,2021-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3893,617,2023-11-11 20:31:42.184229,The effect of aerobic training at home and vitamin D supplementation in MS During Covid-19 quarantine,,http://en.irct.ir/trial/55602,2021-05-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3894,616,2023-11-11 20:31:42.184229,Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002700-39,2021-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3895,615,2023-11-11 20:31:42.184229,"A study to investigate the safety, tolerability, and processing by the body of intravenous RO7121932 in patients with multiple sclerosis",,https://www.isrctn.com/ISRCTN16295177,2021-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3896,614,2023-11-11 20:31:42.184229,"A preliminary, multicenter study on the relationship between cortical damage and blood brain barrier damage in Multiple Sclerosis patients with high cortical disease activity,",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001202-34,2021-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3897,613,2023-11-11 20:31:42.184229,"German translation, cultural adaptation for Austria and validation of the Neurological Sleep Index - Multiple Sclerosis (NSI-MS)",,http://drks.de/search/en/trial/DRKS00025573,2021-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3898,612,2023-11-11 20:31:42.184229,Light Therapy for Fatigue and Daytime Sleepiness in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12621000773831.aspx,2021-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3899,611,2023-11-11 20:31:42.184229,Investigating effects of CO-OP approach on people with Multiple Sclerosis,,http://en.irct.ir/trial/56983,2021-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3900,610,2023-11-11 20:31:42.184229,Protocol Number; COMB157G1401,,https://jrct.niph.go.jp/latest-detail/jRCT2031210175,2021-06-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3901,609,2023-11-11 20:31:42.184229,A Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005117-41,2021-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3902,608,2023-11-11 20:31:42.184229,"A multicenter, prospective cohort study to document the immunization status of MS patients in Germany with focus on anti-SARS-CoV-2 vaccination response (COVID-19)",,http://drks.de/search/en/trial/DRKS00025893,2021-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3903,607,2023-11-11 20:31:42.184229,A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004128-41,2021-07-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3904,606,2023-11-11 20:31:42.184229,A Study to Evaluate B Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000062-14,2021-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3905,605,2023-11-11 20:31:42.184229,A Study to Evaluate B Cell Levels in Infants of Lactating Women with Clinically Isolated Syndrome or Multiple sclerosis Receiving Ocrelizumab,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000063-79,2021-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3906,604,2023-11-11 20:31:42.184229,"A multicentre, retrospective study in patients with multiple sclerosis treated with natalizumab in real-world setting in Japan",,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051357,2021-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3907,603,2023-11-11 20:31:42.184229,The importance of early brain changes in patients with MS with regard to cognitive and physical outcome,,https://www.onderzoekmetmensen.nl/en/trial/28418,2021-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3908,602,2023-11-11 20:31:42.184229,The effect of consuming the liposomal form of pistachio kernel oil on multiple sclerosis,,http://en.irct.ir/trial/57607,2021-08-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3909,601,2023-11-11 20:31:42.184229,Timed acoustic stimulation of sleep in relapsing-remitting multiple sclerosis,,https://www.isrctn.com/ISRCTN11468655,2021-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3910,600,2023-11-11 20:31:42.184229,Effect of synbiotic and anti-inflammatory-antioxidant rich diet in progressive multiple sclerosis,,http://en.irct.ir/trial/55617,2021-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3911,599,2023-11-11 20:31:42.184229,The effect of kharatin oil on improving limb stiffness in patients with neurological disorders,,http://en.irct.ir/trial/58070,2021-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3912,598,2023-11-11 20:31:42.184229,"A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab versus Intravenous (IV) Ocrelizumab in Patients with Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005448-48,2021-05-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3913,597,2023-11-11 20:31:42.184229,Detecting Multiple Sclerosis via breath analysis using an eNose,,https://www.onderzoekmetmensen.nl/en/trial/26204,2021-08-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3914,596,2023-11-11 20:31:42.184229,A Study to Evaluate B Cell Levels in Infants of Lactating Women with Clinically Isolated Syndrome or Multiple sclerosis Receiving Ocrelizumab - The Sopranino Study,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000063-79,2021-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3915,595,2023-11-11 20:31:42.184229,Pregnancy after Alemtuzumab or Teriflunomide Treatment – a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry,,http://drks.de/search/en/trial/DRKS00026105,2021-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3916,594,2023-11-11 20:31:42.184229,PEER CONNECT: peer coaching for long term conditions,,https://www.isrctn.com/ISRCTN12623577,2021-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3917,593,2022-03-08 15:25:06.601663,Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).,Condition:    Multiple SclerosisInterventions:    Behavioral: N-back Cognitive Training;   Behavioral: Virtual Reality Motor and Cognitive TrainingSponsor :    Universitat Jaume IRecruiting ,https://clinicaltrials.gov/show/NCT05270239,2022-01-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3918,592,2022-03-08 15:25:06.599812,Covid-19 Vaccine Immune Response in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Other: Blood Test 1;   Other: Blood Test 2Sponsor :    University Hospitals of North Midlands NHS TrustRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05269888,2022-02-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3919,591,2022-03-08 15:25:06.595685,Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype,"Conditions:    Multiple Sclerosis;   Sleep;   PainInterventions:    Drug: Cannabidiol (CBD);   Drug: Tetrahydrocannabinol (THC);   Drug: Placebo CBD;   Drug: Placebo THCSponsors :    Tiffany J. Braley, MD, MS;   National Center for Complementary and Integrative Health (NCCIH)Not yet recruiting ",https://clinicaltrials.gov/show/NCT05269628,2022-02-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3920,590,2023-11-11 20:31:42.184229,Evaluation of the effectiveness of tele rehabilitation program on upper limb function in people with MS : Pilot study,,http://en.irct.ir/trial/57267,2021-09-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3921,589,2023-11-11 20:31:42.184229,The effect of empowerment program on self-management of patients with Multiple sclerosis,,http://en.irct.ir/trial/58331,2021-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3922,588,2023-11-11 20:31:42.184229,Evaluation of the effect of extracorporeal shockwave therapy after botulinum toxin injection on cuff muscle spasticity improvement,,http://en.irct.ir/trial/58566,2021-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3923,587,2023-11-11 20:31:42.184229,Study to test IMU-838 in patients with progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000048-23,2021-09-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3924,586,2023-11-11 20:31:42.184229,Evaluation of the effect of Levetiracetam on cognitive impairment in patients with MS,,http://en.irct.ir/trial/57352,2021-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3925,585,2023-11-11 20:31:42.184229,The effect of ginger consumption in patients with multiple sclerosis,,http://en.irct.ir/trial/58779,2021-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3926,584,2023-11-11 20:31:42.184229,The effect of rosuvastatin in multiple sclerosis,,http://en.irct.ir/trial/56962,2021-09-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3927,583,2023-11-11 20:31:42.184229,Effect of siponimod on progressive multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005947-22,2021-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3928,582,2023-11-11 20:31:42.184229,The effect of stabilizing exercises on urinary incontinence in patients with MS,,http://en.irct.ir/trial/57518,2021-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3929,581,2023-11-11 20:31:42.184229,"A study to investigate the concordance of smartphone-based self-monitoring, imaging, and blood-based biomarkers with clinical disability in participants with multiple sclerosis",,https://www.isrctn.com/ISRCTN11088592,2021-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3930,580,2023-11-11 20:31:42.184229,Impact of ocrelizumab on patient-reported fatigue and quality of life in patients with relapsing multiple sclerosis treated for the first time with ocrelizumab,,https://www.isrctn.com/ISRCTN55332718,2021-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3931,579,2023-11-11 20:31:42.184229,"Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial.",,https://anzctr.org.au/ACTRN12621001502820.aspx,2021-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3932,578,2023-11-11 20:31:42.184229,"Acute optic neuritis study: a monocentric, prospective observational study on symptomatology, diagnosis, therapy and prognosis of acute optic neuritis.",,http://drks.de/search/en/trial/DRKS00027095,2021-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3933,577,2023-11-11 20:31:42.184229,Expressive Writing and Sexual Self-Concept Of Men With M.S,,http://en.irct.ir/trial/59664,2021-11-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3934,576,2023-11-11 20:31:42.184229,"Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005929-89,2021-09-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3935,575,2023-11-11 20:31:42.184229,Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54954,2021-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3936,574,2023-11-11 20:31:42.184229,A study to asses the effects of Nabiximols on spasticity associated with multiple sclerosis.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004306-58,2021-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3937,573,2023-11-11 20:31:42.184229,An online lifestyle modification course for people with multiple sclerosis: a randomised controlled trial of course effectiveness.,,https://anzctr.org.au/ACTRN12621001605886.aspx,2021-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3938,572,2023-11-11 20:31:42.184229,Comparison of the effect of Cichorium intybus and N-acetylcysteine versus placebo on the reduction of liver complications of Fingolimod in patients with multiple sclerosis,,http://en.irct.ir/trial/60495,2021-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3939,571,2023-11-11 20:31:42.184229,"The effect of training on postural control, performance and fatigue index in women with multiple sclerosis",,http://en.irct.ir/trial/60280,2021-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3940,570,2023-11-11 20:31:42.184229,L-carnitine in patients with MS,,http://en.irct.ir/trial/59711,2021-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3941,569,2023-11-11 20:31:42.184229,Clemastine fumarate as a treament for eye movement disorders in patients with multiple sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003677-66,2021-12-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3942,568,2023-11-11 20:31:42.184229,A study to evaluate specific unmet needs in the current clinical practice of multiple sclerosis,,https://www.isrctn.com/ISRCTN40939838,2021-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3943,567,2023-11-11 20:31:42.184229,AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-004868-95,2021-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3944,566,2023-11-11 20:31:42.184229,OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION IN MULTIPLE SCLEROSIS (LEGATO),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003296-33,2021-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3945,565,2023-11-11 20:31:42.184229,The effect of exercise on fatigue in MS,,http://en.irct.ir/trial/60731,2021-12-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3946,564,2023-11-11 20:31:42.184229,Characterization of patients and evaluation of drug treatment for Multiple Sclerosis,,http://ensaiosclinicos.gov.br/rg/RBR-9x6yxbv,2021-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3947,563,2023-11-11 20:31:42.184229,A phase II trial examining the safety and preliminary efficacy of repetitive transcranial magnetic stimulation (rTMS) for people living with multiple sclerosis,,https://anzctr.org.au/ACTRN12622000064707.aspx,2022-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3948,562,2023-11-11 20:31:42.184229,Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004819-12,2022-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3949,561,2023-11-11 20:31:42.184229,tele- dysphagia treatments in patients with multiple sclerosis,,http://en.irct.ir/trial/57170,2022-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3950,560,2023-11-11 20:31:42.184229,"The effect of self-management program based on virtual group discussion on fatigue, sleep quality and quality of life in patients with multiple sclerosis",,http://en.irct.ir/trial/60736,2022-02-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3951,559,2023-11-11 20:31:42.184229,Home-based virtual reality for help with symptoms of multiple sclerosis,,https://www.isrctn.com/ISRCTN76033536,2022-04-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3952,558,2023-11-11 20:31:42.184229,The effect of education and telephone follow-up on self-care and quality of life in patients with multiple sclerosis,,http://en.irct.ir/trial/60566,2022-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3953,557,2023-11-11 20:31:42.184229,A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000639-30,2021-09-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3954,556,2023-11-11 20:31:42.184229,"Investigating the effect of peer-based education based on Pender health promotion model on quality of life, stress management and Self-efficacy in patients with multiple sclerosis",,http://en.irct.ir/trial/61691,2022-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3955,555,2023-11-11 20:31:42.184229,A Pilot Study of Cognitive Behavioural Therapy for Migraine in Multiple Sclerosis,,https://anzctr.org.au/ACTRN12622000227796.aspx,2022-08-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3956,554,2023-11-11 20:31:42.184229,"The effect of exercise on biochemical, psychological, and physical factors of women with MS",,http://en.irct.ir/trial/60162,2022-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3957,553,2023-11-11 20:31:42.184229,Vojta therapy in multiple sclerosis rehabilitation,,https://www.isrctn.com/ISRCTN12817871,2022-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3958,552,2023-11-11 20:31:42.184229,A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE 1),,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=64814,2022-02-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3959,551,2023-11-11 20:31:42.184229,Project Twenty21 Australia- A Prospective Observational Study Investigating Medicinal Cannabis in Four Clinical Conditions,,https://anzctr.org.au/ACTRN12622000390785.aspx,2022-07-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3960,550,2023-11-11 20:31:42.184229,A study to investigate the feasibility of smartphone-based self-monitoring to characterise cognitive and neurological impairment in participants with multiple sclerosis (Floodlight MS_More Active),,https://www.isrctn.com/ISRCTN62225263,2022-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3961,549,2023-11-11 20:31:42.184229,Effect of nano crocin on cognition among MS patients,,http://en.irct.ir/trial/61965,2022-03-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3962,548,2023-11-11 20:31:42.184229,The effect of exercise and grape juice on multiple sclerosis(Ms),,http://en.irct.ir/trial/61394,2022-03-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3963,547,2023-11-11 20:31:42.184229,Personalized dosing of ocrelizumab in MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-004791-34,2022-03-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3964,546,2023-11-11 20:31:42.184229,"Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE ""CONTINENCE"" Clinical Study",,https://clinicaltrials.gov/ct2/show/NCT05301335,2022-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3965,545,2023-11-11 20:31:42.184229,Effect of Nigella Sativa on tremor,,http://en.irct.ir/trial/60520,2022-03-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3966,544,2023-11-11 20:31:42.184229,"A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis
(ENSURE-2)",,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=63600,2022-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3967,543,2023-11-11 20:31:42.184229,Implementation and scientific evaluation of an online sports medical consultation for people with multiple sclerosis (MS).,,http://drks.de/search/en/trial/DRKS00028704,2022-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3968,542,2023-11-11 20:31:42.184229,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005746-15,2022-02-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3969,541,2023-11-11 20:31:42.184229,MINDS-MS: Detection and treatment of depression in people with multiple sclerosis through neurology healthcare services,,https://anzctr.org.au/ACTRN12622000543785.aspx,2022-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3970,540,2023-11-11 20:31:42.184229,Effect of acupuncture in relieving fatigue of multiple sclerosis,,http://en.irct.ir/trial/57659,2022-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3971,539,2023-11-11 20:31:42.184229,Examining the effectiveness of a digital psychological intervention in people with Multiple Sclerosis attending the Multiple Sclerosis Clinic at Royal North Shore Hospital.,,https://anzctr.org.au/ACTRN12622000670774.aspx,2022-09-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3972,538,2023-11-11 20:31:42.184229,Not applicable,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000028-36,2021-04-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3973,537,2023-11-11 20:31:42.184229,Measurements of CNS-reactive B cells and their specificity in the blood of ocrelizumab-treated patients,,http://drks.de/search/en/trial/DRKS00029110,2022-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3974,536,2023-11-11 20:31:42.184229,Masitinib in patients with primary progressive or secondary progressive multiple sclerosis,,https://www.isrctn.com/ISRCTN93303620,2022-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3975,535,2023-11-11 20:31:42.184229,The Wellbeing Neuro Course: A Randomised Controlled Trial of an Online Treatment Program for Adults with Multiple Sclerosis,,https://anzctr.org.au/ACTRN12622000736741.aspx,2022-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3976,534,2023-11-11 20:31:42.184229,Evaluation of exercise therapy on quality of life in patients with multiple sclerosis,,http://en.irct.ir/trial/60436,2022-05-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3977,533,2023-11-11 20:31:42.184229,Multi-modal recording of biokinematic data of neurological patients using wearable sensors,,http://drks.de/search/en/trial/DRKS00029684,2022-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3978,532,2023-11-11 20:31:42.184229,Is Epstein-Barr Virus (EBV) the cause of multiple sclerosis? A preliminary study,,https://www.isrctn.com/ISRCTN69709064,2022-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3979,531,2023-11-11 20:31:42.184229,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple",,https://jrct.niph.go.jp/latest-detail/jRCT2071220034,2022-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3980,530,2023-11-11 20:31:42.184229,A study in healthy volunteers to investigate how different recipes and the particle size of an ingredient in the test medicine affects how the test medicine behaves,,https://www.isrctn.com/ISRCTN17780768,2022-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3981,529,2023-11-11 20:31:42.184229,Multiple sclerosis exercise mode and intensity study,,https://anzctr.org.au/ACTRN12622001115729.aspx,2022-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3982,528,2023-11-11 20:31:42.184229,Phase 2 study of SAR443820 in participants with multiple sclerosis (MS),,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000049-34,2022-07-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3983,527,2023-11-11 20:31:42.184229,Lacosamide efficasy and safety on pain in patients with multiple sclerosis: A randomized double_blind clinical trial,,http://en.irct.ir/trial/65347,2022-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3984,526,2023-11-11 20:31:42.184229,The relevance of evolving grey and white matter pathology to the development of neurodegeneration and disability in multiple sclerosis,,https://www.isrctn.com/ISRCTN61223124,2022-09-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3985,525,2023-11-11 20:31:42.184229,Disease Activity and Fertility in Women with highly active Multiple Sclerosis seeking Pregnancy,,http://drks.de/search/en/trial/DRKS00030049,2022-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3986,524,2023-11-11 20:31:42.184229,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS),,https://clinicaltrials.gov/ct2/show/NCT05156281,2021-01-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3987,523,2023-11-11 20:31:42.184229,Effect of transcranial direct current stimulation in treatment of dysphagia in MS,,http://en.irct.ir/trial/65692,2022-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3988,522,2023-11-11 20:31:42.184229,"Development and validation of a  documentation of therapy aims, content and outcome measures to improve mobility in people with multiple sclerosis during inpatient neurological rehabilitation in Austria",,http://drks.de/search/en/trial/DRKS00030391,2022-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3989,521,2023-11-11 20:31:42.184229,Hydroxychloroquine in progressive MS,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-003170-23,2022-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3990,520,2023-11-11 20:31:42.184229,"A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000049-34,2022-11-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3991,519,2023-11-11 20:31:42.184229,Testing and comparing multiple drugs at once against the standard treatment for progressive multiple sclerosis treatment,,https://www.isrctn.com/ISRCTN14048364,2022-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3992,518,2023-11-11 20:31:42.184229,"A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis",,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004431-24,2022-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3993,517,2023-11-11 20:31:42.184229,Increasing T-regulatory cells after alemtuzumab or cladribine treatment in people with multiple sclerosis,,https://www.isrctn.com/ISRCTN17601680,2022-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3994,516,2023-11-11 20:31:42.184229,Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS,,https://euclinicaltrials.eu/app/#/view/2022-502664-21-00?lang=en,2022-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3995,515,2023-11-11 20:31:42.184229,The effectiveness of group therapy based on improving the quality of life in patients with MS,,http://en.irct.ir/trial/66036,2022-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3996,514,2023-11-11 20:31:42.184229,"Characterization of nutritional, AhR-dependent immune responses in patients with chronic kidney disease and multiple sclerosis",,http://drks.de/search/en/trial/DRKS00030864,2022-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3997,513,2023-11-11 20:31:42.184229,The effect of royal jelly on inflammatory mediators in multiple sclerosis patients,,http://en.irct.ir/trial/66120,2022-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3998,512,2023-11-11 20:31:42.184229,The effect of exercise therapy on balance in patients with multiple sclerosis,,http://en.irct.ir/trial/65164,2023-01-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
3999,511,2023-11-11 20:31:42.184229,The effect of stabilizing exercises on MS patients,,http://en.irct.ir/trial/57219,2023-01-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4000,510,2023-11-11 20:31:42.184229,Investigation of safety and efficacy of intrathecal and intravenous injection of umbilical cord-derived mesenchymal stem cells,,http://en.irct.ir/trial/67054,2023-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4001,509,2023-11-11 20:31:42.184229,Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2023-000018-16,2023-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4002,508,2023-11-11 20:31:42.184229,Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000801-28,2023-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4003,507,2023-11-11 20:31:42.184229,"Identification and analysis of biomarkers for the course of demyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosis",,http://drks.de/search/en/trial/DRKS00031139,2023-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4004,506,2023-11-11 20:31:42.184229,The effect of educational intervention of self-care behaviors on the quality of life and resilience of multiple sclerosis (MS) patients.,,http://en.irct.ir/trial/66678,2023-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4005,505,2023-11-11 20:31:42.184229,"Comparing the effects of dry needling of ankle plantar flexor muscles on neuromodulation, spasticity, and balance in people with MS and stroke.",,http://en.irct.ir/trial/68454,2023-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4006,504,2023-11-11 20:31:42.184229,"The role of local and systemic inflammation in inflammatory bowel disease, autoimmune disease, and cardiometabolic disease.",,http://drks.de/search/en/trial/DRKS00031203,2023-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4007,503,2023-11-11 20:31:42.184229,Comparing effect of two counseling method (Leventhal's self-regulation model and BETTER Model) on Sexual Satisfaction & function in Women with multiple sclerosis: A three armed randomized controlled trial,,http://en.irct.ir/trial/68432,2023-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4008,502,2023-11-11 20:31:42.184229,"The Effectivness of Functional Exercises with the Approach of Ultimate fit on the Parameters of Balance Muscle Strengths, Fatigue, Gait and Activity of Daily Living of Women with Multiple sclerosis.",,http://en.irct.ir/trial/67411,2023-02-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4009,501,2023-11-11 20:31:42.184229,infLuence Of anovulaTion and menopaUSe on the course of MS,,http://drks.de/search/en/trial/DRKS00031183,2023-02-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4010,500,2023-11-11 20:31:42.184229,Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Sepsis and Multiple Sclerosis,,https://www.chictr.org.cn/showproj.html?proj=191652,2023-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4011,499,2023-11-11 20:31:42.184229,Developing and assessing the feasibility of a psychosexual treatment for sexual difficulties in people with multiple sclerosis.,,https://www.isrctn.com/ISRCTN12202900,2023-02-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4012,498,2023-11-11 20:31:42.184229,Investigating the effect of lavender on depression in patients with multiple sclerosis,,http://en.irct.ir/trial/68643,2023-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4013,497,2023-11-11 20:31:42.184229,Study to Analyse Clinical and Paraclinical Parameters of Disease Activity in Patients with Multiple Sclerosis,,http://drks.de/search/en/trial/DRKS00028178,2023-06-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4014,496,2023-11-11 20:31:42.184229,Association of health-related quality of life with disability severity and its components in people with multiple sclerosis.,,http://drks.de/search/en/trial/DRKS00031556,2023-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4015,495,2023-11-11 20:31:42.184229,Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis,,http://en.irct.ir/trial/69402,2023-04-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4016,494,2023-11-11 20:31:42.184229,Effective physical assessment in ITB screening trials,,https://jrct.niph.go.jp/latest-detail/jRCT1030230011,2023-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4017,493,2023-11-11 20:31:42.184229,Evaluation of complementary therapy with Capparis spinosa on MS patients,,http://en.irct.ir/trial/69356,2023-04-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4018,492,2023-11-11 20:31:42.184229,Long-term effect of CoDuSe balance exercise program,,http://en.irct.ir/trial/69712,2023-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4019,491,2023-11-11 20:31:42.184229,Effects of telerehabilitation in multiple sclerosis,,http://en.irct.ir/trial/69528,2023-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4020,490,2023-11-11 20:31:42.184229,Needs and design analysis of a counselling service for couples affected by multiple sclerosis - a mixed-methods study design within the framework of a participatory health research approach (PGF),,http://drks.de/search/en/trial/DRKS00031739,2023-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4021,489,2023-11-11 20:31:42.184229,Assessment of the effect of lisdexamfetamine on fatigue in patients with multiple sclerosis,,http://en.irct.ir/trial/68213,2023-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4022,488,2023-11-11 20:31:42.184229,Identifying genetic determinants of outcome in multiple sclerosis,,https://www.isrctn.com/ISRCTN41688895,2023-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4023,487,2023-11-11 20:31:42.184229,"Implementation of Sole Sensor Technology in Neurological Rehabilitation
to reveal Inter- and Intraindividual Differences in Temporospatial Gait Patterns of Neurological Patients",,http://drks.de/search/en/trial/DRKS00031818,2023-08-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4024,486,2023-11-11 20:31:42.184229,Probiotic supplementation in multiple sclerosis,,http://en.irct.ir/trial/64785,2022-08-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4025,485,2023-11-11 20:31:42.184229,Effect of vitamin D on serum levels of CHI3L1 inflammatory factor and oxidative stress in patients with multiple sclerosis,,http://en.irct.ir/trial/69702,2023-05-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4026,484,2023-11-11 20:31:42.184229,Resveratrol in multiple sclerosis,,http://en.irct.ir/trial/69227,2023-05-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4027,483,2023-11-11 20:31:42.184229,"Analysis of the interplay between glucose variability, microbiomics and metabolomics in patients with multiple sclerosis during relapse and recovery",,http://drks.de/search/en/trial/DRKS00031852,2023-05-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4028,482,2023-11-11 20:31:42.184229,"Determining the combined effect of MitoQ supplementation and endurance training on cognitive and motor functions, changes in oxidative indices and miR-223 and miR-146a gene expression in postmenopausal and non-menopausal women with multiple sclerosis",,http://en.irct.ir/trial/67041,2023-05-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4029,481,2023-11-11 20:31:42.184229,Non-invasive treatment of urinary symptoms and quality of life in women with Multiple Sclerosis,,https://ensaiosclinicos.gov.br/rg/RBR-29fy354,2023-06-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4030,480,2023-11-11 20:31:42.184229,The effect of L-carnitin on EDSS score and Quality of life of MS patients,,http://en.irct.ir/trial/70238,2023-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4031,479,2023-11-11 20:31:42.184229,The effect of slow and fast music on anxiety and quality of life of people with multiple sclerosis,,http://en.irct.ir/trial/69981,2023-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4032,478,2023-11-11 20:31:42.184229,Evaluation of the effect of vitamin C on flu-like syndrome in multiple sclerosis patients receiving beta-interferon,,http://en.irct.ir/trial/69555,2023-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4033,477,2023-11-11 20:31:42.184229,Effect of education based on mobile application on physical activity of people with multiple sclerosis,,http://en.irct.ir/trial/71012,2023-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4034,476,2023-11-11 20:31:42.184229,Infusion-related reactions of Ocrelizumab,,http://en.irct.ir/trial/70922,2023-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4035,475,2023-11-11 20:31:42.184229,The Effect of Strengthening  hip Abductors in People with Multiple Sclerosis,,http://en.irct.ir/trial/71788,2023-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4036,474,2023-11-11 20:31:42.184229,"Multivariate prediction of disease course and progression in multiple sclerosis using imaging, microbiome, and genetic, immunological, and neuropsychological parameters: a multicenter prospective cohort study",,http://drks.de/search/en/trial/DRKS00032184,2023-08-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4037,473,2023-11-11 20:31:42.184229,"VAC-MAC: Vaccination and infection rates in multiple sclerosis (MS), chronic inflammatory rheumatic diseases (CIRD) or chronic inflammatory bowel diseases (CED)",,http://drks.de/search/en/trial/DRKS00031559,2023-08-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4038,472,2023-11-11 20:31:42.184229,The Effect of Foot Reflexology on Restless leg syndrome and Sleep Quality,,http://en.irct.ir/trial/71552,2023-09-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4039,471,2023-11-11 20:31:42.184229,The Effects of Pyridostigmine on Dysphagia in Patients With Multiple Sclerosis,,http://en.irct.ir/trial/72487,2023-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4040,470,2023-11-11 20:31:42.184229,Telerehabilitation Education on Anxiety in People with Multiple Sclerosis,,http://en.irct.ir/trial/72514,2023-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4041,469,2023-11-11 20:31:42.184229,Safety evaluation ofstem cells in multiple sclerosis patients,,http://en.irct.ir/trial/71954,2023-09-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4042,468,2023-11-11 20:31:42.184229,Comparing the effects of trans-cranial direct current stimulation in patients with multiple sclerosis,,http://en.irct.ir/trial/71113,2023-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4043,467,2023-11-11 20:31:42.184229,The effect of alpha-ipoic acid supplementation along with neuromuscular training in the recovery of multiple sclerosis,,http://en.irct.ir/trial/72601,2023-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4044,466,2023-11-11 20:31:42.184229,Investigation of rehabilitation for the dysesthesias by peripheral and central neuropathy,,https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059765,2023-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4045,465,2023-11-11 20:31:42.184229,A study to evaluate the effect of highly reduced kidney function on the processing of fenebrutinib in the body,,https://www.isrctn.com/ISRCTN41455091,2023-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4046,464,2023-11-11 20:31:42.184229,A study to evaluate the effect of various degrees of reduced liver function on the processing of fenebrutinib in the body,,https://www.isrctn.com/ISRCTN46432183,2023-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4047,463,2023-11-09 13:53:27.810808,Multiple Sclerosis Self Monitoring Study,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Device: MS Sherpa
<br /><b>Sponsors</b>: Amsterdam UMC, location VUmc
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06125301,2022-11-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4048,462,2023-11-09 08:23:15.937241,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis","<p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000637-41,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4049,461,2023-11-08 19:03:23.014315,The Effects of Two Types of t-DCS Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis; Transcranial Direct Current Stimulation
<br /><b>Interventions</b>: Combination Product: Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation; Combination Product: Sham ts-DCS and sham t-DCS
<br /><b>Sponsors</b>: Istanbul Medeniyet University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06121635,2023-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4050,460,2023-11-08 19:03:23.005812,Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36,"<b>Conditions</b>: Parkinson Disease; Multiple Sclerosis; Stroke; Upper Extremity Problem
<br /><b>Interventions</b>: Other: Turkish Validity and Reliability of The MAM-36 Scale
<br /><b>Sponsors</b>: Istanbul Medeniyet University
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06122740,2023-03-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4051,459,2023-11-08 19:03:22.994781,Effect of Hydrotherapy on Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: hydrotherapy; Other: neurological physiotherapy
<br /><b>Sponsors</b>: University of Thessaly
<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06121648,2023-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4052,458,2023-11-07 14:23:20.045065,WOE of Anti-CD20 Therapies,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: ocrelizumab; Drug: ofatumumab
<br /><b>Sponsors</b>: Novartis Pharmaceuticals
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06121349,2023-10-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4053,457,2023-11-03 15:33:19.767087,Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals,"<b>Conditions</b>: Muscle Spasticity; Hypertonia, Muscle; Cerebral Palsy; Multiple Sclerosis; Stroke; Hereditary Spastic Paraplegia; Dystonia; Spinal Cord Injuries
<br /><b>Interventions</b>: Drug: MTR-601
<br /><b>Sponsors</b>: Motric Bio
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06117020,2023-10-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4054,456,2023-11-03 10:33:28.178582,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL...","<p>EudraCT Number: 2020-000894-26<br />Sponsor Protocol Number: BN42083<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-10-12<br />Medical condition: Primary Progressive Multiple Sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000894-26/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000894-26,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4055,455,2023-11-02 13:02:36.626092,A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.,"<b>Conditions</b>: Multiple Sclerosis; Insomnia
<br /><b>Interventions</b>: Behavioral: Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I); Behavioral: Digital patient education about insomnia (PE)
<br /><b>Sponsors</b>: St. Olavs Hospital
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06113666,2023-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4056,454,2023-11-01 12:40:48.609927,Effects of Transcutaneous Spinal Direct Current Stimulation on Mobility in Cases With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis; Transcranial Direct Current Stimulation
<br /><b>Interventions</b>: Device: Transcutaneous Spinal Direct Current Stimulation
<br /><b>Sponsors</b>: Istanbul Medeniyet University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06110936,2023-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4057,453,2023-11-01 12:40:48.600929,The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders,"<b>Conditions</b>: Sclerosis, Multiple; Neurocognitive Impairment, Mild; Neurocognitive Dysfunction
<br /><b>Interventions</b>: Device: DANCEREX-DTx; Device: Multidimensional dance-based program; Device: Educational Program
<br /><b>Sponsors</b>: Fondazione Don Carlo Gnocchi Onlus; IRCCS Centro San Giovanni di Dio Fatebenefratelli; University of Milano Bicocca; IRCCS Centro Neurolesi ""Bonino-Pulejo""
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06112639,2023-10-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4058,452,2023-11-01 10:10:48.160936,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...","<p>EudraCT Number: 2010-020337-99<br />Sponsor Protocol Number: WA21092<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2011-10-20<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2010-020337-99,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4059,451,2023-10-31 12:32:27.335597,"Physical Function, Health and Employment for People With Multiple Sclerosis","<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: CoreDISTParticipation
<br /><b>Sponsors</b>: Nordlandssykehuset HF; The Royal Norwegian Ministry of Health; University Hospital of North Norway; Nord University; UiT The Arctic University of Norway; Helgeland Hospital Trust; University of Tasmania; Norwegian Labour and Welfare Administration
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06110468,2023-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4060,450,2023-10-30 13:02:39.289418,Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Tolebrutinib; Drug: Placebo
<br /><b>Sponsors</b>: Sanofi
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06106074,2023-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4061,449,2023-10-30 13:02:39.277736,Action Observation Training With 3D Virtual Reality in Patients With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Behavioral: Action observation training; Behavioral: sham action observation training
<br /><b>Sponsors</b>: Abant Izzet Baysal University
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06107023,2023-10-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4062,448,2023-10-30 13:02:39.267150,Regulating Together in Tuberous Sclerosis Complex,"<b>Conditions</b>: TSC; Behavioral Symptoms
<br /><b>Interventions</b>: Behavioral: Behavioral Intervention in a small group platform
<br /><b>Sponsors</b>: University of North Carolina, Chapel Hill; United States Department of Defense
<br /><b>Recruiting</b>",https://clinicaltrials.gov/study/NCT06105736?cond=Multiple+Sclerosis,2023-10-30 04:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4063,447,2023-10-27 13:02:28.744567,A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis,"<b>Conditions</b>: Relapsing Multiple Sclerosis; Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Placebo; Drug: Pirtobrutinib
<br /><b>Sponsors</b>: Loxo Oncology, Inc.; Eli Lilly and Company
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06104683,2023-10-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4064,446,2023-10-27 13:02:28.733695,"Multiple Sclerosis, Menstrual Cycle and Physical Acivity","<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Strength training sessions and High-interval intensity training sessions
<br /><b>Sponsors</b>: Universidad de Almeria
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06105463,2023-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4065,445,2023-10-26 12:40:52.305576,The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson in Patients With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: PNF Group; Other: Control Group
<br /><b>Sponsors</b>: Nilay Comuk Balci
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06102148,2023-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4066,444,2023-10-23 15:32:27.126902,MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC,"<b>Conditions</b>: Multiple Sclerosis, Relapsing-Remitting
<br /><b>Interventions</b>: Diagnostic Test: serum Neurofilament Filament Light chain (sNfL) monitoring
<br /><b>Sponsors</b>: University Hospital, Basel, Switzerland
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06095271,2023-10-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4067,443,2023-10-23 15:32:27.116804,Effect of Cooling on Balance Performance in Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: 20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest
<br /><b>Sponsors</b>: Hunter College of City University of New York
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06094855,2023-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4068,442,2023-10-19 12:42:27.215618,Investigation of Factors Affecting Functional Capasity in Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Evaluation
<br /><b>Sponsors</b>: Izmir Bakircay University
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06090084,2023-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4069,441,2023-10-19 12:42:27.207500,Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex),"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Behavioral: levidex; Behavioral: Control; Other: treatment as usual (TAU)
<br /><b>Sponsors</b>: Gaia AG; University Hospital Schleswig-Holstein; Universität Duisburg-Essen
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06090305,2023-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4070,440,2023-10-19 11:32:30.064579,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","<p>EudraCT Number: 2015-002500-91<br />Sponsor Protocol Number: RPC01-3001<br />Sponsor Name: Celgene International II Sàrl (CIS II)<br />Start Date: 2015-10-12<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002500-91,2015-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4071,439,2023-10-16 12:42:30.324307,Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis,"<b>Conditions</b>: Relapsing Remitting Multiple Sclerosis
<br /><b>Interventions</b>: Drug: PIPE-307 Dose A; Drug: PIPE-307 Dose B; Drug: Placebo
<br /><b>Sponsors</b>: Pipeline Therapeutics, Inc.
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06083753,2023-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4072,438,2023-10-16 12:42:30.313406,Cognitive Function in Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment
<br /><b>Sponsors</b>: Inonu University
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06084182,2022-11-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4073,437,2023-10-13 19:40:49.375082,Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders,"<b>Conditions</b>: Neurodevelopmental Disorders; Autism; Autism Spectrum Disorder; Fragile X Syndrome; Tuberous Sclerosis; 22Q11 Deletion Syndrome; 22Q11 Deletion; ADHD; Tic Disorders; Tourette Syndrome; Tourette Syndrome in Children; Tourette Syndrome in Adolescence; ADHD - Combined Type; ADHD Predominantly Inattentive Type; ADHD, Predominantly Hyperactive - Impulsive; Provisional Tic Disorder; Anxiety; Anxiety Disorders; Agoraphobia; Generalized Anxiety; Generalized Anxiety Disorder; Social Anxiety; Social Anxiety Disorder; Unspecified Anxiety Disorder; Other Specified Anxiety Disorders; Separation Anxiety
<br /><b>Interventions</b>: Drug: Sertraline; Other: Placebo
<br /><b>Sponsors</b>: Anagnostou, Evdokia, M.D.; Azrieli Foundation; Canadian Institutes of Health Research (CIHR); Ontario Brain Institute; Holland Bloorview Kids Rehabilitation Hospital; McMaster University; Western University; Queen's University; University of Alberta; Alberta Health services; St. Justine's Hospital; Dalhousie University; Unity Health Toronto; University of Toronto; The Hospital for Sick Children
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06081348?cond=Multiple+Sclerosis,2023-10-13 04:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4074,436,2023-10-13 19:40:49.361909,"Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).","<b>Conditions</b>: Multiple Sclerosis
<br /><b>Sponsors</b>: University Hospital, Clermont-Ferrand
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06083194,2023-09-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4075,435,2023-10-13 09:52:58.138928,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2018-001511-73<br />Sponsor Protocol Number: WA40404<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2019-12-23<br />Medical condition: <br />Disease: <br />Population Age: <br />Gender: <br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-001511-73,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4076,434,2023-10-12 05:42:22.898659,Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004557-24<br />Sponsor Protocol Number: UKM17_0056<br />Sponsor Name: Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel <br />Start Date: 2019-07-29<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004557-24/DE"">DE</a> (Temporarily Halted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004557-24,2019-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4077,433,2023-10-11 10:22:23.648427,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","<p>EudraCT Number: 2020-000645-14<br />Sponsor Protocol Number: EFC16035<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-10-13<br />Medical condition: Primary Progressive Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NO"">NO</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HR"">HR</a> (Ongoing)</p>",https://repec.ins.gob.pe/maestro/ajax/exportar-ficha-datos-publico/1959/en/,,17,,17,WHO XML import,https://trialsearch.who.int/
4078,432,2023-10-11 09:40:47.418658,"Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...","<p>EudraCT Number: 2018-001896-19<br />Sponsor Protocol Number: P2-IMU-838-MS<br />Sponsor Name: Immunic AG<br />Start Date: 2018-12-17<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001896-19/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001896-19/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001896-19/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-001896-19,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4079,431,2023-10-10 13:32:30.574880,The Living With a Long-Term Condition Study,"<b>Conditions</b>: Asthma; Atrial Fibrillation; Cancer; Cerebrovascular Disorders; Stroke; CKD; Copd; Fibromyalgia; Pain; Heart Diseases; Heart Disease Chronic; Dementia; Diabetes; Epilepsy; Heart Failure; High Blood Pressure; Hypertension; Hiv; AIDS; IBD; IBS; Liver Diseases; Long COVID; Lupus Erythematosus; Multiple Sclerosis; Obesity; Osteoarthritis; Arthritis; Rheumatoid Arthritis; Osteoporosis; Parkinson Disease; Sickle Cell Disease; Hepatitis; Endometriosis; PCOS; Neurological Disorder; POTS - Postural Orthostatic Tachycardia Syndrome; MND (Motor Neurone DIsease); Cystic Fibrosis; Migraine; Spondylitis; Celiac Disease; Hidradenitis Suppurativa; Eczema; ME/CFS
<br /><b>Interventions</b>: Diagnostic Test: Living with LTC Questionnaire
<br /><b>Sponsors</b>: King's College London
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06072287,2023-02-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4080,430,2023-10-10 13:32:30.567355,Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS,"<b>Conditions</b>: Neurogenic Bladder; Multiple Sclerosis; Overactive Bladder
<br /><b>Interventions</b>: Device: Magstim Rapid2 System
<br /><b>Sponsors</b>: The Methodist Hospital Research Institute
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06072703,2023-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4081,429,2023-10-10 13:32:30.558194,The Effect of Inspiratory Muscle Training on Balance and Postural Control in Multiple Sclerosis Patients,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Inspiratory Muscle Training; Other: Balance Exercises
<br /><b>Sponsors</b>: Marmara University
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06075472,2022-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4082,428,2023-10-10 12:52:24.197184,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,"<b>Conditions</b>: Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central Neuropathic Pain; Paraplegia; Multiple Sclerosis; Stroke; Phantom Limb Syndrome With Pain; Phantom Pain; Traumatic Brain Injury
<br /><b>Interventions</b>: Drug: Adezunap (AP707); Drug: Placebo
<br /><b>Sponsors</b>: Apurano Pharmaceuticals GmbH
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06072001,2023-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4083,427,2023-10-10 12:52:24.189132,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,"<b>Conditions</b>: Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central Neuropathic Pain; Paraplegia; Multiple Sclerosis; Stroke; Phantom Limb Syndrome With Pain; Phantom Pain; Traumatic Brain Injury
<br /><b>Interventions</b>: Drug: Adezunap; Drug: Placebo
<br /><b>Sponsors</b>: Apurano Pharmaceuticals GmbH
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06071949,2023-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4084,426,2022-03-03 12:52:45.000000,"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","Condition:    Multiple Sclerosis, Relapsing-RemittingIntervention:    Drug: NatalizumabSponsor :    BiogenNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05265728,2022-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4085,425,2022-02-28 22:52:11.000000,Exploring Cortical Remyelination in Children With Multiple Sclerosis,Condition:    Children With Multiple SclerosisIntervention:    Other: MRI without injection of contrast productSponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05258396?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-28 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4086,424,2022-02-23 16:12:11.000000,Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS),Condition:    Multiple SclerosisIntervention:    Sponsors :    University of Michigan;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wayne State University;   University of WashingtonNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05252195,2022-12-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4087,423,2023-10-10 12:52:24.159814,Effects of Virtual Reality on Sleep Quality and Mental Well-being,"<b>Conditions</b>: Nursing Caries
<br /><b>Interventions</b>: Device: Occulus quest 2 virtual reality glasses
<br /><b>Sponsors</b>: Ataturk University; Ataturk University SCIENTIFIC RESEARCH PROJECTS COORDINATION UNIT
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06074419?cond=Multiple+Sclerosis,2023-10-10 04:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4088,422,2023-10-06 14:32:23.730162,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","<p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2022-08-05<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-005746-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4089,421,2022-02-21 13:32:11.000000,Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Behavioral: QuestionnaireSponsors :    University Hospital, Bordeaux;   Merck Sharp & Dohme Corp.Not yet recruiting ",https://clinicaltrials.gov/show/NCT05248438,2022-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4090,420,2022-02-19 21:55:32.000000,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,,https://www.novartis.com/clinicaltrials/study/nct04417621,2022-02-19 21:55:32.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4091,419,2023-10-06 11:02:33.944360,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...","<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV"">LV</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-001341-40,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4092,418,2022-02-19 01:55:33.000000,A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP,,https://www.novartis.com/clinicaltrials/study/nct04346654,2022-02-19 01:55:33.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4093,417,2023-10-05 15:22:23.061434,Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Behavioral: Strenghtening the brain; Behavioral: Strengthening the mind
<br /><b>Sponsors</b>: Amsterdam UMC, location VUmc; Universiteit Leiden; Personal Fitness Nederland; MS Vereniging Nederland; Merck BV; Genzyme, a Sanofi Company; MS Sherpa
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06068582,2023-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4094,416,2022-02-19 01:55:33.000000,Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy,,https://www.novartis.com/clinicaltrials/study/nct04816214,2022-02-19 01:55:33.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4095,415,2022-02-19 01:55:33.000000,"Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",,https://www.novartis.com/clinicaltrials/study/nct04940052,2022-02-19 01:55:33.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4096,414,2022-02-19 01:55:33.000000,Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies,,https://www.novartis.com/clinicaltrials/study/nct04000529,2022-02-19 01:55:33.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4097,413,2022-02-18 13:53:27.000000,The Effect of Iyengar Yoga Practice on Patients With Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Iyengar Yoga;   Yoga;   EDSSIntervention:    Other: The effect of Iyengar yoga practice on patients with multiple sclerosisSponsor :    University Hospital, MotolActive, not recruiting ",https://clinicaltrials.gov/show/NCT05247372,2022-03-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4098,412,2023-10-05 09:52:15.125140,"RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS
A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis

Ob...","<p>EudraCT Number: 2015-004116-38<br />Sponsor Protocol Number: RIFUND-MS<br />Sponsor Name: Department of Clinical Sciences, Danderyd Hospital<br />Start Date: 2015-12-18<br />Medical condition: Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 year...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004116-38/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2015-004116-38,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4099,411,2022-02-17 12:33:27.000000,Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study,Conditions:    Relapsing-Remitting Multiple Sclerosis (RRMS);   Neuromyelitis Optica;   HealthyIntervention:    Procedure: Peripheral blood withdrawalSponsors :    Neuromed IRCCS;   University of Rome Tor VergataNot yet recruiting ,https://clinicaltrials.gov/show/NCT05245344,2021-12-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4100,410,2022-02-17 12:33:27.000000,Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M),Condition:    Disease With a Risk for ChronicityIntervention:    Sponsors :    University of Zurich;   Kliniken ValensNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05243407?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-17 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4101,409,2022-02-17 05:46:47.000000,A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines,,https://www.novartis.com/clinicaltrials/study/nct05030311,2022-02-17 05:46:47.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4102,408,2023-10-04 16:22:33.999871,National Registry of Rare Kidney Diseases,"<b>Conditions</b>: Adenine Phosphoribosyltransferase Deficiency; AH Amyloidosis; AHL Amyloidosis; AL Amyloidosis; Alport Syndrome; Atypical Hemolytic Uremic Syndrome; Autoimmune Distal Renal Tubular Acidosis; Autosomal Recessive Proximal Renal Tubular Acidosis; Autosomal Recessive Distal Renal Tubular Acidosis; Autosomal Dominant Polycystic Kidney Disease; Autosomal Recessive Polycystic Kidney Disease; Bartter Syndrome; BK Nephropathy; C3 Glomerulopathy With Monoclonal Gammopathy; C3 Glomerulopathy; Calciphylaxis; Crystalglobulinaemia; Crystal-storing Histiocytosis; Cystinosis; Cystinuria; Dense Deposit Disease; Dent Disease; Denys-Drash Syndrome; Dominant Hypophosphataemia With Nephrolithiasis and/or Osteoporosis; Drug Induced Fanconi Syndrome; Drug-Induced Hypomagnesemia; Drug-Induced Nephrogenic Diabetes Insipidus; Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy; Fabry Disease; Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis; Familial Primary Hypomagnesemia With Hypocalcuria; Familial Primary Hypomagnesaemia With Normocalciuria; Familial Renal Glucosuria; Fanconi Renotubular Syndrome 1; Fanconi Renotubular Syndrome 2; Fanconi Renotubular Syndrome 3; Fibrillary Glomerulonephritis; Fibromuscular Dysplasia; Focal Segmental Glomerulosclerosis; Generalised Pseudohypoaldosteronism Type 1; Gitelman Syndrome; Heavy-Metal-Induced Fanconi Syndrome; Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes; Hereditary Renal Hypouricemia; Hereditary Hypophosphatemic Rickets With Hypercalciuria; Hyperuricaemic Nephropathy; IgA Nephropathy; Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits; Inherited Renal Cancer Syndromes; Intracapillary Monoclonal IgM Without Cryoglobulin; Intraglomerular/Capillary Lymphoma/Leukaemia; Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type; Liddle Syndrome; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy Without Crystals; Light Chain Proximal Tubulopathy With Crystals; Lowe Syndrome; Membranous Nephropathy; Membranoproliferative Glomerulonephritis; Medullary Cystic Kidney Disease; Minimal Change Nephropathy; Mitochondrial Disease Of The Kidney; Monoclonal Immunoglobulin Deposition Disease; Nail Patella Syndrome; Nephrogenic Diabetes Insipidus; Nephrogenic Syndrome of Inappropriate Antidiuresis; Nephronophthisis; Primary Hypomagnesemia With Secondary Hypocalcemia; Primary Hyperoxaluria; Proliferative Glomerulonephritis With Monoclonal IgG Deposits; Proximal Tubulopathy Without Crystals; Pseudohypoaldosteronism Type 1, 2A-2E; Pure Red Cell Aplasia; Retroperitoneal Fibrosis; Sickle Cell Nephropathy; Shiga Toxin Associated Haemolytic Uraemic Syndrome; Steroid Resistant Nephrotic Syndrome; Steroid-Sensitive Nephrotic Syndrome; Thin Basement Membrane Nephropathy; Thrombotic Microangiopathy With Monoclonal Gammopathy; Type 1 Cryoglobulinaemic Glomerulonephritis; Tuberous Sclerosis; Unclassified Monoclonal Gammopathy Of Renal Significance; Vasculitis
<br /><b>Sponsors</b>: UK Kidney Association
<br /><b>Recruiting</b>",https://clinicaltrials.gov/study/NCT06065852?cond=Multiple+Sclerosis,2023-10-04 04:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4103,407,2022-02-16 14:23:27.000000,Telemonitoring and Connected Care Applied to Multiple Sclerose,"Condition:    Multiple SclerosisInterventions:    Device: MSmonitor, a self-management/education program with e-health interventions;   Device: Video calling program ""Better-close"";   Device: Researchmanager programSponsor :    IsalaRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05242731,2022-01-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4104,406,2022-02-16 14:23:27.000000,Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis,"Condition:    Relapsing Remitting Multiple Sclerosis (RRMS)Interventions:    Drug: Pegylated interferon beta-1a;   Drug: Interferon Beta-1A Prefilled SyringeSponsor :    CinnagenActive, not recruiting ",https://clinicaltrials.gov/show/NCT05242133,2022-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4105,405,2023-10-04 13:22:26.018199,Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy,"<b>Conditions</b>: Demyelinating Diseases; Demyelination; Corpus Callosum; Multiple Sclerosis Brain Lesion; Multiple Sclerosis Acute and Progressive; Clinically Isolated Syndrome, CNS Demyelinating
<br /><b>Interventions</b>: Drug: Clemastine Fumarate; Drug: Placebo
<br /><b>Sponsors</b>: University of California, San Francisco
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06065670,2023-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4106,404,2022-02-15 03:46:48.000000,Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct05089656,2022-02-15 03:46:48.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4107,403,2023-10-04 00:42:29.415068,AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy,"<b>Conditions</b>: Mesial Temporal Lobe Epilepsy
<br /><b>Interventions</b>: Genetic: AAV9-hSyn1-miGRIK2
<br /><b>Sponsors</b>: uniQure France SAS
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/study/NCT06063850?cond=Multiple+Sclerosis,2023-10-03 04:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4108,402,2022-02-11 19:46:49.000000,Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria,,https://www.novartis.com/clinicaltrials/study/nct04747613,2022-02-11 19:46:49.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4109,401,2022-02-11 14:03:27.000000,TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants,"Condition:    Multiple SclerosisIntervention:    Drug: NatalizumabSponsors :    Biogen;   Association for Functional Rehabilitation, Recreation and Applied Kinesiology ImpulseRecruiting ",https://clinicaltrials.gov/show/NCT05236777,2022-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4110,400,2022-02-10 23:46:50.000000,An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study,,https://www.novartis.com/clinicaltrials/study/nct04597632,2022-02-10 23:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4111,399,2022-02-10 23:46:50.000000,Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD),,https://www.novartis.com/clinicaltrials/study/nct04268823,2022-02-10 23:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4112,398,2022-02-10 23:46:50.000000,"A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China",,https://www.novartis.com/clinicaltrials/study/nct04894890,2022-02-10 23:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4113,397,2022-02-10 23:46:50.000000,Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia,,https://www.novartis.com/clinicaltrials/study/nct04784390,2022-02-10 23:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4114,396,2022-02-10 13:46:49.000000,A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),,https://www.novartis.com/clinicaltrials/study/nct04737330,2022-02-10 13:46:49.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4115,395,2022-02-10 12:43:27.000000,The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Frame RunningSponsors :    Queen Margaret University;   Multiple Sclerosis SocietyNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05234879,2022-01-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4116,394,2022-02-10 12:43:27.000000,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",Conditions:    Relapsing Multiple Sclerosis;   Primary Progressive Multiple SclerosisInterventions:    Drug: Ocrelizumab IV;   Drug: Ocrelizumab SC;   Drug: Methylprednisolone IV;   Drug: Diphenhydramine IV;   Drug: Dexamethasone given orally;   Drug: Desloratadine given orallySponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05232825,2022-01-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4117,393,2022-02-10 03:46:48.000000,"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+&#x2F;HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia",,https://www.novartis.com/clinicaltrials/study/nct04943497,2022-02-10 03:46:48.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4118,392,2022-02-10 03:46:48.000000,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,,https://www.novartis.com/clinicaltrials/study/nct04862143,2022-02-10 03:46:48.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4119,391,2022-02-10 03:46:48.000000,STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS,,https://www.novartis.com/clinicaltrials/study/nct04878432,2022-02-10 03:46:48.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4120,390,2022-02-09 17:46:50.000000,Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma,,https://www.novartis.com/clinicaltrials/study/nct04903197,2022-02-09 17:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4121,389,2022-02-09 17:46:50.000000,CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril&#x2F;Valsartan in Pediatric Patients With HF,,https://www.novartis.com/clinicaltrials/study/nct03785405,2022-02-09 17:46:50.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4122,388,2023-10-03 15:40:49.859605,Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: Tolebrutinib; Drug: gemfibrozil; Drug: rifampicin
<br /><b>Sponsors</b>: Sanofi
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06064539,2023-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4123,387,2023-10-03 15:40:49.846700,Ketamine for MS Fatigue,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Drug: ketamine
<br /><b>Sponsors</b>: Alta Bates Summit Medical Center
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06064162,2023-09-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4124,386,2022-02-08 21:46:49.000000,"Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.",,https://www.novartis.com/clinicaltrials/study/nct05078580,2022-02-08 21:46:49.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4125,385,2023-10-02 13:40:49.716616,New Interactive Sensor-home-based Hand Training to Improve Dexterity,"<b>Conditions</b>: Stroke; Multiple Sclerosis; Parkinson Disease
<br /><b>Interventions</b>: Device: smart sensor egg training
<br /><b>Sponsors</b>: Luzerner Kantonsspital
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06062693,2023-04-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4126,384,2022-02-08 13:13:27.000000,The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS,"Conditions:    Primary Progressive Multiple Sclerosis;   Exercise;   Cardiorespiratory FitnessInterventions:    Behavioral: HIIT;   Behavioral: MCTSponsors :    Klinik Valens;   Technische Universität Dortmund, GermanyNot yet recruiting ",https://clinicaltrials.gov/show/NCT05229861,2022-01-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4127,383,2023-09-29 13:40:46.650823,Effects of Blood Flow Restriction Training on Middle-aged People With Multiple Sclerosis.,"<b>Conditions</b>: Sclerosis, Multiple
<br /><b>Interventions</b>: Other: Blood Flow Restriction training with Oclussion Cuff.
<br /><b>Sponsors</b>: University of Jaén
<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06061939,2023-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4128,382,2022-02-07 20:46:47.000000,Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection,,https://www.novartis.com/clinicaltrials/study/nct04838626,2022-02-07 20:46:47.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4129,381,2022-02-07 15:03:27.000000,3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME),"Condition:    Multiple SclerosisIntervention:    Device: 3D OPTIMIZED WMN MPRAGESponsor :    University Hospital, BordeauxNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05227092,2022-01-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4130,380,2023-09-28 13:42:24.975300,Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part B,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Tailored Physical Activity
<br /><b>Sponsors</b>: Fondazione Don Carlo Gnocchi Onlus; IRCCS San Raffaele; Azienda Sanitaria Locale di Cagliari
<br /><b>Enrolling by invitation</b>",https://clinicaltrials.gov/ct2/show/NCT06056960,2023-11-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4131,379,2023-09-26 15:40:49.052627,An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden,"<b>Conditions</b>: Multiple Sclerosis (MS)
<br /><b>Interventions</b>: Drug: Avonex (IFNβ-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs)
<br /><b>Sponsors</b>: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06053749,2023-09-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4132,378,2022-02-05 10:10:47.000000,Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.,,https://www.novartis.com/clinicaltrials/study/nct04774926,2022-02-05 10:10:47.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4133,377,2022-02-05 00:10:44.000000,Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects,,https://www.novartis.com/clinicaltrials/study/nct04129528,2022-02-05 00:10:44.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4134,376,2022-02-05 00:10:44.000000,A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070&#x2F;Branaplam in Early Manifest Huntington&#39;s Disease,,https://www.novartis.com/clinicaltrials/study/nct05111249,2022-02-05 00:10:44.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4135,375,2022-02-05 00:10:44.000000,A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration,,https://www.novartis.com/clinicaltrials/study/nct04239027,2022-02-05 00:10:44.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4136,374,2023-09-23 15:41:19.866429,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis","<p>EudraCT Number: 2020-003271-18<br />Sponsor Protocol Number: GWSP20105<br />Sponsor Name: GW Pharma Limited<br />Start Date: 2021-06-07<br />Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003271-18/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003271-18/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003271-18,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4137,373,2022-02-04 15:47:25.000000,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2,Condition:    Multiple SclerosisIntervention:    Other: Acceptance and Commitment TherapySponsor :    University of NottinghamNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05225012,2022-10-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4138,372,2022-02-01 14:57:18.000000,Evaluation of Relapse Presence in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis RelapseIntervention:    Diagnostic Test: in-vivo Corneal Confocal MicroscopySponsor :    Marmara UniversityCompleted ",https://clinicaltrials.gov/ct2/show/NCT05218317?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-01 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4139,371,2022-02-01 14:57:18.000000,Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: partial-body cryotherapy chamber sessionSponsors :    Fondation Ildys;   Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT05219201,2022-07-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4140,370,2022-01-28 15:57:18.000000,Promoting Aerobic Training in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Aerobic exercise;   Behavioral: Task-oriented upper-limb training;   Behavioral: Sport events participationSponsors :    Fondazione Italiana Sclerosi Multipla;   University of Genoa;   University Grenoble AlpsRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05212805?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-28 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4141,369,2022-01-27 17:47:18.000000,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05210621?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-27 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4142,368,2022-01-27 17:47:18.000000,Safety of Exposure to Natalizumab During Pregnancy,"Condition:    Multiple SclerosisIntervention:    Behavioral: QuestionnaireSponsors :    University Hospital, Bordeaux;   BiogenNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05209815,2022-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4143,367,2022-01-26 13:17:18.000000,Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis,"Condition:    Self EfficacyIntervention:    Other: EducationSponsor :    Hacettepe UniversityActive, not recruiting ",https://clinicaltrials.gov/show/NCT05209113,2022-01-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4144,366,2022-01-26 13:17:18.000000,A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Hoffmann-La RocheRecruiting ,https://clinicaltrials.gov/show/NCT05208840,2022-12-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4145,365,2022-01-24 16:57:17.000000,MS-ResearchBiomarkerS,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive;   Clinically Isolated Syndrome;   Radiologically Isolated Syndrome;   Neuromyelitis Optica Spectrum Disorders;   Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease;   Neurologic Autoimmune Disease;   Neurologic Disorder;   Healthy AgingIntervention:    Sponsor :    Cedars-Sinai Medical CenterRecruiting ",https://clinicaltrials.gov/show/NCT05204459,2022-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4146,364,2022-01-21 14:40:27.000000,"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tabletsSponsor :    Immunic AGNot yet recruiting ",https://clinicaltrials.gov/show/NCT05201638,2021-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4147,363,2023-09-23 04:02:25.349396,Effect of Aerobic Training vs Balance Training on Fatigue Symptom in Multiple Sclerosis Patient (FATI-gate),"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Aerobic training; Other: Balance training
<br /><b>Sponsors</b>: Istituto Auxologico Italiano
<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT06051019,2023-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4148,362,2022-01-19 17:16:55.000000,Expression of PARP-1 in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Genetic: Blood samplingSponsor :    Sohag UniversityRecruiting ,https://clinicaltrials.gov/show/NCT05196425,2021-07-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4149,361,2022-01-19 17:16:55.000000,Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study,Condition:    Multiple Sclerosis (MS)Intervention:    Sponsor :    BiogenRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05197699,2022-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4150,360,2022-01-18 12:46:55.000000,Reinventing Yourself With Multiple Sclerosis (MS),Condition:    Multiple SclerosisIntervention:    Behavioral: Reinvention with MSSponsors :    Kessler Foundation;   Craig Hospital;   University of MinnesotaNot yet recruiting ,https://clinicaltrials.gov/show/NCT05195320,2021-11-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4151,359,2022-01-12 15:40:19.000000,Validity and Reliability of the Dual-task Questionnaire,"Condition:    Multiple SclerosisIntervention:    Procedure: validity and reability studySponsor :    Gazi UniversityActive, not recruiting ",https://clinicaltrials.gov/show/NCT05188937,2021-12-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4152,358,2022-01-11 17:30:19.000000,Investigating the Home-based RCTs of Pilates Exercises and Cognitive Rehabilitation Exercises for Executive Functions and Anxiety in MS.,Condition:    Multiple SclerosisInterventions:    Behavioral: Home-Based Pilates exercise;   Other: Home-based Cognitive Rehabilitation;   Other: waiting list groupSponsors :    Arak University of Medical Sciences;   Pardis Specialized Wellness InstituteRecruiting ,https://clinicaltrials.gov/show/NCT05185986,2021-12-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4153,357,2022-01-10 13:00:20.000000,Validity and Reliability of Turkish Version Leg Activity Measure,Conditions:    Spinal Cord Injuries;   Multiple Sclerosis;   StrokeIntervention:    Other: assessmentSponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT05182411,2021-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4154,356,2022-01-10 13:00:19.000000,Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: AssesmentSponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT05182398,2021-12-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4155,355,2022-01-06 23:30:19.000000,Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects,Condition:    Relapsing Remitting Multiple SclerosisInterventions:    Drug: Monomethyl Fumarate 190 Mg;   Drug: Diroximel Fumarate 462 mgSponsor :    Banner Life Sciences LLCCompleted ,https://clinicaltrials.gov/ct2/show/NCT05181215?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-06 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4156,354,2022-01-05 12:40:19.000000,Natalizumab and Chronic Inflammation,Condition:    Multiple SclerosisIntervention:    Drug: Natalizumab 300 MG in 15 ML InjectionSponsors :    Vanderbilt University Medical Center;   BiogenNot yet recruiting ,https://clinicaltrials.gov/show/NCT05177718,2021-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4157,353,2022-01-05 12:40:19.000000,Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis,Conditions:    Training Study;   Multiple Sclerosis;   Blood Flow RestrictionInterventions:    Other: Blood Flow Restriction;   Other: Standard of CareSponsors :    University of Central Florida;   AdventHealthRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05177952?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-05 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4158,352,2022-01-05 12:40:19.000000,A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis,"Condition:    SpasticityInterventions:    Drug: Arbaclofen;   Drug: PlaceboSponsor :    RVL Pharmaceuticals, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05179577?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-05 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4159,351,2022-01-04 14:30:19.000000,Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis,"Conditions:    Multiple Sclerosis (MS);   Relapsing-remitting Multiple Sclerosis (RRMS);   Secondary-progressive Multiple Sclerosis (SPMS);   Primary Progressive Multiple Sclerosis (PPMS)Interventions:    Diagnostic Test: MRI;   Other: Neurocognitive examination for healthy subjects;   Other: blood samplingSponsors :    University Hospital, Basel, Switzerland;   Swiss National Science FoundationRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05177523?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-04 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4160,350,2022-01-03 16:20:19.000000,Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study,"Condition:    Multiple SclerosisIntervention:    Other: Lifestyle interventionSponsors :    Iaso Maternity Hospital, Athens, Greece;   Harokopio University;   G.Gennimatas General HospitalCompleted ",https://clinicaltrials.gov/ct2/show/NCT05175378?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-31 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4161,349,2021-12-29 15:24:10.000000,Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: OfatumumabSponsors :    University of Southern California;   Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/show/NCT05171972,2021-10-12 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4162,348,2021-12-29 15:24:10.000000,"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab",Condition:    Relapsing-remitting Multiple Sclerosis (RRMS)Intervention:    Device: BeCare applicationSponsor :    Icahn School of Medicine at Mount SinaiRecruiting ,https://clinicaltrials.gov/show/NCT05172466,2021-11-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4163,347,2021-12-27 15:42:42.000000,A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring,Condition:    Multiple SclerosisIntervention:    Sponsor :    Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05170126,2021-12-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4164,346,2021-12-23 15:29:41.000000,Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Combination Product: Extracorporeal Photopheresis;   Combination Product: MS standard of careSponsor :    Abu Dhabi Stem Cells CenterNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05168384,2021-11-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4165,345,2021-12-21 15:17:55.000000,Impact Program for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: Impact of four week coaching program on dietary habitsSponsor :    University of Alabama at BirminghamNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05165238,2021-12-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4166,344,2021-12-17 16:17:56.000000,Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation,Conditions:    Multiple Sclerosis;   HealthyIntervention:    Procedure: thoracic duct cannulationSponsors :    University of Pennsylvania;   Novartis Pharmaceuticals;   Novartis Institutes for BioMedical ResearchNot yet recruiting ,https://clinicaltrials.gov/show/NCT05162638,2021-02-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4167,343,2023-09-19 19:42:24.090784,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)","<p>EudraCT Number: 2021-000029-28<br />Sponsor Protocol Number: P3-IMU-838-RMS-02<br />Sponsor Name: Immunic AG<br />Start Date: 2022-09-05<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000029-28/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000029-28,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4168,342,2021-12-13 14:07:55.000000,Safety of Therapeutic Step-down in Neuromyelitis Optica,"Condition:    Neuromyelitis OpticaIntervention:    Sponsor :    University Hospital, Strasbourg, FranceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05155644?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-13 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4169,341,2021-12-13 14:07:55.000000,China National Registry of Neuro-Inflammatory Diseases,Conditions:    Multiple Sclerosis;   NMO Spectrum Disorder;   Clinically Isolated Syndrome;   CNS Demyelinating Autoimmune Diseases;   Acute Disseminated EncephalomyelitisIntervention:    Drug: Intravenous steroidSponsor :    Beijing Tiantan HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05154370,2021-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4170,340,2021-12-07 13:52:09.000000,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis,Condition:    Relapsing Multiple SclerosisInterventions:    Drug: Remibrutinib;   Drug: TeriflunomideSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05147220,2021-11-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4171,339,2021-12-07 13:52:09.000000,Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation,Conditions:    Multiple Sclerosis;   Inflammatory DiseaseIntervention:    Procedure: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714Sponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05147532,2021-10-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4172,338,2021-12-02 15:12:45.000000,Impact of Fingolimod Adherence on Outcomes,Condition:    Multiple SclerosisIntervention:    Drug: FingolimodSponsor :    Novartis PharmaceuticalsCompleted ,https://clinicaltrials.gov/show/NCT05141669,2021-11-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4173,337,2021-12-02 15:12:45.000000,Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life,"Conditions:    Multiple Sclerosis;   Spinal Cord InjuriesIntervention:    Behavioral: TherapySponsor :    IRCCS San Camillo, Venezia, ItalyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05142111,2021-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4174,336,2021-11-26 16:07:43.000000,"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis",Condition:    Multiple SclerosisInterventions:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tabletsSponsor :    Immunic AGNot yet recruiting ,https://clinicaltrials.gov/show/NCT05134441,2021-09-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4175,335,2021-11-23 15:17:43.000000,"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy",Condition:    Multiple SclerosisInterventions:    Drug: Metformin and clemastine in combination;   Drug: PlaceboSponsors :    Cambridge University Hospitals NHS Foundation Trust;   University of CambridgeNot yet recruiting ,https://clinicaltrials.gov/show/NCT05131828,2021-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4176,334,2021-11-23 15:17:43.000000,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants",Condition:    Multiple SclerosisInterventions:    Drug: GSK3888130B;   Drug: PlaceboSponsor :    GlaxoSmithKlineRecruiting ,https://clinicaltrials.gov/show/NCT05131971,2021-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4177,333,2021-11-23 15:17:43.000000,Ocrelizumab Access by Socio-Economic Status,"Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    Brigham and Women's Hospital;   Genentech, Inc.;   Boston Medical CenterNot yet recruiting ",https://clinicaltrials.gov/show/NCT05131984,2021-10-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4178,332,2021-11-22 13:57:43.000000,Improving Prospective Memory Via Telehealth,Condition:    Multiple SclerosisInterventions:    Behavioral: Prospective Memory Intervention;   Behavioral: EducationalSponsor :    Saint Francis CareRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05129293,2021-10-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4179,331,2021-11-18 18:07:42.000000,An Individualized-health eLibrary App for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: SavvyHealthSponsor :    University of Illinois at Urbana-ChampaignRecruiting ,https://clinicaltrials.gov/show/NCT05124600,2021-10-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4180,330,2021-11-18 18:07:42.000000,A Health Action Process Approach Online Intervention for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: MSPA eClassSponsor :    University of Illinois at Urbana-ChampaignRecruiting ,https://clinicaltrials.gov/show/NCT05124522,2021-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4181,329,2021-11-17 13:37:42.000000,Longitudinal Assessment of Iron Rims in MS Lesions,Condition:    Multiple SclerosisInterventions:    Biological: Blood sample provided;   Diagnostic Test: 7-T MRI scanSponsors :    Nottingham University Hospitals NHS Trust;   Johns Hopkins UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05123443?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-17 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4182,328,2021-11-17 13:37:42.000000,Respiratory Functions in Pediatric-Onset Multiple Sclerosis,"Condition:    Pediatric-onset Multiple SclerosisIntervention:    Other: Evaluation of respiratory capacity, respiratory muscle strength and fatigueSponsor :    Istanbul University-CerrahpasaRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05123924?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-17 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4183,327,2021-11-17 13:37:42.000000,A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis,Condition:    Relapsing-Remitting Multiple SclerosisInterventions:    Drug: Ocrelizumab;   Other: Ocrelizumab Placebo;   Drug: Fingolimod;   Other: Fingolimod PlaceboSponsors :    Hoffmann-La Roche;   PPDNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05123703,2021-11-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4184,326,2021-11-16 12:17:42.000000,COVID-19 Vaccine Biomarker Study in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   COVID-19Intervention:    Sponsors :    Columbia University;   NovartisRecruiting ,https://clinicaltrials.gov/show/NCT05121662,2021-12-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4185,325,2021-11-16 12:17:42.000000,Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Drug: N-acetyl cysteine;   Drug: PlaceboSponsors :    Emmanuelle Waubant;   United States Department of DefenseNot yet recruiting ",https://clinicaltrials.gov/show/NCT05122559,2021-08-11 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4186,324,2021-11-15 14:07:42.000000,A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS),Condition:    Relapsing Multiple SclerosisInterventions:    Drug: fenebrutinib;   Drug: placeboSponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05119569,2021-10-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4187,323,2023-09-18 15:32:26.374839,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","<p>EudraCT Number: 2020-005929-89<br />Sponsor Protocol Number: CLOU064C12302<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-01<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/EE"">EE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-005929-89,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4188,322,2023-09-18 15:32:25.772357,Multimodal Exercise Training to Reduce Frailty in People With Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis; Frailty
<br /><b>Interventions</b>: Other: Multimodal Exercise Group; Other: Waitlist
<br /><b>Sponsors</b>: University of Kansas Medical Center
<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06042244,2023-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4189,321,2021-11-12 15:31:05.000000,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",,https://www.novartis.com/clinicaltrials/study/nct04635800,2021-11-12 15:31:05.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4190,320,2021-11-11 19:31:04.000000,Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH),,https://www.novartis.com/clinicaltrials/study/nct04147195,2021-11-11 19:31:04.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4191,319,2021-11-11 15:07:42.000000,Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Biological: HB-adMSCs;   Drug: PlaceboSponsor :    Hope Biosciences Stem Cell Research FoundationRecruiting ,https://clinicaltrials.gov/show/NCT05116540,2021-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4192,318,2021-11-11 09:31:04.000000,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,,https://www.novartis.com/clinicaltrials/study/nct04427072,2021-11-11 09:31:04.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4193,317,2021-11-10 23:31:04.000000,DFF332 as a Single Agent and in Combination With Everolimus &amp; Immuno-Oncology Agents in Advanced&#x2F;Relapsed Renal Cancer &amp; Other Malignancies,,https://www.novartis.com/clinicaltrials/study/nct04895748,2021-11-10 23:31:04.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4194,316,2021-11-10 13:31:04.000000,Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study,,https://www.novartis.com/clinicaltrials/study/nct04657822,2021-11-10 13:31:04.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4195,315,2021-11-10 13:31:04.000000,A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP,,https://www.novartis.com/clinicaltrials/study/nct04971226,2021-11-10 13:31:04.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4196,314,2023-09-15 17:02:23.866350,A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Dietary Supplement: 7-day Fasting-Mimicking Diet (7-DAY FMD)
<br /><b>Sponsors</b>: Ospedale Policlinico San Martino
<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06039007,2023-08-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4197,313,2023-09-15 10:40:58.744113,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","<p>EudraCT Number: 2021-000028-36<br />Sponsor Protocol Number: P3-IMU-838-RMS-01<br />Sponsor Name: Immunic AG<br />Start Date: 2022-04-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000028-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4198,312,2023-09-15 10:40:58.736070,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with
Progressive Multiple Sclerosis","<p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-11-04<br />Medical condition: Progressive forms of Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000048-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4199,311,2021-11-09 12:26:59.000000,Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Diagnostic Test: Measurement of concentrations of orally-used DMDs;   Diagnostic Test: Genetic testing;   Diagnostic Test: Parameters for routine use of DMDs;   Other: Side effects of orally used DMDsSponsors :    University Hospital Ostrava;   University of OstravaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05112484,2021-10-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4200,310,2021-11-08 14:27:35.000000,"Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis",Condition:    Multiple SclerosisIntervention:    Other: ElectrotherapySponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT05110586,2021-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4201,309,2021-11-08 14:27:34.000000,A Study to Evaluate White Matter Hyperintensities in Migraine,Conditions:    Migraine;   Small Vessel Ischemic Disease;   Multiple SclerosisIntervention:    Diagnostic Test: Brain NeuroimagingSponsor :    Mayo ClinicRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05112289,2021-12-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4202,308,2023-09-13 14:42:27.637802,ARC Intellicare for Telerehabilitation,<b>Conditions</b>:    Parkinson Disease;   Multiple Sclerosis;   Stroke<br /><b>Interventions</b>:    Device: ARC Intellicare;   Other: Rehabilitation sheets<br /><b>Sponsor</b>:    Fondazione Policlinico Universitario Agostino Gemelli IRCCS<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06032468,2023-12-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4203,307,2021-11-07 17:02:39.000000,Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC,,https://www.novartis.com/clinicaltrials/study/nct04926831,2021-11-07 17:02:39.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4204,306,2021-11-07 17:02:39.000000,Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.,,https://www.novartis.com/clinicaltrials/study/nct04948333,2021-11-07 17:02:39.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4205,305,2021-11-06 07:04:31.000000,"Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis",,https://www.novartis.com/clinicaltrials/study/nct04886258,2021-11-06 07:04:31.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4206,304,2023-09-13 12:02:28.174870,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis","<p>EudraCT Number: 2020-000647-30<br />Sponsor Protocol Number: EFC16645<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-08-27<br />Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/NO"">NO</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000647-30,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4207,303,2023-09-12 13:40:50.707488,"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis","<p>EudraCT Number: 2016-002937-31<br />Sponsor Protocol Number: MA30143<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2017-09-12<br />Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SI"">SI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-002937-31,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4208,302,2021-11-04 20:04:29.000000,A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC,,https://www.novartis.com/clinicaltrials/study/nct04452877,2021-11-04 20:04:29.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4209,301,2021-11-04 20:04:29.000000,Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments,,https://www.novartis.com/clinicaltrials/study/nct04058756,2021-11-04 20:04:29.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4210,300,2023-09-08 22:42:22.054991,A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS),"<p>EudraCT Number: 2020-003995-42<br />Sponsor Protocol Number: MS700568_0157<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-12-18<br />Medical condition: Highly-active relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003995-42/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-003995-42,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4211,299,2021-11-03 12:21:08.000000,A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage,Condition:    Multiple Sclerosis (MS)Intervention:    Device: Konectom platformSponsor :    BiogenNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05106465,2021-10-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4212,298,2021-11-01 12:51:08.000000,Robotics for Mobility Rehabilitation in MS,Conditions:    Multiple Sclerosis;   MSIntervention:    Other: Balance exercise program using exoskeleton deviceSponsor :    East Kent Hospitals University NHS Foundation TrustCompleted ,https://clinicaltrials.gov/show/NCT05102682,2021-10-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4213,297,2021-10-28 13:51:08.000000,"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Conditions:    Alopecia Areata;   Alopecia Totalis;   Alopecia Universalis;   Alopecia Areata (& Ophiasis);   Alopecia Barbae;   Alopecia Diffuse;   Autoimmune Diseases;   Autoimmune Hyperthyroidism;   Autoimmune Hypothyroidism;   Diabetes Mellitus, Type 1;   Ulcerative Colitis;   Inflammatory Bowel Diseases;   Crohn Disease;   Rheumatoid Arthritis;   Down Syndrome;   Atopic Dermatitis;   Atopic Asthma;   Atopic Rhinitis;   Vitiligo;   Psoriasis;   Ankylosing Spondylitis;   Multiple Sclerosis;   Lupus Erythematosus;   COVID-19 Pandemic;   Vaccine Reaction;   Infections;   Anemia, PerniciousIntervention:    Other: Exposure of interestSponsor :    Faculty Hospital Kralovske VinohradyActive, not recruiting ",https://clinicaltrials.gov/show/NCT05098600,2021-10-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4214,296,2021-10-25 13:01:08.000000,MS Spinal Mobilisation Study,Condition:    Multiple SclerosisInterventions:    Other: Spinal Mobilisation Intervention;   Other: General MassageSponsors :    Edinburgh Napier University;   Scottish Hospital Endowments Research Trust;   Pacla Medical LtdCompleted ,https://clinicaltrials.gov/show/NCT05090709,2021-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4215,295,2021-10-25 13:01:07.000000,Cannabis as a Complementary Treatment in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: Cannabis oil vs placeboSponsors :    Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Multiple Sclerosis Society of CanadaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05092191,2021-01-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4216,294,2023-09-08 19:52:20.033501,"Effects of MS Ballroom Fitness on Balance, Walking Capacity, and Well-being in Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: MS Ballroom Fitness<br /><b>Sponsors</b>:    University of Aarhus;   The Danish MS Society<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06028776,2023-08-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4217,293,2021-10-22 12:11:07.000000,Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases,Conditions:    Central Nervous System Diseases;   Multiple SclerosisIntervention:    Other: Biological collectionSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/show/NCT05088473,2021-07-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4218,292,2021-10-22 12:11:07.000000,Characterizing the Use of Ofatumumab in a Real World Setting,Condition:    Relapsing Multiple SclerosisIntervention:    Other: ofatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05090033,2021-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4219,291,2023-09-08 18:42:20.950728,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-002700-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4220,290,2021-10-19 13:59:14.000000,A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS),Condition:    Relapsing Forms of Multiple SclerosisIntervention:    Drug: Diroximel fumarateSponsor :    BiogenNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05083923,2021-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4221,289,2021-10-18 12:39:14.000000,COVID-19 Booster Vaccination in Persons With Multiple Sclerosis,Condition:    PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial AssayInterventions:    Biological: Homologous booster;   Biological: Heterologous boosterSponsors :    Griffin Hospital;   Yale-Griffin Prevention Research CenterNot yet recruiting ,https://clinicaltrials.gov/show/NCT05081271,2021-10-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4222,288,2021-10-18 12:39:14.000000,A Systems Approach to Understanding Disease Processes in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: All patients in the study will be treated with ocrelizumabSponsors :    Providence Health & Services;   Institute for Systems Biology;   Genentech, Inc.Recruiting ",https://clinicaltrials.gov/show/NCT05081700,2020-11-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4223,287,2021-10-15 14:59:14.000000,Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple SclerosisIntervention:    Biological: Tolerogenic FibroblastsSponsor :    FibroBiologicsCompleted ",https://clinicaltrials.gov/show/NCT05080270,2021-05-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4224,286,2021-10-14 22:52:38.000000,Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.,,https://www.novartis.com/clinicaltrials/study/nct04817618,2021-10-14 22:52:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4225,285,2021-10-14 16:49:14.000000,Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: RituximabSponsor :    St. Petersburg State Pavlov Medical UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05078177?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-14 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4226,284,2021-10-14 16:49:14.000000,Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis,Conditions:    Relapsing Multiple Sclerosis;   Multiple SclerosisIntervention:    Diagnostic Test: Cerebrospinal and Blood Serum Semaphorin 4A LevelsSponsors :    Providence Health & Services;   Milton S. Hershey Medical Center;   Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05077956,2021-01-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4227,283,2021-10-13 13:56:18.000000,Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Urinary Bladder, NeurogenicIntervention:    Other: Initial management of the urinary disorder/s identified during the screening phaseSponsor :    ASP 7 RagusaNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05075642?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-13 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4228,282,2021-10-12 15:46:14.000000,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,Condition:    Multiple SclerosisIntervention:    Biological: COVID-19 vaccinationSponsors :    Sheba Medical Center;   SanofiRecruiting ,https://clinicaltrials.gov/show/NCT05075499,2021-06-10 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4229,281,2021-10-12 00:09:39.000000,Study of Diagnostic Performance of [18F]CTT1057 in BCR,,https://www.novartis.com/clinicaltrials/study/nct04838613,2021-10-12 00:09:39.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4230,280,2021-10-11 14:26:14.000000,Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosageSponsor :    Francis CorazzaRecruiting ,https://clinicaltrials.gov/show/NCT05072691,2021-09-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4231,279,2021-10-11 14:26:14.000000,Telerehabilitation-based Upper Extremity Training in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Telerehabilitation-based Upper Extremity TrainingSponsor :    Dokuz Eylul UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT05073731,2021-09-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4232,278,2021-10-10 08:09:39.000000,Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct04851873,2021-10-10 08:09:39.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4233,277,2021-10-09 12:10:27.000000,Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy,,https://www.novartis.com/clinicaltrials/study/nct04820530,2021-10-09 12:10:27.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4234,276,2021-10-08 16:09:38.000000,"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis",,https://www.novartis.com/clinicaltrials/study/nct04396366,2021-10-08 16:09:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4235,275,2021-10-08 16:09:38.000000,Study of Efficacy of Oral Sacubitril&#x2F;Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy,,https://www.novartis.com/clinicaltrials/study/nct04164732,2021-10-08 16:09:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4236,274,2021-10-08 16:09:38.000000,Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D,,https://www.novartis.com/clinicaltrials/study/nct04491136,2021-10-08 16:09:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4237,273,2021-10-08 16:09:38.000000,"Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD",,https://www.novartis.com/clinicaltrials/study/nct04882124,2021-10-08 16:09:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4238,272,2021-10-08 16:09:38.000000,Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC),,https://www.novartis.com/clinicaltrials/study/nct04390763,2021-10-08 16:09:38.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4239,271,2021-10-07 12:16:14.000000,Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.,Condition:    Paediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum DisorderIntervention:    Behavioral: Observational Study.Sponsors :    Oxford Brookes University;   Great Ormond Street Hospital for Children NHS Foundation Trust;   Guy's and St Thomas' NHS Foundation Trust;   Oxford University Hospitals NHS TrustNot yet recruiting ,https://clinicaltrials.gov/show/NCT05070286,2021-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4240,270,2021-10-01 10:56:35.000000,Neuromuscular Electrostimulation in Multiple Sclerosis People With Dysphagia,Conditions:    Deglutition Disorders;   Multiple SclerosisInterventions:    Device: Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation;   Device: Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulationSponsor :    I.R.C.C.S. Fondazione Santa LuciaRecruiting ,https://clinicaltrials.gov/show/NCT05063708,2021-10-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4241,269,2021-10-01 10:56:35.000000,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",Condition:    Multiple Sclerosis (MS)Intervention:    Drug: 11C-BMS-986196Sponsor :    Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/show/NCT05064436,2021-09-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4242,268,2021-09-30 22:16:35.000000,PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: 11C-MCISponsors :    National Institute of Mental Health (NIMH);   University of Maryland, College ParkRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05062083,2021-09-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4243,267,2021-09-30 22:16:35.000000,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: Eye-TrackingSponsor :    Innodem NeurosciencesNot yet recruiting ,https://clinicaltrials.gov/show/NCT05061953,2021-09-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4244,266,2021-09-29 11:39:07.000000,COVID-19 Vaccine Response in Treated MS Patients,Conditions:    Multiple Sclerosis;   HealthyIntervention:    Other: Blood drawSponsor :    Brigham and Women's HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05060354,2021-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4245,265,2021-09-28 13:29:08.000000,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,Condition:    Multiple Sclerosis (MS)Intervention:    Sponsor :    BiogenRecruiting ,https://clinicaltrials.gov/show/NCT05058729,2021-09-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4246,264,2021-09-27 11:53:46.000000,Autoimmune Intervention Mastery Course Study,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeInterventions:    Behavioral: Immediate Autoimmune Intervention Mastery Course;   Behavioral: Immediate Question and Answer sessions.;   Behavioral: Delayed Autoimmune Intervention Mastery Course;   Behavioral: Delayed Question and Answer sessionsSponsor :    Terry L. WahlsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05057676,2021-09-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4247,263,2021-09-27 11:53:46.000000,"Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study",Condition:    Multiple SclerosisInterventions:    Behavioral: CoreDISTparticipation;   Behavioral: Standard careSponsors :    Nordlandssykehuset HF;   Nord University;   Hasselt University;   Helse NordEnrolling by invitation ,https://clinicaltrials.gov/ct2/show/NCT05057338?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-27 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4248,262,2021-09-23 17:49:58.000000,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",Condition:    Multiple SclerosisInterventions:    Drug: IMU-838;   Drug: Placebo matching IMU-838Sponsor :    Immunic AGNot yet recruiting ,https://clinicaltrials.gov/show/NCT05054140,2021-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4249,261,2021-09-23 17:49:58.000000,Ultrasound-Guided Percutaneous Neuromodulation in Spasticity,Condition:    Multiple SclerosisIntervention:    Procedure: Percutaneous Echoguided NeuromodulationSponsor :    Hospital Universitario de CanariasNot yet recruiting ,https://clinicaltrials.gov/show/NCT05053984,2021-08-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4250,260,2021-09-21 13:11:04.000000,Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Major Depressive DisorderInterventions:    Behavioral: POWER-MS;   Behavioral: FLEX-MSSponsors :    University of Alabama at Birmingham;   Congressionally Directed Medical Research ProgramsNot yet recruiting ,https://clinicaltrials.gov/show/NCT05051618,2021-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4251,259,2021-09-17 15:00:09.000000,A Long-term Extension of Study GNC-401,Condition:    Multiple SclerosisInterventions:    Drug: Temelimab 18 mg/kg;   Drug: Temelimab 36mg/kg;   Drug: Temelimab 54 mg/kgSponsor :    GeNeuro Innovation SASRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05049161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-17 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4252,258,2021-09-16 16:50:09.000000,The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Sleep quality and physical activity;   Genetic: Nicotine dependence;   Diagnostic Test: Nicotine and cotinine serum levels;   Behavioral: SmokingSponsor :    University of JordanNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05046535,2021-05-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4253,257,2021-09-06 00:04:28.000000,Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs,,https://www.novartis.com/clinicaltrials/study/nct04711135,2021-09-06 00:04:28.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4254,256,2021-09-06 00:04:27.000000,A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA),,https://www.novartis.com/clinicaltrials/study/nct04814368,2021-09-06 00:04:27.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4255,255,2021-09-05 16:31:06.000000,Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: questionnaireSponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05033782,2021-02-09 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4256,254,2021-09-02 23:31:19.000000,Dabrafenib and&#x2F;or Trametinib Rollover Study,,https://www.novartis.com/clinicaltrials/study/nct03340506,2021-09-02 23:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4257,253,2021-09-02 23:31:19.000000,"Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis",,https://www.novartis.com/clinicaltrials/study/nct04074590,2021-09-02 23:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4258,252,2021-09-02 23:31:19.000000,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,,https://www.novartis.com/clinicaltrials/study/nct03839823,2021-09-02 23:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4259,251,2023-09-07 08:02:26.169541,"A two-year, double-blind, randomized, multicenter, active controlled
study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...","<p>EudraCT Number: 2011-005677-23<br />Sponsor Protocol Number: CFTY720D2311<br />Sponsor Name: Novartis Farma<br />Start Date: 2013-04-02<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 15.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO"">RO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2011-005677-23,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4260,250,2023-09-06 22:22:22.226228,Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004731-76<br />Sponsor Protocol Number: LTS16004<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2019-04-18<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10067063<br />Term: Progressive relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-004731-76,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4261,249,2021-09-01 16:27:57.000000,Development and Application of Tele-Neuro Rehabilitation System,Conditions:    Stroke;   Multiple Sclerosis;   Parkinson DiseaseInterventions:    Other: Telerehabilitaton;   Other: Home ExerciseSponsors :    Istanbul University-Cerrahpasa;   The Scientific and Technological Research Council of TurkeyRecruiting ,https://clinicaltrials.gov/show/NCT05031403,2021-05-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4262,248,2021-09-01 16:27:57.000000,Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis,Condition:    Multiple Sclerosis Acute and ProgressiveIntervention:    Combination Product: investigations like MRI..Sponsor :    Assiut UniversityRecruiting ,https://clinicaltrials.gov/show/NCT05029830,2021-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4263,247,2021-09-01 02:31:19.000000,Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer,,https://www.novartis.com/clinicaltrials/study/nct04597411,2021-09-01 02:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4264,246,2021-09-01 02:31:19.000000,A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD),,https://www.novartis.com/clinicaltrials/study/nct04632056,2021-09-01 02:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4265,245,2021-09-01 02:31:19.000000,Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients,,https://www.novartis.com/clinicaltrials/study/nct04524442,2021-09-01 02:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4266,244,2021-09-01 02:31:19.000000,[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake,,https://www.novartis.com/clinicaltrials/study/nct03872778,2021-09-01 02:31:19.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4267,243,2021-08-31 15:55:08.000000,Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS,"Conditions:    Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple SclerosisInterventions:    Drug: Intranasal Foralumab Solution;   Drug: PlaceboSponsor :    Tiziana Life Sciences, PLCNot yet recruiting ",https://clinicaltrials.gov/show/NCT05029609,2021-08-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4268,242,2021-08-31 15:55:08.000000,Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-RemittingIntervention:    Procedure: Autologous hematopoietic stem cell transplantationSponsors :    Uppsala University;   Karolinska University Hospital;   Sahlgrenska University Hospital, Sweden;   Uppsala University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   University Hospital, Umeå;   Region Örebro CountyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05029206,2021-09-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4269,241,2021-08-31 15:55:08.000000,The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis,Condition:    Physical TherapyInterventions:    Other: Combined exercise training;   Other: Aerobic trainingSponsor :    Ankara Yildirim Beyazıt UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT05029700?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-31 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4270,240,2021-08-31 15:55:07.000000,Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-ß or No Disease Modifying Therapy,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-RemittingInterventions:    Biological: Tetanus, diphtheria, and acellular pertussis vaccine;   Biological: Pneumococcal polysaccharide vaccine;   Biological: Seasonal influenza vaccineSponsor :    CelgeneNot yet recruiting ",https://clinicaltrials.gov/show/NCT05028634,2021-08-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4271,239,2021-08-31 02:48:29.000000,An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients,,https://www.novartis.com/clinicaltrials/study/nct04662931,2021-08-31 02:48:29.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4272,238,2023-09-06 14:22:22.107024,Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    IRCCS San Raffaele;   Azienda Socio Sanitaria Territoriale della Valle Olona<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06025903,2023-08-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4273,237,2023-09-06 13:40:49.391795,Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Insomnia<br /><b>Interventions</b>:    Behavioral: i-CBT;   Behavioral: Applied relaxation<br /><b>Sponsor</b>:    Uppsala University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06025968,2023-08-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4274,236,2021-08-27 18:48:30.000000,"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer&#39;s Type.",,https://www.novartis.com/clinicaltrials/study/nct02989402,2021-08-27 18:48:30.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4275,235,2021-08-27 18:48:30.000000,Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET,,https://www.novartis.com/clinicaltrials/study/nct03972488,2021-08-27 18:48:30.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4276,234,2021-08-26 20:34:56.000000,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.,,https://www.novartis.com/clinicaltrials/study/nct04712721,2021-08-26 20:34:56.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4277,233,2023-09-05 09:22:52.741066,"A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...","<p>EudraCT Number: 2018-002145-11<br />Sponsor Protocol Number: 101MS329<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-03-21<br />Medical condition: Relapsing-remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-002145-11,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4278,232,2023-09-04 13:32:24.788123,"Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial.","<p>EudraCT Number: 2021-000854-24<br />Sponsor Protocol Number: VE-CIP2001/2021<br />Sponsor Name: ALFASIGMA S.P.A.<br />Start Date: 2021-12-21<br />Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si...<br />Disease: <br />Version: 20.0<br />SOC Term: 10017947 - Gastrointestinal disorders<br />Classification Code: 10017947<br />Term: Gastrointestinal disorders<br />Level: SOC<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000854-24/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000854-24/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000854-24,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4279,231,2023-09-01 15:04:17.179638,Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: TDI;   Diagnostic Test: Trigeminal Test;   Diagnostic Test: Cognitive Evaluation by Montreal Cognitive Assessment;   Diagnostic Test: Anxiety and Depression questionnaire;   Diagnostic Test: Visual Analogue Scale Ratings;   Diagnostic Test: Quality of smell Questionnaire<br /><b>Sponsors</b>:    University of Catania;   University of Roma La Sapienza;   Hospital General Universitario Santa Lucia;   Klinik und Poliklinik fur Kinderheilkunde<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06020937,2023-08-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4280,230,2021-08-26 00:47:17.000000,Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients,,https://www.novartis.com/clinicaltrials/study/nct03814746,2021-08-26 00:47:17.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4281,229,2023-09-01 13:53:57.261458,Orofacial Pain in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Diagnosis of pain<br /><b>Sponsor</b>:    Varazdin General Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06021561,2023-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4282,228,2023-08-31 13:10:48.075835,Epidural Stimulation in Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Demyelinating Disorder;   Autoimmune Diseases<br /><b>Intervention</b>:    Device: Percutaneous epidural stimulation<br /><b>Sponsors</b>:    Kristin Zhao, PhD;   Mayo Clinic<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06019611,2023-02-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4283,227,2021-08-24 18:47:17.000000,A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.,,https://www.novartis.com/clinicaltrials/study/nct04836858,2021-08-24 18:47:17.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4284,226,2023-08-30 13:22:27.884092,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...","<p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT<br />Start Date: 2022-09-29<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/GR"">GR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2022-000049-34,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4285,225,2023-08-30 13:22:27.577848,Insulin Resistance in Egyptian Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Insulin Resistance<br /><b>Intervention</b>:    Other: treatment of insulin resistance with appropriate modality according to each patient<br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06017726,2023-08-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4286,224,2021-08-24 18:47:16.000000,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",,https://www.novartis.com/clinicaltrials/study/nct03798626,2021-08-24 18:47:16.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4287,223,2021-08-24 13:43:55.000000,Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Vaccine Response ImpairedIntervention:    Biological: Most recent vaccine to seasonal influenzaSponsor :    Heinrich-Heine University, DuesseldorfRecruiting ",https://clinicaltrials.gov/show/NCT05019248,2021-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4288,222,2023-08-30 11:23:08.612771,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...","<p>EudraCT Number: 2019-004980-36<br />Sponsor Protocol Number: MS200527-0082<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-09-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-004980-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4289,221,2021-08-23 17:47:17.000000,A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.,,https://www.novartis.com/clinicaltrials/study/nct04806503,2021-08-23 17:47:17.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4290,220,2021-08-23 12:23:55.000000,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),"Conditions:    Optic Neuritis;   Transverse Myelitis;   Acute Disseminated Encephalomyelitis;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Anti-NMDAR Encephalitis;   Anti-GAD65 Associated Autoimmune Encephalitis;   Anti-AMPAR-1/2 Associated Autoimmune Encephalitis;   Anti-Lgi-1 Associated Autoimmune Encephalitis;   Anti-CASPR-2 Associated Autoimmune Encephalitis;   Anti-GABAR-1/2 Associated Autoimmune Encephalitis;   Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis;   Hashimoto Encephalitis;   CNS Vasculitis;   CNS Sarcoidosis;   CNS Lupus;   Rasmussen EncephalitisIntervention:    Sponsors :    University of Bern;   Schweizerische Multiple Sklerose Gesellschaft;   University Hospital Inselspital, Berne;   Roche Pharma (Switzerland) Ltd;   NovartisRecruiting ",https://clinicaltrials.gov/show/NCT05017142,2021-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4291,219,2021-08-23 12:23:55.000000,The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Social and Territorial InequalitiesIntervention:    Sponsor :    Central Hospital, Nancy, FranceRecruiting ",https://clinicaltrials.gov/show/NCT05017038,2021-08-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4292,218,2021-08-19 22:19:09.000000,Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.,,https://www.novartis.com/clinicaltrials/study/nct04711902,2021-08-19 22:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4293,217,2021-08-19 22:19:09.000000,Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions,,https://www.novartis.com/clinicaltrials/study/nct04656223,2021-08-19 22:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4294,216,2021-08-19 15:05:47.000000,Hydroxychloroquine and Indapamide in SPMS,"Condition:    Multiple Sclerosis, Secondary ProgressiveIntervention:    Drug: Hydroxychloroquine and IndapamideSponsor :    University of CalgaryNot yet recruiting ",https://clinicaltrials.gov/show/NCT05013463,2021-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4295,215,2021-08-19 15:05:47.000000,The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis,"Condition:    Motor ActivityIntervention:    Diagnostic Test: Nine Hole Peg TestSponsor :    Charles University, Czech RepublicNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05012241?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-19 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4296,214,2023-08-29 15:04:36.764307,"The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: There is no intervention.<br /><b>Sponsors</b>:    University Medical Center Groningen;   University of Groningen<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT06016309,2023-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4297,213,2021-08-19 12:19:09.000000,Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma,,https://www.novartis.com/clinicaltrials/study/nct03570892,2021-08-19 12:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4298,212,2023-08-28 09:02:26.329259,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...","<p>EudraCT Number: 2017-000748-16<br />Sponsor Protocol Number: MT-2-01<br />Sponsor Name: Minoryx Therapeutics S.L.<br />Start Date: 2017-09-14<br />Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY<br />Disease: <br />Population Age: Adults<br />Gender: Male<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/PL"">PL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000748-16/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-000748-16,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4299,211,2021-08-19 12:19:09.000000,Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration,,https://www.novartis.com/clinicaltrials/study/nct04679935,2021-08-19 12:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4300,210,2021-08-19 12:19:09.000000,"Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis",,https://www.novartis.com/clinicaltrials/study/nct04864392,2021-08-19 12:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4301,209,2023-08-25 19:03:59.284897,Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis,<b>Condition</b>:    Sleep Disorder<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT06012513?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-08-25 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4302,208,2021-08-19 02:19:10.000000,Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab,,https://www.novartis.com/clinicaltrials/study/nct04210843,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4303,207,2021-08-19 02:19:10.000000,Secukinumab Open Label Roll-over Extension Protocol,,https://www.novartis.com/clinicaltrials/study/nct04638647,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4304,206,2021-08-19 02:19:10.000000,Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa,,https://www.novartis.com/clinicaltrials/study/nct04179175,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4305,205,2021-08-19 02:19:10.000000,Study of Out of Specification for Tisagenlecleucel,,https://www.novartis.com/clinicaltrials/study/nct04094311,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4306,204,2023-08-25 16:04:09.018524,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","<p>EudraCT Number: 2020-005899-36<br />Sponsor Protocol Number: CLOU064C12301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-21<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005899-36/DK"">DK</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-005899-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4307,203,2021-08-19 02:19:10.000000,"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up",,https://www.novartis.com/clinicaltrials/study/nct03781414,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4308,202,2021-08-19 02:19:10.000000,"Efficacy, Safety and Tolerability of the Combination of Tropifexor &amp; Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.",,https://www.novartis.com/clinicaltrials/study/nct04065841,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4309,201,2021-08-19 02:19:10.000000,Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis,,https://www.novartis.com/clinicaltrials/study/nct04732117,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4310,200,2021-08-19 02:19:10.000000,A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism,,https://www.novartis.com/clinicaltrials/study/nct03938454,2021-08-19 02:19:10.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4311,199,2021-08-18 13:45:47.000000,Pregnancy Cohort in Multiple Sclerosis (MS),"Conditions:    Multiple Sclerosis (MS);   Clinically Isolated Syndrome (CIS)Intervention:    Sponsor :    Charite University, Berlin, GermanyRecruiting ",https://clinicaltrials.gov/show/NCT05010902,2021-07-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4312,198,2023-08-24 14:54:12.888908,Telerehabilitation Protocols With Digital and Robotic Tools for People With Chronic Neurological Disorders,"<b>Conditions</b>:    Post-stroke;   Parkinson Disease;   Multiple Sclerosis<br /><b>Interventions</b>:    Device: medical device ""Homing"" (TecnoBody); medical device ""Icone"" (Heaxel);   Behavioral: Usual Care<br /><b>Sponsors</b>:    Fondazione Don Carlo Gnocchi Onlus;   Fondazione Ico Falck<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06009770,2023-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4313,197,2023-08-23 13:23:02.242341,Current Exercise Approaches in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Cawthorne-Cooksey Exercises;   Other: Mechanical Hippotherapy Exercises<br /><b>Sponsor</b>:    Uskudar University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT06005909,2023-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4314,196,2023-08-23 12:42:59.173061,Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS),<b>Condition</b>:    Amyotrophic Lateral Sclerosis<br /><b>Intervention</b>:    Drug: Lithium Carbonate 400 MG<br /><b>Sponsors</b>:    Stichting TRICALS Foundation;   Stichting ALS Nederland;   Fight MND;   Research Foundation Flanders;   MNDA;   Thierry Latran Foundation;   Ulla-Carin Lindquist Foundation;   Luzon Foundation;   Alan Davidson Foundation;   My name'5 Doddie Foundation<br /><b>Recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT06008249?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-08-23 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4315,195,2021-08-17 15:35:47.000000,DreaMS - Validation Study 1,"Condition:    Multiple SclerosisIntervention:    Device: dreaMS App R2.0Sponsors :    Research Center for Clinical Neuroimmunology and Neuroscience Basel;   Healios AG;   University Hospital, Basel, Switzerland;   University of Basel;   Innosuisse - Swiss Innovation Agency;   Novartis Pharmaceuticals;   Hoffmann-La RocheNot yet recruiting ",https://clinicaltrials.gov/show/NCT05009160,2021-07-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4316,194,2023-08-22 13:43:08.057565,The Effect of Sexual Counseling With the PLISSIT Model on Sexual Function and Sexual Quality of Life in Women With Multiple Sclerosis: A Randomized Controlled Study,"<b>Conditions</b>:    Multiple Sclerosis;   Female Sexual Dysfunction<br /><b>Intervention</b>:    Other: sexual counselling with PLISSIT model<br /><b>Sponsor</b>:    Istanbul University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT06004518,2023-08-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4317,193,2023-08-21 16:42:23.130703,Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients,<b>Conditions</b>:    Multiple Sclerosis;   Ataxia<br /><b>Interventions</b>:    Other: physical therapy;   Other: life kinetic exercises<br /><b>Sponsor</b>:    Cairo University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT06001424,2021-01-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4318,192,2021-08-17 00:19:09.000000,Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct04174157,2021-08-17 00:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4319,191,2021-08-17 00:19:09.000000,Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren&#39;s Syndrome,,https://www.novartis.com/clinicaltrials/study/nct03905525,2021-08-17 00:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4320,190,2021-08-17 00:19:09.000000,"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration",,https://www.novartis.com/clinicaltrials/study/nct04864834,2021-08-17 00:19:09.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4321,189,2021-08-16 17:25:47.000000,Efficacy of Diet on Quality of Life in Multiple Sclerosis,"Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Dietary Supplement: BodyBio Balance Oil;   Dietary Supplement: Kirunal Fish Oil;   Dietary Supplement: BodyBio PC;   Behavioral: Modified Paleolithic Elimination diet;   Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet;   Behavioral: Dietary Guidelines for Americans DietSponsor :    Terry L. WahlsNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05007483,2021-09-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4322,188,2023-08-21 14:22:34.517427,Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    University of Edinburgh;   NHS Lothian<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT06001138,2023-07-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4323,187,2021-08-13 13:25:47.000000,A Teleheath tDCS Approach to Decrease Cannabis Use,Conditions:    Cannabis Use Disorder;   Multiple SclerosisInterventions:    Other: Transcranial Direct Current Stimulation (tDCS);   Other: Sham - Transcranial Direct Current Stimulation (tDCS);   Other: MindfulnessSponsor :    NYU Langone HealthNot yet recruiting ,https://clinicaltrials.gov/show/NCT05005013,2021-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4324,186,2023-08-21 13:52:27.862950,"Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Ocrelizumab Injection [Ocrevus]<br /><b>Sponsor</b>:    Fondation Ophtalmologique Adolphe de Rothschild<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05999604,2023-11-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4325,185,2023-08-21 13:52:27.821995,Feasibility of Remote Exercise Training for Hispanics/Latinos With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Exercise Training Program;   Behavioral: Flexibility Program<br /><b>Sponsor</b>:    University of Illinois at Chicago<br /><b>Not yet recruiting</b>,http://classic.clinicaltrials.gov/ct2/show/NCT05998616?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-08-21 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4326,184,2021-08-12 15:19:08.000000,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,,https://www.novartis.com/clinicaltrials/study/nct04544189,2021-08-12 15:19:08.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4327,183,2023-08-20 09:02:21.519336,"A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS OF LACTATING WOMEN WITH CIS OR MS RECEIVING OCRELIZUMAB – THE SOPRANINO STUDY","<p>EudraCT Number: 2021-000063-79<br />Sponsor Protocol Number: MN42989<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-10-22<br />Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10071068<br />Term: Clinically isolated syndrome<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Infants and toddlers, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000063-79/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000063-79/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-000063-79,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4328,182,2023-08-15 18:10:51.248423,Impact of Adding Cognitive Behaviour Therapy to Supervised Pilates-based Core Stability Training in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: pilates based core stability training and congnitive therapy;   Other: Pilates based core stability training<br /><b>Sponsor</b>:    Cairo University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05993819,2023-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4329,181,2023-08-15 10:22:19.767282,"Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers...","<p>EudraCT Number: 2020-004431-24<br />Sponsor Protocol Number: 67896153MSC3001<br />Sponsor Name: Janssen-Cilag International NV<br />Start Date: 2022-11-03<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/3rd"">Outside EU/EEA</a></p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-004431-24,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4330,180,2021-08-12 15:09:11.000000,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",,https://clinicaltrials.gov/show/NCT03623243,2018-07-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4331,179,2023-08-14 14:30:46.846091,Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis,"<b>Condition</b>:    MS (Multiple Sclerosis)<br /><b>Interventions</b>:    Other: Deep sensory assisted rehabilitation;   Other: classical rehabilitation<br /><b>Sponsors</b>:    Nermin Çalışır;   Bursa Sevket Yilmaz Training and Research Hospital<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05991297,2023-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4332,178,2021-08-12 15:09:11.000000,Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.,,https://www.novartis.com/clinicaltrials/study/nct04623216,2021-08-12 15:09:11.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4333,177,2021-08-12 15:09:11.000000,A Randomized Study to Evaluate the Effect of an &quot;Inclisiran First&quot; Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE),,https://www.novartis.com/clinicaltrials/study/nct04929249,2021-08-12 15:09:11.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4334,176,2023-08-12 14:10:42.130777,"A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...","<p>EudraCT Number: 2020-005971-11<br />Sponsor Protocol Number: AP101-02<br />Sponsor Name: AL-S Pharma, AG<br />Start Date: 2021-12-22<br />Medical condition: Amyotrophic Lateral Sclerosis  (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005971-11/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-005971-11,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4335,175,2021-08-12 15:09:11.000000,Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation,,https://www.novartis.com/clinicaltrials/study/nct04666259,2021-08-12 15:09:11.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4336,174,2023-08-10 14:21:26.008160,"Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 ...","<p>EudraCT Number: 2009-011470-15<br />Sponsor Protocol Number: AC-058B202<br />Sponsor Name: ACTELION Pharmaceuticals Ltd<br />Start Date: 2010-03-30<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2009-011470-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4337,173,2023-08-10 13:41:24.524294,"An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS...","<p>EudraCT Number: 2008-005021-11<br />Sponsor Protocol Number: 28851<br />Sponsor Name: Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany<br />Start Date: 2009-10-14<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005021-11/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005021-11/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005021-11/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005021-11/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2008-005021-11,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4338,172,2021-08-12 15:09:11.000000,"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy",,https://www.novartis.com/clinicaltrials/study/nct04539041,2021-08-12 15:09:11.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4339,171,2023-08-10 13:01:28.962286,"The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis:
A Phase 2 Randomized, double-blind, four–arm, parallel,...","<p>EudraCT Number: 2009-012716-40<br />Sponsor Protocol Number: CO-200-201<br />Sponsor Name: Peptimmune Inc.<br />Start Date: 2009-12-31<br />Medical condition: Relapsing-remitting multiple sclerosis <br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/EE"">EE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012716-40/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2009-012716-40,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4340,170,2021-08-12 13:29:25.000000,Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS),Conditions:    Multiple Sclerosis;   Fatigue;   StressIntervention:    Behavioral: High-challenging cognitive protocol to provoke stress and (cognitive) fatigueSponsors :    KU Leuven;   National MS Center MelsbroekRecruiting ,https://clinicaltrials.gov/show/NCT05003375,2021-01-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4341,169,2021-08-12 13:29:25.000000,"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients","Condition:    Multiple SclerosisInterventions:    Device: ""RehaCom"" computer-based cognitive training in addition to Conventional physical therapy program;   Other: Conventional physical therapy programSponsor :    Cairo UniversityCompleted ",https://clinicaltrials.gov/show/NCT05002062,2021-12-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4342,168,2021-08-12 13:29:25.000000,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,Condition:    Multiple SclerosisIntervention:    Biological: AlloRxSponsor :    The Foundation for Orthopaedics and Regenerative MedicineRecruiting ,https://clinicaltrials.gov/show/NCT05003388,2021-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4343,167,2021-08-12 13:29:25.000000,Thalamic Nuclei Volumes in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Sponsors :    University Hospital, Bordeaux;   Institut National de la Santé Et de la Recherche Médicale, FranceRecruiting ",https://clinicaltrials.gov/show/NCT05002764,2021-04-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4344,166,2021-08-11 15:21:39.000000,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,"Conditions:    Rheumatoid Arthritis;   Systemic Lupus Erythematosus (SLE);   Pemphigus Vulgaris;   Multiple Sclerosis;   Systemic Sclerosis (SSc)Interventions:    Biological: Moderna mRNA-1273;   Biological: BNT162b2;   Biological: Ad26.COV2.S;   Drug: IS (MMF or MPA);   Drug: IS (MTX);   Biological: IS (B cell depletion therapy)Sponsors :    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence;   Rho Federal Systems Division, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05000216,2021-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4345,165,2021-08-10 14:01:41.000000,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeIntervention:    Drug: OcrelizumabSponsors :    Hoffmann-La Roche;   PPD;   LabCorp;   IllingworthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04998812,2021-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4346,164,2021-08-10 14:01:41.000000,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeIntervention:    Drug: OcrelizumabSponsors :    Hoffmann-La Roche;   PPD;   LabCorp;   IllingworthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04998851,2021-06-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4347,163,2021-08-09 12:36:29.000000,Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q,Conditions:    Multiple Sclerosis;   Constipation;   Fecal IncontinenceIntervention:    Other: Clinical interviewsSponsor :    Pierre and Marie Curie UniversityCompleted ,https://clinicaltrials.gov/show/NCT04996186,2021-07-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4348,162,2021-08-09 12:36:29.000000,Neurophysiological Assessment in Patients With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Demyelinating Disease;   Inflammatory DiseaseInterventions:    Other: Neurophysiological assessment;   Other: clinical assessmentSponsor :    University of Roma La SapienzaNot yet recruiting ,https://clinicaltrials.gov/show/NCT04997343,2021-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4349,161,2021-08-09 12:36:29.000000,Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS),"Condition:    Relapsing-Remitting Multiple SclerosisIntervention:    Sponsors :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, GermanyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04997148,2021-03-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4350,160,2021-08-07 00:23:03.000000,Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment,,https://www.novartis.com/clinicaltrials/study/nct04587622,2021-08-07 00:23:03.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4351,159,2021-08-07 00:23:03.000000,Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD),,https://www.novartis.com/clinicaltrials/study/nct04443907,2021-08-07 00:23:03.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4352,158,2021-08-06 12:10:36.000000,Sensitivity of Motor Assessment in MS - a Prospective Cohort Study,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Chronic ProgressiveIntervention:    Diagnostic Test: PASS-MSSponsors :    Friedemann Paul;   Roche Pharma AGActive, not recruiting ",https://clinicaltrials.gov/show/NCT04993274,2021-09-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4353,157,2021-08-06 12:10:36.000000,Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects,Conditions:    Multiple Sclerosis;   Magnetic Resonance ImagingIntervention:    Diagnostic Test: T1rho imagingSponsor :    Chinese University of Hong KongNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04993196?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-08-06 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4354,156,2023-08-10 10:01:25.471635,Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.,"<p>EudraCT Number: 2011-001956-12<br />Sponsor Protocol Number: NT12385-5<br />Sponsor Name: University Hospital Motol<br />Start Date: 2011-05-25<br />Medical condition: To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS 
To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status
NAbs p...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001956-12/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2011-001956-12,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4355,155,2021-08-05 22:46:35.000000,Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to &lt; 12 Years Old With Asthma,,https://www.novartis.com/clinicaltrials/study/nct04589663,2021-08-05 22:46:35.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4356,154,2021-08-05 22:46:35.000000,Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent,,https://www.novartis.com/clinicaltrials/study/nct04722666,2021-08-05 22:46:35.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4357,153,2021-08-05 22:46:35.000000,"Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis",,https://www.novartis.com/clinicaltrials/study/nct04064242,2021-08-05 22:46:35.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4358,152,2023-08-10 10:01:25.437411,"AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2017-001313-93<br />Sponsor Protocol Number: MN39159<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2018-05-03<br />Medical condition: Progressive multiple sclerosis (PMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-001313-93,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4359,151,2021-08-05 22:46:35.000000,Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients,,https://www.novartis.com/clinicaltrials/study/nct03876769,2021-08-05 22:46:35.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4360,150,2021-08-05 15:59:12.000000,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-004719-10,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4361,149,2021-08-05 15:53:54.000000,177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer,,https://www.novartis.com/clinicaltrials/study/nct04689828,2021-08-05 15:53:54.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4362,148,2021-08-05 15:39:00.000000,Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients,,https://www.novartis.com//clinicaltrials/study/nct04578834,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4363,147,2021-08-05 15:39:00.000000,Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI,,https://www.novartis.com//clinicaltrials/study/nct02859727,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4364,146,2023-08-10 08:40:49.803141,"Možnosti terapeutického ovlivnění neurogenního hyperaktivního detruzoru u pacientů po spinálním poranění a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevřená studie porovná...","<p>EudraCT Number: 2009-012431-15<br />Sponsor Protocol Number: KNL:URO-2009/1<br />Sponsor Name: Krajská nemocnice Liberec, a.s.<br />Start Date: 2010-01-21<br />Medical condition: Studie se zabývá léčbou hyperaktivního neurogeního detruzoru  u pacientů, kteří trpí příznaky hyperaktivního močového měchýře jako důsledek spinálního poranění nebo roztroušené sklerózy. K léčbě se...<br />Disease: <br />Population Age: Adolescents, Under 18, Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012431-15/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2009-012431-15,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4365,145,2021-08-05 15:39:00.000000,Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients,,https://www.novartis.com//clinicaltrials/study/nct04072887,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4366,144,2021-08-05 15:39:00.000000,Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD,,https://www.novartis.com//clinicaltrials/study/nct04023552,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4367,143,2021-08-05 15:39:00.000000,"A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation",,https://www.novartis.com//clinicaltrials/study/nct04582409,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4368,142,2023-08-10 08:01:29.315554,"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis","<p>EudraCT Number: 2008-003098-42<br />Sponsor Protocol Number: 108MS303<br />Sponsor Name: Biogen Idec Ltd<br />Start Date: 2009-01-06<br />Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003098-42,2008-10-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4369,141,2021-08-05 15:39:00.000000,Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment,,https://www.novartis.com//clinicaltrials/study/nct04558918,2021-08-05 15:39:00.000000,13,,13,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
4370,140,2023-08-10 07:21:23.610263,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta 1a (Rebif®) as an...,"<p>EudraCT Number: 2007-004452-36<br />Sponsor Protocol Number: EFC10531<br />Sponsor Name: Sanofi-aventis recherche & développement<br />Start Date: 2009-03-24<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004452-36/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2007-004452-36,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4371,139,2023-08-09 22:11:16.758921,Multiple Sclerosis Pelvic Floor Telerehabilitation,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Telerehabilitation<br /><b>Sponsor</b>:    University of Trieste<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05984095,2023-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4372,138,2023-08-09 22:11:16.751551,Comparison of the Effectiveness of Acupuncture Treatment With Conventional Rehabilitation Methods in Multiple Sclerosis Patients,"<b>Conditions</b>: Multiple Sclerosis
<br /><b>Interventions</b>: Other: Acupuncture; Other: Conventional Rehabilitation
<br /><b>Sponsors</b>: Ankara City Hospital Bilkent
<br /><b>Recruiting</b>",https://clinicaltrials.gov/study/NCT06178029?cond=Multiple+Sclerosis,2023-12-20 05:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4373,137,2023-08-09 22:11:16.635522,Technological Balance and Gait Rehabilitation in Patients With Multiple Sclerosis.,<b>Conditions</b>:    Multiple Sclerosis;   Balance;   Cognitive Impairment<br /><b>Intervention</b>:    Device: Technological rehabilitation<br /><b>Sponsor</b>:    Fondazione Policlinico Universitario Agostino Gemelli IRCCS<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05983809,2023-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4374,136,2021-08-04 13:22:57.000000,Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program,Conditions:    Multiple Sclerosis;   Quality of Life;   Patient Empowerment;   Patient Activation;   Fatigue;   Peer GroupIntervention:    Other: Multiple Sclerosis Expert Patient Program of CataloniaSponsors :    Hospital Universitari Vall d'Hebron Research Institute;   Strategic Plan for Research and Innovation in Health (ref. BDNS 542793)Not yet recruiting ,https://clinicaltrials.gov/show/NCT04988880,2021-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4375,135,2021-08-04 13:22:57.000000,A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: Lu AG06466;   Drug: PlaceboSponsor :    H. Lundbeck A/SNot yet recruiting ,https://clinicaltrials.gov/show/NCT04990219,2021-07-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4376,134,2021-07-30 17:01:11.000000,Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,Condition:    Spasticity With Multiple SclerosisInterventions:    Drug: Nabiximols;   Drug: PlaceboSponsor :    GW Pharmaceuticals Ltd.Not yet recruiting ,https://clinicaltrials.gov/show/NCT04984278,2021-07-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4377,133,2021-07-29 14:28:11.000000,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,Condition:    Multiple Sclerosis Healthy SubjectsIntervention:    Drug: RIPK1 inhibitorSponsor :    SanofiNot yet recruiting ,https://clinicaltrials.gov/show/NCT04982991,2021-07-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4378,132,2021-07-28 18:48:11.000000,Telerehabilitation in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Other: Telerehabilitation;   Other: Video exerciseSponsor :    Marmara UniversityRecruiting ,https://clinicaltrials.gov/show/NCT03444454,2018-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4379,131,2021-07-28 18:48:11.000000,Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Magnetic Resonance Imaging;   MethylprednisoloneIntervention:    Drug: Methylprednisolone succinateSponsor :    Mazandaran University of Medical SciencesEnrolling by invitation ",https://clinicaltrials.gov/show/NCT04979650,2021-02-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4380,130,2021-07-28 18:48:11.000000,Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Anxiety;   Depression;   Patient SatisfactionInterventions:    Other: Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist;   Other: Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating NeurologistSponsors :    University of Alberta;   University Hospital FoundationNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04979546,2021-06-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4381,129,2021-07-28 18:48:11.000000,The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Upper extremity endurance test (UULEX)Sponsor :    Marmara UniversityRecruiting ,https://clinicaltrials.gov/show/NCT04979819,2021-07-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4382,128,2021-07-27 15:16:12.000000,Gray Matter Demyelination in Primary Progressive MS at 7T,Condition:    Primary Progressive Multiple SclerosisIntervention:    Sponsors :    Danish Research Centre for Magnetic Resonance;   Scleroseforeningen;   Danish Multiple Sclerosis CenterNot yet recruiting ,https://clinicaltrials.gov/show/NCT04977622,2021-06-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4383,127,2021-07-23 12:56:11.000000,Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial,"Condition:    Multiple SclerosisInterventions:    Behavioral: SMART;   Behavioral: Sham brain training (Sudoku)Sponsors :    University of Lincoln;   University of Exeter;   Nottinghamshire Healthcare NHS Trust;   National University of Ireland, Maynooth;   University of NottinghamNot yet recruiting ",https://clinicaltrials.gov/show/NCT04975685,2021-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4384,126,2021-07-22 17:03:44.000000,Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis,"Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Other: Spinal Manipulation;   Other: Sham Spinal ManipulationSponsor :    University of Alabama at BirminghamNot yet recruiting ",https://clinicaltrials.gov/show/NCT04972929,2021-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4385,125,2021-07-22 17:03:44.000000,Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Rehabilitation;   Musculoskeletal ComplicationInterventions:    Behavioral: Manual physiotherapeutic correction (MFK) Method;   Behavioral: Dynamic Neuromuscular Stabilization (DNS) MethodSponsor :    Charles University, Czech RepublicCompleted ",https://clinicaltrials.gov/show/NCT04973501,2021-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4386,124,2021-07-21 12:32:44.000000,Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial,Condition:    Relapsing-Remitting Multiple SclerosisInterventions:    Drug: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Ocrelizumab;   Drug: AlemtuzumabSponsors :    Universitätsklinikum Hamburg-Eppendorf;   Neovii Biotech;   Clinical Trial Center North (CTC North GmbH & Co. KG)Not yet recruiting ,https://clinicaltrials.gov/show/NCT04971005,2020-12-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4387,123,2021-07-21 12:32:44.000000,Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device,Condition:    Multiple SclerosisIntervention:    Other: Wearable sensorSponsor :    Nantes University HospitalNot yet recruiting ,https://clinicaltrials.gov/show/NCT04969848,2021-05-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4388,122,2021-07-20 13:49:06.000000,"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis",Conditions:    Multiple Sclerosis;   Anxiety;   Depressive Symptoms;   Distress;   Psychiatric NursingIntervention:    Behavioral: Emotional Freedom TechniqueSponsor :    Dokuz Eylul UniversityRecruiting ,https://clinicaltrials.gov/show/NCT04969562,2021-01-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4389,121,2021-07-19 12:15:08.000000,Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Relapsing-RemittingInterventions:    Biological: Ocrelizumab (CinnaGen, Iran);   Biological: Ocrelizumab (Roche, Switzerland)Sponsor :    CinnagenActive, not recruiting ",https://clinicaltrials.gov/show/NCT04966338,2021-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4390,120,2021-07-16 13:27:06.000000,An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Analysis of B cellsSponsor :    University of OsloRecruiting ,https://clinicaltrials.gov/show/NCT04964336,2021-07-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4391,119,2021-07-16 13:27:06.000000,Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab,"Condition:    Multiple SclerosisIntervention:    Drug: NatalizumabSponsor :    Multiple Sclerosis Center of Northeastern New YorkActive, not recruiting ",https://clinicaltrials.gov/show/NCT04964700,2021-05-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4392,118,2021-07-16 13:27:06.000000,RMS Study of BTK Inhibitor SAR442168,Condition:    Relapsing Multiple SclerosisIntervention:    Drug: SAR442168Sponsor :    Peking University Third HospitalRecruiting ,https://clinicaltrials.gov/show/NCT04964791,2021-06-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4393,117,2021-07-15 12:52:04.000000,Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS,Condition:    Multiple SclerosisIntervention:    Behavioral: Exergame TrainingSponsor :    Eling DeBruinRecruiting ,https://clinicaltrials.gov/show/NCT04963335,2021-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4394,116,2021-07-09 11:20:04.000000,"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis","Condition:    Multiple SclerosisIntervention:    Biological: IMS001Sponsors :    ImStem Biotechnology;   Rho, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04956744,2021-06-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4395,115,2021-07-08 14:32:36.000000,Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: Conscientiousness CoachSponsor :    State University of New York at BuffaloRecruiting ,https://clinicaltrials.gov/show/NCT04953689,2021-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4396,114,2021-07-07 11:59:36.000000,Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis,Conditions:    Clinical Isolation Syndrome of Spinal Cord;   Multiple SclerosisIntervention:    Sponsor :    Peking University Third HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04952246?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-07 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4397,113,2021-07-07 11:59:36.000000,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Conditions:    Kidney Transplant;   Extracorporeal Dialysis;   Myeloma;   Cancer;   Hematologic Malignancy;   Multiple Sclerosis;   Hypergammaglobulinemia;   Malignant Tumor;   Hiv;   Diabetes Type 2Intervention:    Biological: Biological samplesSponsor :    Centre Hospitalier Régional d'OrléansRecruiting ,https://clinicaltrials.gov/show/NCT04952766,2021-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4398,112,2021-06-29 16:46:42.000000,CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: eSupport Health Weekly Group Sessions for PwMSSponsor :    eSupport HealthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04943887?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4399,111,2021-06-29 16:46:42.000000,Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS,Condition:    Multiple SclerosisIntervention:    Device: NeuBieSponsors :    Centura Health;   NeuFit - Neurological Fitness and EducationNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04942938?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4400,110,2021-06-29 16:46:42.000000,Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis,"Condition:    Primary Progressive Multiple SclerosisIntervention:    Biological: DUOC-01Sponsor :    Joanne Kurtzberg, MDNot yet recruiting ",https://clinicaltrials.gov/show/NCT04943289,2021-06-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4401,109,2021-06-29 16:46:42.000000,Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Exercise Intervention;   Neuro-Degenerative DiseaseIntervention:    Behavioral: Regular ExerciseSponsor :    Ege UniversityCompleted ,https://clinicaltrials.gov/show/NCT04944251,2021-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4402,108,2021-06-28 16:23:24.000000,PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers,"Condition:    Multiple SclerosisIntervention:    Drug: PIPE-307Sponsor :    Pipeline Therapeutics, Inc.Not yet recruiting ",https://clinicaltrials.gov/show/NCT04941781,2021-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4403,107,2023-08-09 15:56:18.598579,Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: PIPE-791;   Drug: Placebo<br /><b>Sponsor</b>:    Pipeline Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05983939,2023-07-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4404,106,2021-06-24 16:09:29.000000,Reading Problems Associated With Central Nervous System (CNS) Pathologies.,"Conditions:    Injury Brain;   Eye Abnormalities;   Multiple Sclerosis;   Parkinson Disease;   Ataxia, CerebellarIntervention:    Diagnostic Test: eye trackingSponsors :    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Hospital Clínico Universitario de Valladolid;   Hospital del Río HortegaEnrolling by invitation ",https://clinicaltrials.gov/show/NCT04937725,2021-06-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4405,105,2021-06-23 16:33:29.000000,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Self-AcupressureSponsor :    Istanbul Sabahattin Zaim UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04936555,2021-06-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4406,104,2021-06-22 14:45:49.000000,Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS),"Condition:    Multiple SclerosisIntervention:    Drug: CladribineSponsors :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Hellas sa., GreeceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04934800,2021-06-17 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4407,103,2021-06-21 20:04:49.000000,Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsors :    Uğur OVACIK;   Istanbul University-CerrahpasaNot yet recruiting ,https://clinicaltrials.gov/show/NCT04933110,2021-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4408,102,2021-06-21 20:04:49.000000,Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsor :    Istanbul University-CerrahpasaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04932616?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-21 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4409,101,2021-06-21 20:04:49.000000,Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent,Condition:    Multiple SclerosisIntervention:    Other: SiponimodSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/show/NCT04933552,2021-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4410,100,2021-06-18 22:15:49.000000,Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS,Conditions:    Multiple Sclerosis;   Cognitive ImpairmentInterventions:    Other: Intermittent theta burst stimulation (iTBS);   Other: Sham Intermittent theta burst stimulation (iTBS)Sponsor :    University of NottinghamNot yet recruiting ,https://clinicaltrials.gov/show/NCT04931953,2021-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4411,99,2021-06-18 22:15:49.000000,Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: phone interviewSponsor :    University of SienaRecruiting ,https://clinicaltrials.gov/show/NCT04930380,2021-03-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4412,98,2021-06-18 22:15:49.000000,The Gut Microbiome in Adult Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsor :    National MS Center MelsbroekCompleted ,https://clinicaltrials.gov/show/NCT04929145,2021-10-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4413,97,2021-06-16 18:08:49.000000,Multiple Sclerosis and Voiding Symptoms: How to Assess?,Conditions:    Multiple Sclerosis;   Lower Urinary Tract Symptoms;   Voiding DisordersIntervention:    Other: voiding phase evaluationSponsor :    Pierre and Marie Curie UniversityCompleted ,https://clinicaltrials.gov/show/NCT04928716,2021-06-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4414,96,2021-06-16 18:08:49.000000,Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran,Condition:    Relapsing Multiple SclerosisIntervention:    Drug: Glatiramer AcetateSponsor :    CinnagenCompleted ,https://clinicaltrials.gov/show/NCT04928313,2021-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4415,95,2023-08-09 14:22:18.694991,Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders,"<b>Conditions</b>:    Multiple Sclerosis;   Neuromyelitis Optica;   Demyelinating Autoimmune Diseases, CNS<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Icahn School of Medicine at Mount Sinai<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05982925,2023-01-08 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4416,94,2021-06-14 17:57:48.000000,Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis,"Condition:    Secondary-progressive Multiple SclerosisInterventions:    Drug: Mayzent;   Drug: OcrevusSponsor :    Robert Zivadinov, MD, PhDNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04925557,2021-05-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4417,93,2021-06-14 17:57:48.000000,Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: monomethyl fumarateSponsor :    Banner Life Sciences LLCNot yet recruiting ,https://clinicaltrials.gov/show/NCT04925778,2021-08-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4418,92,2021-06-08 15:45:00.000000,"EEG and TMS-based Biomarkers of ALS, MS and FTD","Conditions:    Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Multiple SclerosisInterventions:    Procedure: 128 electrode electroencephalography (EEG);   Procedure: Transcranial magnetic stimulation (TMS)Sponsors :    University of Dublin, Trinity College;   Motor Neurone Disease Association, UK;   Irish Research Council, IE;   Health Research Board, IE;   Research Motor Neurone, IE;   Thierry Latran Foundation, FR;   ALS Association, USARecruiting ",https://clinicaltrials.gov/show/NCT04918251,2021-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4419,91,2021-06-08 15:45:00.000000,Motor Asymmetry in Progressive Multiple Sclerosis Patients,"Conditions:    Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Radiation: Magnetic Resonance Imaging;   Diagnostic Test: Neurological examination;   Diagnostic Test: Multiple Sclerosis Functional Composite;   Diagnostic Test: Physiotherapist examinationSponsor :    Rennes University HospitalNot yet recruiting ",https://clinicaltrials.gov/show/NCT04918225,2021-02-06 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4420,90,2021-06-03 15:01:28.000000,Exercise Booster Sessions in People With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Combination Product: Systematic aerobic training;   Combination Product: Systematic resistance training;   Combination Product: Aerobic training booster sessions;   Combination Product: Resistance training booster sessionsSponsors :    University of Aarhus;   Oxford Brookes UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04913012,2021-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4421,89,2021-06-01 17:47:28.000000,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness","Conditions:    Multiple Sclerosis;   StrokeInterventions:    Other: Clinical Scapular protocol (ClinScaP);   Other: the prevalence of trunk, scapula and upper limb impairments.;   Other: the interaction between trunk, scapula and upper limb impairments.Sponsors :    Hasselt University;   Revalidatie & MS Centrum Overpelt;   Ziekenhuis Oost-Limburg;   National MS Center Melsbroek;   Jessa HospitalRecruiting ",https://clinicaltrials.gov/show/NCT04908891,2021-05-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4422,88,2021-06-01 17:47:28.000000,"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis",Condition:    Relapsing Forms of Multiple SclerosisInterventions:    Drug: EHP-101 25 mg OD;   Drug: EHP-101 25 mg BID;   Drug: EHP-101 50 mg OD;   Drug: EHP-101 50 mg BIDSponsor :    Emerald Health PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/show/NCT04909502,2021-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4423,87,2021-06-01 17:47:28.000000,Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Quality of LifeIntervention:    Behavioral: Occupational Performance CoachingSponsor :    Queen's UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04908085,2021-05-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4424,86,2021-05-28 12:44:08.000000,Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research,Condition:    Estimate the Number of Spinal Cord Lesions Detected With the 3D FGAPSIR Sequence That Were Not Detected With the 3D PSIR SequenceIntervention:    Device: MRISponsor :    Fondation Ophtalmologique Adolphe de RothschildEnrolling by invitation ,https://clinicaltrials.gov/ct2/show/NCT04906928?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-28 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4425,85,2021-05-28 12:44:08.000000,Next-Gen MS: Feed-forward PRO Data for MS Research,"Condition:    Multiple SclerosisIntervention:    Sponsor :    EMD Serono Research & Development Institute, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04907305,2021-05-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4426,84,2021-05-28 12:44:08.000000,The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Forced Aerobic Exercise (FE);   Behavioral: Voluntary Aerobic Exercise (VE)Sponsor :    The Cleveland ClinicNot yet recruiting ,https://clinicaltrials.gov/show/NCT04906057,2021-10-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4427,83,2021-05-27 12:09:08.000000,Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity,"Conditions:    Multiple Sclerosis;   Spasticity, Muscle;   PainIntervention:    Device: FlowOx™Sponsors :    Otivio AS;   Haukeland University HospitalRecruiting ",https://clinicaltrials.gov/show/NCT04904016,2021-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4428,82,2021-05-26 15:30:08.000000,The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients,"Condition:    Multiple Sclerosis RelapseIntervention:    Sponsor :    IRCCS National Neurological Institute ""C. Mondino"" FoundationNot yet recruiting ",https://clinicaltrials.gov/show/NCT04902690,2021-05-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4429,81,2023-08-08 16:21:00.289218,Acute Effect of Osteopathic Visceral Mobilization Techniques,<b>Conditions</b>:    Multiple Sclerosis;   Pelvic Floor Disorders;   Urinary Incontinence;   Visceral Mobilization;   Osteopathic Manipulative Treatment<br /><b>Interventions</b>:    Other: breathing exercises;   Other: osteopathic manual therapy techniques<br /><b>Sponsor</b>:    University of Gaziantep<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05981339,2023-07-31 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4430,80,2021-05-19 11:05:28.000000,Adapting mHealth Technology to Improve Patient Activation,Conditions:    Spinal Cord Injuries;   Stroke;   Multiple SclerosisIntervention:    Behavioral: Fatigue self-management SMS interventionSponsors :    Washington University School of Medicine;   The Foundation for Barnes-Jewish HospitalRecruiting ,https://clinicaltrials.gov/show/NCT04893590,2021-05-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4431,79,2021-05-19 11:05:27.000000,"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis",Condition:    Multiple SclerosisIntervention:    Other: blood sampleSponsor :    Medical University of GrazRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04892134,2021-04-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4432,78,2021-05-18 10:30:26.000000,Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis,"Condition:    Multiple SclerosisInterventions:    Other: Technology Supported Task-Oriented Circuit Training;   Other: Home-based TelerehabilitationSponsor :    Hacettepe UniversityActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04891341?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-18 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4433,77,2021-05-17 17:47:26.000000,Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.,"Condition:    Multiple SclerosisInterventions:    Device: Actimyo°;   Device: IMUSponsors :    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de LiègeActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04888689,2021-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4434,76,2021-05-14 12:06:26.000000,The Effects of Respiratory-based Telerehabilitaion in Patients With MS,"Conditions:    Multiple Sclerosis;   Telerehabilitation;   Compliance, PatientIntervention:    Other: pulmonory based home exercisesSponsors :    Dr. Anıl Tosun;   Trakya UniversityEnrolling by invitation ",https://clinicaltrials.gov/show/NCT04887051,2021-04-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4435,75,2023-08-07 17:10:44.131056,Observational Study of Persistence on Bafiertam Treatment In Routine Clinical Practice,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Monomethyl Fumarate<br /><b>Sponsor</b>:    Banner Life Sciences LLC<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05978531,2023-07-25 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4436,74,2021-05-13 10:18:31.000000,An Examination of Cognitive Fatigue Using Functional Neuroimaging,"Condition:    Multiple Sclerosis, Relapsing-RemittingIntervention:    Drug: ZeposiaSponsors :    Kessler Foundation;   Celgene;   Hackensack Meridian Health;   St. Barnabas Medical CenterNot yet recruiting ",https://clinicaltrials.gov/show/NCT04885894,2021-11-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4437,73,2021-05-12 10:42:31.000000,Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.,Condition:    Multiple SclerosisIntervention:    Device: ActimyoSponsors :    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de LiègeRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04882891,2021-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4438,72,2021-05-11 11:06:31.000000,"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project",Condition:    Multiple SclerosisIntervention:    Behavioral: B-HIPE (Brief High Impact Preparatory Experience)Sponsor :    Fondazione Don Carlo Gnocchi OnlusRecruiting ,https://clinicaltrials.gov/show/NCT04881422,2021-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4439,71,2021-05-10 12:29:31.000000,Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   FatigueInterventions:    Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];   Drug: PlaceboSponsors :    Harvard Medical School;   Gilead SciencesNot yet recruiting ",https://clinicaltrials.gov/show/NCT04880577,2021-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4440,70,2021-05-10 12:29:31.000000,Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: SAR441344 IV;   Drug: placebo IV;   Drug: SAR441344 SC;   Drug: placebo SC;   Drug: MRI contrast-enhancing preparationsSponsor :    SanofiRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04879628,2021-06-05 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4441,69,2021-05-07 11:43:30.000000,Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.,"Conditions:    Radiologically Isolated Syndrome;   Multiple SclerosisInterventions:    Drug: Ocrelizumab;   Other: PlaceboSponsors :    Yale University;   Genentech, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04877457,2021-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4442,68,2023-08-04 04:40:50.175897,Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS,"<b>Condition</b>:    Primary Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ocrelizumab<br /><b>Sponsors</b>:    State University of New York at Buffalo;   Genentech, Inc.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05974852,2023-12-07 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4443,67,2021-05-06 11:08:31.000000,Sonification Techniques for Gait Training,"Conditions:    Parkinson Disease;   Stroke;   Multiple SclerosisInterventions:    Device: Gait rehabilitation with ""sonification"";   Other: Standard gait rehabilitation (without sonification)Sponsor :    Istituti Clinici Scientifici Maugeri SpARecruiting ",https://clinicaltrials.gov/show/NCT04876339,2021-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4444,66,2021-05-06 11:08:31.000000,EMDR for Depressed People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   DepressionIntervention:    Behavioral: Eye Movement Desensitization and Reprocessing - EMDRSponsors :    Fondazione Don Carlo Gnocchi Onlus;   EMDR Europe;   Catholic University of the Sacred HeartNot yet recruiting ,https://clinicaltrials.gov/show/NCT04875832,2021-04-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4445,65,2021-05-05 10:42:09.000000,Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases,"Conditions:    Stroke;   Multiple Sclerosis;   Parkinson DiseaseInterventions:    Device: Experimental Group;   Other: Control GroupSponsors :    IRCCS San Camillo, Venezia, Italy;   IRCCS San Raffaele;   Istituti Clinici Scientifici Maugeri SpA;   IRCCS National Neurological Institute ""C. Mondino"" Foundation;   I.R.C.C.S. Fondazione Santa LuciaRecruiting ",https://clinicaltrials.gov/show/NCT04874051,2021-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4446,64,2021-05-05 10:42:09.000000,Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    Dr Recai Turkoglu;   Health Sciences University Istanbul Haydarpaşa Numune Training and Research HospitalNot yet recruiting ,https://clinicaltrials.gov/show/NCT04874597,2021-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4447,63,2021-05-05 10:42:09.000000,From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Biological sample collectionSponsor :    Nantes University HospitalRecruiting ,https://clinicaltrials.gov/show/NCT04873492,2021-04-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4448,62,2023-08-03 22:50:54.302396,Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical),"<b>Condition</b>:    Primary Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ocrelizumab<br /><b>Sponsors</b>:    State University of New York at Buffalo;   Genentech, Inc.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05974839,2023-07-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4449,61,2021-04-30 10:48:20.000000,Validation of a Novel Instrument Task for Assessing Upper Limb,Condition:    Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis SubjectsIntervention:    Other: Assessment of the upper limb (VPIT + PPIT)Sponsors :    Swiss Federal Institute of Technology;   Kliniken ValensNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04868370,2021-04-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4450,60,2023-08-03 22:10:56.631336,"An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...","<p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE"">SE</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI"">FI</a> (Temporarily Halted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2019-000826-22,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4451,59,2021-04-28 12:01:02.000000,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,Conditions:    Covid19;   Multiple SclerosisIntervention:    Sponsor :    Nottingham University Hospitals NHS TrustEnrolling by invitation ,https://clinicaltrials.gov/show/NCT04863586,2021-04-27 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4452,58,2021-04-27 12:25:02.000000,Validation of the French Adaptation of the MSWDQ-23 Questionnaire,Condition:    Multiple SclerosisIntervention:    Other: questionnairesSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/show/NCT04860791,2021-04-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4453,57,2021-04-27 12:25:02.000000,"Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients",Condition:    Multiple SclerosisInterventions:    Diagnostic Test: Brain MRI;   Diagnostic Test: Spinal Cord MRI;   Diagnostic Test: Retinal imagingSponsors :    Centre Hospitalier Universitaire de Nīmes;   Institut de Recherches en BiothérapieRecruiting ,https://clinicaltrials.gov/show/NCT04860947,2021-04-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4454,56,2021-04-26 12:49:02.000000,MS Relapses During COVID-19 Pandemic,Conditions:    Multiple Sclerosis;   Covid19;   Relapsing Remitting Multiple SclerosisIntervention:    Other: No InterventionSponsor :    Nottingham University Hospitals NHS TrustNot yet recruiting ,https://clinicaltrials.gov/show/NCT04858763,2021-04-22 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4455,55,2021-04-23 20:54:01.000000,Effect of Variance on Error Correction During Coupling,Conditions:    Multiple Sclerosis;   Progressive Multiple SclerosisIntervention:    Other: synchronisation abilitiesSponsors :    Hasselt University;   National MS Center Melsbroek;   Noorderhart Revalidatie & MSRecruiting ,https://clinicaltrials.gov/show/NCT04856384,2021-01-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4456,54,2021-04-23 20:54:01.000000,Running Title: Walking to Music and in Silence on a Treadmill,Condition:    Multiple SclerosisInterventions:    Other: Walking with music with synchronisation;   Other: Walking with music without synchronisation;   Other: walking without musicSponsors :    Hasselt University;   Noorderhart Revalidatie & MSRecruiting ,https://clinicaltrials.gov/show/NCT04856345,2021-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4457,53,2021-04-23 20:54:01.000000,Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis,Condition:    Relapse Remitting Multiple SclerosisIntervention:    Sponsor :    Thomas Jefferson UniversityRecruiting ,https://clinicaltrials.gov/show/NCT04857489,2021-04-20 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4458,52,2021-04-22 20:19:01.000000,Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS,"Conditions:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Motility Disorder;   Cognitive ImpairmentInterventions:    Device: Robotic Exoskeleton Rehabilitation;   Other: Conventional Gait TherapySponsors :    Kessler Foundation;   Kessler Institute for RehabilitationRecruiting ",https://clinicaltrials.gov/show/NCT04855825,2018-06-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4459,51,2021-04-22 20:19:01.000000,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    NYU Langone Health;   Genentech, Inc.Recruiting ",https://clinicaltrials.gov/show/NCT04855617,2021-04-19 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4460,50,2021-04-21 10:57:40.000000,Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   ExerciseIntervention:    Other: exerciseSponsor :    Sanko UniversityCompleted ,https://clinicaltrials.gov/show/NCT04853654,2021-11-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4461,49,2021-04-19 11:50:37.000000,GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders,Conditions:    Spinal Cord Injuries;   Multiple Sclerosis;   Parkinsonian Disorders;   AllodyniaIntervention:    Device: GentleCath™ Air catheterSponsors :    ConvaTec Inc.;   ClinSearchNot yet recruiting ,https://clinicaltrials.gov/show/NCT04847609,2021-01-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4462,48,2021-04-19 11:50:37.000000,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Condition:    Relapsing Multiple SclerosisInterventions:    Other: Ofatumumab;   Other: Covid-19 vaccineSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/show/NCT04847596,2021-04-14 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4463,47,2021-04-14 10:53:38.000000,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Conditions:    Autoimmune or Autoinflammatory Diseases;   HIV;   Multiple Sclerosis;   Solid Tumors or Cancers;   Solid Organ TransplantIntervention:    Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19Sponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/show/NCT04844489,2021-02-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4464,46,2021-04-14 10:53:38.000000,Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-,"Condition:    Multiple SclerosisInterventions:    Dietary Supplement: Lutein;   Dietary Supplement: PlaceboSponsors :    University of Illinois at Urbana-Champaign;   Division of Nutritional Sciences, University of Illinois at Urbana-ChampaignRecruiting ",https://clinicaltrials.gov/show/NCT04843813,2021-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4465,45,2021-04-14 10:53:38.000000,Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),Condition:    Multiple SclerosisIntervention:    Drug: SARS-COV-2 mRNA VaccineSponsor :    NYU Langone HealthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04843774,2021-09-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4466,44,2021-04-09 13:11:11.000000,The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Telerehabilitation-based Pilates ExerciseSponsor :    Gazi UniversityRecruiting ,https://clinicaltrials.gov/show/NCT04838886,2021-03-30 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4467,43,2021-04-09 13:11:11.000000,TELEMS: Feasibility of Remote Patient Visits in MS,Condition:    Multiple SclerosisInterventions:    Other: EDSS;   Other: Discussion of symptomsSponsor :    Medical University of ViennaRecruiting ,https://clinicaltrials.gov/show/NCT04838990,2021-02-21 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4468,42,2021-04-08 11:57:29.000000,Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab,"Conditions:    Multiple Sclerosis;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic ProcessesIntervention:    Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testSponsor :    Dragonfly Research, LLCRecruiting ",https://clinicaltrials.gov/show/NCT04837651,2021-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4469,41,2021-04-08 11:57:29.000000,Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS,"Condition:    Multiple SclerosisIntervention:    Sponsor :    University Hospital, Strasbourg, FranceRecruiting ",https://clinicaltrials.gov/show/NCT04838015,2021-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4470,40,2021-04-08 11:57:29.000000,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Covid19Intervention:    Sponsor :    St. Barnabas Medical CenterRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04834401?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-07 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4471,39,2021-04-08 11:57:29.000000,Impact of Neuropsychological Disorders in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Three dimensional gait analysis with eyetrackingSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04837365,2021-07-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4472,38,2021-04-08 11:57:29.000000,Therapeutic Adherence of Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Study of the role of sociocognitive factorsSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04837352,2021-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4473,37,2021-04-06 11:14:24.000000,"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial","Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Pain, Chronic;   Fatigue Syndrome, Chronic;   KinesiophobiaInterventions:    Behavioral: PMR: Progressive Muscle Relaxation;   Behavioral: BRT:Benson Relaxation TechniqueSponsor :    Hacettepe UniversityCompleted ",https://clinicaltrials.gov/show/NCT04833673,2021-05-04 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4474,36,2021-04-05 11:38:24.000000,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: NatalizumabSponsor :    BiogenRecruiting ,https://clinicaltrials.gov/show/NCT04832399,2021-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4475,35,2021-04-05 11:38:24.000000,Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour,"Condition:    Multiple SclerosisIntervention:    Other: Exposure to methylprednisolone during pregnancySponsors :    Jena University Hospital;   Ruhr University of Bochum;   Interdisciplinary Center of Clinical Research of the Medical Faculty Jena;   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04832269?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-05 16:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4476,34,2021-03-30 11:05:24.000000,Imaging Evaluation of Central Nervous Autoimmune Diseases,Conditions:    MS (Multiple Sclerosis);   NMO Spectrum DisorderIntervention:    Diagnostic Test: MRISponsor :    Qilu Hospital of Shandong UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04822623,2021-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4477,33,2021-03-30 11:05:24.000000,Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Biological: Mesenchymal Stem Cells (MSC)Sponsor :    Hadassah Medical OrganizationCompleted ,https://clinicaltrials.gov/show/NCT04823000,2021-11-01 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4478,32,2021-03-29 11:19:37.000000,Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences,"Condition:    Multiple Sclerosis (MS)Interventions:    Procedure: SC MRI;   Other: patient questionnaireSponsors :    University Hospital, Basel, Switzerland;   Freie Akademische Gesellschaft BaselNot yet recruiting ",https://clinicaltrials.gov/show/NCT04819737,2021-03-24 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4479,31,2021-03-29 11:19:36.000000,Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Other: biological collectionSponsor :    University Hospital, RouenRecruiting ",https://clinicaltrials.gov/show/NCT04821596,2020-12-29 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4480,30,2021-03-26 13:30:35.000000,Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis,"Conditions:    Urinary Bladder, Neurogenic;   Multiple SclerosisInterventions:    Drug: VESIcare 10Mg Tablet;   Drug: Botox 100 UNT InjectionSponsors :    Brigitte Schürch;   Centre Hospitalier Universitaire VaudoisNot yet recruiting ",https://clinicaltrials.gov/show/NCT04819360,2020-12-13 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4481,29,2021-03-26 13:30:35.000000,The Use of Arabic Otago Exercise Program in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Otago Exercise ProgramSponsor :    University of JordanNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04818008,2021-01-28 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4482,28,2021-03-25 11:16:53.000000,Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity,"Conditions:    Spasticity;   Cerebrovascular Accident;   Multiple Sclerosis;   Traumatic Brain Injury;   Cervical Spinal Cord Injury;   Cerebral PalsyInterventions:    Drug: rimabotulinumtoxinB;   Drug: PlaceboSponsor :    Supernus Pharmaceuticals, Inc.Not yet recruiting ",https://clinicaltrials.gov/show/NCT04815967,2021-11-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4483,27,2021-03-19 11:55:20.000000,MS-NEUROPLAST: Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients With Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Cognitive DeclineIntervention:    Other: Cognitive TrainingSponsors :    Aristotle University Of Thessaloniki;   King Fahad Medical CityActive, not recruiting ",https://clinicaltrials.gov/show/NCT04806568,2021-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4484,26,2021-03-19 11:55:20.000000,Virtual Reality in Physical Therapy in Multiple Sclerosis,"Condition:    Multiple SclerosisInterventions:    Device: Neuroproprioceptive ""facilitation and inhibition"" in virtual reality;   Other: Neuroproprioceptive ""facilitation and inhibition""Sponsor :    Charles University, Czech RepublicNot yet recruiting ",https://clinicaltrials.gov/show/NCT04807738,2021-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4485,25,2021-03-19 11:55:20.000000,Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Theory of MindSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04806217,2021-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4486,24,2021-03-18 11:23:53.000000,Emotions in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Diagnostic Test: Carrying out a tests and questionnaires batterySponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/show/NCT04804787,2021-03-16 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4487,23,2021-03-15 14:45:21.000000,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeInterventions:    Biological: blood sample;   Biological: cerebro-spinal fluidSponsors :    University Hospital, Bordeaux;   University of BordeauxNot yet recruiting ",https://clinicaltrials.gov/show/NCT04798651,2021-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4488,22,2021-03-15 14:45:21.000000,Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication,Condition:    Multiple SclerosisIntervention:    Other: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virusSponsor :    Providence Health & ServicesNot yet recruiting ,https://clinicaltrials.gov/show/NCT04796584,2021-11-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4489,21,2021-03-12 14:58:20.000000,Role of Individualized Versus Traditional Exercise in Combating Fatigue,Condition:    Multiple SclerosisInterventions:    Other: Adapted and individualized physical training program;   Other: traditional training programSponsor :    Centre Hospitalier Universitaire de Saint EtienneNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04796272,2021-01-15 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4490,20,2021-03-11 12:25:31.000000,Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON),Conditions:    Optic Neuritis;   Multiple SclerosisIntervention:    Diagnostic Test: Magnetic Resonance ImagingSponsor :    Fondation Ophtalmologique Adolphe de RothschildCompleted ,https://clinicaltrials.gov/show/NCT04793087,2021-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4491,19,2021-03-11 12:25:31.000000,3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON),Conditions:    Optic Neuritis;   Multiple Sclerosis;   EncephalopathyIntervention:    Diagnostic Test: Magnetic Resonance ImagingSponsor :    Fondation Ophtalmologique Adolphe de RothschildCompleted ,https://clinicaltrials.gov/show/NCT04792866,2021-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4492,18,2021-03-11 12:25:30.000000,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),Condition:    Secondary Progressive Multiple SclerosisInterventions:    Drug: BAF312;   Drug: Baseline disease modifying therapies (DMTs)Sponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/show/NCT04792567,2021-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4493,17,2021-03-09 14:59:53.000000,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,Condition:    Multiple SclerosisInterventions:    Drug: Ofatumumab;   Drug: First line DMTSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04788615,2021-08-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4494,16,2021-03-09 14:59:53.000000,T Cell Profiling in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Blood SampleSponsor :    Boston Children's HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04789551,2021-05-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4495,15,2021-03-08 13:43:03.000000,Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Sexual DysfunctionIntervention:    Behavioral: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)Sponsors :    University of Alabama at Birmingham;   National Multiple Sclerosis SocietyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04768777,2021-10-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4496,14,2021-03-08 13:43:03.000000,miRNA Biomarkers in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   miRNA;   Epigenetic;   BiomarkerIntervention:    Genetic: miRNASponsor :    University of GaziantepCompleted ,https://clinicaltrials.gov/show/NCT04772495,2021-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4497,13,2021-03-08 13:43:03.000000,Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis,Condition:    Multiple Sclerosis (MS)Intervention:    Other: At-home natalizumab treated MS patientSponsors :    Nantes University Hospital;   Rennes University HospitalNot yet recruiting ,https://clinicaltrials.gov/show/NCT04777539,2021-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4498,12,2021-03-08 13:43:03.000000,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,Condition:    Pediatric Multiple SclerosisInterventions:    Behavioral: Physical Activity (PA) Intervention;   Behavioral: Waitlist attention-controlSponsors :    The Hospital for Sick Children;   Children's Hospital of Philadelphia;   University of Alabama at Birmingham;   Queen's University;   National Multiple Sclerosis SocietyRecruiting ,https://clinicaltrials.gov/show/NCT04782466,2021-02-23 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4499,11,2021-03-08 13:43:03.000000,Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsors :    Medical Valley Digital Health Application Center GmbH;   Celgene Corporation;   NeuroSys GmbH;   Fraunhofer Institute for Integrated Circuits IIS;   Portabiles HealthCare Technologies GmbH;   University of RegensburgNot yet recruiting ,https://clinicaltrials.gov/show/NCT04771858,2021-02-02 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4500,10,2021-03-08 13:43:03.000000,Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Pathologic Processes;   Sclerosis;   Autoimmune Diseases of the Nervous System;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune DiseasesInterventions:    Behavioral: Standard Exercise Training;   Device: Phoenix Exoskeleton suitSponsor :    Sheffield Teaching Hospitals NHS Foundation TrustNot yet recruiting ",https://clinicaltrials.gov/show/NCT04786821,2021-01-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4501,9,2021-03-08 13:43:03.000000,Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: Belimumab;   Drug: Short-course Ocrelizumab;   Drug: Continued OcrelizumabSponsors :    Johns Hopkins University;   GlaxoSmithKlineNot yet recruiting ,https://clinicaltrials.gov/show/NCT04767698,2021-02-18 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4502,8,2021-03-08 13:43:03.000000,The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Dietary Supplement: High Phenolic Extra Virgin Olive OilSponsors :    University of Cyprus;   World Olive Center for Health;   Ellis-Farm, Eliama Daily ValueNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04787497,2021-01-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4503,7,2021-03-08 12:17:02.000000,Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),"Condition:    Multiple SclerosisIntervention:    Drug: Mavenclad®Sponsor :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04783935,2021-03-03 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4504,6,2021-03-08 12:17:02.000000,Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension),"Condition:    Multiple SclerosisIntervention:    Drug: Mavenclad®Sponsor :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04776213,2021-02-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
4505,5,2023-08-03 15:41:32.662553,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-002700-39,,15,,15,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
4506,4,2021-01-03 01:00:00.000000,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,Condition:    Chronic Liver DiseaseInterventions:    Biological: BNT162b2;   Biological: CoronaVac;   Biological: AZD1222Sponsor :    Humanity & Health Medical Group LimitedNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04775069?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-01 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4507,3,2021-02-27 01:00:00.000000,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",Conditions:    SARS-CoV-2 Infection;   COVID-19;   Maternal ImmunizationInterventions:    Biological: BNT162b2;   Other: PlaceboSponsors :    BioNTech SE;   PfizerNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04754594?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-15 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4508,2,2021-02-27 01:00:00.000000,National Cohort Study of Effectiveness and Safety of SARS-CoV-2&#x2F;COVID-19 Vaccines (ENFORCE),"Condition:    SARS-CoV InfectionInterventions:    Biological: COMIRNATY - BioNTech Manufacturing GmbH;   Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH;   Biological: COVID-19 Vaccine AstraZeneca suspension for injectionSponsors :    Jens D Lundgren, MD;   Ministry of the Interior and Health, DenmarkRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04760132?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-18 17:00:00.000000,12,,12,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4509,1,2023-08-03 15:41:28.487927,Movement Disorders in Multiple Sclerosis Patients,<b>Conditions</b>:    Multiple Sclerosis;   Movement Disorders<br /><b>Intervention</b>:    Other: Screen for movement disorder and correlates it with MRI findings.<br /><b>Sponsor</b>:    Al-Azhar University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05973929,2023-07-26 00:00:00.000000,17,,17,WHO XML import,https://trialsearch.who.int/
